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Abstract 
Magnetic Resonance Imaging (MRI) is the most useful imaging modality in biomedical 
research and clinical diagnosis thanks to the superb spatial resolution of the 3D images, 
acquired without resorting to ionizing radiation. Contrast in MRI can be dramatically 
enhanced by Contrast Agents (CA). Contrast Agents approved for clinical use, usually 
Gd
3+
 complexes, shorten the relaxation times (enhance the relaxation rates) of the water 
protons of tissues. Relaxivity, the enhancement of the relaxation rates normalized to 1 
mM of paramagnetic centres, measures the efficacy of CA. Simulations, using the 
Solomon-Bloembergen-Morgan theory, predict that simultaneous optimization of the 
parameters that govern relaxivity, in particular of the rotational correlation time (R) and 
the water exchange rate (kex), can generate very relaxivities.  
The complex Gd[DO3A-N-(-amino)propionate], reported previously, displays 
accelerated water exchange (kex= 4 x 10
7 
s
-1
), inside the range considered ideal to attain 
high relaxivities at magnetic fields relevant for clinical imaging (20-120 MHz), 
associated to high stability and inertness towards transmetallation. The pendant amine 
group endows the chelator/chelates with conjugability.  
In this thesis we report expedite synthetic methodologies for amide conjugates of the 
DO3A-N-(-amino)propionate chelator. The relaxometric characterization of the 
Gd[DO3A-N-(-benzoylamido)propionate] complex was performed by 1H Nuclear 
Magnetic Relaxation Dispersion (
1
H NMRD) and 
17
O NMR studies. Simultaneous 
fitting of the 
1
H NMRD and 
17
O NMR data to the SBM theory, established that the 
complex retains the fast water exchange rate (kex= 5.14 x 10
7
 s
-1
) and stability of its 
precursor complex. MRI in mice demonstrated that the complex is stable in vivo and is 
cleared by renal elimination. 
This result suggests that macromolecular/nanosized Gd
3+
 chelates might attain high 
relaxivities as result of simultaneous optimization of R and kex. The Gd[(DO3A-N-(α-
pyrenebutanamido)propionate)] chelate was designed as a potential MRI/fluorescence 
bimodal CA endowed with self-assembly in aqueous solution. The parameters 
characterising the self-assembly, critical micelle concentration (cmc= 0.60 mM) and the 
relaxivity of the monomeric (r1
n.a.
= 6.86 mM
−1
s
−1
) and the aggreagated (r1
a.
= 33.11 
mM
−1
s
−1
) forms, were determined by relaxometric measurements (20 MHz, 25 ºC). 
1
H 
NMRD and 
17
O NMR studies revealed that the observed high relaxivity resulted indeed 
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from simultaneous optimization of R and kex. The relaxivity is still limited by internal 
flexibility (S
2
= 0.24) of the self-assembled chelates. Steady-state fluorescence studies 
allowed also monitoring the self-assembly process owing to concentration-trigged 
monomer-excimer conversion. -Thiol functionalised chelators, DO3A-N-(-
cystamido)propionate and DO3A-N-(-lipoamido)propionate, were designed to 
functionalise gold nanoparticles (AuNPs) with Gd
3+
 chelates as CA for MRI. Synthetic 
methodologies were developed for preparing and to purify functionalized NPs. High 
relaxivities (27-28 mM
-1
s
-1
, 20 MHz, 25 ºC) were attained by the functionalized NPs 
thanks to simultaneous optimization of R and kex, although the relaxivity is still limited 
by fast rotational motions of the immobilized chelates around the anchoring linkers. The 
size of the linker seems to influence little the flexibility of the immobilized chelates, but 
seems to influence the size of the nanocrystal core. Biodistribution studies using the 
surrogate 
153
Sm[DO3A-N-(-lipoamido)propionato]@AuNPs and MRI studies in vivo 
(mice) revealed that the size (Hydrodynamic diameter, HD) of the NPs determines their 
fate in vivo: while the Gd[DO3A-N-(-cystamido)propionato]@AuNPs CA (HD= 3.9 
nm) follows renal elimination the Gd[DO3A-N-(-lipoamido)propionato]@AuNPs 
(HD= 4.8 nm) follows mainly hepatobiliary clearence.  
The bifunctional NODASA e NODAGA chelators (NOTA derivatives) are the gold 
standard for preparing targeted 
68
Ga
3+
 chelates for use as PET tracers.  In this work, the 
synthetic methodologies developed for the DO3A-N-(α-amino/amido)propionate 
chelators were extended to the triazacyclononane scaffold.  The Ga[NO2A-N-(α-
amino)propionate] and Ga[NO2A-N-(α-benzoylamido)propionate] chelates were 
studied by multinuclear (
1
H and 
71
Ga) NMR. The chelate Ga[NO2A-N-(α-
benzoylamido)propionate] displays N3O3 coordination in the pH range 3-11. The 
complex Ga[NO2A-N-(α-amino)propionate] undergoes pH trigged coordination 
isomerisation in the pH range 3-5. At pH values bellow 4 the complex display N3O3 
coordination while at pH values above 6 the N4O2 isomer is present in solution. 
Biodistribution studies revealed that the 
67
Ga[NO2A-N-(α-
pyrenebutanamido)propionate] chelate follows predominantly renal elimination with 
low liver/spleen accumulation and no visible deposition of activity in the bones after 24 
hours.  In this work we illustrate the potential of Ga[NO2A-N-(α-
amino/amido)propionate] chelates  as tracers for 
68
Ga-mediated PET was demonstrated 
also.   
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Resumo 
A Imagiologia por Ressonância Magnética (IRM) é a modalidade de imagem mais 
usada em investigação biomédica e diagnóstico clínico, graças à excelente resolução 
espacial das imagens anatómicas 3D geradas sem recurso a radiação ionizante. O 
contraste em IRM pode ser dramaticamente melhorado através do uso de Agentes de 
Contraste (AC). Os AC em uso clínico, usualmente quelatos de Gd
3+
, encurtam os 
tempos de relaxação (aumentam a velocidade de relaxação) dos protões dos núcleos dos 
átomos de Hidrogénio das moléculas de água dos tecidos. O parâmetro relaxividade 
definido como ―o aumento da velocidade de relaxação dos protões da água normalizado 
para 1 mM de agente paramagnético‖, mede a eficácia dos AC. Simulações, preveem 
que complexos de Gd
3+
 apresentando otimização simultânea dos parâmetros 
moleculares que governam a relaxividade, principalmente do tempo de correlação 
rotacional (R) e da velocidade de troca de água (kex) exibiriam elevadas relaxividades.  
O complexo Gd[DO3A-N-(-amino)propionato] desenvolvido anteriormente, apresenta 
velocidade acelerada de troca de água (kex= 4 x 10
7 
s
-1
), no intervalo considerado ideal 
para atingir relaxividades elevadas a campos magnéticos  relevantes para imagem 
clínica (20-120 MHz), associada a elevada estabilidade e resistência a transmetalação. O 
grupo amina pendente propicia conjugabilidade ao agente quelante. 
Nesta Tese foram desenvolvidas vias sintéticas expeditas para a preparação de 
conjugados amida do agente quelante DO3A-N-(-amino)propionato. A caracterização 
relaxometrica do complexo Gd[DO3A-N-(-benzoilamido)propionato] foi realizada 
através de estudos de Dispersão de Relaxação Magnética Nuclear de Protão (
1
H 
DRMN) e estudos de Ressonância Magnética Nuclear (RMN) de 
17
O. O ajuste 
simultâneo dos dados de 
1
H DRMN e RMN de 
17
O à teoria Solomon-Bloembergen-
Morgan estabeleceu que o complexo mantém a velocidade acelerada de troca de água 
(kex= 5,14 x 10
7 
s
-1
) e a estabilidade do complexo precursor. IRM em ratos demonstrou 
que o complexo é estável in vivo e é eliminado por filtração renal. Este resultado indica 
que complexos de conjugados amida macromoleculares/nanometricos poderão 
apresentar relaxividades elevadas como resultado de otimização simultânea de R e kex. 
O complexo Gd[DO3A-N-(α-pirenebutanamido)propionato] foi desenhado como um 
agente de imagem bimodal IRM/Fluorescência, suscetível de automontagem (self-
assembly) em solução. O processo de automontagem foi caracterizado através de 
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estudos relaxométricos: determinou-se a concentração micelar crítica (cmc) do 
complexo (cmc= 0,60 mM) e a relaxividade das formas monomérica (r1
n.a.
= 6,86 
mM
−1
s
−1
) e agregada (r1
a.
= 33,11 mM
−1
s
−1
). Estudos de 
1
H DRMN e RMN de 
17
O 
demonstraram que a elevada relaxividade exibida pela forma micelar resulta de 
otimização simultânea de R e kex. A relaxividade é limitada por flexibilidade interna dos 
chelatos (S
2
= 0,24).  
Foi desenvolvido um procedimento para a preparação e purificação de AuNPs 
funcionalizadas. Foram obtidas elevadas relaxividades para as NPs funcionalizadas (27-
28 mM
-1
s
-1
, 20 MHz, 25 ºC) como resultado de otimização simultânea de R e de kex, 
ainda que a relaxividade continue a ser limitada por movimentos rotacionais rápidos dos 
chelatos imobilizados (S
2
= 0,42-0,48) em torno dos linkers. O comprimento do linker 
não tem influência determinante na flexibilidade dos chelatos imobilizados, ainda que 
pareça influenciar o tamanho do núcleo metálico das NPs. Estudos de biodistribuição e 
IRM in vivo (ratinhos) revelaram que o tamanho (diâmetro hidrodinâmico, HD) das NPs 
determina o seu comportamento in vivo: o AC Gd[DO3A-N-(-
cistamido)propionato]@AuNPs (HD= 3.9 nm) é eliminado por filtração renal enquanto 
o AC Gd[DO3A-N-(-lipoamido)propionato]@AuNPs (HD= 4,8 nm) segue 
predominantemente a via de eliminação hepatobiliar.  
Os agentes quelantes bifuncionais NODASA e NODAGA (derivados do agente 
quelante NOTA) são o ―gold standard‖ para a preparação de complexos de 68Ga3+ 
endereçados para recetores celulares para uso como traçadores em PET. As vias 
sintéticas desenvolvidas para agentes quelantes do tipo DO3A-N-(α-amino)propionato 
foram estendidas ao núcleo triazaciclononano. Os quelatos Ga[NO2A-N-(α-
amino)propionato] e Ga[NO2A-N-(α-benzoilamido)propionato] foram estudados por 
RMN de 
1
H e 
71
Ga. O quelato Ga[NO2A-N-(α-benzoilamido)propionato] apresenta 
coordenação N3O3 no intervalo de pH (3-11). O complexo Ga[NO2A-N-(α-
amino)propionato] sofre isomerização no intervalo de pH 3-5 da forma N3O3 
(predominante a pH < 4) para o isómero de coordenação N4O2 (predominante a pH> 6). 
Estudos de biodistribuição revelaram que complexo 
67
Ga[NO2A-N-(α-
pirenobutanamido)propionato] segue principalmente a via de eliminação renal com 
baixa acumulação no fígado/baço e sem deposição de atividade nos ossos após 24 horas. 
Nesta Tese ilustramos o potencial de complexos de Ga
3+
 com ligandos do tipo NO2A-
N-(α-amino/amido)propionato como traçadores potenciais para 68Ga PET. 
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Preface  
In a previous work an expeditious synthetic route for the DO3A-N-(-amino)propionate 
chelator was reported. The relaxometric characterization revealed that the Gd[DO3A-N-
(-amino)propionate] chelate displays accelerated water exchange- in the range 
considered ideal for attaining high relaxivities at magnetic fields relevant for clinical 
imaging (20-120 MHz). In addition, inertness towards transmetallation with endogenous 
metal ions (Zn
2+
), stability in a wide pH range (2-10) and conjugability, make this 
ligand/complex a ―lead for potentially safe targeted high relaxivity CA for MRI‖. 
In this thesis, synthetic methodologies were developed for amide conjugates of the 
DO3A-N-(-amino)propionate chelator. Low molecular weight and 
macromolecular/nanosized (micelles and AuNPs) metal chelates were prepared and 
characterised as MRI and multimodal MRI/Fluorescence imaging agents. 
In Chapter 1 (Introduction) the basic physical chemical models and the theory of 
relaxivity are introduced. The strategies described in the literature to attain high 
relaxivities are reviewed in the context of the strategies deployed in this Thesis. The 
relaxometric properties of selected macromolecular/nanosized Contrast Agents are 
reviewed also. 
In Chapter 2 a synthetic methodology for amide conjugates of the DO3A-N-(-
amino)propionate chelator is reported. Relaxometric characterization of the low 
molecular weight Gd[DO3A-N-(-benzoylamido)propionate] chelate is used to make 
the proof of principle that: ―Gd3+ complexes of amide conjugates retain the stability and 
fast water exchange rate of the precursor Gd[DO3A-N-(-amino)propionate] chelate‖. 
In Chapter 3, the hypothesis that ―Gd3+ complexes of slow-tumbling amide conjugates 
could attain high relaxivities‖ is tested. The self-assembling (micellar) Gd[DO3A-N-(α-
pyrenebutanamido)propionate] chelate is characterised as a bimodal MRI/fluorescence 
imaging agent. 
In Chapter 4, the synthetic methodologies described in Chapter 2 are extended to the 
triazacyclononane scaffold with the synthesis of amide conjugates of the NO2A-N-(α-
amino)propionate chelator (NOTA analogues). The coordination chemistry of 
Ga[NO2A-N-(α-amino/amido)propionate] chelates is studied by 1H and 71Ga NMR. 
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Preliminary evaluation of Ga[NO2A-N-(α-amino/amido)propionate] chelates as 
potential as tracers for Ga-PET is reported. 
In Chapters 5 and 6 the preparation and characterization of gold nanoparticles 
functionalized with Gd
3+
 chelates as CA for MRI is described. The effect of fast water 
exchange on the relaxivity of AuNPs functionalised with Gd
3+
 chelates is explicitly 
addressed, for the first time, in this work. The effect of the length of anchoring linkers 
on the size, internal flexibility and relaxivity of the AuNPs is studied also. MRI and 
biodistribution studies were carried out to study the effect of the physical-chemical 
properties of the NPs on their fate in vivo. 
 
XIII 
 
Table of Contents 
Agradecimentos ............................................................................................................................ V 
Abstract ...................................................................................................................................... VII 
Resumo ........................................................................................................................................ IX 
Preface ......................................................................................................................................... XI 
List of figure ........................................................................................................................ XVII 
Listo f tables ...................................................................................................................... XXIII 
Listo f Schemes ................................................................................................................... XXV 
Abbreviations ................................................................................................................... XXVII 
1 - Introduction .............................................................................................................................. 1 
1.1 Medical imaging modalities ................................................................................................ 1 
1.2 MRI ..................................................................................................................................... 3 
1.3 Gadolinium-based Contrast Agents for MRI ...................................................................... 4 
1.4 Gd-based Contrast Agents (CA) ....................................................................................... 10 
1.4.1 High relaxivity CA ..................................................................................................... 14 
1.4.2 Number of inner sphere water molecules ................................................................... 14 
1.4.3 Chelates displaying fast water exchange .................................................................... 15 
1.4.4 Simultaneous optimization of R and kex ..................................................................... 18 
1.5 Macromolecular and nanosized CA .................................................................................. 20 
1.5.1 Amphiphilic Contrast agents ...................................................................................... 21 
1.5.2 Dendrimers as contrast agents .................................................................................... 25 
1.5.3 Viral Capsids as contast Agents ................................................................................. 30 
1.5.4 Monolayer stabilised gold nanoparticles .................................................................... 33 
1.6 References ......................................................................................................................... 49 
2 -Amide conjugates of the DO3A-N-(-amino)propionate ligand: leads for stable, high 
relaxivity contrast agents for MRI? ............................................................................................. 65 
2.1 Introduction ....................................................................................................................... 67 
2.2 Results and discussion ....................................................................................................... 69 
2.2.1. Synthesis ................................................................................................................... 69 
2.2.2. Solution NMR and Relaxometric Studies ................................................................. 71 
2.2.3. MRI Studies............................................................................................................... 75 
2.3. Conclusions ...................................................................................................................... 78 
2.4. Experimental .................................................................................................................... 79 
2.4.1. Materials and Methods .............................................................................................. 79 
2.4.2. [2-(N-t-Butoxycarbonyl)benzamido]-methoxycarbonylethyl- 1,4,7,10-
tetrazacyclododecane-monoalkylated cyclen (4) ................................................................ 80 
XIV 
 
2.4.3. 2-Benzamido-methoxycarbonylethyl-4,7,10-tris- (ethoxycarbonylmethyl)-1,4,7,10-
tetrazacyclododecanetetraalkylated cyclen (5) .................................................................... 80 
2.4.4. 2-Benzamido-carboxyethyl-4,7,10-tris-(carboxymethyl)- 1,4,7,10-
tetrazacyclododecane-DO3A-N-(-benzoylamido) propionate metal chelator (L1) .......... 81 
2.4.5. 
1
H and 
17
O NMR and 
1
H NMRD Experiments ......................................................... 81 
2.4.6. 
17
O NMR Experiments .............................................................................................. 82 
2.4.7. NMRD Measurements ............................................................................................... 82 
2.4.8. Relaxivity Studies of pH Dependence and Zn
2+
 Transmetallation ............................ 83 
2.4.9. MRI Experiments ...................................................................................................... 83 
Acknowledgments ................................................................................................................... 84 
2.5 References ......................................................................................................................... 86 
2.6 Supporting Information ..................................................................................................... 92 
3 - Ln[DO3A-N--(pyrenebutanamido)propionate] complexes: optimized relaxivity and NIR 
optical ........................................................................................................................................ 101 
3.1 Introduction ..................................................................................................................... 103 
3.2 Results and discusion ...................................................................................................... 105 
3.2.1 Synthesis .................................................................................................................. 105 
3.2.2 Relaxometric studies of the GdL complex ............................................................... 106 
3.2.3 
17
O NMR and 
1
H NMRD studies ............................................................................. 108 
3.2.4 Luminescence studies ............................................................................................... 114 
3.2.5 Interaction of GdL with human serum albumin (HSA) ........................................... 117 
3.2.6 Biodistribution studies .............................................................................................. 119 
3.3 Conclusions ..................................................................................................................... 120 
3.4 Experimental ................................................................................................................... 121 
3.4.1Materials and methods .............................................................................................. 121 
3.4.1.1 Synthesis of methyl 3-hydroxy-2-(4-(pyren-1-yl)butanamido)- propanoate (3). .. 121 
3.4.1.2 Synthesis of methyl 2-[N-(tert-butoxycarbonyl)-4-(pyren-1-yl)- 
butanamido]acrylate (4). ................................................................................................... 122 
3.4.1.3 Synthesis of (2-(N-t-butoxycarbonyl)pyrenebutyramido)-methoxycarbonylethyl-
1,4,7,10-tetrazacyclododecane (monoalkylated cyclen) (6). ............................................. 122 
3.4.1.4 Synthesis of 2-pyrenebutyramido-methoxycarbonylethyl- 4,7,10-tris-
(ethoxycarbonylmethyl)-1,4,7,10 tetrazacyclododecane (tetraalkylated cyclen) (7). ....... 123 
3.4.1.5 Synthesis of 2-pyrenebutyramido-carboxyethyl-4,7,10-tris-(carboxymethyl)-
1,4,7,10-tetrazacyclododecane (L) (DO3A-N-(α-pyrenebutyramido)propionate metal 
chelator). ............................................................................................................................ 124 
3.4.2 
1
H and 
17
O NMR and 
1
H NMRD experiments ......................................................... 124 
3.4.3 
17
O NMR experiments .............................................................................................. 125 
3.4.4 NMRD measurements .............................................................................................. 125 
3.4.5 Relaxivity studies of pH dependence and Zn
2+
 transmetallation.............................. 126 
XV 
 
3.4.6 Fluorescence measurements ..................................................................................... 126 
3.4.7 Biodistribution studies .............................................................................................. 126 
3.4.8 Size distribution........................................................................................................ 127 
3.4.9 Data analysis ............................................................................................................ 127 
Acknowledgements ............................................................................................................... 127 
3.5 References ....................................................................................................................... 129 
3.6 Supplementary Information............................................................................................. 133 
4 - Ga[NO2A-N-(-amino)propionate] chelates: synthesis and evaluation as potential tracers for 
68
Ga PET ................................................................................................................................... 145 
4.1 Introduction ..................................................................................................................... 147 
4.2 Results and discussion ..................................................................................................... 151 
4.2.1 Synthesis and characterization ................................................................................. 151 
4.2.2 
1
H and 
71
Ga NMR studies......................................................................................... 152 
4.2.3 Fluorescence studies ................................................................................................. 157 
4.2.4 In vitro stability and biodistribution studies ............................................................. 159 
4.3 Conclusions ..................................................................................................................... 161 
4.4 Experimental ................................................................................................................... 161 
4.4.1 Materials and methods ............................................................................................. 161 
4.4.2 Synthetic procedures ................................................................................................ 162 
Acknowledgements ............................................................................................................... 169 
4.5 References ....................................................................................................................... 171 
4.6 Supplementary Information............................................................................................. 175 
5- Gold nanoparticles functionalised with stable, fast water exchanging Gd
3+
 chelates as high 
relaxivity contrast agents for MRI ............................................................................................ 181 
5.1 Introduction ..................................................................................................................... 183 
5. 2 Results and discusion ..................................................................................................... 184 
5.3 Conclusions ..................................................................................................................... 189 
Acknowledgements ............................................................................................................... 189 
References ............................................................................................................................. 190 
5.4Supplementary Information .............................................................................................. 192 
5.4.1 Materials and methods ............................................................................................. 193 
5.4.2 Synthesis and characterization ................................................................................. 194 
6 - Gold nanoparticles functionalised with Gd
3+
 chelates: effect of linkers on the relaxivity ... 205 
6.1 Introduction ..................................................................................................................... 207 
6.2 Ressults and Discution..................................................................................................... 210 
6.2.1 Synthesis and characterization ................................................................................ 210 
6.2.2 Relaxometric studies of GdL1 ................................................................................... 211 
XVI 
 
6.2.3 Preparation of gold nanoparticles functionalized with GdL1 chelates .................... 212 
6.2.4 Characterization of GdL1@AuNPs............................................................................ 212 
6.2.5 Relaxometric characterization of GdL1@AuNPs ...................................................... 214 
6.2.6 Nuclear Magnetic Relaxation Dispersion Profiles .................................................... 215 
6.2.7 Biodistribution studies ............................................................................................. 219 
6.2.8 MRI Studies .............................................................................................................. 219 
6.3 Conclusions...................................................................................................................... 223 
6.4 Experimental ................................................................................................................... 224 
6.4.1 Materials and methods ............................................................................................ 224 
6.4.2 Preparation of the lipoic acid conjugate DO3A-N-(α-lipoamide)propionic acid- L1 . 224 
6.4.2.2 Preparation of the fully deprotected chelator DO3A-N-(-lipoamido)propionate 
(L1)- 2,2',2''-(10-(2-(5-(1,2-dithiolan-3-yl)pentanamido)-carboxyethyl-4,7,10-tris-
(carboxymethyl)-1,4,7,10-tetrazacyclododecane ............................................................. 225 
6.4.3 Preparation of GdL1 complex for relaxometric measurements .............................. 226 
6.4.4 Preparation gold nanoparticles functionalized with GdL1. ...................................... 226 
6.4.5 NMRD measurements .............................................................................................. 227 
6.4.6 Relaxivity studies of pH dependence and Zn2+ transmetallation ............................. 227 
6.4.7 MRI experiments ...................................................................................................... 227 
6.4.8 Semiempirical calculations, molecular modelling and NPs size estimates .............. 230 
6.5 References ....................................................................................................................... 231 
7- Conclusions and perspectives ............................................................................................... 243 
 
XVII 
 
List of figure 
Chapter 1 
Figure 1.1- Full body MRI of a human subject [20]. ..................................................................................... 4 
Figure 1.2- Schematic representation of the inner sphere mechanism for paramagnetic relaxation. m is 
the residence lifetime of the coordinated water molecule(s); R is the rotational correlation time of the 
complex; and r represents the distance between the protons of the coordinated water molecule(s) and 
the unpaired electronic spins on the paramagnetic centre. (adapted from reference [21]) ........................ 6 
Figure 1.3- Schematic representation of the outer sphere mechanism for paramagnetic relaxation. D is 
the translational correlation time and d the distance of closest approach between the paramagnetic 
center and the bulk water molecules (adapted from reference [21]). .......................................................... 8 
Figure 1.4- 
1
H NMRD profiles (25 °C (▲) and 37 °C (■)) for the Gd[DO3A-N-(-amino)propionate] 
complex. The lines represent the simultaneous fittings of the 
17
O NMR and 
1
H NMRD data to the SBM 
theory. (adapted from ref.[34]) .................................................................................................................... 9 
Figure 1.5- Structure and trade names of Gd-based CA approved for clinical MRI. ................................... 11 
Figure 1.6- Structure of the hepatobiliary CA Teslascan®........................................................................... 13 
Figure 1.7- Structure of selected metal chelators forming bis(aquated) (q= 2) Gd
3+
 chelates. .................. 14 
Figure 1.8- Metal chelators forming Gd
3+
 complexes displaying “steric compression” around the water 
binding site.. ............................................................................................................................................... 17 
Figure 1.9- Simulated 
1
H NMRD profiles for various combinations of τR and τm for a mono(aquated) q= 1 
complex. The gray area highlights the range of magnetic fields relevant to clinical MRI (from reference 
[76]). ........................................................................................................................................................... 18 
Figure 1.10- Simulated effect of the inner-sphere water residence time m (ns) on r1 (—) and r2 (---) under 
optimal rotational conditions: (A) 0.47 T (20 MHz, R 20 ns), (B) 3 T (130 MHz, R 1.5 ns) and (C) 9.4 T 
(400 MHz, R 0.5 ns) [21]............................................................................................................................. 19 
Figure 1.11- Cartoon representation of a micelle (A) and selected amphyphilic metal chelators. ............ 22 
Figure 1.12- PAMAM and DAB/PPI dendrimers functionalized with the metal chelates. .......................... 27 
Figure 1.13- 3D Structure of viral capsids functionalized with  Gd(DTPA) and Gd(DOTA)-type chelates (the 
red dots represent the cysteine-immobilized Gd
3+ 
chelates)[120]. ............................................................. 31 
Figure 1.14- Surfactants used to induce anisotropic grouth of AuNPs. ...................................................... 34 
Figure 1.15- Structural model of gold nanorod growth. Left: Original nanorod with octagonal cross 
section and {100}, {110}, {111} facets. Center: Rod with sharp tips, square cross section, {110} and {111} 
facets. Right: Growth of a sharpened rod into an octahedral particle via deposition of gold atoms (dark 
spheres) along the {110} facets [138]. ........................................................................................................ 34 
Figure 1. 16- Structure of caping agents used for thepreparation of AuNPs ............................................. 35 
Figure 1.17- Schematic representation of a Gold Nanoparticles coated with a cystamine (focal point) 
second Generation PAMAM dendrimer ...................................................................................................... 37 
Figure1.18- Metal chelators employed for preparing gold nanoparticles functionalized with Gd
3+
 
chelates. ..................................................................................................................................................... 38 
Figure 1.19- Cartoon representation of Tillement´s AuNPs coated with Gd(DTDTPA) chelates (adapted 
from [175]). ................................................................................................................................................ 40 
Figure 1.20- Schematic representation of the paramagnetic glyconanoparticles based on GdL34 reported 
by Penadés and co-workers. ....................................................................................................................... 42 
Figure 1.21- Schematic representation of the hyperbranch nanoparticles and the synthetic route [132, 
137]............................................................................................................................................................. 44 
Figure 1.22- Post-synthetic functionalisation of AuNPs with Gd
3+
 chelates via Michael addition [183]. ... 45 
 
Chapter 2 
Figure 2.1- Temperature dependence of the (a) reduced transverse and longitudinal 
17
O relaxation rates 
1/T2r and 1/T1r, and (b) chemical shifts Dwr; B = 9.4 T (ln(1/T1r), (■), (ln(1/T2r), (p)), and (c) NMRD 
profiles (298 K (p) and 310 K (■)) for the Gd[(DO3A-N-(-benzoylamido)propionate)] complex. .............. 72 
XVIII 
 
Figure 2. 2-  Evolution of the relative water proton paramagnetic relaxation rate R1p(t)/R1p(0) (20 MHz, 
pH 7.1, 298 K) versus time for a 1.5 mM solution of Gd[(DO3A-N-(a-benzoylamido)propionate] complex 
in phosphate buffer (10 mM, pH 7.1) (○) and in phosphate buffer containing an equimolar amount of 
Zn
2+
 ions (●). ............................................................................................................................................... 74 
Figure 2.3- Representative coronal T1-weighted spin echo MR images of a Wistar rat before and after 
injection of the contrast agents (A) GdL1, (B) Gd(DTPA) (dose 0.1 mmol kg
-1
 BW). ................................... 76 
Figure 2.4- Time course of signal intensity, relative to the initial value (up to 50 min post-injection) of 
several regions of interest during dynamic contrast enhancement MRI experiments in rats with (A) 
Gd(DTPA) (0.1 mmol kg
-1
 BW) and (B) GdL1 (0.1 mmol kg
-1
 BW). The time courses are data for mean 
values of four animals and the corresponding standard error. .................................................................. 77 
Figure SI2.1- 
1
H NMR spectra (300 MHz, D2O) for the Eu(DO3A-N-(-benzoylamido)propionate) complex 
at different temperatures. .......................................................................................................................... 93 
Figure SI2.2- Temperature dependency of the water proton longitudinal paramagnetic relaxation rates 
R1p (20 MHz, 25 ºC) for a 1.5 mM solution of Gd(DO3A-N-(-benzoylamido)propionate. ......................... 93 
Figure SI2.3- pH dependency of the water proton longitudinal paramagnetic relaxation rates R1p (20 MHz, 
25 ºC) for a 1.5 mM solution of Gd(DO3A-N-(-benzoylamido)propionate. .............................................. 94 
Figure SI2.4- Dependency of  the water proton longitudinal paramagnetic relaxation rates on the 
concentration of the GdL1 complex in water (triangles), and  in the presence of  4% (0.6 mM) HSA 
(circles) in water and in a phosphate buffer (PBS, 5 mM, pH = 7.1) (diamonds) (20 MHz, 298 K). ............ 94 
Figure SI2.5- HPLC chromatogram (RP C18 silica, isocratic elution with acetonitrile/water (70:30), 
detection at  = 265 nm) for a GdL1 aqueous solution (8 mM, pH 7.0). .................................................... 95 
 
 
 
Chapter 3 
Figure 3.1- Concentration dependence of the paramagnetic water proton longitudinal relaxation rate 
               for GdL (20 MHz, 25 °C, pH 7.0). ........................................................................ 107 
Figure 3.2- 
1
H nuclear magnetic relaxation dispersion (NMRD) profiles of GdL in the monomer state at 
0.3 mM at 25 °C (▲) and 37 °C (■). The curves represent results from the fittings as described in the text.
 .................................................................................................................................................................. 108 
Figure 3.3- Temperature dependence of (a) reduced longitudinal, T1r (■), and transverse, T2r (▲), 
relaxation times and (b) chemical shifts (Δωr) of a micellar aqueous solution of GdL at 11.7 T (5.0 mM, 
pH 7.0); (c) NMRD profiles of the aggregated micellar state (2.5 mM, pH 7.0) at 25 °C (■) and 37 °C (▲) 
after subtraction of the relaxation contribution of the monomer form. The curves represent results from 
the simultaneous fittings as described in the text. ................................................................................... 109 
Figure 3.4- Structure of amphiphilic DOTA-type ligands compared in Table 3.2 and discussed in the text.
 .................................................................................................................................................................. 112 
Figure 3.5- Normalized fluorescence spectra for GdL in non-deoxygenated water over the concentration 
range 1 × 10
−7
 –5 × 10
−3
 M (λexc= 345 nm). Inset – changes in the emission properties of GdL as the ratio 
of the fluorescence emission intensity for the excimer (IE, 490 nm) and for the monomer (IM, 377 nm) 
(IE/IM) as a function of GdL concentration. ............................................................................................... 115 
Figure 3.6- Absorbance (black), excitation (λem= 1064 nm, violet) and emission (λexc= 344 nm, red) spectra 
for the NdL complex (a) and YbL complex (b) in water. ............................................................................ 117 
Figure 3.7- Proton relaxation enhancement data (20 MHz, pH 7.4) to assess HSA binding of GdL: E-
titration at 0.1 mM GdL concentration at 25 °C and 37 °C. ...................................................................... 118 
Figure 3.8- Biodistribution, stated as a percentage of injected dose per gram of organ (%ID/g), of 
153
SmL 
in Wistar rats 1 and 24 hours after i.v. injection. Results are the mean of 4 animals. ............................. 119 
Figure SI3.1- Size distribution in: a) volume (%); b) intensity (%) for a GdL solution (5.0 mM, pH 7.0, 25 ºC) 
at a concentration well above the cmc (0.6 mM). .................................................................................... 134 
Figure SI3.2- Temperature dependence of the water proton relaxivity for GdL(20MHz , 1mM, pH 6.0).. 134 
XIX 
 
Figure SI3.3- pH dependence of the water proton relaxivity for GdL (20MHz , 1 mM, pH 6.0). ............... 135 
Figure SI3.4-. Evolution of the relative water proton paramagnetic longitudinal relaxation rate 
R1p(t)/R1p(0) (20 MHz, pH 7.1, 25 ºC) for a 1.5 mM solution of GdL in 10 mM phosphate buffer(○) and in 
phosphate buffer containing an equimolar amount of Zn
2+
 (●). .............................................................. 135 
Figure SI3.5-. UV-Vis spectra for the free ligand L and the GdLcomplex (1.0x10
-5 
M, pH 7.0, 25ºC). ....... 136 
Figure SI3.6- Fluorescence spectra for free ligand L in non-deoxygenated water (pH 7.0) over the 
concentration range 5x10
-5
- 5x10
-3
 mol.dm
-3
 (exc= 345 nm). .................................................................. 136 
Figure SI3.7- Changes in the emission properties of the free ligand L as the ratio of the fluorescence 
emission intensity for the excimer (490 nm) and for the monomer (377 nm) (IE/IM) as function of ligand 
concentration. Line fitted to equation S1. ................................................................................................. 136 
 
 
Chapter 4 
Figure 4.1- pH dependence of the 
71
Ga NMR spectra for: (A) the GaL1 and (B) GaL2 complexes (400 MHz, 
20 mM in D2O, 25 °C). ............................................................................................................................... 152 
Figure 4.2- Struture of triazacyclononane ligands compared in Table 4.1 and discussed in the manuscript: 
NOTP (1,4,7-triazacyclononane-N,N´,N´´-tris(methylenephosphonic) acid); NOTMP (1,4,7-
triazacyclononane-N,N´,N´´-tris(methylene(metylphosphinate))); TRAP-H (1,4,7-triazacyclononane-1,4,7-
tris(methylenephosphinic acid)................................................................................................................. 153 
Figure 4.3- pH dependence of the proton NMR resonances of the CH protons of the propionate side arm 
of the GaL1 and GaL2 complexes (400 MHz, 20 mM in D2O, 25 °C). ....................................................... 156 
Figure 4.4- Normalized fluorescence spectra for GaL3 in non-deoxygenated water over the concentration 
range 5 × 10
−7
–5 × 10
−3
 mol dm
−3
 (λexc= 345 nm). ................................................................................... 157 
Figure 4.5- Percentage of activity in the protein and in the soluble fraction at different incubation times 
of [
67
Ga]L2 with human serum. ................................................................................................................ 159 
Figure 4.6- Biodistribution profiles, presented as % injected activity per gram of organ or tissue, for the 
[
67
Ga]L3 complex at 1 and 24 hours postinjection. Results are the average of 4 animals. ...................... 160 
 
Figure SI4.1- A) 1D proton and B) 2D COSY NMR spectrum (600 MHz) of GaL1 at pH 3.0 (20 mM in D2O, 
25 ºC). ....................................................................................................................................................... 176 
Figure SI4.2- A) 1D proton and B) 2D COSY NMR spectrum (600 MHz) of GaL1 at pH 4.0 (20 mM in D2O, 
25 ºC). ....................................................................................................................................................... 177 
Figure SI4.3- UV-Vis spectra for the free ligand L3 and of the GaL3 complex (1.0x10
-5 
M). ...................... 178 
Figure SI4.4- Fluorescence spectra for ligand L3 in non-deoxygenated water over the concentration range 
1x10
-7
 and 5x10
-3
 mol.dm
-3
 (exc= 345 nm). .............................................................................................. 178 
Figure SI4.5- Optimized structure of GaL3 (Mopac PM6 COSMO, water implicit solvent). ...................... 179 
 
Chapter 5 
Figure 5.1- 
1
H nuclear magnetic relaxation dispersion profiles for gold nanoparticles functionalized with 
Gd[DO3A-N-(-cystamido)propionate] complex (5 mM): 25 °C (□), and 37°C (○). .................................. 187 
Figure SI5.1- IR spectrum (KBr) of gold NPs functionalized with Gd(DO3A-N-(-cystamido)propionate) 
chelates .................................................................................................................................................... 197 
Figure SI5.2- UV-VIS spectrum for the preparation of nanoparticles functionalized with Gd[DO3A-N-(-
cystamido)propionate] chelates (diluted by a factor of 3, pH 7.0). .......................................................... 198 
Figure SI5.3- DLS size distribution (Volume) for the preparation of nanoparticles functionalized with 
Gd[DO3A-N-(-cystamido)propionate] chelates at pH 7.0. ..................................................................... 199 
Figure SI5.4- Zeta potential distribution at pH 7.0 (red curve) and pH 10.0 (green curve) for the 
preparation of nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] chelates. ...... 199 
XX 
 
Figure SI5.5- TEM image of the Au-NPs. The image was measured with a JEOL 2010 UHR transmission 
electron microscope at the Interdisciplinary Centre for Electron Microscopy (CIME) at EPFL, Lausanne. 
TEM samples have been prepared by dropping solutions of gold nanoparticles onto carbon-coated-
copper grids and evaporating the solvent (water) to dryness. ................................................................. 200 
Figure SI5.6- Dependency of the proton longitudinal paramagnetic relaxation rates (R1p) on the Gd
3+
 
concentration for the preparation of nanoparticles functionalized with Gd[DO3A-N-(-
cystamido)propionate] chelates (20 MHz, 25 ºC, pH 7.5). Preparations with different concentrations Gd
3+ 
were obtained by dilution of the stock solution [Gd
3+
]= 1.238 mM. ......................................................... 201 
Figure SI5.7- Dependency of the proton longitudinal paramagnetic relaxation rates (R1p) on temperature 
for the preparation of nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] chelates 
([Gd
3+
]= 1.238 mM, 20 MHz, 25 ºC, pH 7.5). ............................................................................................ 202 
Figure SI5.8- Dependency of the proton longitudinal paramagnetic relaxation rates (R1p) on the solution’s 
pH for the preparation of nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] 
chelates ([Gd
3+
]= 1.238 mM, 20 MHz, 25 ºC). .......................................................................................... 202 
Figure SI5.9- Time evolution of the relative water proton paramagnetic relaxation rate R1p(t)/R1p(0) (20 
MHz, 37 ºC) for the preparation of nanoparticles functionalized with Gd[DO3A-N-(-
cystamido)propionate] chelates ([Gd
3+
] = 0.928 mM) in PBS 2.5 mM, pH 7.1 in the presence (■) and in the 
absence (♦) of 0.75 mM ZnCl2. .................................................................................................................. 203 
Figure SI5.10- 
1
H nuclear magnetic relaxation dispersion profiles for gold nanoparticles functionalized 
with Gd[DO3A-N-(α-cystamido)propionate] complex (5 mM): 25 °C (□), and 37°C (○). The full drawn lines 
are from the fit with parameters in Table SI5.1. The dashed lines are calculated using the same 
parameters except S
2
 = 1. ......................................................................................................................... 204 
 
Chapter 6 
Figure 6.1- Concentration dependence of the paramagnetic water proton relaxation rate R1p = (R1obs-R1d) 
for GdL1 ................................................................................................................................................... 211 
Figure 6.2- Size distribution (% Volume) for GdL1@AuNPs. ................................................................. 212 
Figure 6.3-. Transmission Electron Microscopy (TEM) for GdL1@AuNPs ........................................... 213 
Figure 6.4- 
1
H Nuclear Magnetic Relaxation Dispersion (NMRD) profiles for: GdL1@AuNPs (0.56 mM; 
pH 7.0) 25 °C (■) and 37 °C (●). The fitted curves are represented as continuous lines. ....................... 216 
Figure 6.5- Biodistribution of [
153
Sm
3+
]L1@AuNPs in rats, stated as percent of injected dose per gram of 
organ (% ID/ g): a) 2 and b) 24 hour post-injection. Inset- time evolution of activity in the blood. The 
results are from a group of four animals in each experiment................................................................... 219 
Figure 6.6- Representative coronal T1-weighted spin echo MR images of mice before and after injection 
of contrast agents: (A) Gd(DTPA) (0.1 mmol Gd kg
-1
 BW), (B) GdL1@AuNPs (0.1 mmol Gd kg
-1
 BW), 
(C) GdL3@AuNPs (0.1 mmol Gd kg
-1
 BW); (D) Gd(DTPA) (0.05 mmol Gd kg
-1
 BW), (E) GdL3@AuNPs 
(0.05 mmol Gd kg
-1
 BW). .......................................................................................................................... 220 
Figure 6.7- Time course of signal intensity, up to 60 min post-injection,  for several regions of interest, 
relative to the initial value, during dynamic contrast enhancement MRI experiments in rats administrated 
with: (A) Gd(DTPA) (0.1 mmol kg
-1
 BW) and (B) GdL3@AuNPs (0.1 mmol kg
-1
 BW), (C) GdL1@AuNPs 
(0.1 mmol kg
-1
 BW); (D) Gd(DTPA) (0.05 mmol kg
-1
 BW); (E) GdL3@AuNPs (0.05 mmol kg
-1
 BW). The 
time courses are data from mean values of four animals. ........................................................................ 221 
Figure SI6.1-Temperature dependence of the water proton relaxivity for GdL1 (20 MHz, 1.0 mM pH 7.0)
 .................................................................................................................................................................. 237 
Figure SI6.2- pH dependence of the water proton relaxivity for GdL1 (20 MHz, 1.0 mM, 25 ºC). ............ 237 
Figure SI6.3- Typical chelate lenght estimates from several S…O and S…H top-bottom distances measured 
over the optimized conformations of (A) GdL1, (B) GdL2 and (C) GdL3 obtained from PM6 semi-empirical 
calculations. .............................................................................................................................................. 238 
Figure SI6.4- UV-Vis spectrum of GdL1@AuNPs. ...................................................................................... 239 
Figure SI6.5- Zeta potential distribution, expressed as total counts, for GdL1@AuNPs. .......................... 239 
Figure SI6.6- Concentration dependence of the paramagnetic water proton relaxation rate R1p (R1p = 
R1obs-R1d) for GdL1@NPs (20 MHz, 25ºC, pH=7.1) ..................................................................................... 240 
XXI 
 
Figure SI6.7- pH dependence of the paramagnetic water proton relaxation for GdL1@AuNPs (20 MHz, 25 
ºC, 0.53 mM). ........................................................................................................................................... 240 
Figure SI6.8- Time evolution of the relative water proton paramagnetic relaxation rate R1p(t)/R1p(0) (20 
MHz, 25 ºC) for a solution of GdL1@NPs (0.53 mM in PBS 2.5 mM, pH 7.1) (♦) and following addition of 
0.75 mM ZnCl2 (●)..................................................................................................................................... 241 
XXIII 
 
Listo f tables 
Chapter 1 
Table 1.1- Imaging modalities in clinical diagnosis/prognosis and in biomedical research. ...................... 2 
Table 1.2- Proprieties of Gd-based CA approved for clinical MRI (Figure 1.5). ...................................... 11 
Table 1.3- Molecular parameters for q= 2 chelates. ................................................................................. 15 
Table 1.4- Molecular parameters for Gd
3+
 chelates displaying “steric compression” around the water 
binding site. ................................................................................................................................................ 17 
Table 1.5- Summary of the relaxometric properties of the micellar CA represented in Figure 1.11. ........ 23 
Table 1.6- Summary of the relaxometric properties of selected PAMAM and DAB/PPI dendrimers 
functionalized with Gd
3+
 chelates. .............................................................................................................. 28 
Table 1.7- Relaxometric properties of viral capsids functionalized with Gd(DTPA) and Gd(DOTA)-type 
chelates (60 MHz, 40 °C)[120]. ................................................................................................................. 32 
Table 1.8- Relaxometric properties of selected examples of AuNPs functionalized with ........................... 39 
Table 1.9 - Composition and relaxometric properties of the paramagnetic glyconanoparticles reported by 
Penadès and co-workers [181]................................................................................................................... 42 
Table 1.10- Selected examples (Figure 1.18, Table 1.8) of in vivo MRI studies using AuNPs 
functionalized with Gd
3+
 chelates as CA . .................................................................................................. 47 
 
 Chapter 2 
Table 2. 1- Best fit parameters obtained for the Gd[DO3A-N-(-benzoylamido)propionate] chelate from 
the simultaneous fitting of the NMRD data, 17O NMR longitudinal (1/T1r) and transverse (1/T2r) 
relaxation rates and chemical shifts (Δor) ................................................................................................. 73 
  
Chapter 3 
Table SI3.1- Best fit values for the fitting (Prima GraphPad) of the experimental data of IExc/IMono vs 
[GdL] (Figure 5 in manuscript and Figure S6) to equation S1 ............................................................... 137 
Table SI3.2- Biodistribution, stated as percentage of injected doseper gram of organ (%ID/g ±SD), of 
153
SmL inWistar rats 1hand 24 h after i.v. injection. Results are the mean of 4 animals. ........................ 138 
 
Chapter 4 
Table 4.1- 
71
Ga NMR chemical shifts and linewidths for the GaL1 and GaL2 complexes studied in this 
work, compared with other triazamacrocyclic complexes reported in the literature.[40] ....................... 153 
Table 4.2- Quantum yields (F) for the ligand L3 and GaL3 complex (ex= 345 nm) in non-deoxygenated 
water. ....................................................................................................................................................... 158 
Table SI4.1- Computed LogP values for the GaL2 and GaL3 complexes after structure optimization with 
Mopac PM6 COSMO, water implicit solvent. ........................................................................................... 179 
Table SI4.2- Biodistribution, stated as percentage of injected dose per gram of organ (%ID/g ±SD), of 
[
67
Ga]L3 in Wistar rats at 1 and 24 hours after i.v. injection. Results are the mean of 4 animals. ........... 180 
 
Chapter 5 
Table 5.1- Best fit parameters obtained for Au-NPs functionalized with Gd[DO3A-N-(-
cystamido)propionate] chelates from the fitting of the 
1
H NMRD data.
a
 ................................................ 187 
Table SI5.1- Full list of parameters used for the fitting of the high-field part of the NMRD profiles using 
SBM theory. .............................................................................................................................................. 203 
  
XXIV 
 
Chapter 6 
Table 6. 1 Characterization of GdL1@AuNPs ........................................................................................ 213 
Table 6.2- Best fit parameters obtained for GdL1@AuNPs from the fitting of the 
1
H NMRD profiles to the 
SMB theory, including the Lipari-Szabo approach for internal flexibility ............................................... 216 
Table 6.3- Selected molecular parameters for GdL1AuNPs and other related systems reported in the 
literature. .................................................................................................................................................. 217 
Table SI6.1- Zeta potencial for GdL1@AuNPs ........................................................................................... 239 
Table SI6.2-. Characterization of GdL1@AuNPs ....................................................................................... 241 
 
 
 
XXV 
 
Listo f Schemes 
 
Chapter 3 
Scheme 3.1- Synthetic pathway for the metal chelator DO3A-N-(α-pyrenebutanamido)propionate (L) and 
its Ln
3+
 complexes LnL: (a) K2CO3/MeCN; (b) i. TFA/DCM, ii. ethyl bromoacetate, K2CO3/MeCN; (c) i. 
Dowex 1X2 OH
−
, ii. elution with hydrochloric acid 0.1 M; (d) LnCl3·xH2O. ................................................ 105 
Scheme 3.2- Synthesis of the dehydroalanine (Pyrene, Boc)-Δ-AlaOMe reactive block (4): (a) i. TEA 2 
molar equivalents/MeCN, ii. DCC/HOBt; (b) Boc2O, DMAP, dry MeCN. .............................................. 106 
 
Chapter 4 
Scheme 4.1- Synthetic pathway for the metal chelators NO2A-N- (α-amino)propionic acid (L1), NO2A-N-
(α-benzoylamido)propionic acid (L2) and NO2A-N-(α-pyrenebutanamido)propionic acid (L3). (a) 
K2CO3/MeCN; (b) tert-butyl bromoacetate, K2CO3/MeCN; (c) i. hydrochloric acid/EtOH, ii. Dowex 1X2 OH
−
, 
elution with diluted hydrochloric acid; (d) GaCl3·xH2O; (e) i. TFA/CH2Cl2; ii. ethyl bromoacetate, 
K2CO3/MeCN; (f ) Dowex 1X2 OH
−
, elution with diluted hydrochloric acid. .............................................. 150 
 
Chapter 5 
Scheme 5.1- Synthesis of cysteine conjugate DO3A-N-(-cystamido)propionate (4) and preparation of 
gold nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] chelates (5): a) i. 
TFA/DCM; ii. DIPEA/DCM, N-Boc-S-Trt-Cys, DCC/HOBt b) i. aqueous HCl, ii. Dowex 1X2 OH
-
 resin, elution 
with hydrochloric acid 0.1 M; c) i. aqueous HAuCl4, NaBH4, ii) GdCl3.6H2O, iii) SEC- Sephadex G10, iv) 
dialysis cellulose membrane MWCO 1000................................................................................................ 185 
Scheme SI5.1- General strategy (cartoon representation) for the preparation of gold nanoparticles 
functionalized with Gd[DO3A-N-(-cystamido)propionate] chelates ...................................................... 196 
 
 Chapter 6 
Scheme 6.1- Synthetic pathway for -thioalkyl conjugates of the DO3A-N-(-amino)propionate chelator: 
a) K2CO3/MeCN; b) ethyl bromoacetate, K2CO3/MeCN; c) i. TFA/CH2Cl2, ii. DIPEA/CH2Cl2, lipoic acid, 
DCC/HOBt; d) i. NaOH aq. ii. Flash chromatography silica gel, iii. SEM (Sephadex G10); e) 
GdCl3.xH2O; f) i. HAuCl4, ii. GdCl3.xH2O, iii. SEM (Sephadex G10) followed by dialysis (cellulose tubing 
MWCO 10 KDa). ...................................................................................................................................... 210 
XXVII 
 
Abbreviations 
2D DQF-COSY Two-dimensional double quantum filtered correlation spectroscopy 
AAZTA (6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid 
AuNPs Gold Nanoparticles 
AuNRs Gold Nanorods 
CA Contrast Agent 
CAT Computerized Axial Tomography 
CDCl3 Deuterated chloroform 
cmc critical micelar concentraton 
CTAB Cetyltrimethylammonium bromide 
d Distance of closest approach between the paramagnetic center and the 
bulk water molecules 
D Diffusion coeficient 
DAB Diaminobutane 
DCC N,N'-Dicyclohexylcarbodiimide 
DCE Dynamic Contrast Enhanced 
DCM Dichlorometane 
DDAB Didodecyldimethylammonium bromide 
DLS Dynamic Ligth Scattering 
DMSO Dimethyl sulfoxide 
DOTA 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetraacetic acid 
DPDP N,N'-dipyridoxylethylenediamine-N,N'-diacetate-5,5'-bisphosphate 
DRMN Dispersão de Relaxação Magnética Nuclear 
DTPA Diethylenetriamine pentaacetic acid 
DTTA Diethylenetriaminetetraacetic acid 
EDTA Ethylenediaminetetraacetic acid 
EPR Electron Paramagnetic Resonance 
EPTPA Ethylenepropylenetriaminepentaacetic acid 
EtOH Ethanol 
FDG Fluorodeoxyglucose 
g Electronic g factor 
H2O Water 
XXVIII 
 
HAuCl4 Hydrogen tetrachloroaurate 
HD Hydrodynamic Diameter 
HER2 Human epidermal growth factor receptor 2 
HMQC Heteronuclear Multiple-Quantum Correlation 
HOBt Hydroxybenzotriazole 
HOPO Hydroxypyridone 
HPLC High-Performance Liquid Chromatography 
HRMS (ESI) High-Resolution Mass Spectrometry (Electrospray Ionization) 
HSA Human Serum Albumin 
ICP-AES Inductively Coupled Plasma Atomic Emission Spectroscopy 
ICP-MS Inductively Coupled Plasma Mass Spectrometry 
ICP-OES Inductively Coupled Plasma Optical Emission Spectrometry 
IONPs Iron Oxide Nanoparticles 
IRM Imagiologia por Ressonância Magnética 
IS Inner Sphere 
K2CO3 Potassium carbonate 
kex Water exchange rate 
KHSO4 Potassium bisulfate 
KOH Potassium hydroxide 
MeCN Acetonitrile 
MeOH Methanol 
MgSO4 Magnesium sulfate 
MMCM Macromolecular contrast media 
MRA Magnetic Resonance Angiography 
MRI Magnetic resonance imaging 
MW Molecular weight 
n.d. Not determined 
NaBH4 Sodium borohydride 
NaHCO3 Sodium bicarbonate 
NH3 Ammonia 
NHS N-hydroxysuccinimide 
NIRF Near InfraRed Fluorescence 
XXIX 
 
NMR Nuclear Magnetic Resonance 
NMRD Nuclear Magnetic Relaxation Dispersion 
NODAGA 1,4,7-triazacyclononane-N-glutaric-N′,N″-diacetic acid 
NODASA 1,4,7-triazacyclononane-N-succinic-N′,N″-diacetic acid 
NOESY Nuclear Overhauser effect spectroscopy 
NOTA 1,4,7-triazacyclononane-1,4,7- triacetic acid 
NPs Nanoparticles 
OEGA Oligoethyleneglycol methylether acrylate 
OS Outer sphere 
PAA Polyacrylic acid 
PAI PhotoAcoustic Imaging 
PAMAM Poly(amidoamine) 
PBS Phosphate buffered saline 
PEG Polyethyleneglycol 
PET Positron emission tomography 
PFPA Pentafluorophenyl acrylate 
PL 1,2-dipalmitoyl-sn-glycero-3- phosphothio-ethanol 
PPI Poly(propyleneimine) 
PVP Poly(vinylpyrrolidone) 
q Number of water molecules directly coordinated to the metal center- 
inner sphere water molecules. 
r Distance between the protons of the coordinated water molecule(s) and 
the unpaired electronic spins on the paramagnetic centre 
r1 Relaxivity 
r1
a.
 Relaxivity of the micellar (aggregated form) 
r1
n.a.
 Relaxivity of the nonaggregated (monomeric form) 
RES Reticuloendothelial system 
RMN Ressonância Magnética Nuclear 
S Electron spin quantum number 
S
2 Degree of spatial restriction of the local motion 
SBM Solomon-Bloembergen-Morgan 
SDS Sodium dodecyl sulfate 
SEC Size Exclusion Chromatography 
XXX 
 
SPECT Single-Photon Emission Computed Tomography 
T1 Longitudinal relaxation times 
T1m Relaxation time of water protons in the first coordination sphere of the 
metal 
T2 Transverse relaxation times 
TACN-TM 1,4,7-triazacyclononane-N,N′,N″-tris(mercaptoethyl) 
TD-NMR Time Domain Nuclear Magnetic Resonance 
TEM Transmission electron microscopy 
TFA Trifluoroacetic acid 
TLC Thin-Layer Chromatography 
TOA Tetraoctammonium 
TSP Trimethylsilyl propionate 
US Ultrasound 
ZnCl2 Zinc chloride 
γH Gyromagnetic ratio for the proton (H) 
2 Mean-square zero-field splitting energy 
 Bohr magneton 
ci Modular correlation time  
D Translational correlation time 
g Correlation time for the global motion 
l Correlation time for the fast local motion 
𝜏  Residence lifetime of the coordinated water molecule(s) 
𝜏  Rotational correlation time of the complex 
v Correlation time of the modulation of the zero-field splitting 
S,H Angular frequency for the electron (S) and proton (H) 
 
Não foi encontrada nenhuma entrada do índice de ilustrações.
  
1 - Introduction 
 
1.1 Medical imaging modalities 
Cancer is often referred to as "disease of the century". Cancer is quiet, but still one of 
the most destructive diseases known, usually detected already at advanced stages. There 
is no definition that describes all cancers. Cancer includes a large family of diseases 
which form the neoplasms subset, all showing features that suggest malignancy. A 
neoplasm or tumour is a group of cells that have undergone unregulated growth and 
often form a mass or lump or may be distributed diffusely [1, 2]. The causes of cancer 
are diverse and complex, and only partially understood. Many factors are known to 
increase the risk of cancer: tobacco use, dietary factors, certain infections, exposure to 
radiation, lack of physical activity, obesity, and environmental pollutants [1]. These 
factors can directly damage genes or combine with existing genetic faults to cause 
cancerous mutations[2]. Approximately 5-10% of cancers can be traced directly to 
inherited genetic defects [1]. Over 200 types of tumours, benign and malignant, are 
currently known. Malignant cancers, form cells that separate from the initial neoplasic 
mass and invade other parts of the body. The high number of known cancers, combined 
with the occurrence of metastases, demands early diagnosis and effective treatments. 
Early detection of cancer, allowing therapeutic or surgical intervention at an early stage, 
results in a significant reduction of the mortality rate. Cancer can be detected by the 
presence of certain signs and symptoms, screening tests, or medical imaging 
procedures. Continual scientific developments have introduced more specific 
chemotherapy and radiation therapy which reduce secondary effects (cytotoxicity) [3].   
Imagiology is well established in the clinical practice and in biomedical research for 
early diagnosis of cancer and other pathological conditions, drug discovery, etc. Several 
imaging modalities are routinely used in hospitals (and pre-clinically) for diagnosis and 
disease prognosis: Near Infrared Fluorescence (NIRF) [4], Positron Emission 
Tomography (PET) [5], Single-Photon Emission Computed Tomography (SPECT) [6], 
X-Ray and CT (TAC) [7], Ultrasounds (U.S.) [8], Photo-Acoustic Imaging (PAI) [9], 
Magnetic Resonance Imaging (MRI) [10] and combined modalities MRI/PET, MRI/CT 
and others. 
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Table 1.1- Imaging modalities in clinical diagnosis/prognosis and in biomedical research. 
Imaging 
Modality 
Spatial 
Resolution 
Radiation 
Energy 
(keV) 
Scan 
Time 
Contrast Agents and 
Molecular Probes 
 
Tracer - 
contrast agent 
concentration 
(mol/kg body 
mass) 
Key Use 
NIRF 
15-1000 
nm 
1.77 x 10
-3
 Secs 
Fluorescent proteins, 
dyes, rhodamine 
amide, quantum 
dots 
10
-3
 
Visualization 
of cell 
structures 
PET 
MicroPET 
1-2 mm 511 Mins 
Fluorodeoxyglucose 
(FDG), 
18
F, 
11
C, 
15
O-
labelled 
biomolecules, 
68
Ga
3+
 
and 
64
Cu
2+
 complexes 
10
-9
 - 10
-12
 
Metabolic 
imaging 
Receptor 
imaging 
US 50 μm 1.24 x 10
-8
 Secs 
Microbubbles, 
nanoparticles 
 
Vascular 
imaging 
CT/MicroC
T 
12-50 μm 40-140 Mins 
Iodinated 
compounds 
10
-3
 
Lung and 
bone tumor 
imaging 
MRI 4-100 μm 
8.27-124  x 
10
-11
 
Mins 
– Hrs 
Gadolinium. 
iron oxide 
nanoparticles 
 
10
-5
 
Anatomical 
imaging 
 
All imaging modalities, although based on different physical-chemical principles, rely 
on the interaction of electromagnetic radiation with life tissues (Table 1.1). The 
frequency (energy) of the electromagnetic radiation employed varies widely between 
different modalities: from radiofrequencies (and magnetic fields) in MRI to -radiation 
(ionizing radiation) in PET/SPECT imaging. The low energy modalities, US, PAI, 
NIRF, MRI, are generally considered safe for repeated imaging [11]. The high energy, 
PET and SPECT, and to a lesser extent CT, modalities, are restricted to serious 
conditions, mostly cancer diagnosis and prognosis, with extended safety interval 
between consecutive imaging [12]. US, PAI and MRI are strictly non-invasive, i.e. 
independent of external imaging agents, although their performance can be dramatically 
enhanced by imaging agents [11, 13]. NIRF, PET and SPECT are totally dependent on 
external Imaging Agents. The different imaging modalities display also a wide range of 
detection sensitivity. The high energy modalities PET and SPECT display very high 
detection sensitivity while the low energy modalities MRI, US and PAI display low 
detection sensitivity- inherent to the underlying physical-chemical phenomena. In this 
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regard, NIRF is unique, relying in low energy radiation but displaying a detection 
sensitivity of the same order of magnitude as the radioactive modalities. The spatial 
resolution varies also widely amongst different modalities: MRI displays depth-
independent, high spatial resolution, while the radioactivity-dependent modalities 
display quantifiable high detection sensitivity but low/moderate spatial resolution. NIRF 
exhibits detection sensitivity similar to the radioactivity-dependent modalities but is 
severely limited by light penetration into tissues. Combined modalities MRI/PET, 
MRI/NIRF hold great potential for medical imaging [14].  
 
1.2 MRI 
Magnetic Resonance Imaging (MRI) and Nuclear Magnetic Resonance Spectroscopy 
(NMRS) are based on the Nuclear Magnetic Resonance (NMR) phenomenon, 
discovered in 1946 by Bloch and co-workers. at Stanford University [15] and Purcell 
and co-workers. at Harvard University [16]. MRI does not expose the patient to ionizing 
radiation since it relies on the interaction of magnetic fields and radio frequencies with 
the water protons of tissues. Image contrast in MRI depends on several parameters 
characteristic of the state of biological organization of tissues [17]. 
 MRI results from the magnetic properties of protons, 
1
H, one of the most abundant 
nuclides in body tissues as circa 60% of the body weight is made of water. Detailed 
anatomical images are obtained by exposing the 
1
H nuclei to an external (static) 
magnetic field and excitation pulses in the form of radiofrequencies (oscillating 
electromagnetic field). Spatial information on the distribution of the magnetic nuclei in 
the body is acquired by the use of an inhomogeneous magnetic field that varies linearly 
along the body forming the so-called magnetic field gradient. The magnetic field 
gradient induces Larmor precession frequencies for protons at different spatial locations 
proportional to the field strength. The resonance frequency range is determined by the 
magnetic field gradient. This results in the characteristic contrast, between the various 
anatomical structures of the human body, obtained by MRI [18, 19] (Figure 1.1).  
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Figure 1.1- Full body MRI of a human subject [20]. 
 
 1.3 Gadolinium-based Contrast Agents for MRI 
Molecular imaging ―imaging of events relevant for disease diagnostic and prognostic at 
the cellular and molecular level‖ using MRI, requires targeted CA endowed with high 
specificity and detection sensitivity. Many studies have been devoted to the 
development of targeted CA for molecular imaging by MRI . Peptides, antibodies and 
small protein domains, such as HER2 affibodies, and small molecule ligands for cellular 
receptors, have been used as targeting epitopes. To enhance detection sensitivity, the 
targeting moieties are usually linked to high payload (multimeric) CA or MRI contrast 
agents displaying high relaxivities [17].  
The term contrast defines the relative intensity difference, represented in a gray scale, 
between two adjacent regions. Contrast results from signal intensity differences between 
pixels or voxels. Contrast in MRI images is the result of intrinsic (longitudinal and 
transverse relaxation times, T1 and T2, respectively, T2
*
, proton density, flow, diffusion 
and perfusion) and extrinsic contributions (type of pulse sequence, magnetic field 
strength) to signal intensity (eq. 1) [21]. 
 
   , -  ,   (      ⁄ )*  (     ⁄ )+- (eq. 1) 
 
According to eq. 1, selective reduction of T1 leads to signal intensity enhancement. 
Shortening T2 leads to signal intensity decrease. The intrinsic contrast in MRI is often 
sufficient to acquire images displaying contrast suitable for clinical diagnosis. 
Nonetheless, the diagnosis of various pathologies may require the administration of 
contrast agents (CA) to enhance the contrast between normal and diseased tissues.  
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Paramagnetic species, species containing unpaired electrons (Gd
3+
, Mn
2+
, Fe
3+
, stable 
nitroxide radicals, Iron Oxide Nanoparticles (IONPs), etc) promote  relaxation of the 
water protons (paramagnetic relaxers) leading to dramatic contrast enhancements. In 
general, IONPs have a more pronounced (selective) effect on T2 shortening leading to 
signal intensity reductions that result in dark images- negative contrast [22]. Gd
3+
, Mn
2+
 
and organic radicals selectively reduce T1 resulting in signal intensity enhancement and 
bright images- positive contrast [23]. In general, positive contrast is preferred for 
clinical imaging. Gd
3+
 is the most effective relaxer for T1-weighed imaging: high 
paramagnetism (4f
7 
- 7 unpaired electrons), high magnetic moment and long electronic 
relaxation times [21]. Contrast enhancement in MRI depends on the relaxivities (r1 and 
r2) of the particular CA. Relaxivity (r1,2, expressed in units of mM
-1
s
-1
) is defined as the 
enhancement of  the relaxation rates (R1,2= 1/T1,2) normalized to 1 mM of paramagnetic 
centers [21]. 
The longitudinal paramagnetic relaxation rate measured for the water protons in the 
presence of a Gd
3+ 
complex,   
    (  
   = 1/T1) has a diamagnetic,   
 , and 
paramagnetic,    
               (eq. 2) [24]: 
 
  
      
    
    
    ,  
  - (eq. 2) 
 
   (mM
-1
s
-1
) is the relaxivity, and ,    - (mM) represents the analytical concentration of 
Gadolinium. 
 
There are well established theoretical models describing quantitatively the relaxation of 
the water protons promoted by paramagnetic relaxers. The efficacy (relaxivity) of CA is 
determined by the interplay of molecular motions of the paramagnetic species and 
intrinsic properties of the nuclei (magnetic moment, gyromagnetic ratio, spin). The 
paramagnetic relaxation of the water protons can be accounted by two different 
mechanisms: an inner sphere mechanism (IS) and an outer sphere mechanism (OS) [25]. 
The inner sphere relaxation (Figure 1.2) is a chemical exchange process: one or more 
water molecules leave the first coordination sphere of the paramagnetic center being 
replaced by bulk water molecules[25].  
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Figure 1.2- Schematic representation of the inner sphere mechanism for paramagnetic 
relaxation. m is the residence lifetime of the coordinated water molecule(s); R is the rotational 
correlation time of the complex; and r represents the distance between the protons of the 
coordinated water molecule(s) and the unpaired electronic spins on the paramagnetic centre 
(adapted from reference [21]). 
 
This mechanism allows propagation of the paramagnetic relaxation to the whole solvent 
(bulk water). The inner sphere (IS) model is adequately described by the Solomon-
Bloembergen-Morgan  (SBM) theory [25]. 
The IS and OS coordination spheres make both a contribution to the relaxivity of 
aquated (q = 1, 2) Gd3+ complexes (eq. 3) [25]: 
     
      
   (eq. 3) 
 
  
   and   
   represent the inner and outer sphere relavivities, respectivelly. 
The inner sphere contribution to the relaxivity is given by (eq. 4) [26]: 
  
    
,  - 
     
    𝜏 
 
(eq. 4) 
T1m represents the relaxation time of water protons in the first coordination sphere of the metal; 
q represents the number of water molecules directly coordinated to the metal center- inner 
sphere water molecules. 
 
The numerator in equation 4 represents the molar fraction of bound (inner sphere) 
water. Thus, complex hydration strongly influences the inner sphere contribution to 
relaxivity:  the inner sphere relaxivity is directly proportional to the number of 
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coordinated water molecules. All Gd-based CA in clinical use are mono(aquated) (q= 1) 
Gd
3+
 complexes [21]. As the inner sphere relaxation is based on water exchange, an 
optimal water exchange rate, kex (kex= 1/m) is essential for propagating efficiently the 
paramagnetism of the metal center to the bulk water: slow water exchange means that 
relaxed water molecules needlessly occupy the binding site; too fast exchange (very 
short residence lifetime) precludes relaxation. Structural effects and chelate charge have 
been widely exploited in the design of complexes displaying accelerated water 
exchange rate [27, 28]. 
According to the Solomon-Bloembergen-Morgan model (eq. 5) T1m is determined by 
time fluctuation of the dipolar coupling between the electron magnetic moment of the 
metal ion and the nuclear magnetic moment of the solvent nuclei [29]. The following 
equations are written in a simplified form commonly used for the analysis of the 
relaxivity of Gd
3+
 complexes[26]: 
 
   
  
 
  
  
    (   )  
  
 [
 𝜏  
  (  𝜏  ) 
 
 𝜏  
  (  𝜏  ) 
] (eq. 5) 
 
𝜏  
 
 
𝜏 
 
 
𝜏 
 
 
   
 (eq. 6) 
 
   
 
 
  
  𝜏 *  (   )   + *
 
    
 𝜏 
  
 
      
 𝜏 
 + (eq. 7) 
 
   
   𝜏 *
    
         
 𝜏 
  
    
        𝜏 
+ (eq. 8) 
γH represents the gyromagnetic ratio for the proton (H) and S is the electron spin quantum 
number; g and  are the electronic g factor and the bohr magneton, respectively; S,H  is the 
angular frequency for the electron (S) and proton (H); rH represents the distance between the 
protons of the coordinated water molecule(s) and the unpaired electronic spins on the 
paramagnetic center; ci  is a modular correlation time aggregating the rotational correlation 
time of the complex (R); the residence lifetime of the coordinated water molecule (m) and the 
electron relaxation times T1,2;  The longitudinal and tranverse electron spin relaxation times, T1e 
and T2e are magnetic field dependent according to equation 7 and 8 and are characterized by the 
correlation time of the modulation of the zero-field splitting (v) and the mean-square zero-field 
splitting energy (2). 
 
The inner sphere contribution to the relaxivity is modulated by dipolar interactions. The 
efficiency of the engine dipole is proportional to 1/r
6
, r is the distance between the 
paramagnetic metal ion and the protons of the coordinated water molecule(s). Hence, 
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small changes in this parameter can have a very pronounced impact on the relaxivity 
[30]. 
The outer sphere contribution to the paramagnetic relaxation, results from long distance 
dipolar interactions between the electron spin of the paramagnetic center and the nuclear 
spin of the  protons of water molecules, that although not directly coordinated to metal 
center, diffuse in the vicinity of the complex (Figure 1.3).  
 
Figure 1.3- Schematic representation of the outer sphere mechanism for paramagnetic 
relaxation. D is the translational correlation time and d the distance of closest approach between 
the paramagnetic center and the bulk water molecules (adapted from reference [21]). 
 
The outer sphere relaxation mechanism, proposed by Freed, is modulated by the 
translational correlation time (D), which takes into account the relative diffusion (D) of 
the paramagnetic center and the solvent molecules, as well as the distance of closest 
approach (d) (eq. 9) [31]. 
𝜏  
  
 
 (eq. 9) 
The relaxivity depends on external parameters, such as the strength of the applied field 
and temperature and on molecular parameters of the metal complex. The complexity of 
the paramagnetic relaxation is reflected in the need to use eight parameters (m, q, R, r, 
V, C, D, d) to fully describe the inner and outer sphere contributions to the relaxivity 
[32, 33].  
The relaxivity is dependent on the external magnetic field. The magnetic field 
dependence of the relaxivity, derives ultimately from the dependence of the angular 
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frequency of the proton (H in eq. 5) and the electron (S in eqs 7 and 8) of the 
magnetic field. The parameters that govern relaxivity, can in principle, be determined 
by studying the magnetic field dependence of the protonic relaxivity, r1- Nuclear 
Magnetic Relaxation Dispersion (
1
H NMRD) profiles and fitting the experimental data 
to the SBM  theory (Figure 1.4) [34]. 
 
Figure 1.4- 
1
H NMRD profiles (25 °C (▲) and 37 °C (■)) for the Gd[DO3A-N-(-
amino)propionate] complex. The lines represent the simultaneous fittings of the 
17
O NMR and 
1
H NMRD data to the SBM theory. (adapted from ref.[34])   
 
Fittings of the NMRD profiles alone often fail to deliver reliable values for all the 
parameters (m, q, R, r, V, S0, D, d) that govern relaxivity. The relative contributions 
from outer- and inner-sphere relaxivity to the NMRD curve, in particular, cannot be 
determined. The outer-sphere relaxivity is normally, either assumed to be equal to that 
of a structurally similar Gd
3+
 complex without no water in the inner-coordination sphere 
(q= 0), or estimated from reasonable parameters [35]. An accurate interpretation of 
NMRD profiles can be made only by reference to independent information from other 
techniques [36]. Complex hydration can be determined directly by X-ray structure 
determination [37], diffraction of neutrons in the solid state [38], or In solution by 
fluorescence lifetime measurements of Eu
3+
 and Yb
3+
 complexes [39]. Electron 
Paramagnetic Resonance (EPR) combined with 
17
O NMR, are especially useful to 
determine independently  a number of parameters relevant to proton relaxivity [40]. 
EPR line widths give direct access to transverse electronic relaxation times (T2e). 
Electronic longitudinal relaxation times may be calculated from EPR measurements at 
multiple magnetic fields. Nonetheless, the electronic relaxation of Gd
3+
 is too fast 
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precluding direct determination of  the longitudinal relaxation rates using pulse 
sequences [41]. 
17
O NMR transverse and longitudinal relaxation rates and chemical 
shifts measurements, over a range of magnetic fields, as a function of temperature, 
affords estimates of the number of inner-sphere water molecules, the rotational 
correlation time (RO- reorientation of the Gd-O vector of the coordinated water 
molecule), and the longitudinal electronic relaxation rate of complexes [27, 28]. This 
technique allows also accurate determinations of the water exchange rate between the 
inner-sphere and bulk water. Variable pressure 
17
O NMR measurements allow to 
elucidate the water exchange mechanism [42].  
 
1.4 Gd-based Contrast Agents (CA) 
Relaxivity and stability (thermodynamic stability and kinetic inertness) are the most 
important physicochemical properties in the development of efficacious CA [24]. The 
relaxivity of a CA is determined mainly by its effective molecular volume (size) and the 
structure of the complex: number and exchange rate of the coordinated water molecules 
[24]. 
CA for clinical MRI must fulfil strict requirements: relaxation enhancement and 
appropriate sensitivity, tolerance, safety, low toxicity, stability, suitable biodistribution 
and elimination. Most MRI CA are not specific to diseases but are instead specific for 
pathological changes[21].  
Paramagnetic Mn
2+
 chelates were originally introduced by Lauterbur as the first contrast 
agents for T1-weighed MRI [43]. Nowadays, despite a recent revival in interest on Mn
2+
 
chelates as CA for MRI, Gd
3+
 chelates are consensually accepted as the most efficacious 
CA for T1-weighed MRI [44]. The relative efficacy of CA can be directly compared by 
the parameter relaxivity. Beyond, high relaxivity, complex stability, equated as safety, 
has become the most important requisite in CA design. All Gd-based CA approved for 
clinical MRI are monoaquated (q= 1) Gd
3+
 chelates with octadentate 
poly(aminocarboxylate) ligands (Figure 1.5; Table 1.2) [29].   
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Figure 1.5- Structure and trade names of Gd-based CA approved for clinical MRI. 
 
Table 1.2- Proprieties of Gd-based CA approved for clinical MRI (Figure 1.5).  
Trade Name Type Charge 
Relaxivity 
(mM-1s-1; 1.5 T, 37 ºC) 
LogKGdL Ref 
Magnevist Linear -2 4.3 22.5 [29, 45] 
Dotarem Macrocycle -1 4.2 24.7 [29, 45] 
Omniscan Linear 0 4.6 16.8 [29, 45] 
ProHance Macrocycle 0 4.4 23.8 [29, 45] 
OptiMARK Linear 0 5.2 16.8 [29] 
Gadovist Macrocycle 0 5.3 20.8 [29, 45] 
Vasovist Linear -2 5.5 - [46] 
Primovist Linear -2 7.3 23.5 [29] 
Multihance Linear -2 6.7 22.6 [29, 45] 
 
Gd-based CA in clinical MRI can be classified as extracellular agents, blood-pool 
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agents and hepatobiliary agents. Extracellular agents are low molecular weight, 
hydrophilic complexes that spread rapidly through the blood plasma into the interstitial 
spaces and are rapidly excreted by renal filtration. The extracellular agents are clinically 
used for detection of brain tumours and other conditions in which the blood brain 
barrier is compromised. The anionic Gd(DTPA) complex (Magnevist, Schering, Berlin, 
Germany) was the first CA approved for clinical MRI (Figure 1.5 L1). The side effects 
of this class of CA (headaches, nausea, metallic taste) are minimized by rapid renal 
excretion, which avoids cell exposure, potential internalization by endocytosis and the 
possibility of demetallating and/or in vivo transmetallation by endogenous metal ions, 
especially Zn
2+
 and Ca
2+
. Gd
3+
 ion and free ligands are both acutely toxic [47]. 
In general, Gd
3+
 chelates with linear ligands, such as Gd(DTPA) are thermodynamically 
less stable and kinetically more labile than chelates with macrocyclic ligands, such as 
Gd(DOTA). Chelates with DTPA-bis-amide ligands, e.g. Gd(DTPA-BMA), are even 
less stable (Table 1.2). Complex dissociation in vivo can result from interaction of the 
chelate with endogenous metal ions (transmetallation) or spontaneous demetallation 
processes. Biological interactions leading to complex dissociation can be related to the 
size, shape, charge and lipophilicity of the chelate, whereas the thermodynamics and 
kinetics of the metal-ligand is governed by spontaneous processes [48, 49]. The 
discovery in 2006 of the adverse reaction Nephrogenic Systemic Fibrosis (NSF), 
associated with  repeated use of mainly the Gd(DTPA-BMA) (Omniscan®) CA in 
patients with renal failure has exposed dramatic limitations of Gd(DTPA-bis-amide)-
type CA for human use [50]. 
Magnetic Resonance Angiography (MRA) generates images of the arteries to diagnose 
stenosis (abnormal narrowing) or aneurysms (vessel wall dilatations at risk of rupture). 
MRA is often used to evaluate the arteries of the neck and brain, the thoracic and 
abdominal aorta, the renal arteries, and the legs arteries [51]. 
CA for MRA must display high relaxivity and long residence time in the vascular 
compartment [52]. Prolonged retention in the vasculature and high relaxivities are 
usually attained with colloidal (liposomes, micelles, nanoparticles) [53] or 
macromolecular (polymer, and (bio)conjugates) CA  [54] and also by non-covalent  
reversible association of monomeric chelates with plasma proteins, usually Serum 
Albumin (HSA) [55, 56]. 
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Accumulation of colloidal and macromolecular CA in the organs of the 
reticuloendothelial system (RES), liver and spleen, and higher probability of chelate 
demetallation/transmetallation, as result of prolonged vascular retention, associated to 
elaborated synthetic routes (high prices), restrict the number of CA approved for clinical 
MRA (Table 1.2). MS-325 is the only CA approved for clinical MRA. Binding to HAS 
generates high relaxivity and long retention in the vascular compartment [57]. Although, 
potentially improving the differential image diagnosis of liver, extracellular CA are not 
specific to the liver: they spread quickly into the interstitial space and do not cross the 
plasmatic membrane [45, 58].  Liver-specific- hepatobiliary CA, must be internalized by 
hepatocytes and follow biliary excretion. Mangafodipir trisodium Mn(DPDP), 
gadoxetate disodium Gd(EOB-DTPA) and gadobenate dimeglumine Gd(BOPTA) are 
the only hepatobiliary CA approved for clinical MRI of liver (Figure 1.6).  
 
Figure 1.6- Structure of the hepatobiliary CA Teslascan®.  
 
The Gd(BOPTA) and Gd(EOB-DTPA) complexes, although derivatized with lipophilic 
moieties, which contributes to  hepatocellular uptake through the anion transport protein 
and  non-covalent association with Serum Albumin, are still soluble in water [59]. 
The image improvement produced by hepatobiliary CA results from the vascularization 
of tumors, during the distribution of the contrast agent, and at later stages from selective 
CA internalization by cancer cells [60, 61].  
The chemical similarity between the Mn(DPDP) complex and vitamin B6- DPDP 
(DPDP = N,N'-dipyridoxylethylenediamine-N,N'-diacetate-5,5'-bisphosphate) is an 
analogue of vitamin B6, contributes to CA uptake by the hepatocytes. The Mn(DPDP) 
complex is metabolized in vivo by dephosphorylation and transmetallation by Zn
2+
. Free 
Mn
2+
 ions are probably complexed with α2-macroglobulin and transported to the liver 
[62].  
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1.4.1 High relaxivity CA 
The design and synthesis of stable (safe) high relaxivity Gd
3+
 chelates has dominated 
the CA research field in the last decades. Some of the molecular parameters that govern 
relaxivity, such as qm and R, can be tuned by ligand design. Chelates displaying 
optimized molecular parameters can potentially attain relaxivities much higher than the 
parent Gd(DOTA) and Gd(DTPA)-type chelates in clinical use. High relaxivity CA can 
attain suitable contrast at lower doses, reducing potential side effects and cost [63]. 
Moreover, emerging applications of MRI, such as cell labelling and tracking , where the 
amount of CA that can be safely delivery to cells is limited, can be attained only by 
(multimeric) CA carrying a high payload of (high relaxivity) Gd
3+
 chelates [64]. 
1.4.2 Number of inner sphere water molecules 
Gd(DOTA) and Gd(DTPA) and all Gd
3+
 chelates in clinical use are (mono)aquated (q= 
1) chelates [65]. According to eq. 5, increasing the number of exchanging inner sphere 
water molecules has the potential to enhance proportionally CA relaxivity. Reducing the 
denticity of the octadentate DOTA and DTPA ligands creates space in the coordination 
sphere of the Gd
3+
 chelates for extra water molecules [66]. Removing a coordinating 
acetate group on the structure of the DOTA and DTPA ligands generates the 
heptadentate DO3A and DTTA ligands, respectively, whose Gd
3+
 complexes are 
bis(aquated) (q= 2) chelates [59, 67] (Figure 1.7, Table 1.3).  
 
Figure 1.7- Structure of selected metal chelators forming bis(aquated) (q= 2) Gd
3+
 chelates. 
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Table 1.3- Molecular parameters for q= 2 chelates. 
Complex q    (× 10
7 s-1) 𝜏  (ps)   (mM
-1s-1)a logKGdL Ref. 
GdL11 2 8.6 82 7.3 19 [67] 
GdL12 2 0.62 66 4.8 - [68] 
GdL13 2 1.1 74 7.1 19.26 [69] 
GdL14 2 2.0 104 9.5 19.3 [70] 
a)20MHz, 25ºC 
 
Beyond structural modifications of the parent DOTA and DTPA chelators, new scaffolds 
allowing the formation of stable bis(aquated) chelates have been introduced more 
recently. The hydroxypyridone (HOPO) (Figure 1.7, L14) class of chelators, developed 
by Raymond and co-workers, forms stable bis(aquated)complexes resistant to anion 
coordination [70]. The X-ray structure of the Gd(HOPO) complex shows that it is 8-
coordinated, with the ligand coordinated in a hexadentate fashion through the 
hydroxypyridone Oxygen atoms, with two water molecules completing the coordination 
sphere [70]. The Gd(HOPO) complex displays a relaxivity about 2.5 times higher than 
that displayed by the (mono)aquated Gd(DTPA) complex. Moreover, the Gd(HOPO) 
complex is more stable than Gd(DTPA-BMA) towards transmetallation with Zn
2+
 and 
Ca
2+
. The low solubility of the Gd(HOPO) complex precludes practical applications. 
Soluble derivatives, carrying hydrophilic substituents in the TREN scaffold, have been 
developed as potential CA[70, 71]. 
The heptadendate AAZTA (Figure 1.7, L13) scaffold, introduced by Aime and co-
workers, allows also formation of stable bis(aquated)complexes [69]. The Gd(AAZTA) 
chelate is also resistant to replacement of the inner sphere water molecules by 
coordinating anions, owing presumably to the negative charge of the complex. The 
synthetic route of AAZTA ligands is versatile allowing the synthesis of functional 
ligands able of self-assembly or conjugation to biomolecules [29]. From a practical 
standpoint, the low thermodynamic stability and kinetic lability of q= 2 complexes 
precludes their use as CA for human use. Nonetheless, q= 2 chelates are good models 
for in vitro and in vivo pharmacokinetic studies. 
1.4.3 Chelates displaying fast water exchange  
According to eq. 5, in addition to the number of inner sphere water molecules, the 
relaxivity is also determined by the relative magnitude of T1m and m. In conditions 
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where m<<T1m (fast water exchange regime) the relaxivity is not limited by the water 
exchange rate. Moreover, as the value of T1m (relaxivity) depends on the magnetic field 
strenght the m value that fulfils the fast water exchange regime condition is also 
magnetic field dependent. For low molecular weight chelates such as Gd(DOTA) and 
Gd(DTPA), exhibiting T1m values of the order of magnitude 3-7 s (10-70 MHz), very 
short R values (of the order of magnitude 0.1 ns, fast rotation in solution) effectively 
dominate the modular correlation time c (eq. 6) [29]. Thus, the typical m values for 
Gd(DOTA) and Gd(DTPA) chelates (m= 5-500 ns, kex= 0.2–20 x 10
7
 s
-1
), do not 
become limiting of the relaxivity. In opposition, macromolecular systems displaying 
longer R values (of the order of magnitude 0.5-50 ns) exhibit much shorter T1m values 
(high relaxivities) at intermediate fields (20-120 MHz). As consequence, long m values 
can dominate c. In practice, low molecular weight Gd
3+
 complexes display T1m values 
of the order of magnitude 3-7 s, while macromolecular complexes exhibit much 
shorter T1m values, circa 0.9-0.2 s (20 MHz, 25 °C). As such, m values ≤ 0.2 s (kex ≥ 
5 x 10
6
 s
-1) and τm ~ 0.03 s (kex ~ 3 x 10
7
 s
-1
) satisfy the fast exchange regime condition 
for low molecular weight and macromolecular complexes, respectively [29].  
Reducing the space available for water coordination- ―steric compression around the 
water binding site‖, has been demonstrated to increase the water exchange rate (kex) 
(reduce the water residence lifetime, m) in complexes undergoing  dissociatively 
activated water exchange [72]. This is the case for the Gd(DOTA) and Gd(DTPA)  
complexes. From a practical standpoint, "steric compression around the water binding 
site‖ can be enforced by extending an ethylenediamine bridge by a methylene group on 
the DTPA and DOTA skeletons, generating the EPTPA and TRITA chelators, 
respectively [73].  Replacement of two ethylenediamine bridges results in q= 0 
complexes, displaying outer-sphere relaxivity only [73]. Alternatively, replacing a 
pendant acetate by a propionate group on the DTPA and DOTA chelators results also in 
substantial, although less dramatic, water exchange rate enhancements (Figure 1.8, 
Table 1.4).  
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Figure 1.8- Metal chelators forming Gd
3+
 complexes displaying ―steric compression‖ around 
the water binding site.  
 
Table 1.4- Molecular parameters for Gd
3+
 chelates displaying ―steric compression‖ around the 
water binding site. 
Complex LogKGdL    (× 10
7 s-1) Ref 
GdL2 24.7 0.46 [29] 
GdL15 ~22 6.1 ± 1.9 [73] 
GdL16 19.17 27 ± 4 [73, 74] 
GdL17 n.d. 4 ± 0.4 [73] 
GdL1 22.46 0.38 [29] 
GdL18 22.77 33 [73] 
GdL19 16.7 3.1 [73] 
GdL20 19.7 8.0 [73] 
 
Introducing a propylenediamine bridge in the skeleton of the DOTA and DTPA 
chelators is far more effective for attaining fast water exchange than extending a 
pendant acetate to a propionate group (Table 1.4) [75]. 
The Gd(TRITA) complex displays an exceptionally fast water exchange rate, around  60 
fold higher than the water exchange rate displayed by Gd(DOTA), already outside the 
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range considered ideal (1-10 x 10
7
 s
-1
) to attain high relaxivities at intermediate fields 
[73]. Introducing a propionate arm into the DOTA and DTPA skeleton results in 
moderate water exchange rate accelerations, inside the range considered ideal for 
attaining high relaxivities at intermediate fields (Table 1.4) [73, 74]. Moreover, with 
Gd(DTPA)-type complexes, the position of the propionate arm (terminal or central)  
influences also the water-exchange rate. The complex Gd(DTPA-Nprop), with a 
propionate group on the terminal Nitrogen  atom of  DTPA scaffold exhibits a water 
exchange rate 2.6 times higher than the complex Gd(DTTA-N’prop), with the 
propionate group in the central Nitrogen atom [73].   
Complex stability is of paramount importance for in vivo applications. In this regard, 
structural changes on the skeleton of the parent DTPA and DOTA chelators show a 
much higher impact on complex stability (decrease of around 5 log units in logKGdL for 
the Gd(EPTPA) and Gd(TRITA) chelates comparing to their parent complexes) than 
introducing propionate arms (reduction of around 2-3 log units in in logKGdL for the 
Gd(DO3A-NProp) and Gd(DTPA-NProp) chelates) [73].  
The higher thermodynamic stability and kinetic inertness of Gd(DOTA)-type complexes 
make propionate functionalized Gd(DOTA)-type chelates, bearing pendant reactive 
groups, attractive for attaining high relaxivities.  
1.4.4 Simultaneous optimization of R and kex 
Simulations of the magnetic field dependence of the relaxivity (
1
H NMRD profiles) for 
different combinations of m and R (Figure 1.9) helps to understand the interplay of 
water exchange rate, rotational dynamics and magnetic field strength in the design of 
high relaxivity Gd
3+
 complexes. 
 
Figure 1.9- Simulated 
1
H NMRD profiles for various combinations of τR and τm for a 
mono(aquated) q= 1 complex. The gray area highlights the range of magnetic fields relevant to 
clinical MRI (from reference [76]). 
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As can be seen, the rotational correlation time R is the single most important parameter, 
amenable to optimization via ligand design, that governs relaxivity. Even with a slow 
water exchange rate, of the order of magnitude of that exhibited by low molecular 
weight chelates such as Gd(DOTA) and Gd(DTPA) (m= 500 ns; kex= 2.0 x 10
6 
s
-1
), 
increasing the rotational correlation time, R, (red curves) predicts substantial relaxivity 
enhancements (~ 40 mM
-1
s
-1
for macromolecular objects, R= 10 ns) in the range of 
magnetic fields relevant for clinical MRI (20-120 MHz). For macromolecular objects 
(R= 10 ns) displaying fast water exchange (m= 10 ns, kex= 10 x 10
7
 s
-1
) very high 
relaxivities (~ 65 M
-1
s
-1
) are predicted at intermediate fields relevant for clinical 
imaging. For low and intermediate molecular weight chelates (R= 0.1 and 1 ns, 
respectively) the effect of fast water exchange on the relaxivity at intermediate fields is 
negligible. Moreover, at high magnetic fields (
1
H Larmor frequencies > 100 MHz, 3T) 
chelates with intermediate molecular weight (R= 1 ns) are preferred, although much 
lower relaxivities are attainable. Detailed simulations of the effect of R and m on the 
relaxivities attainable at different magnetic fields, show that while much higher 
relaxivities are attainable at low/intermediate magnetic fields, there is a much larger 
dynamic space to attain the predicted (lower) relaxivities at higher magnetic fields 
(Figure 1.10) [21]. 
 
Figure 1.10- Simulated effect of the inner-sphere water residence time m (ns) on r1 (—) and r2 
(---) under optimal rotational conditions: (A) 0.47 T (20 MHz, R 20 ns), (B) 3 T (130 MHz, R 
1.5 ns) and (C) 9.4 T (400 MHz, R 0.5 ns) [21]. 
 
The combination r/m 10 ns/10 ns is ideal (possibly not realistic) for attaining very high 
relaxivities at intermediate fields relevant for clinical imaging.  
Chapter 1 
20 
 
Macromolecular and nanosized objects functionalized with chelates displaying fast 
water exchange are promising to attain the predicted very high relaxivities at 
intermediate fields relevant for clinical imaging.  
 
1.5 Macromolecular and nanosized CA 
Low molecular weight Contrast Agents have been the pioneers, and still occupy the 
central stage in MRI. Rapid elimination and extravasation out of the vasculature, 
narrowing the imaging time window and reducing contrast from surrounding tissue, 
limit their in vivo performance [77]. To overcome these shortcomings, researchers have 
turned their attention to macromolecular CA, known as well as blood pool agents or 
macromolecular contrast media (MMCM). Macromolecular CA are high molecular 
weight agents, generally with MW above 30 kDa, originally designed to address low 
relaxivity per chelate and CA extravasation out of the vascular compartment [77]. Slow 
tumbling in solution (long rotational correlation times - R) and rigidity of the 
immobilized  chelates, result in considerable relaxivity enhancements per unit dose of 
paramagnetic ion comparing to  low molecular weight CA. Additionally, many chelates 
can be appended to macromolecular platforms, bringing high concentrations of Gd
3+
, 
difficult to attain with low molecular weight chelates, to specific locations [77].  
In order to attach covalently Gd
3+
 chelates to macromolecular carriers, the structure of 
the parent DTPA and DOTA chelators needs to be elaborated to include a reactive 
handle for conjugation, either on the macrocycle scaffold or on a pendant 
acetate/propionate group. DOTA-monoamide and DTPA-bis-amide bifunctional 
chelators, although facile to synthesise, form (neutral) Gd
3+
 chelates displaying water 
exchange rates around one order of magnitude lower than their parent Gd(DOTA) and 
Gd(DTPA) chelates, limiting the attainable relaxivity [78]. Moreover, the less 
coordinating amide group leads to complexes displaying lower thermodynamic stability 
and higher kinetic lability, comparing to the parent complexes [78]. 
Associating stability, fast water exchange (via steric compression around the water 
binding site) and conjugability on a macrocyclic DOTA type ligand seems ideal for the 
synthesis of very high relaxivity macromolecular and nanosized CA [72]. In general, 
active leaving groups undergoing displacement by nucleophiles from 
(bio)macromolecules (anhydride, bromo, iodoacetamide, isothiocyanate, N-
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hydroxysuccinimide (NHS) ester, and maleimide groups), are preferred for conjugation 
purposes owing to facile conjugation, high yields and easy purification of conjugates 
[75]. 
1.5.1 Amphiphilic Contrast agents 
Self-assembly is an expeditious alternative to covalent attachment of Gd
3+
 chelates to 
macromolecular carriers, to construct macromolecular/nanosized objects for MRI [79]. 
Self-assembly is a bottom-up strategy in which a ―disordered system of pre-existing 
components spontaneously forms organized structures or patterns as consequence of 
specific local interactions among the components themselves without external direction 
or resulting indirectly from interactions with the environment‖ [80].  
Self-assembly of amphiphilic molecules into micelle-type structures, directed by the 
hydrophobic effect, is the most common and amenable to design form of self-assembly. 
The self-assembly of amphiphilic Gd
3+
 chelates into micelle-type structures has been 
widely explored for attaining high relaxivities [81]. To prepare amphiphilic Gd
3+
 
chelates, the (hydrophilic/charged) DOTA and DTPA coordinating cages are covalently 
derivatised with lipophilic moieties. The hydrophobic modifier can be a long alkyl chain 
or any other type of organic molecule that promotes aggregation in aqueous 
environment. The length, shape and flexibility of the lipophilic moiety determine the 
overall wedge-like shape (geometry) of the amphiphile, influencing the critical micelle 
concentration (cmc), stability, size and the aggregation number, number of monomers in 
the micelle [82]. In micelles, the Gd
3+
 chelates are directed towards the aqueous 
environment benefiting from unrestricted access to the bulk water (Figure 1.11). 
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Figure 1.11- Cartoon representation of a micelle (A) and selected amphyphilic metal chelators.  
 
Merbach and co-workers described the synthesis and relaxometric characterization of a 
series of micellar Gd(DOTA)-like chelates derivatised with linear alkyl chains with 
lengths between10 and 18 carbon atoms (chelates GdL21, GdL22 and GdL23). A 
mathematical model describing the chelate concentration dependence of the relaxivity 
and its interplay with the critical micelle concentration (cmc) (eqs 10-11) was devised 
[83, 84]. 
At concentrations bellow the cmc only the monomeric chelate contributes to the 
paramagnetic 
1
H relaxation rate (Eq 10). 
 
  
      
    
         (eq. 10) 
  
  is the diamagnetic contribution to the observed protonic relaxation rate (the relaxation rate 
of pure water),   
    represents the relaxivity (mM
-1
s
-1
) of the nonaggregated (monomeric) Gd
3+
 
chelate and CGd is the analytical concentration of Gd. 
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At concentrations above the cmc, the observed relaxation rate has two contributions: 
one due to monomers, present in solution at a concentration equal to the cmc value,   
and another one due to the aggregated form (micelles) (Eq 11) [84]. 
 
  
      
  (  
      
 )      
      (eq. 11) 
  
  is the relaxivity (mM
-1
s
-1
) of the micellar (aggregated) form. 
 
 Moreover, these authors described for the first time the analysis of the longitudinal 
17
O 
and 
1
H relaxation rates of the aggregates, using a modified form of the Solomon-
Bloembergen-Morgan theory including the Lipari-Szabo approach for internal 
flexibility [85]. The relaxometric properties of the micellar systems represented in 
Figure 1.11 are summarized in Table 1.5. 
 
Table 1.5- Summary of the relaxometric properties of the micellar CA represented in Figure 
1.11. 
Chelate@micelle
a 
Lenght
b cmc
c
 
(mM) 
R
d 
S
2 e
 
r1
a f
 
(mM
-1
s
-1
) 
ref 
Rg (s) Rl (s) 
GdL21 10 7.20 470 n.d. 9.32 [83] 
GdL22 12 4.45 1600 430 0.23 17.24 [83] 
GdL23 14 0.87 2220 820 0.17 21.45 [83] 
GdL24 12 0.35 920 n.d. 18.3
b
 [84] 
GdL25 18 0.06 2810 330 0.28 17
a
 [84] 
GdL26 12 0.15 473 n.d. 29.2 [86] 
GdL27 22 n.d. n.d. n.d. 27.2 [87] 
GdL28 20 n.d. n.d. n.d. 4.42 [88] 
a
Structure of chelates on Figure 1.11; 
b
Lenght of the lipophilic moiety; 
c
Critical micelle concentration; 
d
Lipary-Szabo approach; 
e
Order parameter from the Lipary-Szabo approach; 
f
relaxivity of the 
aggregated from (20 MHz; 25 ºC) 
 
The Lipari-Szabo model considers that the interactions causing the relaxation are 
modulated by two different types of motions: a slow global isotropic molecular 
reorientation, characterized by a global rotational correlation time common to the entire 
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aggregate, Rg, and a faster local reorientation of the Gd
3+
 chelate, characterized by a 
local rotational correlation time, Rl (eq 12-14): 
 
   
  
 
  
  
    (   )  
  
*
   𝜏   
    
 𝜏   
  
 (    )𝜏  
     𝜏  
 + (eq. 12) 
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 (eq.13) 
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𝜏  
 
 
𝜏  
 (eq.14) 
γH represents the gyromagnetic ratio for the proton (H) and S is the electron spin quantum 
number; g and  are the electronic g factor and the bohr magneton, respectively; S,H  is the 
angular frequency for the electron (S) and proton (H); rH represents the distance between the 
protons of the coordinated water molecule(s) and the unpaired electronic spins on the 
paramagnetic center; In the Lipari-Szabo approach the parameter S
2
 (1>S
2
>0) describes the 
degree of spatial restriction of the local motion; S= 0, if the local motion is isotropic and S= 1 if 
the local motion is completely restricted to the global motion; ci is a modular correlation time 
aggregating the rotational correlation time of the complex (Rglobal and Rlocal), the residence 
lifetime of the coordinated water molecule (m) and the electron relaxation times. 
 The relaxivity of the aggregated (micellar form) increases with the length of the 
lipophilic chain within the series GdL21-GdL23 (Table 1.5, Figure 1.11). This effect 
can be ascribed to increase of the global rotational correlation time, Rg, resulting 
probably from an increase in size of the micelles. A correlation between the cmc and the 
length of the alkyl chain can be established also within the series GdL21-23 [83]. For 
the aspartic acid derivatives GdL24 and GdL25 the increase in size of the alkyl chain 
does not lead to a relaxivity enhancement, despite a much lower cmc for GdL25. The 
parameter S
2
 for GdL25 has a relatively low value implying that the coordination cage 
displays a high degree of flexibility within the micelles. As the water exchange rate is in 
the slow exchange regime (for macromolecular chelate) the relaxivity is limited both by 
slow water exchange and internal flexibility [84]. Moreover, the relaxivity of micellar 
aggregates is influenced not only by their hydrophobic moiety, but also by the chelate 
head-group. The chelate GdL26 reported by Glogard exhibits a relaxivity substantially 
higher than GdL22 and GdL24 despite the same length of the lipophilic moiety [86]. 
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Beyond promoting self-assembly, lipophilic moieties can also endow contrast agents 
with new functionalities. The micellar GdL27 cholesterol conjugate, reported in 2003 
by Lattuada and co-workers, in addition to high relaxivity (27.2 mM
−1
 s
−1
; 20 MHz, 25 
ºC),  is also able to target a variety of cells via the cholesterol moiety [87]. The need of 
a subtle balance of molecular properties for self-assembly, is well illustrated by the 
GdL28 chelate which does not undergo self-assembly in the concentration range 0.48-
1.72 mM, as demonstrated by its low relaxivity (r1 = 4.42 mM
−1
s
−1
, 20 MHz, 25 ºC) 
comparable to DOTArem [88].  Presumably, the overall neutral charge of the GdL28 
chelate, comparing to GdL27 (overall charge -1), reduces its amphiphilic character. 
Self-assembly of monomeric amphiphilic Gd
3+
 chelates into micelle-type structures is 
an expeditious strategy to attain high relaxivities, thanks to enhancement of the 
rotational correlation time (slow tumbling rates) of complexes. Nonetheless, the attained 
relaxivities appear lower than expected. Internal motions (demonstrated by the 
relatively low values of order parameter S
2
) limit the relaxivity potentially attainable. In 
addition the water exchange rate of the DOTA and DTPA chelates becomes also 
limiting of the attainable relaxivity.  
In this Thesis (Chapter 3) we describe the relaxometric characterisation of the self-
assembling complex Gd[DO3A-N-(-pyrenebutanamido)propionate] (Figure 1.11). 
The Gd
3+
 complex of the amide conjugate DO3A-N-(-pyrenebutanamido)propionate 
was designed to display fast water exchange allowing to study the effect of 
simultaneous optimization of the water exchange rate and rotational dynamics on the 
relaxivity. The pyrene moiety, beyond promoting self-assembly, was select to endow 
the Gd
3+
 complex with pyrene-centred concentration sensitive-fluorescence reporting 
properties. Pyrene sensitization of NIR fluorescence in Yb
3+
 and Nd
3+
 complexes was 
studied also. 
 1.5.2 Dendrimers as contrast agents 
Dendritic molecules, dendrimers and hyperbranched polymers, have been extensively 
developed for a variety of applications: catalysis, drug and gene delivery, imaging, 
biomimetics and as supports for solution phase combinatorial chemistry.  Uniform 
surface chemistry, available internal cavities, spherical and highly branched structure, 
monodispersity, and a large number of reactive functional groups per unit mass and 
volume available for modification, make these molecular polymers unique [89]. 
Regarding the development of CA for MRI, multiple chelates can be delivered to cells 
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by functionalized dendrimers as single high relaxivity nanoparticles. The first 
dendrimeric MRI CA were reported by Adam and co-workers [90] and Wiener and co-
workers [91]. Many other dendrimeric CA have since been reported using various 
dendrimers: poly(amidoamine) (PAMAM) [90-92], poly(propyleneimine) (PPI) [93, 
94], and polyethyleneglycol (PEG) [95]. In general, dendrimeric CA show higher 
relaxivity than their linear polymeric counterparts due to their more rigid/compact near 
spherical structure [89]. Two different strategies have been developed for the molecular 
assembly of dendrimers: a divergent and a convergent strategy. In the divergent 
strategy, the dendrimer is assembled from a multifunctional core, which is extended 
outward by a series of iterative reactions, usually Michael addition. Each step of the 
reaction must be driven to completion to prevent defects in the dendrimer structure- 
trailing generations with shorter branches. Such impurities, which degrade the 
functionality and symmetry of the dendrimer, are extremely difficult to remove, owing 
to  similar size and properties comparing to the ―perfect‖ dendrimer [96]. In the 
convergent approach, dendrimers are built inward from smaller dendron units that end 
up at the surface. The bigger difference in molecular weight between generations, 
makes it easier to remove impurities and shorter branches along the way. However, 
dendrimers synthesised by this methodology are not as large as those made by divergent 
methods as increasing crowding towards the core limits dendrimer size [97].  
As result of the three-dimensional growth, the number of terminal reactive groups, 
usually amine or carboxylic acids, increases exponentially with the generation number. 
Owing to commercial availability of different generations (sizes) and different terminal 
groups, PAMAM dendrimers have dominated  the development of dendrimer-based 
MRI CA [98]. Poly(propyleneimine) (PPI) dendrimers, based on a diaminobutane 
(DAB) core have also been synthesized [99, 100], the first five generations of which 
were found to have an polydispersity index of 1.002 [101]. PAMAM and PPI 
dendrimers are highly soluble in aqueous solution. Amine terminated dendrimers are 
convenient for attaching Gd
3+
 chelates (trough a variety of linkages) and targeting 
moieties, such as antibodies, for site-specific targeting [102] and molecular imaging 
applications [103], (Figure 1.12, Table 1.6). 
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Figure 1.12- PAMAM and DAB/PPI dendrimers functionalized with the metal chelates. 
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Table 1.6- Summary of the relaxometric properties of selected PAMAM and DAB/PPI 
dendrimers functionalized with Gd
3+
 chelates. 
Dendrimer Generation Chelate 
ionic r1 
(mM−1s−1) 
molec. r1 
(mM−1s−1) 
Field 
Strength 
(MHz) 
temp 
(°C) 
ref 
PAMAM 
1 
DO3A-PABn 
14.8 118.4 20 25 [104] 
1 10.1 80.8 20 37 [104] 
PAMAM 2 DTPA 21.3 ± 0.3 234 25 20 [91] 
PAMAM 
2 
DO3A-PABn 
19.7 315 20 25 [104] 
2 14.1 225 20 37 [104] 
PAMAM 3 DO3A 14.8 ± 0.4 355 25 37 [105] 
PAMAM 4 DO3A 16.9 ± 0.4 642 20 37 [105] 
PAMAM 
4 
DO3A-PABn 
25.8 1522 20 25 [104] 
4 18.6 1097 20 37 [104] 
PAMAM 
5 
EPTPA 
25.1 2786 20 20 [106] 
5 17.1 1898 20 37 [106] 
PAMAM 5 DOTA 30 2880 20 23 [107] 
PAMAM 5 DO3A 18.8 ± 0.2 1071 25 37 [105] 
PAMAM 6 DTPA 34 ± 4 5800 25 20 [91] 
PAMAM 
7 
EPTPA 
35.8 9057 20 25 [106] 
7 25.6 6476 20 37 [106] 
PAMAM 7 DOTA 35 13300 20 23 [107] 
PAMAM 
9 
EPTPA 
29.2 33784 20 25 [106] 
9 24.2 27999 20 37 [106] 
PAMAM 9 DOTA 36 47520 20 23 [107] 
PAMAM 10 DOTA 36 66960 20 23 [107] 
PPI 0 DTPA 14.4 ± 0.2 45.6 60 20 [103] 
PPI 2 DTPA 15.2 ± 0.2 243 60 20 [103] 
PPI 4 DTPA 19.3 ± 0.2 1234 60 20 [103] 
 
Dendrimers with a cystamine functional group in the focal point have been developed 
for easy conjugation to peptides, monoclonal antibodies, biotin, and other targeting 
moieties [102]. 
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Table 1.5 summarizes the relaxometric properties of selected examples of PAMAM and 
PPI dendrimers functionalized with Gd
3+
 chelates. In general, attaching chelates to 
dendrimers leads to an increase, generation dependent, of the relaxivity comparing to 
the soluble chelates. Very high relaxivity enhancements can be attained, as illustrated by 
the PAMAMG5-G10-Gd(DOTA) dendrimer series (r1= 3.5 vs 30-36 mM
−1
s
−1
, 20 MHz, 
25 ºC, for Gd(DOTA) and PAMAMG5-10-Gd(DOTA), respectively) [107].  The 
relaxivity enhancements are attributed to optimization of the rotational tumbling (long 
R values) resulting from an increase of the effective molecular volume of the chelates. 
The relaxivity is in general limited by internal flexibility of the conjugated chelates and 
by slow water exchange[26]. In fact, the stepwise increase in relaxivity with the 
dendrimer generation is not proportional revealing that for higher generations the 
limiting effect of slow water exchange becomes more important than for lower 
generations [107]. The effect of fast water exchange on the relaxivity was studied within 
the series PAMAMG5,G7,G9-EPTPA dendrimers. The temperature dependence of the 
relaxivity for all dendrimer generations, higher relaxivity at lower temperatures, 
indicates that the relaxivity is not limited by slow water exchange. Moreover, the 
EPTPA-functionalised PAMAM dendrimers revealed pH-dependent relaxometric 
properties [106]. The G5 functionalised PAMAM dendrimer exhibits a global rotational 
correlation time, Rg, considerably higher at acidic than under basic conditions (Rg= 
4040 and 2950 ps, at pH 6.0 and 9.9, respectively). Local motions are less influenced by 
pH (Rl= 150 and 125 ps, at pH 6.0 and 9.9, respectively). The order parameter, 
characterizing the rigidity of the appended chelates, is also higher at pH 6.0 than at pH 
9.9 (S
2
= 0.43 and 0.36, respectively). The pH dependence of the global rotational 
correlation time was atributed to protonation of the tertiary amine groups in the 
PAMAM skeleton. Electrostatic repulsion of the protonated amine groups leads to an 
expanded, more rigid dendrimeric structure at acidic pH. The pH dependence of the 
relaxivity is attributed to the increase of Rg at acidic pH. The proton relaxivity of 
PAMAMG5-Gd(EPTPA)  dendrimer is mainly limited by the flexibility of the 
dendrimer structure, and to a smaller extent, by faster than optimal water exchange rate 
[106]. 
1
H Nuclear Magnetic Resonance Dispersion (NMRD) and 
17
O NMR measurements  
demonstrated that the dendrimers in the series PAMAMG1-G4-Gd(DO3A-PABn) 
exhibit relaxivities (25.8 mM
-1
s
-1
) higher than expected, thanks to optimized (fast) water 
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exchange rate, steric crowding (rigidity) and the formation of a secondary hydration 
sphere by the bulky phosphinate group [104]. 
Systemic intravenous injection, interstitial (localized) injection and ocular delivery are 
the main administration routes for dendrimers [108]. Dendrimer-based CA display 
tunable, size-dependent, pharmacokinetic properties such as permeability across the 
vascular barrier, excretion rate and route, and clearance/avoidance of the 
reticuloendothelial system [109]. In vivo MRI studies have demonstrated that low 
generation dendrimer CA (HD<5 nm) leak from the vascular space to the interstitial 
compartment at only slightly slower rate than low molecular weight monomeric 
chelates. Low dendrimer generation CA show potential for assessing renal function 
[110, 111]. Intermediate dendrimer generations (G4 - G7, between 5-8 nm in diameter), 
leak through the hyperpermeable tumor vasculature but are retained by normal vessels 
(Enhanced Permeability and Retention) showing properties suitable for tumor imaging 
[112]. Larger generations (G9 and G10, above 13 nm in diameter) provide enhancement 
of the organs of the reticuloendothelial system, liver and spleen. In addition to size, the 
chemical properties determine also the in vivo behavior of dendrimers. Particle 
hydrophilicity greatly affects the pharmacokinetics of dendrimers: PEGylation of G4-
PAMAM dendrimers decreases renal excretion and increases particle circulation half-
life providing a suitable time window for vasculature imaging [54]. 
Beyond, high relaxivity, the potential for delivery of cargos in the ―dendrimer box‖ and 
tunable size at the nanoscale and tumble biodistribution make dendrimers potential 
theragnostics [113]. 
1.5.3 Viral Capsids as contast Agents 
Viral capsids are multimeric protein assemblies that form cage architectures, generally 
classified as protein cages. Heatshock proteins, ferritins, and vault ribonucleoprotein 
particles, amongst others, are examples of non-viral protein cages [114]. Protein cages 
are robust synthetic platforms, chemically and genetically malleable and readily 
modified. Pioneer studies explored protein cages as delivery vehicles for therapeutic and 
imaging agents [115, 116]. Cell targeting was demonstrated with capsids exhibiting 
natural affinity for cellular receptors and by chemically appending targeting molecules, 
peptides and antibodies, to protein cage architectures [117, 118]. Targeted protein cages 
loaded with doxorubicin (anticancer molecule) demonstrated the multifunctionality of 
protein cages for biomedical applications [119]. 
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Kang and co-workers. report recently 3 different types of capsids functionalized with 
Gd
3+
 chelates as CAs for MRI [120]. Two viral capsids are from the protein cage P22 
(64 nm outer diameter), isolated from the Salmonella typhimurium bacteriophage P22. 
Two mutants, S133C and K118C, were obtained by replacing (by PCR mutagenesis) the 
serine residue at position 133 (S133) (in the capsid exterior surface) and the lysine at 
position 118 (in the capsid inner surface) by cysteine residues.  The Pf_Fn capsid (12 
nm outer diameter) was isolated from the hyperthermophile Pyrococcus furiosus. 
Introducing cysteine residues selectively in the inner (K118C mutant) and outer 
(S133C) capsid surface allowed Kang and co-workers. to address the surface-selective 
functionalisation of the capsids via Michael addition of DOTA- and DTPA-type 
chelators functionalized with a maleimido functional group. The Pf_Fn capsids contain 
only a cysteine residue, in the inner surface (Figure 1.13).  
 
Figure 1.13- 3D Structure of viral capsids functionalized with  Gd(DTPA) and Gd(DOTA)-type 
chelates (the red dots represent the cysteine-immobilized Gd
3+ 
chelates) [120].  
 
The P22 capsids can accommodate a much higher number of Gd
3+
 chelates, comparing 
to the Pf_Fn capsids, owing to their larger external diameter (64 nm comparing to 12 
nm) (Table 1.7). 
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Table 1.7- Relaxometric properties of viral capsids functionalized with Gd(DTPA) and 
Gd(DOTA)-type chelates (60 MHz, 40 °C) [120]. 
Capsid GdL@Capsida 
Nb 
 
r1
 
(mM−1s−1) c 
r1
capsid  
(mM−1s−1) d 
r1
Vol  
(mM-1s-1 nm-3) e 
P22K118C 
 
Gd(DTPA) 360 35.8 12888 0.167 
Gd(DOTA) 360 57.0 20520 0.266 
Pf_Fn 
Gd(DTPA) 24 19.9 477.6 0.939 
Gd(DOTA) 24 24.6 589.9 1.161 
P22S133C 
Gd(DTPA) 360 26.2 8856 0.115 
Gd(DOTA) 360 53.8 19354.8 0.251 
a
Structure of chelates in Figure 1.13; 
b
Number of immobilized chelates; 
c
Relaxivity per immobilized 
chelate; 
d
Relaxivity per capsid= Nxr1; 
e
Volumetric density of relaxivity= Nxr1/V 
 
Viewed as contrast agent units, the mutant P22 capsids functionalized with Gd
3+
 
chelates  exhibit exceptional relaxivities, of the order of magnitude 2.0 x 10
5
 mM
−1
s
−1
  
for the K118C mutant functionalized with Gd(DTPA)-type chelates (Table 1.7). By 
contrast, the Gd(DTPA)-functionalised Pf_Fn capside exhibits a much lower relaxivity 
(590 mM
−1
s
−1
), around 30 fold lower, attributed to a lower chelate payload (24 vs 360 
immobilized chelates for the Pf_Fn and P22 capsids, respectively) and to a lower ionic 
(per chelate) relaxivity of the immobilized chelates (Table 1.7). Time Domain Nuclear 
Magnetic Resonance (TD-NMR) studies, demonstrated that the higher relaxivity of the 
chelates immobilized onto the P22 K118C capsid, comparing to the Pf_Fn capsid, can 
be ascribed to  slower tumbling (longer rotational correlation time) of the larger P22 
K118C capsid. The Gd(DOTA) and Gd(DTPA)-functionalized P22 S133C and P22 
K119C capsids display similar relaxation patterns and relaxivities of the same order of 
magnitude (slightly lower for the S133C mutant) suggesting that the Gd
3+
 chelates 
immobilized onto the inner surface of the capsid seem to make sufficient contact with 
the bulk water trough the large holes on the capsids [121]. Moreover, the conjugation 
position (microenvironment of the immobilized chelate) seems not to have a significant 
influence on the relaxivity of the immobilized Gd
3+
 complexes. The relaxivity of the 
large capsules is likely limited by slow water exchange of the DOTA-monoamide and 
DTPA-monoamide chelates [120]. Functionalizing the P22 capsules with Gd
3+
 chelates 
displaying fast water exchange might be a valuable strategy to attain much higher 
relaxivities. Viral capsules are very promising multifunctional platforms integrating 
targeting, imaging and delivery of therapeutic cargos to cells [120, 121].  
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An interesting point, not addressed by the authors is the (volumetric) density of 
relaxivity of the capsids. Although the larger P22 capsids display higher (superb) 
relaxivity per particle, in fact the smaller Pf_En capsids display a density of relaxivity 
considerably higher than the larger capsids. 
1.5.4 Monolayer stabilised gold nanoparticles 
Gold nanoparticles (AuNPs) stabilized with thiols are reminiscent of self-assembled 
thiol monolayers on flat Au surfaces [122]. Bifunctional thiol constructs, -thiol--
functionalised molecules, allow stable and directional binding of the thiol terminal to 
the Au surface, leaving the -terminal available for further chemical elaboration, 
sensing or (bio)recognition purposes [123-125]. Simple thiols proved more effective for 
preparing functionalized AuNPs than multidentate thiols, affording higher monolayer 
densities [126]. A recent study, showed that AuNPs functionalized with citrate, 13 nm 
in diameter, could be functionalized with 110-120 (mono)thiolated oligonucleotide 
chains but with only 40-50 chains of the same tetrathiolated oligonucleotide. The 
preparation of AuNPs is a well established art. Nanoparticles in the shape of  spheres 
[122, 127, 128], cubes [129], rods [130], cages [129, 131] and wires [132] can be 
prepared in a controlled way and in large quantities. The size, shape and surface 
composition determine the physical and chemical properties of AuNPs and their in vivo 
behavior and fate. The design of AuNPs for a particular imaging application, e.g. CT, 
PAI and Surface-Enhanced Raman Spectroscopy (SERS) demands precise size and 
shape control [133]. For instance, spherical AuNPs 10 nm in diameter display the 
characteristic surface plasmon absorption at 520 nm, while 48.3 and 99.4 nm AuNPs 
display the plasmonic band at 533 nm and 575 nm, respectively [134]. Changing AuNPs 
shape from spherical to rod-like pushes the plasmon band to the NIR region (650-900 
nm), suggesting potential applications as probes for Photoacoustic Imaging (PAI) or 
mediators in photothermal therapy [130, 131]. 
The preparation of non-spherical AuNPs demands anisotropic growth of nuclei or seed 
particles. Surfactants that form oblongated micelles, cetyltrimethylammonium bromide 
(CTAB), sodium dodecylsulfate (SDS) and poly(vinylpyrrolidone) (PVP), are 
commonly used to induce anisotropic growth (Figure 1.14) [135-137].  
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Figure 1.14- Surfactants used to induce anisotropic grouth of AuNPs. 
 
CTAB is the most common surfactant used for the preparation of gold nanorods 
(AuNRs) from AuNPs seed solutions.  
The size and aspect ratio, of the AuNRs depends on the CTAB concentration and the 
ionic strength of the solution. The growth of AuNRs is also influenced by the size and 
structure of the seed particles, surfactant, aging time, temperature and pH. CTAB binds 
preferentially to the NRs {110} face leading to slower growth on that side. Liu and co-
workers have introduced the use of Ag
+
 ions (AgNO3) to control the aspect ratio of 
AuNRs [138]. Ag atoms depose preferentially by reduction in the {110} face of Au 
allowing growth along the 100 direction (Figure 1.15). 
 
Figure 1.15- Structural model of gold nanorod growth. Left: Original nanorod with octagonal 
cross section and {100}, {110}, {111} facets. Center: Rod with sharp tips, square cross section, 
{110} and {111} facets. Right: Growth of a sharpened rod into an octahedral particle via 
deposition of gold atoms (dark spheres) along the {110} facets [138].  
 
Raising the concentration of Ag
+
 produces AuNRs displaying higher aspect ratios. Too 
high concentrations of Ag
+
 will eventually stop the growth of AuNRs as the Ag atoms 
in excess will cover all the Au surface blocking further growth. The size and the nature 
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of the seed particles influence also the growth, with bigger seed particles producing 
AuNRs with lower aspect ratio [139]. Moreover, negatively charged seeds will create 
AuNRs with higher aspect ratios than positively charged seeds [139]. 
1.5.4.1 Biomolecules as coating agents  
Biomolecules have been used as stabilizing agents in the preparation of stable AuNPs 
[140-142]. Higashi and co-workers described the preparation of AuNPs stabilized with 
a monlayer of the  polypeptide poly(-benzyl-glutamate), using the modified Brust–
Schiffrin method [141]. The preparation of water-stable monodisperse AuNPs decorated 
with a biomolecular recognition multifunctional peptide was demonstrated by Naik and 
co-workers [140]. In addition to biorecognition function, the multifunctional peptide 
acted also as reducing agent for the choloraurate ion [140]. Other peptides, based on R-
aminoisobutyric acid, have been reported also as stabilizing agents for AuNPs [142]. 
Cysteine containing peptides revealed particularly suitable for stabilizing AuNPs owing 
to the strong interaction Au-S [143]. In addition to peptides, other types of biomoleculas 
revealed also efficacious for the preparation of AuNPs. Lipids, such as phospholipids 
[144-146] or synthetic lipids, and  surfactant molecules such as 
didodecyldimethylammonium bromide (DDAB) [147, 148], cetyltrimethylammonium 
bromide (CTAB) [149], tetraoctammonium (TOA) [150, 151], proved also useful as 
capping agents in the synthesis of AuNPs (Figure 1.16).  
 
Figure 1. 16- Structure of caping agents used for thepreparation of AuNPs. 
 
Urban  and co-workers described a simple two-step approach for modifying  1 nm 
diameter AuNPs (stabilized with citrate) using an aqueous solution of the thiolated 
phospholipid 1,2-dipalmitoyl-sn-glycero-3-phosphothio-ethanol (PL) [144]. Shape and 
size control of AuNPs by phospholipids has been reported by Zhu and co-workers. 
[146]. Other groups have employed in situ reduction of HAuCl4 with NaBH4 in the 
Chapter 1 
36 
 
presence of didodecyldimethylammonium bromide (DDAB) for the preparation of the 
AuNPs [147, 148]. AuNPs decorated with chiral ligands N-isobutyryl-L-cysteine or N-
isobutyryl-D-cysteine have been reported recently [152]. Proteins, mainly Bovine 
Serum Albumin, have been recently used as stabilizing agents in the synthesis of 
fluorescent gold nanoclusters. Appending metal chelates to the protein exterior 
generates bimodal fluorescence/MRI contrast agents [140]. 
Interestingly, microorganisms such as the extremophilic  actinomycetes 
Thermomonospora sp and Escherichia coli DH5a, can be used also as capping agents in 
the preparation of nanomaterials [151, 153, 154]. 
1.5.4.2.Polymers as coating agents 
Specific applications such as electrochemical quantized capacitance charging, single-
electron transistors, and biosensing require monodisperse NPs [155]. Production of 
monodisperse NPs was accomplished by replacing low molecular weight thiols by 
polymers.  Brust and co-workers used alkyl thioether end functionalized 
poly(methacrylic acid) to prepare near-monodisperse AuNPs in the 1-4 nm diameter 
range [156]. The particle size was controlled by the molar ratio of Au to capping ligand 
[157].  Other polymer such as polyampholyte [158], hyperbranched polymers [159], 
linear polymers [160], conjugated polymers [161], amphiphilic polymer [162-164], 
thermoresponsive and pH-responsive polymers [165, 166] have been designed or used 
as effective stabilizing agents for AuNPs. 
1.5.4.3. Dendrimers as coating agents  
Dendimers have received also  considerable attention as coating agents for AuNPs[167]: 
dendrimer templates, monodisperse and with uniform composition and structure, yield 
well-defined nanoparticle replicas; agglomeration of the NPs is prevented by 
stabilization of the NPs by encapsulation within the dendrimer; the dendrimer branches 
can be used as selective gates to control access of small molecules (substrates) to the 
encapsulated nanoparticles; the AuNPs can have applications in catalysis due to their 
high activity and surface-to-volume ratio [167]. 
Gracia and co-workers reported the first examples of dendimer  coating of AuNPs, 
using poly(amidoamine) (PAMAM) dendimers containing amine terminals (Figure 
1.17) [168]. 
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Figure 1.17- Schematic representation of a Gold Nanoparticles coated with a cystamine (focal 
point) second Generation PAMAM dendrimer. 
 
Subsequently, other PAMAM-based coating agents, such as PAMAM dendrimers end-
functionalised with sugars, methyl esters, or alkyl groups, have been reported for the 
preparation of the AuNPs. Nevertheless, these PAMAM functionalized AuNPs exhibit 
broad size distribution- particles with 2.1-12.8 nm in diameter [169].  
Crooks and co-workers [170] demonstrated that OH-terminated PAMAM dendrimers 
created highly monodisperse AuNPs, diameter between 1-2 nm. Kono and co-workers 
reported that PAMAM dendrimers end-functionalized with PEG  produced AuNPs with 
2 nm diameter [157]. 
Other dendrimeric materials such as poly(propyleneimine) (PPI) [171], oligothia and 
Dendron have been also studied as coating agents [172, 173]. 
Wang and co-workers [171] demonstrated that dendrimer protected AuNPs could be 
easily obtained by heating an aqueous solution containing third-generation 
poly(propyleneimine) dendrimers and HAuCl4, in the absence other reducing agents. 
Nanoparticles coated with dendrimers can be useful in the fields of catalysis, 
biotechnology, medicine, and other areas due to their small size (1-5 nm), electrical and 
thermal properties. 
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1.5.4.4 Gold nanoparticles functionalized with Gd
3+
 chelates as Contrast Agents for 
MRI 
Gold nanoparticles functionalized with Gd
3+ 
chelates have received recently much 
attention, owing to their great potential as contrast agents for MRI, bimodal MRI/X-ray 
imaging and imaging coupled to therapy (hyperthermia and X-ray sensitization) [174]. 
A variety of -thiol functionalised chelators has been employed in the preparation of 
gold nanoparticles (AuNPs) functionalised with Gd
3+
 chelates (Figure 1.18, Table 1.8). 
  
Figure1.18- Metal chelators employed for preparing gold nanoparticles functionalized with 
Gd
3+
 chelates.  
Introdution 
39 
 
 
Table 1.8- Relaxometric properties of selected examples of AuNPs functionalized with  
Gd
3+
 chelates (Figure 1.18). 
 GdL@AuNPs 
HD
 
(nm)
 a
 
r1
 
(mM
-1
s
-1
)
 b
 
N
c 
 
 
r1
NP  
 
(mM
-1
s
-1
)
 d 
r1
Vol    
(mM
-1
s
-1
nm
-3
)
 e 

(MHz) 
Ref. 
GdL29 2.0-2.5 3.9 150 585 174.5 300 [175] 
GdL30 5.0-7.0 13.8 1.36x10
4
 1.87x10
5
 2.91x10
3
 60 [176] 
GdL31 14.0 17.9 2.9x10
3
 4.6x10
5
 570 60 [177] 
GdL32 4.8 60.0 56 3360 103 30 [178] 
GdL33 1.75 4.8 - - - 300 [179, 180] 
GdL34 1.9- 3.1 1.4-25.2 - - - 300 [181] 
GdL35 26.0 28.0 430 1.20x10
5
 2.33 40 [182] 
GdL36 3.0 2.2 56 123 15.5 400 [183] 
GdL37 4.0 41.5 10.9 452 24.0 20 [184] 
a
Hydrodynamic diameter from DLS; 
b
Relaxivity per immobilized chelate; 
c
Number of chelates per NP; 
d
Relaxivity per NP= r1xN; 
e
Volumetric density of relaxivity= r1xN/(4/3πr
3
) 
 
In 2006 Tillement and co-workers reported for the first time, the preparation and 
characterization of  gold nanoparticles functionalized with Gd
3+
 chelates as CA for MRI 
[175]. The AuNPs were prepared by a modification of Brust´s method: addition of an 
aqueous solution of the reducing agent sodium borohydride (NaBH4) to an aqueous 
solution containing a mixture of tetrachloroauric acid (HAuCl4) and the thiol 
functionalized chelator DTDTPA (Figure 1.18, L29). AuNPs with diameter between 2 
and 2.5 nm, decorated with approximately 150 chelators (a ratio of approximately two 
chelators per Au atom) were produced. 
Relaxivities of the same order of magnitude were obtained for the soluble GdL29 
chelate and for the chelates immobilized onto the AuNPs (r1 = 3.0 and 3.9 mM
-1
s
-1
, 25 
°C, 300 MHz, respectively) [175]. Concentrating 150 chelates in a small molecular 
volume,  around the gold core, lead to high relaxivity per nanoparticle and also  high  
density of relaxivity (585 mM
-1
s
-1
 and 174 mM
-1
s
-1
nm
-3
, respectively,  25 °C, 300 MHz) 
(Figure 1.19) [175]. 
 
Chapter 1 
40 
 
 
Figure 1.19- Cartoon representation of Tillement´s AuNPs coated with Gd(DTDTPA) chelates 
(adapted from [175]). 
 
However, full complexation of the immobilized chelators, resulted in particle 
agglomeration and precipitation owing to the overall neutral charge of the immobilized 
Gd(DTPA-bis-amide)-type chelates, resulting in NPs displaying  near neutral zeta 
potential. Limiting the Gd
3+
 payload to ~ 50 chelates per nanoparticle (DTDTPA/Gd 
molar ratio 3:1) resulted in NPs stable enough for in vivo applications [185]. More 
recently, in 2008, Park and co-workers reported the preparation of gold nanoparticles 
functionalized with the DTPA-bis-amide L-glutathione conjugate L30 (Figure 1.18) 
[176]. The nanoparticles, with diameter between 5 and 7 nm, determined by TEM and 
DLS, displayed exceptional density of chelates, around 1.36 x 10
4
 chelates per 
nanoparticle. Such high density of immobilized chelates can be explained only by the 
formation of disulfide chelate polymers on the gold nanocrystal surface, as suggested 
originally by Tillement (Figure 1.19, GdL30). Although chelate immobilization did not 
result in substantial relaxivity enhancement (r1= 10.5 vs 13.4 mM
-1
s
-1
; 25 °C, 60 MHz, 
for the soluble and immobilized chelate, respectively) the high chelate density translates 
into superb relaxivity per nanoparticle and a very high density of relaxivity (r1 = 1.85 x 
10
5 
mM
-1
s
-1
 and 2.91 x 10
3 
mM
-1
s
-1
nm
-3
; 25 °C, 60 MHz).  
Park´s group reported also the preparation and characterization of AuNPs decorated 
with the DTPA-bis-amide cysteine conjugate GdL31 [177]. While the GdL30 
functionalized NPs were prepared by Brust´s method, the GdL31 coated NPs were 
prepared by the ―ligand substitution method‖ using (preformed) citrate-stabilized 12 nm 
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NPs. The functionalised NPs displayed an HD of 14 nm with around 2.9 x 10
3
 
immobilized chelates [186]. Chelate immobilization resulted in a substantial relaxivity 
enhancement, from 3.9 to 17.9 mM
-1
s
-1
 (25 ºC, 60 MHz).  Superb relaxivity per NP (r1= 
4.6 x 10
5
 mM
-1
s
-1
, 25 ºC, 60 MHz) was attained, thanks to the combined effect of high 
relaxivity per immobilized chelate and high chelate density. The relaxivity enhancement 
attained upon immobilization of GdL3 can probably be attributed to slower tumbling of 
the bigger NPs and a more rigid thiol monolayer, comparing to the GdL30 decorated 
NPs. 
In 2009 the (mono)thiol-functionalised chelators (L32 and L33), which do not undergo 
polymerization, thus forming a well defined chelate monolayer around the gold core, 
were reported.  
Helm and co-workers reported the synthesis of gold nanoparticles functionalized with  
Gd
3+
 chelates of the DTTA-type ligand Dt (L32) bearing a short aromatic thiol linker 
[178]. NPs with an average HD diameter of 4.8 nm (size distribution between 1 and 13 
nm) were obtained. An exceptional relaxivity per immobilized chelate (r1= 60 mM
-1
s
-1
, 
25 °C, 30 MHz) was attained, thanks to two water molecules in the first coordination 
sphere of the immobilised Gd(DTTA)-type complexes (q= 2) and total rigidity (S
2
= 1) 
of the chelates immobilized onto the gold surface by a short aromatic (rigid) linker. The 
relaxivity was limited by slow water exchange, suggesting that even higher relaxivities 
can be attained by rigid chelates displaying fast water exchange. 
Chechik and co-workers reported AuNPs functionalized with GdL33 chelates (Figure 
1.18). Built around the DTPA scaffold, the thiolated lysine linker on the central DTPA 
Nitrogen atom keeps the overall negative charge of the Gd
3+
 complex, preventing 
aggregation of the NPs [180]. The nanoparticles functionalized with GdL33 exhibit 
modest relaxivity per chelate (r1= 4.8 mM
-1
s
-1
; 25 °C, 300 MHz). This modest increase 
in relaxivity is likely due to longer rotational correlation times of the immobilized 
chelates, suggesting that fast local rotational motions of the immobilized chelates still 
limit the relaxivity. In an attempt to restrict local rotational motions of the immobilized 
chelates, Chechik and co-workers described the layer-by-layer coverage, of the 
negatively charged NP, with alternating layers of the positive and negatively charged 
polymers Polyethylenimine (PPI) and Polyacrylic acid (PAA). The first coating, with 
PEI, resulted in a considerable (38%) increase in relaxivity, suggesting that the PEI 
layer rigidifies the chelate monolayer without interfering with the water exchange 
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process [179]. Further coating cycles (2-4 polymer layers) resulted in additional 
relaxivity enhancements. Thicker layers resulted in relaxivity decrease presumably due 
restricted water access to the chelates. 
Mixed monolayer NPs, containing combinations of different sugars and Gd(DO3A)-
type chelates bearing -thiolalkyl linkers with different lengths, were proposed by 
Penadés and co-workers as new paramagnetic probes for MRI (Figure 1.18 L34) 
(Figure 1.20, Table 1.9) [181].  
 
  
Figure 1.20- Schematic representation of the paramagnetic glyconanoparticles based on GdL34 
reported by Penadés and co-workers.  
 
Table 1.9 - Composition and relaxometric properties of the paramagnetic glyconanoparticles 
reported by Penadès and co-workers [181]. 
 
 
 
 
 
 
 
 
 
Length of the 
sugar linker 
Length of the chelate linker 
m = 5 m = 11 
n sugar r1 (mM
-1s-1)a) sugar r1 (mM
-1s-1)a) 
2 Glucose 5.33 Glucose 1.40 
5 Glucose 2.11 Glucose 3.1 
5 Galactose 22.13 Galactose 10.34 
5 Lactose 14.9 Lactose 25.2 
a)300MHz, 37 ºC 
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Paramagnetic glyconanoparticles with HD between 2-3 nm were obtained. The 
relaxivity attained by the immobilized chelates (r1= 1.40 - 25 mM
-1
s
-1
, 37 °C, 300 MHz) 
revealed to be dependent on the sugar and on the length of both thiol linkers anchoring 
the sugar and the chelates to the Au core (Table 1.9). Most combinations resulted in 
modest relaxivity enhancements per immobilized chelate comparing to Gd(DOTA) (r1= 
~3.0 mM
-1
s
-1
; 37 °C, 300 MHz), although the particular combinations Gal-5/DO3A-5 (5 
Carbon atoms linkers) and Lac-5/DO3A-11 (5 and 11 C atoms linkers) attained very 
high relaxivities (r1= 22.13 and 25.20 mM
-1
s
-1
, 37 °C, 300 MHz, respectivelly). 
Galatose and Lactose (with a terminal galactosyl residue) revelead particularly effective 
in attaining high relaxivities, presumably due to effects of the hydrated sugar layer on 
the water exchange rate of the coordinated water and/or second sphere effects. It is 
noteworthy that the Gd(DO3A)-type chelates decorating the glyconanoparticles are 
overall neutral, suggesting that the hydrophilic sugar coating prevents agglomeration 
and precipitation of the AuNPs.  
More recently, brush-type macromolecular thiol ligands, consisting of copolymers of 
oligoethyleneglycol methylether acrylate (OEGA) and ethylenediamine functionalized 
DOTA-monoamide chelators L35, have been proposed as novel capping agents for 
AuNPs [187]. This synthetic strategy exploits statistical polymerization of linear 
copolymers of OEGA with the active ester monomer pentafluorophenyl acrylate 
(PFPA). Post-polymerization modification with a protected amine-functionalised 
DOTA-monoamide prochelator, followed by acidic deprotection and Gd
3+
 complexation 
afforded the macromolecular capping agent. Functionalization of citrate- stabilised 
AuNPs (HD= 12 nm) with the macromolecular capping agent (via ligand exchange) 
afforded AuNPs (HD= 26 nm) stabilised by a polyOEGA(POEGA)-based shell 
decorated with 430 Gd
3+
 chelates (Figure 1.21)[182]. 
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Figure 1.21- Schematic representation of the hyperbranch nanoparticles and the synthetic route 
[132, 137]. 
 
The hyperbranch nanoparticles show substantial relaxivity enhancement per chelate 
comparing to Gd(DOTA) (28 vs 4.8 mM
-1
s
-1
, 37 ºC, 40 MHz, for the hyperbranch NPs 
and Gd(DOTA), respectively). Moreover, the hyperbranch nanoparticle exhibit high 
molar relaxivity (r1= 1.2 x 10
4
 mM
-1
s
-1
; 37ºC, 40 MHz), only comparable to those 
reported by Park and co-workers , owing to the high number of high relaxivity Gd
3+
 
chelates per particle [132]. Besides relaxivity, higher thermodynamic stability and 
kinetic inertness of Gd(DOTA-monoamide)-type chelates compaing to Gd(DTPA-bis-
amide)-type chelates [21], makes the hyperbranch NPs potentially safer for in vivo 
applications than the NPs reported by Park and Tillement. The PEG coating endows the 
hyperbranch NPs with stability (by steric stabilization) as Gd(DOTA-monoamide)-type 
complexes are overall neutral. 
Hudson and co-workers reported an innovative synthetic route for AuNPs 
functionalized with Gd
3+
 chelates [183]. NPs stabilized with a monolayer of thiolated 
triethylene glycol monomethyl ether were functionalized, via ligand exchange, with 
thiolated PEG molecules end-terminated with protected maleimido groups (Figure 1.18, 
L36). Retro Diels-Alder deprotection uncovered the reactive maleimido group for post-
synthetic functionalisation via Michael addition of ethylenediamine functionalised 
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Gd(DOTA-monoamide) chelates [183]. The AuNPs (HD= 3 nm) could be 
functionalized with 56 Gd
3+
 chelates (Figure 1.22).  
 
Figure 1.22- Post-synthetic functionalisation of AuNPs with Gd
3+
 chelates via Michael addition 
[183]. 
 
No relaxivity enhancement per immobilized chelate could be demonstrated at high 
magnetic field comparing to Gd(DTPA) (r1 = 2.2 mM
-1
s
-1
; 25 °C, 400 MHz). 
Presumably, the low chelate density projecting from the PEG layer results in high 
flexibility of the immobilised chelates. Nonetheless, clustering 56 chelates around the 
Au core translates into a relaxivity per nanoparticle (r1 = 123 mM
-1
s
-1
; 25 °C, 400 MHz) 
still interesting for high magnetic field MRI. 
Established conjugation routes for -thiol-functionalised DTPA- and DOTA-type 
chelators and facile preparation of monolayer stabilised AuNPs, together with the 
proven robustness of their Gd
3+
 chelates as CA for MRI, has centred the research into 
AuNPs functionalised with Gd(DOTA)-type and Gd(DTPA)-type chelates. Pioneering 
work of Delangle and co-workers  demonstrated that the tridimensional conformation 
analogues of cyclopeptide L37 creates an octadentate coordination cage, formed by the 
aspartate and glutamate side chains and scaffold amides, suitable for complexation of 
Ln
3+
 ions [188]. Kong and co-workers , managed to endow the coordination cage with 
gold-binding properties by replacing the glycine residues by cysteines [184]. Moreover, 
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the peptide fulfilled also the role of reducing agent, generating AuNPs (HD= 4.0 nm) 
displaying high molar ratio Au/Gd (10.9, ICP-AES). Very high relaxivity enhancement 
per immobilized chelate (11.6 vs 41.5 mM
-1
s
-1
; 20 MHz, 32 ºC, for the solube and 
immobilized chelate, respectively) was attained. Despite the superb relaxivity per Gd3+ 
chelate, gradual aggregation of the NPs over time into big clusters limits their 
applications. Interestingly, the CP functionalized NPs display intense red fluorescence 
in solution. Combining the high detection sensitivity of fluorescence with depth-
independent MRI imaging makes Gold nanoparticles and Nanoclusters attractive 
platforms for bimodal MRI/Fluorescence imaging [189].  
Gold has a long history in medical practice. Gold is still in use for treating conditions 
such as rheumatoid arthritis, being generally accepted as safe [190]. Nonetheless, small 
size, ability to disseminate, penetrate, and persist in organ systems, raise reasonable 
safety concerns regarding in vivo use of gold nanoformulations [191]. Small 
nanoparticles have been implicated in apoptosis, generation of reactive oxygen species, 
and necrosis of various tissues [192]. Studies have shown only a 9% decrease in the 
content of gold in the liver from day 1 to 6 months, following intravenous injection of 
40 nm AuNPs stabilized with citrate [193]. Another study revealed inflammatory and 
apoptotic changes in liver tissue after injection of 13 nm AuNPs stabilized with PEG 
molecules [194]. AuNPs can penetrate renal cells and accumulate in kidney tissue [195]. 
However, when 12.5 nm AuNPs stabilized with Citrate were administered to mice daily 
for 8 days, no evidence of toxicity was observed in terms of survival, behavior, animal 
weight, organ morphology, blood biochemistry, and tissue histology over a period of 
two-plus months [196]. In general, nanoparticles smaller them 6 nm are primarily 
cleared by renal filtration and display short circulation times. Larger particles enjoy 
prolonged systemic circulation and accumulation within tumors [197]. 
In vivo MRI studies have been performed with some of the NPs discussed above (Table 
1.10). 
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Table 1.10- Selected examples (Figure 1.18, Table 1.8) of in vivo MRI studies using AuNPs 
functionalized with Gd
3+
 chelates as CA . 
GdL@AuNPs 
dose   
(mmol [Gd] Kg
-1
) 
major uptake 
GdL29@AuNPs 0.01 kidneys 
GdL31@AuNPs 0.03 liver 
GdL33@AuNPs 0.1 liver 
GdL34@AuNPs 0.1 liver
 
GdL36@AuNPs 0.1 kidneys 
GdL37@AuNPs 0.02 Liver, kidney 
 
Animal MRI studies are usually performed in dedicated preclinical animal imaging 
platforms operating at (very) high magnetic fields (300 MHz - 7 Tesla, and higher). 
Clinical diagnostic is generally performed at intermediate fields (20-120 MHz) [198]. 
The substantial relaxivity enhancements attained at intermediate fields (20-60 MHz) by 
macromolecular/nanosized CA, comparing to low molecular weight CA, is partially lost 
at high magnetic fields [199]. Thus, the apparently low relaxivities attained by GdL29, 
GdL33, GdL34 and GdL36 at high fields (300 and 400 MHz) can not be compared with 
the high relaxivities attained by GdL30, GdL31, GdL32, GdL35 and GdL37 at 
intermediate fields (20-60 MHz). As consequence, the MRI studies performed at high 
field made use of AuNPs doses that afford final concentrations of Gd comparable to the 
standard imaging doses (0.1 mmol Gd/Kg BW) of low molecular CA such as 
Gd(DTPA) (Table 1.10). MRI studies at intermediate fields (20-60 MHz) take 
adavantage of the high relaxivity of the nanosized CA (r1= 17.9 and 41.5 mM
-1
s
-1 
for 
GdL31@AuNPs and GdL38@AuNPs at 60 and 20 MHz, respectively) which allows 
reducing the imaging dose by around an order of magnitude.   
MRI studies in vivo using GdL29@AuNPs (HD= 2-2.5 nm) as CA showed strong 
contrast enhancement of the kidney structures and to a lesser extent of the lungs, liver, 
spleen, and heart. Accumulation of gold NPs in the kidneys was ascribed to their natural 
filtration function. The detection of gold in the lungs, liver, and spleen was assigned to 
the presence of blood in these organs as their gold content was found to be almost the 
same as that  in the heart [175]. GdL31@AuNPs generates strong contrast enhancement 
of the liver, probably due to uptake of ―large‖ NPs (HD= 14 nm) by the kuppfer cells. 
Prolonged, strong contrast enhancement of the abdominal aorta was attributed to long 
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circulation- blood-pool effect [200]. Penadés paramagnetic glyconanoparticles 
GdL33@AuNPs, demonstrated superior contrast enhancement of glioma tumoral zones, 
comparing to the low molecular weight CA Gd(DTPA) and Gd(DOTA) in clinical use, 
although liver uptake compromises in vivo contrast enhancement [181]. AuNPs 
functionalised with GdL36 show comparable enhancement of the kidney structures and 
longer excretion time, comparing to Gd(DTPA), providing an extended imaging 
window [183]. GdL37@AuNPs showed prolonged circulation in the blood pool, 
without significant accumulation in the liver and spleen, coupled predominantly to renal 
clearance [184].  
The ability to freely circulate in the blood pool without undesirable accumulation in the 
lungs, liver, and spleen, associated to bimodal MRI/X-ray reporting and therapeutic 
properties (hyperthermia and X-ray sensitization), make AuNPs functionalized with 
Gd
3+
 chelates very attractive for coupled imaging/therapy. 
Targeting gold nanoparticles functionalized with Gd
3+
 chelates to cellular receptors, 
seems the logical step towards clinical translation of AuNPs into human applications.  
The synthesis of the -thiol functionalised ligands L38 and L39 and the preparation and 
characterization of AuNPs functionalized with their Gd
3+
 chelates is described in this 
thesis (Chapters 5 and 6). Our work addressed, for first time, the effect of fast water 
exchange on the relaxivity of AuNPs functionalized with Gd
3+
 chelates. The effect of 
the length of the -thiol linker on chelate flexibility, NPs size and relaxivity is also 
addressed in this work. Animal MRI and biodistribution studies were carried out to get 
insight into the influence of the physical-chemical properties of the NPs on their 
behaviour in vivo.  
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2 -Amide conjugates of the DO3A-N-(-
amino)propionate ligand: leads for stable, 
high relaxivity contrast agents for MRI? 
 
 Adapted from Contrast Media Mol. Imaging 2013, 8, 40–49 
 
A novel synthetic methodology for preparing amide conjugates of the DO3A-N-(-
amino)propionate chelator is described, using the synthesis of the DO3A-N-(-
benzoylamido)propionate chelator as an illustrative example. The model Gd[DO3A-N-
(-benzoylamido)propionate] chelate displays accelerated water exchange, stability in a 
wide pH range and inertness towards transmetallation by Zn
2+
. The Gd[DO3A-N-(-
benzoylamido)propionate] complex is mainly excreted via the kidneys, producing a 
significant increase in the kidney medulla/cortex enhancement ratio in MR images of 
Wistar rats, reflecting probably its higher lipophilicity compared with Gd(DTPA). The 
results presented suggest that Gd[DO3A-N-(-amido)propionate] chelates can be 
valuable leads for preparing potentially safe high relaxivity MRI contrast agents. 
 
 
Keywords: DO3A-N-(-amido)propionate chelators; Gd[DO3A-N-(-
benzoylamido)propionate] chelate; fast water exchange; pH stability; safety; in vivo 
MRI 
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2.1 Introduction 
Since its introduction around 30 years ago, magnetic resonance imaging (MRI) has 
evolved into the leading imaging modality both in the clinics and in biomedical sciences 
[1]. Incremental developments in instrumentation, particularly the use of increasingly 
higher magnetic fields, and the use of contrast agents (CAs), have driven MRI to the 
forefront of medical imaging [2]. Gd
3+
 chelates are the most useful CAs for MRI owing 
to the high paramagnetism (seven unpaired electrons) and long electronic relaxation 
times of the Gd
3+
 ion [3]. To ensure safety, Gd
3+
 ions are used as complexes with 
poly(aminocarboxylate) ligands, which prevents the inherent toxicity of the free metal 
ion and modulates its unfavorable pharmacokinetic behavior. The efficacy of a CA is 
measured by its relaxivity (r1, r2) – the enhancement of the relaxation rate of the water 
protons brought about by a 1mM concentration of Gd
3+
 [4, 5]. Increasing detection 
sensitivity, by maximizing relaxivity, has been the driving force in the development of 
new CAs [6]. Nonetheless, the high relaxivities predicted theoretically have not yet been 
achieved in spite of the tremendous efforts and developments in the field [7]. The main 
approaches to enhancing detection sensitivity involve optimizing the relaxivity of 
individual chelates, clustering a high number of (high relaxivity) chelates into 
(bio)macromolecular carriers or self-assembling monomeric chelates into 
supramolecular structures, and directing chelate constructs to the sites of interest by 
attaching targeting moieties recognized specifically by cellular receptors [6, 8]. All 
these approaches require chemical modification of the basic chelator structure in order 
to introduce ‗handles‘ for chemical functionalization. 
A few years ago, the discovery of severe toxicity associated with repeated CA MRI in 
individuals suffering from kidney function impairment cast doubt on the safety of MRI 
CAs [9, 10]. This condition, named nefrogenic systemic fibrosis, owing to generalized 
formation of fibrotic (scarring) plates in the skin and internal organs, was correlated 
with the use of Gd
3+
 chelates of DTPA-bis-amide chelators [11]. Release of Gd
3+
 ions in 
vivo, owing to insufficient kinetic and thermodynamic stability of the Gd(DTPA-bis-
amide) chelates, seems the most likely reason for CA toxicity [12, 13]. Importantly, 
only a few cases have been associated with macrocyclic CAs of the DOTA family, all in 
patients suffering from kidney disease [13–15]. The much higher kinetic and 
thermodynamic stability of the macrocyclic DOTA-type CAs precludes release of Gd
3+
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ions in vivo. The adoption of stricter guidelines concerning the use of Gd
3+
-based CA 
has drastically reduced the number of nefrogenic systemic fibrosis cases reported [16]. 
Nonetheless, safety, associated with chelate stability, rather than high relaxivity (high 
detection sensitivity), is becoming the new paradigm in CA MRI, which favors the use 
of macrocyclic, DOTA-type CAs. There are several CAs of this type approved for 
clinical use in Europe, most of which are extracellular CAs. Gd(HPDO3A) (Prohance®) 
has become one of the CAs of choice in the clinical setting [17]. Improving the 
performance of DOTA-type CAs (targeting, multimerization, responsiveness, etc.) 
requires chemical elaboration of the basic DOTA scaffold to allow conjugation to 
(bio)molecules. Endowing DOTA chelators with conjugability without compromising 
stability is a core problem in CA research. In fact, the most convenient route for 
chemical functionalization of the DOTA skeleton, differentiating an acetate arm for 
amide coupling, reduces the thermodynamic and kinetic inertness of 
Gd(DOTAmonoamide)- type chelates [18]. Furthermore, neutral 
Gd(DOTAmonoamide)-type chelates display much slower water exchange, limiting the 
relaxivities potentially achievable by chelates displaying optimized rotational 
correlation times (R). Introducing pendant functional groups on the ethylenediamine 
bridges on the DOTA skeleton is an effective, although costly, solution [19]. It is 
preferable from the synthetic point of view to elaborate the (pre-formed) available 
cyclen skeleton rather than starting chelator synthesis from scratch. We have recently 
reported the synthesis of a new chelator, DO3A-N-(-amino)propionate (L2, Scheme 1) 
and the relaxometric characterization of its Gd
3+
 complex. The a-amino substituted 
propionate arm presumably imposes steric compression around the water binding site on 
the complex, resulting in an accelerated water exchange rate kex [20]. In the same year, 
Botta and and co-workers reported a bifunctional chelator, DOTAMAP-En, and an 
amide conjugate, DOTAMAP-En-C18, bearing a propionamide arm. Even higher water 
exchange rates were demonstrated for the Gd(DOTAMAP-En) and for the 
Gd(DOTAMAP-En-C18) chelates, presumably also owing to steric compression [21]. 
The kex value for the Gd[DO3A-N-(-amino)propionate] (GdL2) chelate is of the same 
order of magnitude as that reported for its (unsubstituted) propionate analog Gd(DOTA-
N-propionate)- in the range considered ideal for attaining high relativities at 
intermediate/high field [18, 20, 22]. Moreover, the GdL2 complex is stable in the pH 
range 2–10 and inert towards transmetallation with Zn2+. The pendant available amine 
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group is ideal for conjugation through a variety of ligation chemistries. We have 
recently reported the preparation of a cysteinyl conjugate of the DO3A-N-(-
amino)propionate chelator using an advanced protected intermediate on route to the 
DO3A-N-(-amino)propionate chelator, as originally proposed [23]. However, an 
important issue remains to be addressed: what is the effect of amide conjugation on the 
stability and water exchange rate of Gd[DO3A-N-(-amido)propionate] chelates? In 
this manuscript we describe a novel expeditious methodology for the synthesis of amide 
conjugates of the DO3A-N-(-amino)propionate chelator. The relaxometric 
characterization and in vivo MRI evaluation of a model amide chelate, Gd[DO3A-N-(-
benzoylamido)propionate] (GdL1), is reported. 
 
2.2 Results and discussion 
2.2.1. Synthesis 
Allying stability to conjugability is an important requisite for developing metal chelates 
into imaging and/or therapeutic agents. We have proposed before that the pendant 
amine group on the -aminopropionate arm on the DO3A-N-(-amino)propionate 
chelator is an ideal handle for conjugation to (bio)molecules [20]. There are literature 
precedents for the direct conjugation of functionalized (pre-formed) chelates [24]. 
However, solubility issues and difficult manipulations and purifications can be avoided, 
especially with radio-labeled metal chelates, by labeling fully deprotected conjugates. A 
cysteinyl conjugate of the DO3A-N-(-amino)propionate chelator was recently 
described by us using the ―conventional approach‖: amide coupling of an S,N-protected 
cysteinyl block to a protected advanced intermediate followed by deprotection [23]. In 
this work we disclose a new expeditious strategy for the synthesis of amide conjugates 
of the DO3A-N-(-amino)propionate scaffold (Scheme 2.1). 
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Scheme 2.1- Synthetic sequence for the DO3A-N-(-benzoylamido)propionate ligand and its Gd3+ 
chelate. a) K2CO3, MeCN; b) i. TFA/DCM, ii. K2CO3/ethyl bromoacetate, MeCN; c) i. Dowex 1X2 OH
-
 
resin, ii. Elution with hydrochloric acid 0.1 M; d) GdCl3.xH2O. 
 
Introducing a pre-formed Boc-dehydroamide (Ph, Boc)-Δ-AlaOMe 2 into the cyclen 
scaffold via Michael addition is the key step in this reaction sequence. Building up on 
our previous experience on the synthesis of bifunctional chelator L2 we envisaged that 
(Boc, amide)-dehydroalanines of type 2 could fulfil electronic and steric requirements to 
perform well as electrophiles in Michael addition to cyclen. (Boc, amide)-
dehydroalanines of type 2 can be readily prepared in two steps from serine methyl ester 
hydrochloride 1 and stored at room temperature for extended periods [25]. Michael 
addition of block (2) to cyclen 3 proceeded smoothly in acetonitrile, using K2CO3 as 
base, in 2–3 h. An excess of cyclen, 1.5 equiv., was used in order to bias the statistical 
mixture towards the monoalkylated product 4. Removing the Boc group at the 
monoalkylated intermediate 4 stage could avert retro-elimination during the next 
alkylation step. In fact, one-pot treatment of 4 with TFA, followed by alkylation with 
ethyl bromoacetate in the presence of a large excess of K2CO3, produced the fully 
alkylated amide 5 in moderate yield without evidence of retro-elimination. One-step 
deprotection of the fully alkylated pro-chelator 5 with ion-exchange resin Dowex 1X2 
OH
-
 followed by elution with hydrochloric acid yielded the fully deprotected DO3A-N-
(-benzoylamido)propionate chelator L1 in overall (non-optimized yield) of 16% over 
three steps. Introducing the pre-formed amide onto the cyclen scaffold early on the 
synthesis is an unusual strategy. This conjugation strategy avoids orthogonal protection 
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schemes and multistep deprotection for obtaining the final conjugates. Moreover, 
synthesizing the amide separately and performing the ‗coupling‘ early on the synthesis 
avoids difficult purifications and reduces the risk of contamination of the final 
conjugates with bi-products of (carbodiimide-based) coupling reagents [23]. This 
approach is general, applicable to simple Boc-dehydroamides of type 2 lacking acid 
sensitive moieties/protecting groups and basic sites susceptible to alkylation on the 
amide moiety. 
2.2.2. Solution NMR and Relaxometric Studies 
As discussed above, the aim of this work is to ascertain if Gd
3+
 chelates of amide 
conjugates of the DO3A-N-(-amino)propionate metal chelator retain the high stability, 
inertness and fast water exchange of its parent GdL2 complex. The soluble, low-
molecular weight GdL1 complex (Scheme 2.1) was selected as a model system in order 
to avoid solubility and self-assembly complicating issues.  
1
H NMR spectra at 600 MHz of LnL1 complexes (Ln
3+
 = La, Sm and Eu) at 298 K and 
neutral pH were found to contain very broad resonances for the macrocyclic and 
pendant arm methylene protons, indicating the presence of an internal isomerization 
process at intermediate exchange on the NMR time scale [26]. The temperature 
dependence of the 
1
H spectrum of the EuL1 complex studied at lower frequency 
(300MHz) provides direct proof of this process. In fact, the spectrum at 280 K contains 
more than 50 sharp resonances, corresponding to slow exchange between two isomers 
of C1 symmetry, which are broadened at higher temperature (Figure SI2.1). The large 
positive shifts of the two sets of four resonances observed in the low-temperature 
spectrum result from the four axial protons of the Eu
3+
 complex in the square 
antiprismatic and twisted square antiprismatic conformations with a 60:40 population 
ratio, while the parent EuL2 complex in the same conditions indicates a 98% 
predominance of the square antiprismatic conformation [20]. 
Thus, the derivatization of the amine function of L2 favors the twisted square 
antiprismatic form. The water exchange rate,    
   , for the GdL1 complex was 
determined from variable-temperature 
17
O NMR studies (Figure 2.1a and b).  
Additionally, the magnetic field dependence of the longitudinal water proton relaxivities 
(r1) was measured by 
1
H nuclear magnetic relaxation dispersion (NMRD) at 298 and 
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310 K (Figure 2.1c) with the objective of determining the parameters that describe 
water exchange and rotational dynamics for the GdL1 complex.  
 
Figure 2.1- Temperature dependence of the (a) reduced transverse and longitudinal 
17
O relaxation rates 
1/T2r and 1/T1r, and (b) chemical shifts Dwr; B = 9.4 T (ln(1/T1r), (■), (ln(1/T2r), (p)), and (c) NMRD 
profiles (298 K (p) and 310 K (■)) for the Gd[(DO3A-N-(-benzoylamido)propionate)] complex. 
 
The Solomon–Blombergen–Morgan theory was used for analyzing simultaneously the 
experimental 
1
H NMRD data, as well as the 
17
O NMR reduced longitudinal (1/T1r) and 
transverse (1/T2r) relaxation rates and chemical shifts (Δr) (5). In the analysis, the 
following parameters have been fitted: rate (   
   ), activation enthalpy (ΔH‡) and 
activation entropy (Δ ‡) of the water exchange, the rotational correlation time (  
   ) 
and its activation energy (ER), the electron spin relaxation parameters ( 
   , Δ2 and EV) 
and the scalar coupling constant (A/ħ). The diffusion constant and its activation energy 
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were fixed to     
     =26 x 10
-10
 m
2
s
-1
 and     
    = 22 kJ mol
-1
, respectively. The Gd–
water proton distance was fixed to rGdH = 3.1 Å, and the distance of closest approach 
between the Gd
3+
 ion and the outer sphere protons to GdH = 3.6 Å [22, 27].  
The parameters obtained from the simultaneous fitting of the data are shown in Table 
2.1, and the corresponding fitted curves are shown in Figure 2.1. 
Table 2. 1- Best fit parameters obtained for the Gd[DO3A-N-(-benzoylamido)propionate] 
chelate from the simultaneous fitting of the NMRD data, 17O NMR longitudinal (1/T1r) and 
transverse (1/T2r) relaxation rates and chemical shifts (Δor) 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the fitting, one inner sphere water molecule was assumed in analogy with the parent 
GdL2 complex [20]. This assumption was confirmed by the value obtained for the 
parameter A/ħ, characteristic of q=1 complexes of the DOTA family. The rate constant 
for water exchange for the GdL1 complex [   
    = (5.14 ± 0.4) X 10
7
 s
-1
] is of the same 
order of magnitude as that reported for its parent GdL2 complex [   
   = (4 ± 0.4) X 10
7
 
s
-1
] [20] and for the unsubstituted Gd (DOTA-N-propionate) complex (   
   =6.1 ± 10
7
 s
-
1
) [18]. Moreover, kex is around one order of magnitude higher than that reported for 
Gd(DOTA) [27]. This result confirms our working hypothesis, that Gd
3+
 chelates of 
amide conjugates of the DO3A-N-(-amino)propionate chelator retain the fast water 
Parameters GdL1
a 
GdL2
b 
Gd(DOTA)
c 
q(H2O)  1 1 1 
ΔH‡[J/K/mol] 17 ± 1.1 19.1 54.5 
ΔS‡[kJ/mol] -40 ± 6 -35 +65 
kex
298
 [10
7
 s
-1
] 5.14 ± 0.4 4 0.46 
ER [kJ/mol] 26.2 ± 1.1 17 20 
τRH
298
[ps] 182 ± 10 71 100 
EV [kJ/mol]  4.8 ± 0.5 1 8.6 
τV
298
 [ps] 7.2 ± 1.5 11 0.65 
Δ2 [1020 s-2] 0.5 ± 0.06 0.25 0.12d 
A/ħ [106 rad/s] -3.13 ± 0.4 -3.6 -4.0 
a
Parameters underlined have been fixed. 
b
From Ferreira et al. [20]. 
c
From Powell  and co-workers  [27]. dFrom Micskei  and co-
workers [28]. 
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exchange displayed by its parent GdL2 complex. This is an important result, suggesting 
that amide conjugates displaying an optimized rotational correlation time, R, could 
attain high relaxivities at intermediate fields. The value for the rotational correlation 
time obtained from the 
1
H longitudinal relaxation rates (  
   = 182 ps) is characteristic 
of low-molecular-weight chelates, indicating that the complex does not self-assemble in 
the concentration range studied. At high magnetic fields, the relaxivity is dominated by 
fast rotation in solution, as demonstrated by its temperature dependence (Figure. SI2.2).  
Besides thermodynamic stability, the kinetic stability of the Gd
3+
 complexes is of 
paramount importance for meaningful biological applications. The in vivo dissociation 
of a GdL1 complex depends on the exchange reactions taking place in the blood 
plasma, such as with the most abundant bidentate anions like carbonate (~26mΜ), L-
lactate (~2.3mΜ) or phosphate (~1.1 mΜ) (29, 30). The time dependence of the relative 
water proton paramagnetic relaxation rate R1p(t)/R1p(0) for the GdL1 complex in 10 mΜ 
phosphate buffer is shown in Figure 2.2. 
 
Figure 2. 2-  Evolution of the relative water proton paramagnetic relaxation rate R1p(t)/R1p(0) 
(20 MHz, pH 7.1, 298 K) versus time for a 1.5 mM solution of Gd[(DO3A-N-(a-
benzoylamido)propionate] complex in phosphate buffer (10 mM, pH 7.1) (○) and in phosphate 
buffer containing an equimolar amount of Zn
2+
 ions (●). 
 
 Addition of 6.7 equiv. of phosphate to a 1.5 mΜ solution of the complex causes a fast 
decrease in R1p of 10%, indicating a weak interaction of the complex with phosphate, 
possibly replacing the inner-sphere water molecule by adduct formation in a 
monodentate binding mode (31). Larger (~25% decreasing) effects of phosphate on the 
relaxivity of Gd
3+
 complexes with two inner-sphere water molecules have been 
observed [32].  
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Metal exchange reactions with endogenous metal ions, the most abundant of which in 
blood plasma (besides Ca
2+
 and Mg
2+
) is Zn
2+
 (29,30), have been proposed to be the 
most likely mechanisms for Gd
3+
 leakage [33,34]. This can occur via the direct attack of 
the endogenous metal on GdL, or via proton-assisted dissociation of GdL, followed by 
recombination of the ligand with the attacking metal ion [35–37]. Kinetic studies carried 
out close to physiological pH using much higher cationic concentrations than the free 
concentrations expected in plasma, led to the general conclusion that the dissociation of 
DTPA-like linear complexes occurs mainly via direct transmetallation, while the much 
slower dissociation of DOTA-like macrocyclic chelates uses mainly proton-assisted 
pathways [35–37]. 
The kinetic inertness of the GdL1 complex was evaluated using the simple 
transmetallation assay developed by Muller and and co-workers [38]. Complex 
transmetallation by Zn
2+
 was studied in phosphate-buffer (10 mΜ, pH 7.1; Figure 2.2). 
Replacement of Gd
3+
 by Zn
2+
 in the initial complex generates a time-dependent 
decrease of the paramagnetic contribution to the water proton spin-lattice relaxation rate 
(R1p) owing to precipitation of GdPO4. The time evolution of the relative water proton 
paramagnetic relaxation rate R1p(t)/R1p(0) for the GdL1 complex in phosphate buffer, in 
the absence and in the presence of Zn
2+
 (Figure 2.2), fulfils the accepted empirical 
criteria for kinetic and thermodynamic stability [38]. Although the Zn
2+
 concentrations 
used in this empirical assay are several orders of magnitude higher than its free or 
exchangeable concentrations in plasma [30], the results provide a fast initial screening 
between inert and labile Gd
3+
 complexes. Furthermore, the independence of the 
paramagnetic relaxation rates for the GdL1 complex from the solution pH (Figure 
SI2.3) confirms that the complex is stable in the pH range 2–11. 
The interaction of the GdL1 complex with human serum albumin was studied by 
relaxometric titration (Figure SI2.4). A very weak binding was detected, which is not 
likely to affect the pharmacokinetic behavior of the complex in vivo. 
2.2.3. MRI Studies  
Comparative MRI studies have been performed at 7.0 T in male Wistar rats with GdL1 
and Gd(DTPA). The GdL1 contrast agent was well tolerated by the animals at the dose 
used. No gross side effects were observed during the injection, immediately or several 
days after the experiment. During experiments, rats‘ body temperature remained stable 
and no alteration on the body functions was observed. Overall, GdL1 seemed to be 
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harmless to the animals. Nevertheless, a more detailed study would be required to 
further assess its toxicology.  
Figure 2.3 shows a representative series of T1-weighted spin-echo axial images of the 
dynamic contrast enhanced (DCE) experiments obtained before and after injection of 
the GdL1 complex (dose 0.1 mmol Gd kg
-1
 body weight) and, for comparison purposes, 
Gd(DTPA) at the same dose. 
 
Figure 2.3- Representative coronal T1-weighted spin echo MR images of a Wistar rat before 
and after injection of the contrast agents (A) GdL1, (B) Gd(DTPA) (dose 0.1 mmol kg
-1
 BW). 
 
In the pre-injection image, kidney structures (cortex, inner and outer medulla) and 
adjacent tissues were dark owing to the particular inversion delay chosen. After bolus 
injection in the vascular system, a strong signal enhancement was observed in the 
kidneys for the two CAs, as a result of the T1 shortening. A slighter signal enhancement 
was observed in liver and muscle for both CAs. As can be seen, both complexes follow 
mainly renal elimination by glomerular filtration with a very small hepatobiliary 
contribution to excretion. The features of the data in Figure 2.3 are better understood, 
as illustrated in Figure 2.4, which shows their quantitative analysis. Each time point 
corresponds to the average intensity within regions of interest placed on the different 
organs. In order to compare the results for all the animals under study (n = 4), the data 
were normalized by calculating the mean relative enhancement of each regions of 
interest. The scattering in the time course curves of the average relative enhancement of 
the regions of interest was caused by animal respiratory motion. Muscle and liver 
enhancement is comparably low with both complexes. The relative enhancement 
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obtained with Gd(DTPA) increased almost immediately after intravenous injection from 
0 up to about 250% in the kidney medulla and 200% in the kidney cortex, followed by a 
steady decrease to values around 120 and 80%, respectively, after 50 min. The time 
course of the average relative enhancement after injection of Gd(DTPA) (Figure 2.4A) 
is in good agreement with the literature for Gd(DTPA) (39, 40) or other low molecular 
weight Gd-based contrast agents [41–45]. 
 
Figure 2.4- Time course of signal intensity, relative to the initial value (up to 50 min post-
injection) of several regions of interest during dynamic contrast enhancement MRI experiments 
in rats with (A) Gd(DTPA) (0.1 mmol kg
-1
 BW) and (B) GdL1 (0.1 mmol kg
-1
 BW). The time 
courses are data for mean values of four animals and the corresponding standard error. 
 
The renal pharmacokinetic behavior of GdL1 is significantly different from that 
observed for Gd(DTPA). Kidney cortex enhancement build-up is slower than for 
Gd(DTPA), reaching a maximum of about 100% after 10 min post-injection, followed 
by a steady decrease to a value (~80%) comparable to that reached by Gd(DTPA) after 
50 min. 
However, the main difference between GdL1 and Gd(DTPA) regards kidney medulla 
enhancement. While for Gd(DTPA) there is a sharp increase just after injection, 
followed by a steady decrease, for the GdL1 complex a saturation-like kinetic behavior 
is observable. After 50 min, a significantly higher enhancement of the kidney medulla is 
attained with the GdL1 complex compared with Gd(DTPA) (200 vs 120%). At the same 
dose, the GdL1 complex resulted in a considerably lower initial signal enhancement 
than Gd (DTPA) at both the cortex and medulla, which is not in agreement with their in 
vitro relaxivities, which are comparable. As a consequence of the disparate 
pharmacokinetics, the ratio of medulla/cortex enhancement increases significantly for 
the GdL1 complex over the duration of the experiment, while it is approximately 
constant for the Gd(DTPA) complex. 
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The pharmacokinetic behavior in rats of the Gd(DOTA) complex regarding kidney 
excretion is similar to that displayed by the Gd(DTPA) complex (41): a sharp 
enhancement of kidney medulla and cortex after injection followed by a steady decrease 
with the enhancement ratio medulla/cortex approximately constant over the experiment 
duration. This suggests that, although charge effects [-2 for the Gd(DTPA) complex and 
-1 for the GdL1 complex] cannot be ruled out, the observed difference in 
pharmacokinetic behavior is probably due to the higher lipophilicity of the GdL1 
complex compared with the Gd(DTPA) complex. 
It has been shown previously that the in vitro and in vivo relaxivities of Gd-based CAs 
can be significantly different, as the latter are affected by tissue structure and 
physiology [39, 46]. Gd(DTPA) was found to display relaxivities considerably lower in 
rat kidney cortex or medulla compared with the values measured in saline solution or in 
other tissues. This effect is related to CA compartmentalization in the kidney [47, 48]. 
The quantitative determination of the in vivo relaxivity of a CA requires knowledge of 
its local concentration. In some cases, CA concentration has been obtained from 
independent measurements. 
These studies, however, are not without difficulties, since they often induce significant 
perturbations to the tissues, by studying intact excised tissues [49], making 
measurements post-mortem [47], or ensuring a constant infusion of the CA in order to 
establish a steady-state concentration [48].  
Lacking such experiments, estimation of the relative in vivo relaxivities would require 
measurement of the effective T1 values on different regions of interest, to assume a 
linear dependence of signal enhancement with the local CA concentration, and the 
unacceptable assumption of similar pharmacokinetics for Gd(DTPA) and GdL1 [43]. 
Therefore, this quantitative pharmacokinetic study, which is beyond the scope of the 
present work, is not feasible in the present case. One can safely conclude from the 
present study that the pharmacokinetic behavior of both CAs is different, especially in 
the kidney medulla at later stages of excretion. 
2.3. Conclusions 
In this manuscript we describe the synthesis of the benzoylamide conjugate of the 
DO3A-N-(-amino)propionate chelator as an illustrative example of a new, general 
methodology for the expeditious preparation of amide conjugates. The Gd [DO3A-N-
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(-benzoylamido)propionate] chelate retains the fast water exchange and stability of its 
parent Gd[DO3A-N-(-amino)propionate] complex. 
DCE-MRI studies in rats revealed that the Gd[DO3A-N-(-benzoylamido)propionate] 
chelate is mainly excreted via the kidneys. A significant increase of the kidney 
medulla/kidney cortex enhancement ratio is produced by the contrast agent after 50 min, 
reflecting probably its higher lipophilicity compared to Gd(DTPA). 
The results presented here suggest that Gd[DO3A-N-(-amido)propionate] chelates are 
valuable leads for preparing potentially safe high-relaxivity MRI CAs. In fact, 
Gd[DO3A-N-(-amido)propionate] chelates with optimized water exchange features, 
when bound to suitable carriers, are likely to originate high relaxivities at intermediate 
fields by virtue of the simultaneous optimization of kex and R [23]. The high relaxivities 
of such imaging platforms allied to chelate stability and safety could find many uses in 
biomedical and pre-clinical diagnostic MRI applications. 
2.4. Experimental 
2.4.1. Materials and Methods 
Chemicals were purchased from Sigma-Aldrich and used without further purification. 
Solvents used were of reagent grade and purified by usual methods. Cyclen was 
purchased from CheMatech. Reactions were monitored by TLC on Kieselgel 60 F254 
(Merck) on  aluminum support. Detection was by examination under UV light (254 nm) 
and by adsorption of iodine vapour. Flash chromatography was performed on Kieselgel 
60 (Merck, mesh 230–400). The relevant fractions from flash chromatography were 
pooled and concentrated under reduced pressure, T< 313 K. Ion exchange 
chromatography was performed on Dowex1X2-100-OH
-
 resin (Sigma Aldrich). The 
resin was purchase as the Cl form and converted to the OH form by the standard 
procedure. 
1
H and 
13
C NMR spectra (assigned by 2D DQF-COSY and HMQC 
techniques) were run on a Varian Unity Plus 300 NMR spectrometer, operating at 
299.938 MHz and 75.428 MHz, for 
1
H and 
13
C, respectively. Chemical shifts () are 
given in ppm relative to the CDCl3 solvent (
1
H, 7.27; 13C,  77.36) as internal 
standard. For 
1
H and 
13
C spectra recorded in D2O, chemical shifts (d) are given in ppm 
relative to TSP as internal reference (1H, d 0.0) and tert-butanol as external reference 
(
13
C, CH3  30.29). The Gd
3+
 concentration of the complex preparation used for in vivo 
MRI was determined by inductively coupled plasma optical emission spectrometry. 
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2.4.2. [2-(N-t-Butoxycarbonyl)benzamido]-methoxycarbonylethyl- 1,4,7,10-
tetrazacyclododecane-monoalkylated cyclen (4) 
K2CO3 (4.07 g, 29.5 mmol) was added to a solution of cyclen (1.27 g, 7.37 mmol) in 
MeCN (50 ml). To this solution was added (Ph, Boc)-Δ-AlaOMe 2 (1.5 g, 4.91 mmol). 
The suspension was stirred vigorously at room temperature for 3 h. The suspension was 
filtered and the filtrate was evaporated under reduced pressure. The residue was purified 
by flash chromatography [100% CH2Cl2CH2Cl2/EtOH/NH3/H2O (70:30:5:5)] to 
afford compound 4 as a viscous light yellow oil (1.34 g, 59.1%). 
1
H NMR (300 MHz, 
CDCl3): = 1.47 (s, 9H, Boc), 2.50–2.90 [m, 16H, N(CH2)2N], 3.01 (dd, J = 14.1 and 6 
Hz, 1H, NCHaHbCH), 3.49 (dd, J = 14.4 and 5.1 Hz, 1H, NCHaHbCH), 3.76 (s, 3H, 
C(O)OCH3), 5.25 (t, J = 6 and 5.1 Hz, 1H, NCHaHbCH), 7.30–7.70 (m, 5H, Ar). 13C 
NMR (75.4 MHz, CDCl3): d = 27.27 [C(CH3)3], 44.77 (CH2), 45.83 (CH2), 46.70 
(CH2), 51.27 (CH2), 52.51 (OCH3), 55.61 (NCH2CH), 56.08 (CH), 83.88 [C(CH3)3], 
127.87 (Ar), 127.96 (Ar), 131.27 (Ar), 137.02 (Ar), 152.72 [NC(O)O], 170.57 
[C(O)Ph], 172.62 [C(O)OCH3]. HRMS (ESI): m/z – calcd for C24H39N5O5, 478.3029; 
found, 478.3024.  
2.4.3. 2-Benzamido-methoxycarbonylethyl-4,7,10-tris- (ethoxycarbonylmethyl)-
1,4,7,10-tetrazacyclododecanetetraalkylated cyclen (5) 
A solution of monoalkylated cyclen 4 (1.30 g, 2.72 mmol) in a solution of 
trifluoroacetic acid in dichlorometane (60%, 25 ml) was stirred overnight at room 
temperature. The solvent was evaporated at reduced pressure and the residue was 
redissolved in dichloromethane. This procedure was repeated several times to give a 
light yellow thick oil. 
1
H NMR spectroscopy (CDCl3) revealed the disappearance of the 
signals assigned to the Boc groups in the precursor compound 4. Quantitative 
deprotection was assumed. To a solution of Boc-deprotected compound 4 (2.72mmol, 
assuming quantitative deprotection) in MeCN (40 ml) was added K2CO3 (4.51 g, 
32.6mmol). The suspension was vigorously stirred for 30min at room temperature 
before adding ethyl bromoacetate (1.06ml, 9.52mmol). The suspension was further 
stirred at room temperature for 2.5 h. The suspended solid was removed by filtration, 
the filtrate was evaporated under reduce pressure and the residue was purified by flash 
chromatography [100% CH2Cl2CH2Cl2/EtOH (1:1] to afford compound 5 (0.632 g, 
37%) as a white foam. 
1
H NMR (300MHz, CDCl3): d=1.22 (m, 9H, CH2CH3), 2.2–3.60 
(broad, overlapped signals with a integration corresponding to, 24 H, NCH2 and 
NCHaHbCH), 3.71 (s, 3H, C(O)OCH3), 4.14 (m, 6H, CH2CH3), 5.14 [m (br), 1H, 
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NCHaHbCH], 7.44–8.03 (m, 5H, Ar). 
13
C NMR (75.4MHz, CDCl3): selected signals: 
13.95 (CH2CH3), 48.74 (CH), 49.04 (CH2), 50.38 (CH2), 51.48 (CH2), 52.59 (CH2), 
52.95 (OCH3), 53.62 (CH2CH), 53.62 (CH2), 54.86 (CH2), 54.96 (CH2), 55.19 (CH2), 
55.37 (CH2), 55.75 (CH2), 56.18 (CH2), 60.62 (CH2), 60.94, 61.13, 61.21 (OCH2), 
127.83 (Ar), 128.12 (Ar), 128.41 (Ar), 131.53 (Ar), 131.84 (Ar), 132.62 (Ar), 167.79 
(C(O)Ph), 170.29 [2X C(O)OCH2], 170.52 [C(O)OCH3], 170.91 [C(O)OCH2]. HRMS 
(ESI): m/z – calcd for C31H49N5O9, 636.3609; found, 636.3590. 
2.4.4. 2-Benzamido-carboxyethyl-4,7,10-tris-(carboxymethyl)- 1,4,7,10-
tetrazacyclododecane-DO3A-N-(-benzoylamido) propionate metal chelator (L1) 
Compound 5 (0.566 g, 0.89 mmol) was dissolved in a mixture made up of 20 ml of 
water and 20 ml of ethanol. The solution was adjusted to pH ~ 10–11 by adding small 
portions of Dowex 1X2 OH
-
 resin. The suspension was kept under stirring at room 
temperature for 2 h. The wet resin was transferred into a chromatography column, 
washed with water (~50 ml) and eluted with 0.1 M hydrochloric acid. The relevant 
fractions, identified by TLC (ethanol water 1:1, revelation with iodine vapor) were 
pooled, concentrated at room temperature and further dried under vacuum to afford the 
final deprotected compound, in the hydrochloride form, as a light yellow solid (L1) 
(0.276 g, 71.2%). 
1
H NMR (300 MHz, CDCl3): d = 2.9–3.6 [broad, overlapped signals 
with a integration corresponding to, 18 H, N(CH2)2N and NCHaHbCH], 3.81 (broad, 
overlapped signals with a integration corresponding to, 6H, NCH2), 4.80 (m (br), 1H, 
CH), 7.53–7.88 (m, 5H, Ar). 13C NMR (75.4 MHz, CDCl3): selected signals: 43.02 
(CH2), 48.11 (CH2), 48.93 (CH2), 49.03 (CH2), 49.78 (CH2), 51.39 (CH2), 51.71 (CH), 
51.91 (CH2), 54.53 (CH2), 56.08 (CH2), 56.77 (2x CH2), 127,46 (2X Ar), 129,04 (2X 
Ar), 132,60 (Ar), 133.32 (Ar), 170.20 [C(O)], 177.17 [C(O)Ph]. HRMS (ESI): m/z – 
calcd for C24H36N5O9, 538.2513; found, 538.2508. 
2.4.5. 
1
H and 
17
O NMR and 
1
H NMRD Experiments 
2.4.5.1. Sample preparation 
To an aqueous solution of the ligand (pH = 5.0) was added drop-wise an aqueous 
solution of the corresponding LnCl3
.
H2O lanthanide in a 1:1 mole ratio. The solution 
was stirred at room temperature over 1 h while keeping its pH at around 5.7 by adding 
aqueous KOH. The solution was left stirring at room temperature overnight. The 
solution was concentrated under reduced pressure to afford off white solids. The 
solutions for NMR measurements were obtained by dissolution of the appropriate 
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amounts of solid complexes in D2O (V = 1 ml) to obtain 20mM concentrations. Proton 
1D spectra of the solutions of the paramagnetic (Sm
3+
 and Eu
3+
) and diamagnetic (La
3+
) 
complexes were obtained at 298 K on a Varian VNMRS 600 (14.09 T, 600.14MHz) 
NMR spectrometer and the temperature dependence of the 
1
H NMR spectra of the Eu
3+
 
complex on a Varian Unity Plus 300 NMR spectrometer.  
The solutions of the GdL1 complex for 
17
O NMR and 
1
H NMRD experiments were 
prepared by mixing equimolar amounts of GdCl3 and ligand. A slight excess (5%) of 
ligand was used. The solution was adjusted to pH ~5.8 with aqueous NaOH and was 
allowed to react for 24 h at room temperature. The absence of free metal was checked in 
each sample by testing with xylenol orange (50, 51). HPLC analysis (RP C18 silica, 
isocratic elution with acetonitrile–water (70:30), detection at =265nm) of an aqueous 
solutiom of the Gd[DO3A-N-(-benzoylamido)propionate] complex (8 mM, pH 7.0) 
indicated that the complex was >95% pure (Figure SI2.5). The pH of the stock solution 
was adjusted by adding aqueous NaOH (0.1 mM). 
17
O-enriched water (
17
O: 11.4%) was 
added to the solutions for 
17
O measurements to improve sensitivity. The final 
concentration of the complex solution was 17.56 mmol kg
-1
 at pH = 6.90. For the 
NMRD experiments, a 5.00 mM solution of complex at pH 6.98 was used. 
2.4.6. 
17
O NMR Experiments 
Variable-temperature 
17
O NMR measurements were performed on a Bruker Avance-500 
(11.7 T) spectrometer. A BVT-3000 temperature control unit was used to stabilize the 
temperature, measured by a substitution technique. The samples were sealed in glass 
spheres that fitted into 10mmo.d. NMR tubes, to eliminate susceptibility corrections to 
the chemical shifts [52]. Longitudinal relaxation rates (1/T1) were obtained by the 
inversion recovery method, and transverse relaxation rates (1/T2) by the Carr–Purcell–
Meiboom–Gill spin-echo technique. As an external reference, acidified water of pH 3.4 
was used. 
2.4.7. NMRD Measurements 
The measurements were performed by using a Stelar Spinmaster FFC NMR relaxometer 
(0.01–20 MHz) equipped with a VTC90 temperature control unit. At higher fields, the 
1
H relaxivity measurements were performed on a Bruker Electromagnet at the 
frequencies of 30, 40, 60 and 80 MHz. In each case, the temperature was measured by a 
substitution technique. Variable temperature measurements were performed at 25 and 
37 C. 
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2.4.8. Relaxivity Studies of pH Dependence and Zn
2+
 Transmetallation  
The transmetallation reaction of GdL1 with Zn
2+
 was studied by following the time-
dependent decrease of the water proton longitudinal relaxation rate, R1, of a phosphate-
buffered saline solution (PBS, pH 7.1, 10mM) containing 1.5mM of GdL1 after adding 
an equimolar amount of ZnCl2 while the sample was vigorously stirred (53). The water 
longitudinal relaxation rate was also measured as a function of time on the PBS 
buffered solution (pH 7.1, 10mM) containing 2.5mM GdL1 (54). The pH dependence 
of the relaxivity of the GdL1 solution was also measured. A Bruker Minispec mq20 (20 
MHz, 298 K) relaxometer was used for all measurements. 
2.4.9. MRI Experiments 
2.4.9.1. In vivo MRI studies 
The experimental protocols performed were approved by the appropriate institutional 
review committees and meet the guidelines of their responsible governmental agency. 
The MRI experiments were all performed on a Bruker Pharmascan platform (Bruker 
Medical Gmbh, Ettlingen, Germany) using a 7.0 T horizontal-bore superconducting 
magnet, equipped with a 
1
H selective 60mm birdcage resonator and a Bruker gradient 
insert with 90mm diameter (maximum intensity 360 mT m
-1
). Data were acquired using 
a Hewlett-Packard console running Paravision software (Bruker Medical Gmbh, 
Ettlingen, Germany) under a LINUX environment.  
All MRI examinations were carried out on male Wistar rats (n = 4, 250–260 g body 
weight) anesthetized initially by inhalation in an induction box with O2 (1 Lmin
-1
) 
containing 3% isoflurane, and maintained during the experiment using a face mask 
allowing free breathing and 1 – 2% isoflurane on O2. Animals were taped down into a 
holder, to minimize breathing-related motion, and were then placed in a heated probe, 
which maintained the core body temperature at 37 ± 0.5 ºC, monitored by a rectal probe. 
The physiological state of the animal was monitored throughout the entire experiment 
by a Biotrig physiological monitor (Bruker Medical Gmbh, Ettlingen, Germany), using 
the respiratory rate and body temperature. Solutions, 100mM, of Gd [DO3A-N-(-
benzoylamido)propionate] (GdL1) and Gd(DTPA) (MagnevistW, Schering, Berlin, 
Germany) were prepared in distilled water and the pH was adjusted to 7.2. The 
solutions were injected into the catheterized tail vein as a bolus in 20 s (0.1 mmol Gd 
kg
-1
 body weight) using an infusion pump (Panlab, Barcelona, Spain). Regional contrast 
agent uptake was assessed using DCE MRI. DCE MRI experiments were performed 
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with series of T1-weighted spin echo images sequentially acquired over 1 h, before and 
following the injection of the contrast agent 10 min after the beginning of the study. The 
acquisition parameters were: TR = 310ms, TE = 10.58ms, number of averages = 2, 10 
coronal slices, slice thickness = 2mm, field of view= 5.0 x 5.0 cm, matrix = 256 x 256, 
30 repetitions with a total acquision time of 119 s. 
2.4.9.2. MRI data analysis 
Data were analyzed with the public domain software Image J (http://rsbweb.nih.gov/ij/). 
With the aim of comparing the pharmacokinetics obtained from different animals, the 
data were normalized by calculating the percentage of relative, rather than absolute, 
enhancement: 
   
(    )
  
     
 
where I is the signal intensity at any given time after CA injection and I0 is the intensity 
before injection. Pharmacokinetic behavior was analyzed by calculating the average 
enhancements within the different regions of interest placed on each one of the 
following regions: liver, kidney medulla, kidney cortex and muscle. 
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Figure SI2.1- 
1
H NMR spectra (300 MHz, D2O) for the Eu(DO3A-N-(-
benzoylamido)propionate) complex at different temperatures. 
 
 
Figure SI2.2- Temperature dependency of the water proton longitudinal paramagnetic 
relaxation rates R1p (20 MHz, 25 ºC) for a 1.5 mM solution of Gd(DO3A-N-(-
benzoylamido)propionate. 
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Figure SI2.3- pH dependency of the water proton longitudinal paramagnetic relaxation rates R1p 
(20 MHz, 25 ºC) for a 1.5 mM solution of Gd(DO3A-N-(-benzoylamido)propionate. 
 
 
 
Figure SI2.4- Dependency of  the water proton longitudinal paramagnetic relaxation rates on 
the concentration of the GdL1 complex in water (triangles), and  in the presence of  4% (0.6 
mM) HSA (circles) in water and in a phosphate buffer (PBS, 5 mM, pH = 7.1) (diamonds) (20 
MHz, 298 K).  
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Figure SI2.5- HPLC chromatogram (RP C18 silica, isocratic elution with acetonitrile/water 
(70:30), detection at  = 265 nm) for a GdL1 aqueous solution (8 mM, pH 7.0). 
 
 
Equations used for the analysis of NMRD and 
17
O NMR data 
 
NMRD and 
17
O NMR data have been analysed within the framework of the Solomon-
Bloembergen-Morgan theory.  
 
 
17
O NMR spectroscopy 
 
From the measured 
17
O NMR relaxation rates and angular frequencies of the 
paramagnetic solutions, 1/T2 and , and of the acidified water reference, 1/T2A and , 
one can calculate the reduced relaxation rates and chemical shifts, 1/T2r and r, which 
may be written as in Equations (A1)-(A2), where, 1/T2m is the relaxation rate of the 
bound water and m is the chemical shift difference between bound and bulk water, m 
is the mean residence time or the inverse of the water exchange rate kex and Pm is the 
mole fraction of the bound water [1, 2].
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Previous studies have shown that outer sphere contributions to the 
17
O relaxation rates 
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are negligible [3].
 
 
In equation (A2) the chemical shift of the bound water molecule, m, depends on the 
hyperfine interaction between the Gd
III
 electron spin and the 
17
O nucleus and is directly 
proportional to the scalar coupling constant, 

A
, as expressed in Equation (A3) [4].
 
 

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The isotopic Landé g factor is equal to 2.0 for the Gd
III
, B represents the magnetic field, 
and kB is the Boltzmann constant. 
 
The outer-sphere contribution to the chemical shift is assumed to be linearly related to 
Δωm  by a constant Cos [Equation (A4)] [5].
 
 
 
Δωos= C osΔωm  (A4) 
 
In the transverse relaxation, the scalar contribution, 1/T2sc, is the most important 
[Equation (A9)]. 1/s1 is the sum of the exchange rate constant and the electron spin 
relaxation rate.  
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The exchange rate is supposed to obey the Eyring equation. In equation (A7) S‡ and 
H‡ are the entropy and enthalpy of activation for the water exchange process, and 
kex
298
 
 
is the exchange rate at 298.15 K. 
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The measured longitudinal proton relaxation rate, R1
obs
= 1/T1
obs
, is the sum of a 
paramagnetic and a diamagnetic contribution as expressed in Equation (A12), where r1 
is the proton relaxivity: 
 
][+R=R+R=R +dpdobs 311111 Gdr  (A8) 
 
The relaxivity can be divided into an inner and an outer sphere term as follows: 
 
1os1is1 r+r=r  (A9) 
 
The inner sphere term is given in Equation (A14), where q is the number of inner sphere 
water molecules [6].
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The longitudinal relaxation rate of inner sphere protons, 1/T1m
H
 is expressed by 
Equation (A11), where rGdH is the effective distance between the electron charge and the 
1
H nucleus, I is the proton resonance frequency and S is the Larmor frequency of the 
Gd
III
 electron spin. 
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                for  (A12) 
 
where RH is the rotational correlation time of the Gd-Hwater vector. 
 
 
The rotational correlation time, RH is assumed to have simple exponential temperature 
dependence with an ER activation energy as given in equation (A13). 
 
1 1 1 1
di m RH ieT  
   1,2=i
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 (A13) 
 
The outer-sphere contribution can be described by Equation (A14) where NA is the 
Avogadro constant, and Jos is its associated spectral density function as given by 
Equation (A15). [8, 9]
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The longitudinal and transverse electronic relaxation rates, 1/T1e and 1/T2e are expressed 
by Equation (A16)-(A17), where v is the electronic correlation time for the modulation 
of the zero-field-splitting interaction, Ev the corresponding activation energy and 
2
 is 
the mean square zero-field-splitting energy. We assumed a simple exponential 
dependence of v versus 1/T as written in Equation (A18). 
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The diffusion coefficient for the diffusion of a water proton away from a Gd
III
 complex, 
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DGdH, is assumed to obey an exponential law versus the inverse of the temperature, with 
an activation energy EDGdH, as given in Equation (A19). DGdH
298
 is the diffusion 
coefficient at 298.15K. 
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3 - Ln[DO3A-N--
(pyrenebutanamido)propionate] complexes: 
optimized relaxivity and NIR optical 
 
 Adapted from Dalton Trans., 2014, 43, 3162-3173 
We have proposed recently that the DO3A-N-α-(amino)propionate chelator and its 
amide conjugates are leads to targeted, high relaxivity, safe contrast agents for magnetic 
resonance imaging. In this work we illustrate further the expeditious nature and 
robustness of the synthetic methodologies developed by preparing the DO3A-N-(α- 
pyrenebutanamido)propionate chelator. Its Gd
3+
 chelate retains the optimized water 
exchange, high stability and inertness of the parent complex. The pyrene moiety imparts 
concentration- dependent self-assembly properties and aggregation-sensitive 
fluorescence emission to the Gd
3+
 complex. The Gd
3+
 complex displays pyrene-centred 
fluorescence whilst the Yb
3+
 and Nd
3+
 complexes exhibit sensitized lanthanide-centred 
near-infrared luminescence. The aggregated form of the complex displays high 
relaxivity (32 mM
−1
 s
−1
, 20 MHz, 25 °C) thanks to simultaneous optimization of the 
rotational correlation time and of the water exchange rate. The relaxivity is however still 
limited by chelate flexibility. This report demonstrates that the DO3A-N-(α-
amino)propionate chelator is a valuable platform for constructing high relaxivity CA 
using simple design principles and robust chemistries accessible to most chemistry labs. 
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3.1 Introduction 
Positron emission tomography (PET), single photon emission correlated tomography 
(SPECT), magnetic resonance imaging (MRI), ultra sound (US), and X-ray 
computerized axial tomography (CAT) are imaging modalities used nowadays regularly 
in hospitals for diagnostic and prognostic purposes [1]. MRI has become in recent years 
the most useful imaging modality in the clinical setup. This results from its superb 
spatial resolution, use of non-ionizing radiation (radiofrequencies and magnetic fields), 
depth independent imaging and the possibility of repeated imaging to offset the low 
detection sensitivity of MRI which is intrinsic to the nuclear magnetic resonance 
phenomenon. Signal intensity differences in MRI (contrast) arise mainly from intrinsic 
differences of the relaxation times (T1,2) of the water protons of tissues. The contrast 
between normal and diseased tissues can be dramatically improved by paramagnetic 
contrast agents (CA) (Gd
3+
, Mn
2+
, stable nitroxide radicals, iron oxide nanoparticles, 
etc.), which shorten the relaxation times of the water protons [2]. Relaxivity (r1,2), 
which is the paramagnetic enhancement of water proton relaxation rates R1,2 (R1,2 = 
1/T1,2) normalized to 1 mM concentration, measures CA efficacy [2, 3]. The currently 
used CAs for T1-weighted MRI imaging are Gd
3+
 chelates of linear (DTPA-type) or 
macrocyclic (DOTA-type) poly(aminocarboxylate) chelators. Due to its long electronic 
relaxation times and high paramagnetism, Gd
3+
 efficiently enhances T1 relaxation, 
resulting in signal intensity enhancement and bright images – positive contrast [4]. High 
relaxivity CA can lead to T1 reductions sufficient to generate effective contrast at low 
doses. Moreover, delivering CA to diseased areas can allow further dose reduction. 
Effective contrast at low CA doses (CAs in clinical use are normally used at a dose of 
0.1 mmol kg
−1
) became more important recently with the identification of the 
nephrogenic systemic fibrosis (NSF) which is a debilitating and even deadly condition 
associated with in vivo Gd
3+
 release from Gd-based CAs [5]. In fact, free (non-
complexed) Gd
3+
 (and all the other Ln
3+
 ions) are acutely toxic. Most NSF cases have 
been associated with the use of Gd
3+
 DTPA-type complexes, particularly Gd(DTPA-bis-
amide) CA [6]. Low thermodynamic stability and kinetic lability, coupled to slow 
kidney clearance, results in extensive complex demetallation in vivo [7]. Macrocyclic, 
DOTA-type Gd
3+
 complexes are generally considered safe given their higher 
thermodynamic stability and kinetic inertness [8]. Chelates displaying simultaneous 
optimization of the molecular parameters that govern relaxivity, namely the rotational 
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correlation time (R), the water exchange rate (kex= 1/M) and the electronic relaxation 
parameters, are expected to display very high relaxivities [9]. There are well established 
strategies for tuning R and kex into the optimal range to attain high relaxivities at 
intermediate fields relevant for clinical MRI. Tuning the Gd
3+
 ion electronic relaxation 
parameters turns out to be more challenging [10]. Increasing the molecular weight of 
chelates leads to longer rotational correlation times (R) (slower tumbling rates) 
enhancing CA relaxivity at intermediate fields. 
Self-assembly of amphiphilic chelates into micelle-type supramolecular structures [11], 
non-covalent association with serum albumin [12] and covalent attachment of chelates 
to macromolecular and nanoobjects (proteins [13], dendrimers [14], nanoparticles [15], 
viral capsules [16], quantum dots [17], etc.) are well established strategies to tune R. 
Replacement of an ethylenediamine by a propylenediamine bridge or a pendant acetate 
by a propionate group on the DOTA and DTPA scaffolds enforces steric compression 
around the water binding site on Gd
3+
 complexes, leading to accelerated water exchange 
[11, 18, 19]. A pendant propionate group leads to water exchange rate enhancements 
suitable for attaining high relaxivities at intermediate fields, without compromising the 
thermodynamic and kinetic stability of the chelates [18, 20, 21]. Still, connecting 
linkers/spacers permit fast local rotational motions of the immobilized chelates 
superimposed on global slow rotational motions of the (entire) macromolecular object, 
resulting in suboptimal effective rotational correlation times [11, 15].  
Endowing targeted high relaxivity Gd
3+
 chelates with a fluorescence reporting 
capability results in bimodal MRI/fluorescence imaging agents. This approach has the 
potential to improve CA performance: the high detection sensitivity of fluorescence 
complements the low detection sensitivity of MRI, whilst the depth independent 
properties of MRI complement the limited light crossing into live tissues [22]. 
Conjugates of metal chelate-fluorophores [23], quantum dots [17, 24], silica 
nanoparticles [25, 26] and other nanomaterials functionalised with Gd
3+
 chelates have 
been described as bimodal MRI/fluorescence imaging agents. The aggregation sensitive 
fluorescence properties of the pyrene fluorophore [27] make pyrene conjugates 
especially attractive as ―responsive‖ probes for structural [28], biochemical and cellular 
studies [29] and as chemical sensors [30]. Moreover, pyrene has been used as an 
antenna for sensitizing near infrared (NIR) emitting Ln
3+
 ions (Yb
3+
, Nd
3+ 
and Er
3+
) in 
DOTA and DTPA chelates [31, 32].  
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We have recently described methodologies for the synthesis of the DO3A-N-(α-
amino)propionate chelator and for preparing its amide conjugates [18, 21]. Gd
3+
 
complexes of those amide conjugates retain the optimal water exchange, high stability 
and kinetic inertness of the parent complex [18]. In this work we describe the synthesis 
of the pyrenebutyric acid conjugate of the DO3A-N-(α-amino)propionate chelator and 
its Ln
3+
 complexes. The effect of self-assembly on the relaxivity and fluorescence 
properties of the Gd[(DO3A-N-(α-pyrenebutanamido)-propionate)] complex was 
studied by relaxometry and steady state fluorescence. The potential of the pyrene 
moiety to sensitize NIR emitting Ln
3+
 ions has also been addressed. 
3.2 Results and discusion 
3.2.1 Synthesis 
The DO3A-N-(α-pyrenebutanamido)propionate chelator (L) was synthesised following 
the (indirect) methodology proposed before for amide conjugates of the DO3A-N-(α-
amino)propionate chelator (Scheme 3.1) [21].  
 
Scheme 3.1- Synthetic pathway for the metal chelator DO3A-N-(α-
pyrenebutanamido)propionate (L) and its Ln
3+
 complexes LnL: (a) K2CO3/MeCN; (b) i. 
TFA/DCM, ii. ethyl bromoacetate, K2CO3/MeCN; (c) i. Dowex 1X2 OH
−
, ii. elution with 
hydrochloric acid 0.1 M; (d) LnCl3·xH2O. 
The N-(α-pyrenebutanamido)propionate pendant group was introduced, early on the 
synthesis, into the cyclen scaffold via Michael addition of the dehydroalanine (Pyrene, 
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Boc)-Δ-AlaOMe reactive block 4. Synthetic block 4 was prepared in 2 steps in 70% 
overall yield following the procedure developed by Ferreira et al. (Scheme 3.2) [33]. 
 
Scheme 3.2- Synthesis of the dehydroalanine (Pyrene, Boc)-Δ-AlaOMe reactive block (4): (a) i. 
TEA 2 molar equivalents/MeCN, ii. DCC/HOBt; (b) Boc2O, DMAP, dry MeCN. 
 
After removing the tert-butyloxycarbonyl protecting group from the monoalkylated 
intermediate 6 with TFA, one pot N-alkylation of the cyclen scaffold with ethyl 
bromoacetate afforded prochelator 7. Alkaline deprotection of 7 with Dowex 1X2 OH
−
 
resin, followed by resin elution with diluted hydrochloric acid, afforded the DO3A-N-
(α-pyrenebutanamido)propionate chelator (L) as hydrochloride in 30% overall yield 
over 3 steps. Recently, Caravan and co-workers have reported a similar pathway for the 
synthesis of conjugates of the DO3A-N-(α-amino)propionate chelator [34]. The 
synthesis of the DO3A-N-(α-pyrenebutanamido)propionate chelator further supports the 
use of the indirect pathway for amide conjugates of the DO3AN-(α-amino)propionate 
chelator. 
 
3.2.2 Relaxometric studies of the GdL complex 
The concentration dependence of the paramagnetic water proton relaxation rate (R1p) 
was evaluated for GdL (20 MHz, 25 °C, pH 7.0) in the concentration range 0.05–5.0 
mM (Figure 3.1).  
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Figure 3.1- Concentration dependence of the paramagnetic water proton longitudinal relaxation 
rate       
      
   for GdL (20 MHz, 25 °C, pH 7.0). 
 
The paramagnetic longitudinal relaxation rate data vs. [GdL] define two straight lines 
with different slopes. This behavior is characteristic of chelate self-assembly in aqueous 
solution, presumably into micelle-type structures, driven by the hydrophobic effect [11]. 
The break point gives an estimation of the critical micelle concentration, cmc (0.60 ± 
0.02 mM), for GdL. Below the cmc, the complex is in a monomeric, nonaggregated 
form in solution (eq 1).  
      
      
    
         (1) 
Above the cmc, it is present in the form of aggregates as well as monomers whose 
concentration corresponds to the cmc (eq 2). 
      
      
  (  
       
  )        
        (2) 
   
  is the diamagnetic contribution to the longitudinal relaxation rate (the relaxation 
rate of pure water),   
     (6.86 ± 0.03 mM
−1
s
−1
) represents the relaxivity of the free, 
non-aggregated Gd
3+
 chelate,   
   (33.11 ± 0.04 mM
−1
s
−1
) is the relaxivity of the micellar 
(aggregated) form and CGd is the analytical Gd
3+
 concentration. 
The micellar nature of GdL above the cmc (5.0 mM, pH 7.0) was confirmed by 
dynamic light scattering (DLS) analysis (Figure SI3.1). A bimodal intensity 
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distribution, with the main population of particles displaying an average radius of 1.7 
nm and a minor population exhibiting an average radius of 73 nm, was obtained by 
DLS, resulting in a population weighted mean hydrodynamic radius, expressed by the z-
average parameter, of 49 nm. The temperature (Figure SI3.2) and pH dependences 
(Figure SI3.3) of the paramagnetic water proton relaxation rate were studied at 20 
MHz. Transmetallation studies against Zn
2+
 ions were also performed to evaluate the 
kinetic inertness of the complex (Figure SI3.4). The temperature dependence study 
strongly suggests that below 50 °C, the relaxivity is not limited by slow water exchange. 
The pH-dependence and the transmetallation studies indicate that the GdL complex, like 
its non-associating Gd[(DO3A-N-(α-benzoylamido)propionate)] analogue, is stable 
towards protonation-assisted demetallation and inert towards transmetallation with Zn
2+ 
[21]. 
3.2.3 17O NMR and 1H NMRD studies 
The magnetic field dependence of the longitudinal water proton relaxivities (
1
H NMRD 
profiles) of GdL was recorded at 25 °C and 37 °C in the frequency range 0.01 to 80 
MHz and at concentrations below (Figure 3.2) and above (Figure 3.3c) the cmc. 
 
Figure 3.2- 
1
H nuclear magnetic relaxation dispersion (NMRD) profiles of GdL in the monomer 
state at 0.3 mM at 25 °C (▲) and 37 °C (■). The curves represent results from the fittings as 
described in the text. 
 
 The NMRD curves are influenced by many parameters, the most important being the 
hydration number (q), the water exchange rate (kex), the electron relaxation parameters 
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(v and 2) and the rotational correlation time (R). The NMRD measurements have 
been completed with 
17
O NMR data (Figure 3.3a and b).  
.  
Figure 3.3- Temperature dependence of (a) reduced longitudinal, T1r (■), and transverse, T2r 
(▲), relaxation times and (b) chemical shifts (Δωr) of a micellar aqueous solution of GdL at 
11.7 T (5.0 mM, pH 7.0); (c) NMRD profiles of the aggregated micellar state (2.5 mM, pH 7.0) 
at 25 °C (■) and 37 °C (▲) after subtraction of the relaxation contribution of the monomer 
form. The curves represent results from the simultaneous fittings as described in the text. 
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Indeed, from variable temperature 
17
O T2 measurements, one can accurately determine 
the water exchange rate. The rotational correlation time can be assessed by variable 
temperature 
17
O T1 measurements. On the other hand, variable temperature 
measurements of the chemical shift difference between bulk and bound water (r) 
give an indication of the q value. 
The proton relaxation rates measured above the cmc represent the sum of the relaxivity 
contribution of the monomer complex, present at a concentration equal to the cmc, and 
the relaxivity contribution of the aggregated state. In order to calculate the relaxivity of 
the aggregated form, the relaxivity contribution of the monomer has been subtracted 
from the relaxation rates measured above the cmc. These profiles present the 
characteristic high field peak typical of slowly tumbling Gd
3+
 complexes. The 
17
O NMR 
measurements have been performed at 5.0 mM concentration, largely above the cmc 
(0.6 mM). Under these conditions, one can consider that the rotational dynamics, as 
assessed by 
17
O T1 data, corresponds to the micellar state. Therefore, the 
17
O NMR data 
have been fitted together with the NMRD curves of the micellar state to the Solomon–
Bloembergen–Morgan theory by including the Lipari–Szabo treatment for the 
description of the rotational motion (Table 3.1) [35].  
Table 3.1- Best fit parameters obtained for the aggregated form of GdL from the simultaneous 
analysis of the 
17
O NMR and 
1
H NMRD data and for the monomer from NMRD data
a
 
 
 
 
 
 
 
 
 
 
 
 
Parameter 
Aggregated 
form 
Monomer 
H¹ [kJmol-1] 21.5 ± 1.5 21.5
 
kex
298
 [10
7
 s
-1
] 6.2 ± 0.5 6.2 
g
298
 [ps] 3780 ± 100 116 ± 5 
lO
298
 [ps] 930 ± 50 ------- 
S
2
 0.24 ±0.02 ------- 
lH
298
/lO
298
 0.80 ±0.05 ------- 
Eg[kJmol
-1
] 25.4 ± 0.7 ------- 
El[kJmol
-1
] 12 ± 1 24.3 ± 0.2 
2 [1020 s-1] 0.033 ± 0.004 0.38 ± 0.04 
v
298
 [ps] 53 ± 5 6.3 ± 0.5 
A/ћ [106 rads-1] -3. 2 ± 0.4 ------- 
a)
 Parameters in italics have been fixed; RO
298
 values from 
17
O 
T1 data. 
Ln[DO3A-N-α-(pyrenebutanamido)propionate] complexes 
111 
 
 
In this approach, two kinds of motion are assumed to modulate the interaction causing 
the relaxation, namely a rapid, local motion which lies in the extreme narrowing limit 
and a slower, global motion 
We calculate therefore g, the correlation time for the global motion (common to the 
whole micelle), and l, the correlation time for the fast local motion, which is specific 
for the individual relaxation axis and thus related to the motion of the individual Gd
3+
 
chelate units. The generalized order parameter, S, is a model-independent measure of 
the degree of spatial restriction of the local motion, with S = 0 if the internal motion is 
isotropic and S = 1 if the motion is completely restricted. 
It was assumed that the GdL complex has one inner sphere water molecule (q = 1) like 
the low molecular weight amide analogue Gd[(DO3A-N-(α-benzoylamido)propionate)] 
[21] and the parent amine Gd[(DO3A-N-(α-amino)propionate)] [18]. This assumption 
was confirmed by the value obtained for the scalar coupling parameter (A/ћ = −3.2 × 
10
6
 rad s
−1
) [36].  
The NMRD curves of the monomer sample (0.3 mM) have been analyzed by fixing the 
water exchange parameters (   
    , ΔH‡) to those obtained from the 17O NMR data. In 
the fits, we have fixed the rGdH distance to 3.10 Å and the distance of closest approach 
of the bulk water protons to the Gd
3+
, aGdH, to 3.65 Å. The diffusion constant has been 
fixed to 23 × 10
−10
 m
2
s
−1
 and its activation energy to 20 kJmol
−1
. 
The NMRD profile for the monomeric form is characteristic of low molecular weight 
complexes (Figure 3.2). The relaxivity at intermediate field (5.9 mM
−1
s
−1
; 25 °C, 20 
MHz) is dominated by fast rotation in solution as indicated by the short R value 
obtained (116 ps). In contrast, above the cmc the NMRD profile of GdL displays a 
hump at intermediate field, typical of slow tumbling species (Figure 3.3c) (11, 15, 35). 
The relaxivity decreases with increasing temperature, indicating that it is not limited by 
slow water exchange. The same behaviour was previously observed for gold 
nanoparticles functionalized with the analogous cysteine conjugate Gd[(DO3A-N-(α-
cystamido)propionate)] [15]. The water exchange rate on GdL is similar to that reported 
for the low molecular weight amide analogue Gd[(DO3A-N-(α-
benzoylamido)propionate)] [21] and slightly higher than that reported for the parent 
Gd[(DO3A-N-(α-amino)propionate)] [18] complex (   
    /10
7
= 6.2, 5.7 and 4.0 s
−1
, 
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respectively). This value is in the ideal range for attaining high relaxivities at 
intermediate magnetic fields relevant for clinical applications [19]. 
The Lipari–Szabo analysis of the longitudinal 1H and 17O relaxation rates allows 
separating fast local rotational motions of the chelate (Rl = 930 ps) from the global 
rotational correlation time (Rg = 3780 ps) of the micellar aggregate. The value of the 
order parameter for GdL (S
2
 = 0.24) is similar to those calculated for amphiphilic 
DOTA-type complexes functionalized with hexadecyl alkyl chains: Gd(DOTASAC18) 
(37) and Gd (DOTAMAP-En-C18) (38) (S
2
 = 0.24 and 0.28, respectively) (Figure 3.4 
and Table 3.2). 
 
Figure 3.4- Structure of amphiphilic DOTA-type ligands compared in Table 3.2 and discussed 
in the text. 
 
Table 3.2- Molecular parameters for amphiphilic DOTA-type complexes 
Chelate MW 
(g/mol) 
cmc 
(mM) 
l
298
 
(ps) 
g
298
 
(ps) 
S
2
 kex
298 
(x10
7
s
-1
) 
r1
m 
 
(mM
-1
s
-1
)
 f
 
GdL1
a 
881.2 0.06 330 2810 0.28 0.48 20.7 
GdL2
b 
881.2 - 271 2696 0.21 8.12 24,2 
GdL3
c 
1036 <0.1 820 4700 0.70 0.34 34,8 
GdL4
d 
1285 0.004 135 5206 0.78 0.30 35 
GdL
e 
857 0.6 930 3780 0.24 6.2 32,2 
 
aref 37; bref. 38; cref. 40; dref. 39;ethis work; f(20MHz, 25ºC) 
 
Complexes functionalised with two long alkyl chains, Gd-[(C18)2DOTAda)] [39] and 
Gd[(DOTA(GAC12)2)] [40], are characterized by substantially higher order parameters 
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(S
2
 = 0.78 and 0.70, respectively). Tighter packing of the monomers and double 
anchoring through adjacent sites into the micelle structure restrict internal rotational 
movements of the chelates. 
Moreover, the complex Gd[(C18)2DOTAda)] functionalized with two alkyl chains 
displays a much lower cmc value than the complex Gd(DOTASAC18) functionalised 
with one alkyl chain. In this respect, the GdL complex displays a relatively high cmc 
value (0.6 vs. 0.06 and 0.004 mM for Gd-[(C18)2DOTAda)] and Gd(DOTASAC18), 
respectively) reflecting probably the aromatic nature of the pyrene lipophilic moiety and 
the deviation of the overall shape of the conjugate from the wedge-like geometry which 
would be ideal for micelle formation. 
The relaxivity displayed by the micellar form of GdL (32 mM
−1
s
−1
, 20 MHz, 25 °C) is 
substantially higher than that shown by the Gd(DOTASAC18) and Gd(DOTAMAP-En-
C18) complexes (24.2 and 20.7 mM
−1
s
−1
, respectively) and it is similar to the relaxivity 
of the double chain chelates Gd-[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)] (35 and 
34.8 mM
−1
s
−1
, respectively). The high relaxivity of the double chain chelates has been 
ascribed to restricted local motions of the complex (S
2
= 0.78) and to the slow global 
rotational motion (g). Importantly, GdL displays a relaxivity similar to that of the 
double chain chelates, despite a lower global rotational correlation time (g= 3780 vs. 
5206 and 4700 ps for Gd[(C18)2DOTAda)] and Gd[(DOTA(GAC12)2)], respectively) 
and a substantially lower degree of coupling of global and local rotational motions 
(higher flexibility) (S
2
= 0.24 vs. 0.78 and 0.70 for Gd[(C18)2DOTAda)] and 
Gd[(DOTA(GAC12)2)], respectively). Importantly, the relaxivity of the double chain 
chelates is limited by slow water exchange (   
   /10
7
= 6.2 vs. 0.30 and 0.34 s
−1
 for GdL 
and Gd[(C18)2DOTAda)] and Gd[(DOTA-(GAC12)2)], respectively). 
The high relaxivity attained by GdL can be thus ascribed to simultaneous optimization 
of R and kex. The optimization of the rotational dynamics of complexes has been firmly 
established for relaxivity enhancement at intermediate fields. The simultaneous 
optimization of R and kex is far more demanding and often achieved at the expense of 
complex stability compromising potential biological applications. This study highlights 
the importance of simultaneous optimization of all molecular parameters in order to 
attain high relaxivities and provides further support for our claim that amide conjugates 
of the DO3A-N-α-aminopropionate chelator are valuable synthons for constructing high 
relaxivity safe CA for MRI. 
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3.2.4 Luminescence studies 
The Gd[(DO3A-N-(α-pyrenebutanamido)propionate)] complex was designed as a 
bimodal MRI/fluorescence probe. The pyrene fluorophore was selected to impart self-
assembly properties and concentration-dependent fluorescence reporting capability to 
the paramagnetic complex [27].  
The absorption (Figure SI3.6) and the fluorescence emission properties (Figure SI3.7) 
of the free ligand L and the GdL complex were studied in non-deoxygenated water (pH 
7.0) at concentrations well below the cmc by UV-Vis and steady-state fluorescence 
spectroscopy (Table 3.3). 
Table 3.3- Maximum absorption (λabs) and emission wavelengths (λem), molar extinction 
coefficients (ε) and fluorescence quantum yields (ΦF) for ligand L and GdL complex (λex 345 
nm) in non-deoxygenated water at concentrations below the cmc. 
 
 
 
 
 
 
 
 
 
 
At concentrations below the cmc (cmc= 2.7 mM for L, see below, and 0.6 mM for 
GdL), L and GdL display similar absorption spectra in the region characteristic of 
pyrene (300–350 nm) assigned to intraligand π–π* transitions (32).  elective irradiation 
of the pyrene chromophore on L and GdL at 345 nm yields fluorescence spectra 
displaying vibronically structured features, assigned to intraligand 1π–π* transitions, 
characteristic of pyrene monomer emission (Figure SI3.5) (32, 41). At the 
concentration studied (well below the cmc), no excimer emission (broad featureless 
band with an emission with an apparent maximum located at 490–500 nm) was 
observed for both the free ligand and the Gd
3+
 complex. The fluorescence quantum 
abs(nm) 
(/104 M-1cm-1)b 
em(nm) F
a,c
 
L GdL L GdL L GdL 
344 (3.26) 
328 (2.35) 
314 (1.00) 
277 (3.60) 
266 (2.05) 
243 (5.62) 
344 (4.43) 
328 (3.20) 
314 (1.59) 
277 (5.59) 
266 (3.78) 
243 (9.19) 
377 
397 
417 
377 
398 
418 
0.22 0.17 
a
 Relative to anthracene in ethanol (Φ = 0.27). b Ligand and complex at 1 × 10−5 
M concentration. 
c
 Ligand and complex at 1 × 10
−6
 M concentration, non-
deoxygenated solutions. 
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yields for L and for the pyrene-centred emission in GdL are of the same order of 
magnitude as those reported for other pyrene conjugates. 
Complex formation with paramagnetic Gd
3+
 seems to have only a minor effect on the 
fluorescence quantum yield of L (41). 
We envisaged that it could be possible to monitor the self-assembly process of L and 
GdL by taking advantage of the aggregation-sensitive fluorescence properties of the 
pyrenyl moiety (27). With this aim, we studied by steady-state fluorescence the effect of 
the concentration on the fluorescence properties of L (Figure SI3.7) and GdL (Figure. 
3.5). 
 
Figure 3.5- Normalized fluorescence spectra for GdL in non-deoxygenated water over the 
concentration range 1 × 10
−7
 –5 × 10−3 M (λexc= 345 nm). Inset – changes in the emission 
properties of GdL as the ratio of the fluorescence emission intensity for the excimer (IE, 490 
nm) and for the monomer (IM, 377 nm) (IE/IM) as a function of GdL concentration. 
 
For low micromolar concentrations of L and GdL, the fluorescence spectra display the 
characteristic vibronically structured pyrene monomer emission band. For higher (low 
millimolar) concentrations, the intensity of the monomer emission band is reduced and a 
new broad, red-shifted, featureless band, assigned to excimer formation, appears. The 
concentration dependence of the ratio of fluorescence emission intensity for the excimer 
(490 nm) and for the monomer (377 nm) (IE/IM) was used to determine independently 
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the cmc for L (Figure SI3.7) and GdL (Figure 3.5) by fitting the experimental data 
points to a sigmoidal curve model (Table SI3.1) [42, 43]. A cmc value of 
approximately 0.64 mM, in excellent agreement with the value determined by 
relaxometry (0.60 mM), was derived for GdL from the fluorescence study (Figure. 3.5). 
A much higher cmc value (2.7 mM) was determined for the free ligand (Figure SI3.7), 
reflecting the ionization state (multi-charged) of the free metal chelator. Below the cmc, 
the ligand and the complex are molecularly dissolved and the fluorescence arises from 
the decay of excited monomers. Above the cmc, fluorescence emission arises 
predominantly from the decay of excited dimers – excimers. Higher concentrations of 
GdL increase the number of micelles and enhance excimer formation and the 
corresponding fluorescence emission intensity. Two different mechanisms have been 
established for excimer emission: diffusive encounter of an excited monomer with a 
ground state molecule and the direct excitation of (preassociated) ground state dimers. 
The partitioning of the different modes of excimer formation depends on the fluidity of 
the micelle environment. Time-resolved fluorescence experiments suggest that the 
diffusive mechanism is the main contributor to excimer formation in cationic gemini 
surfactants containing a pyrene moiety and a long alkyl chain [44]. The order parameter 
determined for the micellar form of GdL (S
2
= 0.24) indicates that the micelles are fluid, 
suggesting that the diffusive mechanism might be responsible for excimer formation. 
Deciphering the mechanism of excimer formation in GdL micelles is outside the scope 
of the present study. The pyrene-centered fluorescence of GdL effectively provides this 
complex with MRI/fluorescence bimodal imaging agent activity. From a practical point 
of view, the pyrene centred fluorescence of GdL could be used for imaging studies in 
small animal models, for ex vivo characterization of tissue distribution, cell 
internalization and intracellular chelate localization and studies with cell lines [45]. 
Lanthanide centred fluorescence in the visible (Eu
3+
 and Tb
3+
) and in the NIR region 
(Nd
3+
, Yb
3+
) is well suited for biological imaging for the following reasons: enhanced 
light penetration into biological tissues (especially in the NIR region); elimination of 
interference from tissue auto-fluorescence using time-gating techniques; long 
wavelength excitation, far into the visible region. Very low molar absorptivities (f–f 
transitions are forbidden by Laporte‘s and parity rules) make the direct excitation of 
Ln
3+
 ions impracticable. The formation of emissive Ln
3+
 excited states requires 
sensitization by sensitizing groups that absorb excitation light and transfer the resulting 
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energy to the Ln
3+
 excited states (antenna effect), usually through ligand-centred triplet 
excited states [46]. In this study, we tested the possibility of using the pyrene 
chromophore to sensitize near infrared emitting Ln
3+
 ions in the corresponding LnL 
complexes (Ln= Nd and Yb) (Figure 3.6). 
 
Figure 3.6- Absorbance (black), excitation (λem= 1064 nm, violet) and emission (λexc= 344 nm, 
red) spectra for the NdL complex (a) and YbL complex (b) in water. 
Emission spectra of the NdL and YbL complexes under ligand excitation exhibit metal-
centred NIR emission bands at ca. 1064 nm (
4
F3/2 → 
4
F13/2) for NdL and a band with an 
apparent maximum at ca. 1000 nm (
2
F5/2 → 
2
F7/2) for YbL (31, 32). The excitation 
spectra for both luminescent Nd
3+
 and Yb
3+
 complexes are similar to each other and 
match well the profile of the corresponding absorption spectra as an indication that the 
sensitization of the lanthanide luminescence is occurring through the same electronic 
levels centred on pyrene. 
3.2.5 Interaction of GdL with human serum albumin (HSA) 
Self-assembly of chelates into supramolecular structures (as discussed in this work) and 
binding to serum albumin (HSA) are robust strategies to enhance chelate relaxivity via 
optimization of R. In addition to relaxivity enhancement, self-assembly and binding of 
chelates to HSA slow down CA leakage into the interstitial compartment, providing an 
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extended time window for vasculature imaging (MRI angiography) [47]. The binding 
affinity of GdL to HSA was assessed by Proton Relaxation Enhancement (PRE) 
measurements. The PRE methods are tailored to determine the differences in the NMR 
water solvent relaxation rates between protein-bound (resulting in an increase of the 
relaxation rates) and free substrates. Experimentally, it consists of measuring the water 
proton relaxation rates   
    in solution at increasing concentrations of the protein while 
keeping the concentration of the metal chelate constant (E-titration) or vice versa (M-
titration). The data obtained for the E-titration using a GdL concentration below the cmc 
(0.1 mM) and increasing HSA concentrations (Figure 3.7) were fitted to a one site 
binding model (eq (SI 3.1)). 
 
Figure 3.7- Proton relaxation enhancement data (20 MHz, pH 7.4) to assess HSA binding of 
GdL: E-titration at 0.1 mM GdL concentration at 25 °C and 37 °C. 
 
The fitting affords an estimation of the relaxivity of the HSA-bound form,   
  (53.1 ± 
6.7 and 47.0 ± 5.6 mM
−1
s
−1
 at 25 and 37 °C, respectively), and an apparent HSA-GdL 
association constant, KA (KA= 1/Kd) ((1.9 ± 0.1) × 10
3
 and (1.7 ± 0.1) × 10
3
 M
−1
 at 25 
and 37 °C, respectively). These values correspond to binding affinities similar to 
Gd(BOPTA)
2−
 but weaker than those for MS-325, two blood pool agents presenting 
strong HSA binding [48]. Under the limiting E-titration conditions ([GdL] = 0.1 mM 
and [HSA] = 4%), the fraction of bound chelate can be estimated as higher than 90%. 
These values are in line with those reported recently by Caravan for similar amide 
conjugates [12]. It is known that HSA has multiple binding sites. Among the many 
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studies published on HAS binding of Gd
3+
 complexes, typically those involving 
ultrafiltration experiments have reported binding to more than one independent site with 
different binding constants [49, 50]. Those stepwise binding constants show that one 
binding site is much stronger than the others, justifying the common use of a 1 : 1 
binding isotherm in interpreting the relaxometric data for albumin binding of Gd
3+
 
complexes [51]. In fact, most often relaxometric data alone do not allow for 
distinguishing between different binding models. An independent evaluation of KA and 
n may be, in principle, pursued through the analysis of the data obtained from an M-
titration, in which a fixed concentration of HSA is titrated with the Gd
3+
 complex. The 
titration of 4% HSA with GdL is restricted to the narrow range of concentrations below 
cmc precluding a quantitative analysis of the data. The interaction of GdL with HSA is 
prone to modulate the biodistribution of GdL as recently reported for similar conjugates 
[12, 52]. 
3.2.6 Biodistribution studies 
The biodistribution profile of GdL was obtained after 1 and 24 hours post-injection (pi) 
using the 
153
Sm
3+
-labelled surrogate complex (Figure 3.8 and Table SI3.2). 
 
Figure 3.8- Biodistribution, stated as a percentage of injected dose per gram of organ (%ID/g), 
of 
153
SmL in Wistar rats 1 and 24 hours after i.v. injection. Results are the mean of 4 animals. 
 
Chapter 3  
120 
 
A recent patent claims that peptides derivatised with pyrene are able to cross the blood–
brain barrier thanks to (presumably) a correct lipophilicity/hydrophilicity balance 
imparted by the pyrene moiety [53]. This intriguing possibility was considered during 
the biodistribution study. The 
153
SmL chelate displays biodistribution profiles at 1 and 
24 hours pi similar to other micellar systems [54]. After 1 hour pi there is substantial 
activity in the blood, liver, spleen and lungs. The high activity in the blood after 1 hour 
pi reflects the micellar nature of the CA and its strong association with HSA, which 
slows down leakage of the complex into the interstitial compartment. The complex 
follows both hepatic and renal elimination. The hepatic and spleen uptake reflects the 
micellar nature of the CA and the role played by resident macrophages in the liver and 
spleen (Reticulo Endothelial System, RES) in clearing particulate material from the 
blood. The activity in the lungs might again reflect the retention of particulate material 
in narrow blood vessels and the extensive vascularisation of that organ and thus the high 
blood content of the lungs. The increase in activity in the spleen and liver after 24 hours 
pi correlates with the activity clearance from the blood and lungs, suggesting particle 
retention on those organs. Interestingly, after 1 hour pi, a low activity is measurable in 
the brain/cerebellum, suggesting that the complex might cross the blood–brain barrier. 
This possibility deserves further investigation. 
3.3 Conclusions 
The pyrenebutyric acid conjugate of the DO3A-N-(α-amino)propionate chelator was 
synthesized following synthetic methodologies reported previously by us. The lipophilic 
pyrene moiety imparts a concentration-dependent self-assembly ability (presumably 
into micelles) to the Gd[(DO3A-N-(α-pyrenebutanamido) propionate)] chelate. The 
aggregated form of the Gd
3+
 chelate displays high relaxivity thanks to simultaneous 
optimization of the rotational correlation time and of the water exchange rate. 
Nonetheless, the relaxivity is still limited by internal flexibility. The Gd
3+
 complex 
displays pyrene-centred fluorescence properties sensitive to its aggregation state. The 
Nd
3+
 and Yb
3+
 complexes exhibit lanthanide-centred sensitized NIR emission. The 
surrogate 
153
Sm
3+
 complex displays a biodistribution profile similar to other micellar 
systems. Interesting applications of this probe can be based on the recent report that 
carbon-based nanomaterials (graphene, graphene oxide, carbon nanotubes) 
functionalized non-covalently with pyrene conjugates are promising for the 
development of exquisite probes for biological processes [55]. In summary, we have 
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reported recently that Gd
3+
 complexes of amide conjugates of the DO3A-N-(α-
amino)propionate chelator are new leads for targeted, high relaxivity, safe CA for in 
vivo MRI [21]. In this work we provide further evidence to support this claim using 
simple design principles and robust chemistry accessible to all laboratories. 
3.4 Experimental 
3.4.1Materials and methods 
Chemicals were purchased from Sigma-Aldrich and used without further purification. 
Solvents used were of reagent grade and purified by usual methods. Cyclen was 
purchased from CheMatech, France. Reactions were monitored by TLC on Kieselgel 60 
F254 (Merck) on an aluminium support. Detection was done by examination under UV 
light (254, 365 nm) and by adsorption of iodine vapour. Flash chromatography was 
performed on a Kieselgel 60 (Merck, mesh 230–400). The relevant fractions from flash 
chromatography were pooled and concentrated under reduced pressure, T < 313 K. Ion 
exchange chromatography was performed on Dowex 1X2 OH
−
 resin (Sigma Aldrich). 
The resin was purchased as the Cl
−
 form and converted to the OH
−
 form by treatment 
with aqueous NaOH. 
1
H and 
13
C NMR spectra (assigned by 2D DQF-COSY and 
HMQC techniques) were run on a Varian Unity Plus 300 NMR spectrometer, operating 
at 299.938 MHz and 75.428 MHz, for 
1
H and 
13C, respectively. Chemical shifts (δ) are 
given in ppm relative to the CDCl3 solvent (
1H, δ 7.27; 13C, δ 77.36) as an internal 
standard. For 
1
H and 
13
C spectra recorded in D2O, chemical shifts (δ) are given in ppm 
relative to TSP as the internal reference (
1H, δ 0.0) and tert-butanol as the external 
reference (
13C, CH3 δ 30.29).  
3.4.1.1 Synthesis of methyl 3-hydroxy-2-(4-(pyren-1-yl)butanamido)- propanoate (3).  
To a solution of HCl, H-Ser-OMe 1 (5.0 mmol, 0.778 g) and triethylamine (10 mmol) in 
acetonitrile (5.0 mL) were added 1-pyrenebutyric acid 2 (5.0 mmol, 1.44 g), 1-
hidroxybenzotriazole (HOBt) (5.0 mmol, 0.675 g) and dicyclohexylcarbodiimide (DCC) 
(5.5 mmol, 1.13 g). The reaction mixture was left stirring at room temperature for 18 
hours. The reaction mixture was filtered and the solvent was removed under reduced 
pressure. The residue was dissolved in ethyl acetate (100 mL), washed with KHSO4 1 
M, NaHCO3 1 M and brine (3 × 30 mL each) and dried over MgSO4. The solvent was 
removed to give 3 (1.70 g, 87%) as a yellow oil. 
1
H NMR (300 MHz, CDCl3): δ = 2.17–
2.26 (m, 2H, CH2), 2.37 (t, J = 7.2 Hz, 2H, CH2), 3.35–3.41 (m, 2H, CH2), 3.76 (s, 
3H,CH3), 3.86–4.00 (m, 2 H, β-CH2 Ser), 4.66–4.71 (m, 1 H, α-CH Ser), 6.49 (d, J = 7.2 
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Hz, 1H, NH), 7.84 (d, J = 7.8 Hz, 1H, ArH), 7.96–8.02 (m, 3H, ArH), 8.08–8.17 (m, 
4H, ArH), 8.28 (d, J = 9.3 Hz, 1H, ArH) ppm. 
13
C NMR (75.4 MHz, CDCl3): δ = 27.14 
(CH2), 32.58 (CH2), 35.69 (CH2), 52.72 (CH3), 54.61 (CH), 63.40 (CH2), 123.28 (CH), 
124.74 (CH), 124.75 (CH), 124.88 (CH), 124.91 (C), 125.02 (C), 125.81 (CH), 126.68 
(CH), 127.33 (CH), 127.37 (CH), 127.42 (CH), 128.70 (C), 129.91 (C), 130.82 (C), 
131.24 (C), 135.61 (C), 170.93 (C=O), 173.20 (C=O) ppm. HRMS (ESI): m/z: calcd for 
C24H23NNaO4, [M + Na]
+
: 412.1520; found 412.1519. 
3.4.1.2 Synthesis of methyl 2-[N-(tert-butoxycarbonyl)-4-(pyren-1-yl)- 
butanamido]acrylate (4). 
 To a solution of Pyr-Ser-OMe 3 (5.0 mmol, 1.95 g) in dry acetonitrile (5.0 mL) were 
added 4-dimethylaminopyridine (DMAP) (1.7 mmmol, 0.213 g) and tert-
butyldicarbonate (17.5 mmol, 3.82 g). The reaction mixture was left stirring at room 
temperature for 24 hours. The solvent was removed under reduced pressure and the 
residue was dissolved in ethyl acetate (100 mL). The organic layer was washed with 
KHSO4 1 M, NaHCO3 1 M and brine (3 × 30 mL, each), dried over MgSO4 and the 
solvent removed under reduced pressure to give 4 (1.91 g, 81%) as a yellow oil. 
1
H 
NMR (400 MHz, CDCl3): δ = 1.46 (s, 9 H, CH3 Boc), 2.23–2.27 (m, 2H, CH2), 3.17 (t, 
J = 6.8 Hz, 2H, CH2), 3.42–3.46 (m, 2H, CH2), 3.81 (s, 3H, OCH3), 5.67 (s, 1H, CH2), 
6.48 (s, 1H, CH2), 7.91 (d, J = 7.6 Hz, 1H, ArH), 7.98–8.06 (m, 3H, ArH), 8.11–8.13 
(m, 2H, ArH), 8.16–8.18 (m, 2H, ArH), 8.37 (d, J = 9.2 Hz, 1H, ArH) ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 26.82 (CH2), 27.81 [C(CH3)3], 32.91 (CH2), 37.44 (CH2), 
52.47 (OCH3), 83.72 [OC(CH3)3], 123.56 (CH), 124.67 (CH), 124.77 (CH), 124.79 
(CH2), 124.99 (C), 125.06 (C), 125.74 (CH), 125.90 (CH), 126.58 (CH), 127.29 (CH), 
127.34 (CH), 127.47 (CH), 128.77 (C), 129.88 (C), 130.93 (C), 131.40 (C), 135.55 (C), 
136.29 (C), 151.52 (C=O), 163.68 (C=O), 175.21 (C=O) ppm. HRMS (ESI): m/z: calcd 
for C29H29NNaO5, [M + Na]
+
: 494.1943; found 494.1929. 
3.4.1.3 Synthesis of (2-(N-t-butoxycarbonyl)pyrenebutyramido)-methoxycarbonylethyl-
1,4,7,10-tetrazacyclododecane (monoalkylated cyclen) (6).  
K2CO3 (1.47 g, 10.6 mmol) was added to a solution of cyclen 5 (0.460 g, 2.67 mmol) in 
MeCN (30 mL). To this solution was added (pyrene)Boc-Δ-AlaOMe 4 (0.840 g, 1.78 
mmol). The suspension was vigorously stirred at room temperature for 5 hours. The 
suspended solid was removed by filtration and the solvent was evaporated under 
reduced pressure. The residue was purified by flash chromatography (100% CH2Cl2 → 
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CH2Cl2–EtOH–NH4OH–H2O (50 : 50 : 1 : 1)) to afford compound 6 as a viscous light 
yellow oil (0.95 g, 83%). 
1
H NMR (300 MHz, CDCl3): δ = 1.47 (s, 9H, Boc), 2.20 (m, 
2H, CH2CH2CH2), 2.50–2.80 (m, 16H, N(CH2)2N-cyclen), 3.01–3.18 (m, 2H, 
C(O)CH2CH2), 3.38–3.50 (m, 2H, CH2CH2-Pyrene), 2.77 (dd, J = 14.4 and 6.9 Hz, 1 H, 
NCHaHbCH), 3.38 (dd, J = 14.25 and 5.1 Hz, 1 H, NCHaHbCH), 3.70 (s, 3H, OMe), 
5.51 (t, J = 6.9 and 4.8 Hz, 1H, NCHaHbCH), 7.85–8.40 (9H, m, Ar). 
13
C NMR (75.4 
MHz, CDCl3): δ = 26.98 (βCH2-Ser), 27.88 (C(CH3)3), 32.85 (γCH2), 37.79 (αCH2), 
45.02 (CH2), 45.37 (CH2), 46.75 (CH2), 51.22 (CH2), 52.22 (OCH3), 53.52 (CH), 55.97 
(NCH2CH), 84.31 (C(CH3)3), 123.41 (CH-Ar), 124.70 (CH-Ar), 124.72 (CH-Ar), 
124.87 (CH-Ar), 125.83 (CH-Ar), 126,67 (CH-Ar), 127.37 (2 × (CH-Ar)), 127.45 (CH-
Ar), 128.01 (C-Ar), 128.62 (C-Ar), 129.86 (C-Ar), 130.82 (C-Ar), 131.31 (C-Ar), 
136.13 (C-Ar), 151.86 (NC- (O)), 170.63 (C(O)OCH3), 175.37 (C(O)CH2). HRMS 
(ESI): m/z: calcd for C37H50N5O5, [M + H]
+
: 644.3812, found: 644.3807. 
3.4.1.4 Synthesis of 2-pyrenebutyramido-methoxycarbonylethyl- 4,7,10-tris-
(ethoxycarbonylmethyl)-1,4,7,10 tetrazacyclododecane (tetraalkylated cyclen) (7).  
A solution of monoalkylated cyclen 6 (0.860 g, 1.33 mmol) in trifluoroacetic acid in 
dichloromethane (60%, 25 mL) was stirred overnight at room temperature. The solvent 
was evaporated at reduced pressure and the residue was re-dissolved in 
dichloromethane. This procedure was repeated several times to give a light yellow thick 
oil. 
1
H NMR spectroscopy (CDCl3) revealed the disappearance of the signal assigned to 
the tert-butyloxycarbonyl group in compound 6. K2CO3 (2.20 g, 15.96 mmol) was 
added to a solution of deprotected 6 (1.33 mmol, quantitative deprotection was 
assumed) in MeCN (30 mL). To this suspension was added ethyl bromoacetate (0.55 
mL, 4.66 mmol). The suspension was vigorously stirred at room temperature for 2.5 
hours. The solid in suspension was removed by filtration, the solvent was evaporated 
under reduced pressure and the residue was purified by flash chromatography (100% 
CH2Cl2 → CH2Cl2–EtOH (1 : 1)) to afford compound 7 (0.632 g, 59%) as a white foam. 
1
H NMR (300 MHz, CDCl3): δ = 1.26 (m, 9H, 3 × CH2CH3), 2.20 (m, 2H, 
CH2CH2CH2), 2.56 (m, 2H, C(O)CH2CH2), 2.60–2.90 (m, 6H, NCH2C(O)), 2.90–3.70 
(m, 16H, N(CH2)2N), 3.37 (m, 2H, CH2CH2 Pyrene), 3.73 (s, 3H, OMe), 3.92 (bd, 2H, 
NCH2CH), 4.09 (m, 6 H, CH2CH3), 4.94 (bd, 1H, NCH2CH), 7.80–8.40 (9H, m, Ar). 
13
C NMR (75.4 MHz, CDCl3): selected signals: 13.84, 13.88, 14.05 (CH2CH3), 27.36 
(βCH2- er), 32.79 (γCH2), 35.45 (αCH2), 48.21 (CH), 48.91 (CH2), 50.34 (CH2), 51.36 
(CH2), 52.47 (OCH3), 53.01 (CH2), 53.60 (CH2CH), 54.90 (CH2), 55.19 (CH2), 55.71 
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(CH2), 55.98 (CH2), 58.25 (CH2), 60.51 (CH2), 60.99, 61.20, 61.55 (OCH2), 123.63 
(CH-Ar), 124.62 (CH-Ar), 124.75 (CH-Ar), 124.85 (CH-Ar), 125.76 (CH-Ar), 126.51 
(CH-Ar), 127.18 (CH-Ar), 127.41 (CH-Ar), 127.46 (CH-Ar), 128.67 (C-Ar), 129.72 (C-
Ar), 130.87 (C-Ar), 131.32 (2 × (C-Ar)), 136.43 (C-Ar), 136.53 (C-Ar), 170.312 
(C(O)OCH3), 170.53 (C(O)-OCH2), 173.15 (C(O)OCH2), 173.55 (C(O)OCH2), 174.31 
(NC (O)). HRMS (ESI): m/z: calcd for C44H60N5O9, [M + H]
+
: 802.4391, found: 
802.4386. 
3.4.1.5 Synthesis of 2-pyrenebutyramido-carboxyethyl-4,7,10-tris-(carboxymethyl)-
1,4,7,10-tetrazacyclododecane (L) (DO3A-N-(α-pyrenebutyramido)propionate metal 
chelator). 
Compound 7 (0.566 g, 0.710 mmol) was dissolved in a mixture made up of 20 mL of 
water and 20 mL of ethanol. The solution was adjusted to pH 10–11 by adding small 
portions of Dowex 1X2 OH
−
 resin. The suspension was kept stirring at room 
temperature for 2 hours. The wet resin was transferred into a chromatography column, 
washed with water (∼50 mL) and eluted with 0.1 M hydrochloric acid, followed by a 
mixture of hydrochloric acid 0.1 M–ethanol (1 : 1). The relevant fractions, identified by 
TLC (ethanol–water 1/1, detection using iodine vapour and analysis under UV light at 
365 nm), were pooled, concentrated at room temperature and further dried under 
vacuum to afford the final compound L, as a hydrochloride, as a light yellow solid (0.31 
g, 62%). 
1
H NMR (300 MHz, D2O/MeOD): δ = 2.13 (bb, 2H, CH2CH2CH2), 2.50 (m, 
2H, C(O)-CH2CH2), (2.9–3.6, broad, overlapped signals with an integration 
corresponding to 18H, 4 × N(CH2)2N and NCH2CH), 3.33 (m, 2H, CH2CH2Pyrene), 
3.81 (broad, overlapped signals with an integration corresponding to 6H, NCH2), 4.76 
(m (br), 1H, CH), 7.80–8.40 (9H, m, Ar). 13C NMR (75.4 MHz, D2O/MeOD): selected 
signals: 28.22 (βCH2), 33.25 (γCH2), 36.29 (αCH2), 50.49 (bb, CH2), 54.95 (bb, CH2), 
124.31 (CH-Ar), 125.44 (C-Ar), 125.54 (C-Ar), 125.75 (CH-Ar), 125.85 (2 × (CH-Ar)), 
127.08 (CH-Ar), 127.50 (CH-Ar), 127.08 (C-Ar), 128.18 (CH-Ar), 128.37 (CH-Ar), 
128.46 (CH-Ar), 129.41 (C-Ar), 130.75 (C-Ar), 131.75 (C-Ar), 137.27 (C-Ar), 177.47 
(NC(O)). HRMS (ESI): m/z: calcd for C37H46N5O9, [M + H]
+
: 704.3296, found: 
704.3290. 
3.4.2 1H and 17O NMR and 1H NMRD experiments 
Sample preparation. To an aqueous solution of the ligand L (pH 5) was added drop-wise 
an aqueous solution of the corresponding LnCl3·xH2O salt in a 1 : 1 mole ratio. The 
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solution was stirred at room temperature over 1 hour while keeping its pH at around 5.7 
by adding aqueous NaOH. The solution was left stirring at room temperature overnight. 
Concentration under reduced pressure afforded off-white solids. Solutions for NMR 
measurements (20 mM) were obtained by dissolution of appropriate amounts of solid 
complexes in D2O (V = 0.75 mL). Proton 1D spectra of paramagnetic (Sm
3+
 and Eu
3+
) 
and diamagnetic (La
3+
) complexes were obtained at 298 K on a Varian VNMRS 600 
(14.09 T, 600.14 MHz) NMR spectrometer. 
The GdL complex solutions for 
17
O NMR and 
1
H NMRD experiments were prepared by 
mixing equimolar amounts of GdCl3 and the ligand. A slight excess (5%) of the ligand 
was used. The solution was stirred at room temperature over 1 hour while keeping its 
pH at around 5.7 by adding aqueous NaOH. The solution was left stirring at room 
temperature overnight. The absence of free metal was checked by the xylenol orange 
test [56, 57]. The pH of the stock solution was adjusted to the desired value by adding 
aqueous NaOH (0.1 mM). 
17
O enriched water (
17
O: 11.4%) was added to the solutions 
for 
17
O measurements to improve the sensitivity. The final concentration of the complex 
solution was 17.56 mmol kg
−1
 at pH = 6.90. For the NMRD experiments 5.0 mM and 
0.1 mM solutions of the complex at pH 6.98 were used. 
3.4.3 17O NMR experiments 
Variable-temperature 
17
O NMR measurements were performed using a Bruker Avance-
500 (11.7 T) spectrometer. A BVT-3000 temperature control unit was used to stabilize 
the temperature, measured by a substitution technique. The samples were sealed in glass 
spheres that fitted into 10 mm o.d. NMR tubes to eliminate susceptibility corrections to 
the chemical shifts [58] Longitudinal relaxation rates (1/T1) were obtained by the 
inversion recovery method, and transverse relaxation rates (1/T2) by the Carr–Purcell–
Meiboom–Gill spin-echo technique. Acidified water, pH 3.4, was used as the external 
reference. 
3.4.4 NMRD measurements 
The measurements were performed using a Stelar Spinmaster FFC NMR relaxometer 
(0.01–20 MHz) equipped with a VTC90 temperature control unit. At higher fields, the 
1
H relaxivity measurements were performed on a Bruker electromagnet at frequencies 
of 30 MHz, 40 MHz, 60 MHz and 80 MHz. In each case, the temperature was measured 
by a substitution technique. Variable temperature measurements were performed at 25 
and 37 °C. 
Chapter 3  
126 
 
3.4.5 Relaxivity studies of pH dependence and Zn2+ transmetallation 
The transmetallation reaction of GdL with Zn
2+
 was studied by following the time 
dependent decrease of the water proton longitudinal relaxation rate, R1, of a phosphate-
buffered saline solution (PBS, pH 7.1, 10 mM) containing 1.5 mM of GdL after adding 
an equimolar amount of ZnCl2 while the sample was vigorously stirred [59]. The water 
longitudinal relaxation rate was also measured as a function of time on the PBS 
buffered solution (pH 7.1, 10 mM) containing 2.5 mM GdL (60). The pH dependence 
of the relaxivity of the GdL solution was studied by adjusting (pH meter) the pH of a 1 
mM solution of GdL in water with either NaOH or HCl solutions using a pH meter. A 
Bruker Minispec mq20 (20 MHz, 298 K) relaxometer was used for all measurements. 
3.4.6 Fluorescence measurements 
The absorption and the ligand-based fluorescence emission spectra of the free ligand L 
and the GdL complex were recorded, respectively, using a Jasco V-630 UV-Vis 
spectrophotometer and a HORIBA JobinYvon Fluoromax-4 spectrofluorimeter, 
equipped with a monochromator in both excitation and emission and a temperature 
controlled cuvette holder. Fluorescence spectra were corrected for the instrumental 
response of the system. 
The fluorescence quantum yields (s) were determined using a standard method 
(61,62). Anthracene in ethanol (r = 0.27) (63) was used as the reference. 
For lanthanide centred fluorescence studies in the visible (Eu
3+
 and Tb
3+
) and in the NIR 
region (Nd
3+
, Yb
3+
), absorbance UV spectra were performed on a Uvikon 
spectrophotometer, while emission and excitation (lanthanide luminescence) spectra 
were measured using a modified Jobin-Yvon Horiba Fluorolog-322 spectrofluorimeter 
equipped with a Hamamatsu R928 detector (for the visible domain) and a DSS-
IGA020L (Electro-Optical Systems, Inc.) detector (for the NIR domain). Luminescence 
and excitation spectra were corrected for variations in lamp output, the non-linear 
response of the detector and the use of neutral density filters (where applicable). For 
collecting luminescence data, samples were placed in quartz Suprasil cells (Hellma® 
115F-QS, bandpass 0.2 cm). 
3.4.7 Biodistribution studies 
153
SmL for in vivo experiments was prepared by adding 1 mCi of [
153
Sm]Cl3 (produced 
at the Instituto Tecnológico e Nuclear, Lisbon, Portugal with a specific radioactivity >5 
Ln[DO3A-N-α-(pyrenebutanamido)propionate] complexes 
127 
 
GBq mg
−1) to a solution of 1 mg of the chelator in acetate buffer (400 μL, 0.4 M, pH 5) 
and heated at 80 ºC for ca. 1 hour. The radiochemical purity of 
153
SmL was determined 
by TLC. The percentage of chelated metal was found to be greater than 95%. Groups of 
four animals (Wistar male rats weighing ca. 200 g) were anaesthetized with ketamine 
(50.0 mg mL
−1
)/chloropromazine (2.5%) (10 : 3) and injected in the tail vein with ca. 
100 μCi of the tracer. Animals were sacrificed 1 and 24 hours later and the major organs 
were removed, weighed and counted in a  well-counter. 
3.4.8 Size distribution 
The size distribution of particles in a (micellar) solution of GdL at a concentration well 
above the cmc (5.0 mM, pH 7.0) was determined with a Malvern Zetasizer, NANO ZS 
(Malvern Instruments Limited, UK) using an He–Ne laser ( = 633 nm) and a detector 
angle of 173º. The GdL solution in a polystyrene cell (1 mL) was analysed at 25 ºC. The 
mean hydrodynamic radius (z-average) and a width parameter for the distribution, 
polydispersity or polydispersity index (PdI) were calculated from the intensity of the 
scattered light. In the present work, the intensity-based z-average parameter was 
considered the best approach to the actual particle size. 
3.4.9 Data analysis 
Data obtained from 
17
O NMR, 
1
H NMRD, Luminescence and Quantum Yield 
measurement studies were processed using OriginLab Pro 8 SRO. Data from 
relaxometric and transmetallation studies were processed using Microsoft Office Excel 
2007. 
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Figure SI3.1- Size distribution in: a) volume (%); b) intensity (%) for a GdL solution (5.0 mM, 
pH 7.0, 25 ºC) at a concentration well above the cmc (0.6 mM). 
 
 
 
Figure SI3.2- Temperature dependence of the water proton relaxivity for GdL(20MHz , 1mM, 
pH 6.0). 
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Figure SI3.3- pH dependence of the water proton relaxivity for GdL (20MHz , 1 mM, pH 6.0). 
 
 
 
Figure SI3.4-. Evolution of the relative water proton paramagnetic longitudinal relaxation rate 
R1p(t)/R1p(0) (20 MHz, pH 7.1, 25 ºC) for a 1.5 mM solution of GdL in 10 mM phosphate 
buffer(○) and in phosphate buffer containing an equimolar amount of Zn2+ (●). 
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Figure SI3.5-. UV-Vis spectra for the free ligand L and the GdLcomplex (1.0x10
-5 
M, pH 7.0, 
25ºC). 
 
 
Figure SI3.6- Fluorescence spectra for free ligand L in non-deoxygenated water (pH 7.0) over 
the concentration range 5x10
-5
- 5x10
-3
 mol.dm
-3
 (exc= 345 nm). 
 
Figure SI3.7- Changes in the emission properties of the free ligand L as the ratio of the 
fluorescence emission intensity for the excimer (490 nm) and for the monomer (377 nm) 
(IE/IM) as function of ligand concentration. Line fitted to equation S1. 
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The experimental data in Figure 5 (manuscript) and Figure S6 were fitted (Prima GraphPad) to a 
sigmoidal model (equation SI3.1).[1,2] 
 
 
 
Equation SI3.1 
 
c- complex concentration; 
A1 and A2- represent the limits of sigmoidal function that describes the behaviour of d(IExc/IMono)/dc 
(derivative of IExc/IMonoin order to c);: 
d- is the time constant of the function and is related to the range of concentration over which the abrupt 
change in IExc/IMono occurs; 
cmc- is the center of the sigmoidal function. 
 
Table SI3.1- Best fit values for the fitting (Prima GraphPad) of the experimental data of 
IExc/IMono vs [GdL] (Figure 5 in manuscript and Figure S6) to equation S1 
Best-fit values  GdL 
(IExc/IMono)0  -1.764 
A1  0.3660 
d  0.007795 
A2  3.119 
cmc  0.6454 
Std. Error  
(IExc/IMono)0 0.007529 
A1  0.06346 
d  71873 
A2  0.002088 
cmc  0.01454 
 
The E titration data (Figure 7 in manuscript) were fitted to equation SI3.2 with n, 
number of equivalent binding sites, fixed to 1. 
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n - number of equivalent binding sites, fixed to 1 in the fitting. 
r1
f
 - relaxivity of the free GdL form, non-complexed with HSA 
r1
c
 - relaxivity of the GdL form bound to HSA 
c1 - analytical concentration of GdL 
cHSA - analytical concentration of HSA 
KA - association constant GdL/HSA 
 
Table SI3.2- Biodistribution, stated as percentage of injected doseper gram of organ (%ID/g 
±SD), of 
153
SmL inWistar rats 1hand 24 h after i.v. injection. Results are the mean of 4 animals. 
 
 
Organ 
1 h 
%ID+SD 
24h 
%ID+SD 
Blood 
Liver 
Spleen 
Kidney 
Heart 
Lung 
S. Intest. 
L. Intest. 
Bone 
Muscle 
Brain + Cerebellum 
0.3071 ± 0.0290 
0.2095 ± 0.0617 
0.1784 ± 0.0581 
0.0629 ± 0.0105 
0.0385 ± 0.0224 
0.1084 ± 0.0220 
0.0352 ± 0.0190 
0.0125 ± 0.0015 
0.0365 ± 0.0078 
0.0095 ± 0.0048 
0.0213 ± 0.0134 
0.0015 ± 6.5 x 10
-5
 
0.4701 ± 0.1216 
0.3012 ± 0.1646 
0.0242 ± 0.0026 
0.0044 ± 0.0014 
0.0274 ± 0.0104 
0.0066 ± 0.0011 
0.0035 ± 0.0029 
0.0411 ± 0.0057 
0.011 ± 0.00010 
0.0007 ± 8.15 x 10
-5
 
 
 
APPENDIX 1: Analysis of NMRD and 
17
O NMR data 
NMRD and 
17
O NMR data have been analysed within the framework of Solomon-
Bloembergen-Morgan theory.  
17
O NMR spectroscopy 
From the measured 
17
O NMR relaxation rates and angular frequencies of the 
paramagnetic solutions, 1/T1 , 1/T2 and , and of the acidified water reference, 1/T1A, 
1/T2Aand , one can calculate the reduced relaxation rates and chemical shifts, 1/T2rand 
r, which may be written as in Equations (A1)-(A3), where, 1/T1m, 1/T2m is the 
relaxation rate of the bound water and m is the chemical shift difference between 
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bound and bulk water, m is the mean residence timeor the inverse of the water exchange 
rate kexand Pm is the mole fraction of the bound water [3, 4].
 
            (A1) 
            (A2) 
            (A3) 
The outer sphere contributions to the 
17
O relaxation rates 1/T1OS and 1/T2OS can are 
neglected according to previous studies [5]. Therefore, Equations (A1-A2) can be 
further simplified into Equations (A4) and (A5):  
            (A4) 
            (A5) 
The exchange rate is supposed to obey the Eyring equation. In equation (A6) S‡and 
H‡ are the entropy and enthalpy of activation for the water exchange process, and 
kex
298
 is the exchange rate at 298.15 K. 
       (A6) 
In the transverse relaxation, the scalar contribution, 1/T2sc, is the most important 
[Equation (A7)]. 1/s1 is the sum of the exchange rate constant and the electron spin 
relaxation rate [Equation (A8)].  
 (A7) 
 (A8) 
The 
17
O longitudinal relaxation rates in Gd
3+
 solutions are the sum of the contributions 
of the dipole-dipole (dd) and quadrupolar (q) mechanisms as expressed by Equations 
(A11-A13) for non-extreme narrowing conditions, where γSis the electron and γIis the 
nuclear gyromagnetic ratio (γS= 1.7610
11
 rad s
-1
T
-1
, γI=-3.62610
7
 rad s
-1
T
-1
), rGdO is 
the effective distance between the electron charge and the 
17
O nucleus, I is the nuclear 
spin (5/2 for 
17
O),  is the quadrupolar coupling constant and is an asymmetry 
parameter : 
 (A9) 
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with: 
 
         
(A10) 
 
         
(A11) 
In Equation (A3) the chemical shift of the bound water molecule, m, depends on the 
hyperfine interaction between the Gd
3+
 electron spin and the 
17
O nucleus and is directly 
proportional to the scalar coupling constant, , as expressed in Equation (A12) [6].
 
          (A12) 
The isotopic Landé g factor is equal to 2.0 for the Gd
3+
, B represents the magnetic field, 
and kB is the Boltzmann constant. 
The outer-sphere contribution to the chemical shift is assumed to be linearly related to 
 by a constant Cos [Equation (A13)] [7]. 
 
 (A13) 
 
NMRD 
The measured longitudinal proton relaxation rate, = 1/T1
obs
, is the sum of a 
paramagnetic and a diamagnetic contribution as expressed in Equation (A14), where r1 
is the proton relaxivity: 
          (A14) 
The relaxivity can be divided into an inner and an outer sphere term as follows: 
          (A15) 
The inner sphere term is given in Equation (A16), where q is the number of inner sphere 
water molecules [8].
 
          (A16) 
The longitudinal relaxation rate of inner sphere protons, 1/T1m
H
 is expressed by 
Equation (A11), where rGdH is the effective distance between the electron charge and the 
1
H nucleus, I is the proton resonance frequency and S is the Larmor frequency of the 
Gd
3+
 electron spin. 
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         (A17) 
                for           (A18) 
whereRH is the rotational correlation time of the Gd-Hwater vector. 
 
For small molecular weight chelates (fast rotation), the spectral density function is 
expressed as in Equation (A19). 
 
(A19)  
 
For slowly rotating species, the spectral density functions are described the Lipari-
Szabo approach[9]. In this model we distinguish two statistically independent motions; 
a rapid local motion with a correlation time land a slower global motion with a 
correlation time g. Supposing the global molecular reorientation is isotropic, the 
relevant spectral density functions are expressed as in Equations (A20-A24), where the 
general order parameter S
2
 describes the degree of spatial restriction of the local motion. 
If the local motion is isotropic, S
2
 = 0; if the rotational dynamics is only governed by 
the global motion, S
2
 = 1. 
 
 
(A20) 
 
 
         (A21) 
i = 1, 2        (A22) 
        (A23) 
i= 1, 2           (A24) 
The rotational correlation time, RH is assumed to have simple exponential temperature 
dependence with an ER activation energy as given in Equation (A25). 
          (A25) 
The outer-sphere contribution can be described by Equations (A26 and A27) where NA 
is the Avogadro constant, and Jos is its associated spectral density function as given by 
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Equation (A15). [10, 11]
 
 (A26) 
 
(A27) 
 
 
The longitudinal and transverse electronic relaxation rates, 1/T1e and 1/T2e are expressed 
by Equation (A28 and A29), where v is the electronic correlation time for the 
modulation of the zero-field-splitting interaction, Ev the corresponding activation energy 
and 2 is the mean square zero-field-splitting energy. We assumed a simple exponential 
dependence of vversus 1/T as written in Equation (A30). 
          (A28) 
          (A29) 
          (A30) 
The diffusion coefficient for the diffusion of a water proton away from a Gd
3+
 complex, 
DGdH, is assumed to obey an exponential law versus the inverse of the temperature, with 
activation energy EDGdH, as given in Equation (A31). is the diffusion coefficient 
at 298.15K. 
       
 
(A31) 
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4 - Ga[NO2A-N-(-amino)propionate] 
chelates: synthesis and evaluation as 
potential tracers for 68Ga PET 
 
 Adapted from Dalton Trans., 2014,43, 8037-8047  
The availability of commercial 
68
Ge/
68
Ga cyclotron-independent 
68
Ga
3+
 generators is 
making Positron Emission Tomography (PET) accessible to most hospitals, which is 
generating a surge of interest in the design and synthesis of bi-functional chelators for 
Ga
3+
. In this work we introduce the NO2A-N-(α-amino)propionic acid family of 
chelators based on the triazacyclononane scaffold. Complexation of the parent NO2A-
N-(α-amino)propionic acid chelator and of a low molecular weight (model) amide 
conjugate with Ga
3+
 was studied by 
1
H and 
71
Ga NMR. The Ga
3+
 chelate of the amide 
conjugate shows pH independent N3O3 coordination in the pH range 3–10 involving the 
carboxylate group of the pendant propionate arm in a 6 member chelate. For the 
Ga[NO2A-N-(α-amino)propionate] chelate, a reversible pH-triggered switch from Ga3+ 
coordination to the carboxylate group to coordination to the amine group of the 
propionate arm was observed upon pH increase/decrease in the pH range 4–6. This 
phenomenon can conceivably constitute the basis of a physiological pH sensor. Both 
complexes are stable in the physiological range. The 
67
Ga[NO2A-N-(α-
benzoylamido)propionate] chelate was found to be stable in human serum. 
Biodistribution studies of the 
67
Ga
3+
-labeled pyrene butyric acid conjugate NO2A-N-(α-
pyrenebutanamido)propionic acid revealed that, despite its high lipophilicity and  
concentration-dependent aggregation properties, the chelate follows mainly renal 
elimination with very low liver/spleen accumulation and no activity deposition in bones 
after 24 hours. Facile synthesis of amide conjugates of the NO2A-N-(α-amino)propionic 
acid chelator, serum stability of the Ga
3+
 chelates and fast renal elimination warrant 
further evaluation of this novel class of chelators for PET applications. 
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4.1 Introduction 
Endowing thermodynamically stable and kinetically inert metal chelates with 
conjugability is the subject of intensive research given the plethora of properties offered 
by metal ions for imaging and therapy. Non-functionalised metal chelates exhibit high 
hydrophilicity, distribution into the interstitial compartment, fast renal clearance and 
featureless biodistribution profiles. Delivering metal chelates to injury sites, for imaging 
and/or therapeutic purposes, allows reducing the dose and background signals and 
minimizes potential harmful side effects on non-target organs – especially critical with 
complexes of metal-radioisotopes. 
Positron Emission Tomography (PET) is well established in clinical diagnosis for 
functional imaging thanks to its remarkably high detection sensitivity, relatively high 
spatial resolution and potential to quantify tracer uptake within lesions. 
18
F, 
11
C, 
13
N are 
the most widely used radionuclides for PET imaging due to their positron emission 
properties and short lifetimes. These radionuclides are covalently incorporated into 
biomolecules (sugars, amino acids, etc.) through chemical synthesis, starting from 
simple precursor molecules/ions generated in dedicated cyclotron units [1]. Molecules 
labeled with 
11
C and 
13
N are indistinguishable from the natural abundance stable isotope 
unlabelled molecules undergoing the same metabolic pathways. C-2 
18
F labeled glucose 
(2-deoxy-2-[
18
F]fluoroglucose – FDG) is the most widely used tracer inclinical PET 
imaging. Following uptake by the glucose transporters and phosphorylation, FDG is 
trapped inside cells as FDG-6-P, allowing visualization in vivo of glucose avid cells and 
tissues. 
18
F decay allows the resulting 2-[
18
OH]glucose to follow the normal glycolytic 
pathway [2, 3]. 
18
F, and especially 
11
C and 
13
N-labelled PET tracers, with half-lives of 
109.8, 20.3, and 9.96 minutes, respectively, need to be produced in loco in dedicated 
cyclotron units, using fast, high yielding synthetic procedures coupled to expeditious 
purification schemes (operated remotely) to avoid substantial loss of activity [1–3]. 
Many metal ion radionuclides (e.g. 
68
Ga
3+
 and 
64
Cu
2+
) also display positron emission 
properties suitable for PET imaging [4]. Amongst these, 
68
Ga
3+
, with 89% positron 
branching accompanied by low photon emission (1077 keV, 3.22%) and a half life of 
67.6 minutes, is suitable for labelling molecules with fast blood clearance [5, 6]. The 
commercial availability of 
68
Ge/
68
Ga cyclotron-independent 
68
Ga
3+
 generators is making 
PET imaging available to most hospitals [7]. Labeling (bio)molecules with metal ion 
radionuclides requires efficient pathways to attach covalently bi-functional chelators 
Chapter 4  
148 
 
(post-conjugation labeling), or functionalized chelates (pre-conjugation labeling) to 
biomolecules [4–7]. High thermodynamic stability and kinetic inertness of the metal 
complexes are absolutely mandatory for safe and efficient PET imaging [8–10]. 
Transferrin, the iron transport protein, is the main competitor for Ga
3+
 in serum given 
the similar ionic radius and coordination properties of Fe
3+
 and Ga
3+
 [11]. In addition to 
stability, fast complexation, ideally at room temperature, and efficient purification 
procedures of labeled conjugates have to be taken into account in the design of new 
chelators for Ga
3+
 for use as PET tracers [12]. Moreover, complex formation with Ga
3+
, 
obtained as 
68
GaCl3 by elution of 
68
Ge/
68
Ga generators with diluted hydrochloric acid, 
must be carried out at pH values below 4 (usually in acetate or HEPES buffer) to avoid 
precipitation of Ga
3+
 as Ga(OH)3 [13, 14]. 
The coordination chemistry of Ga
3+
 is dominated by its hard character, preferring hard, 
charged base donors such as carboxylates, phosphonates and phosphinates in an 
octahedral geometry [10], although it has also been shown to have good affinity for 
thiolates, such as TACN-TM (TACN-TM = 1,4,7-triazacyclononane-N,N′,N″-
tris(mercaptoethyl)) [10, 15]. Poly(aminocarboxylates) and 
poly(aminophosphonates/phosphinates) are the most efficacious chelators for Ga
3+
. 
Macrocyclic, DOTAtype (DOTA = 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetraacetic 
acid) and NOTA-type (NOTA = 1,4,7-triazacyclononane-1,4,7- triacetic acid) chelators 
form Ga
3+
 complexes displaying exceptional thermodynamic stability and kinetic 
inertness [12, 16–18]. Ga3+ complexes of linear, DTPA [19] (DTPA = 
diethylenetriamine pentaacetic acid) and EDTA-type [20] (EDTA = 
ethylenediaminetetraacetic acid) chelators were found to be kinetically too unstable for 
in vivo use, despite the high thermodynamic stability of its Ga(EDTA)
−
 and 
Ga(DTPA)
2−
 complexes [21, 22]. DOTAmonoamide (octadentate) chelators, developed 
originally as Gd
3+
 complexing agents for use as Contrast Agents (CA) for Magnetic 
Resonance Imaging (MRI), despite forming Ga
3+
 complexes exhibiting lower 
thermodynamic stability and higher kinetic lability than the parent Ga(DOTA)− 
complex, are still kinetically inert enough for in vivo PET [12]. The peptide conjugate 
[
68
Ga](DOTATOC) (DOTATOC = DOTA, Tyr
3
-octreotide) is used worldwide in 
hospitals for diagnosis of neuroendocrine tumors expressing somatostatin receptors [23, 
24]. 
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The macrocycle cavity of DOTA-type chelators, optimal for Ln
3+
 ions, is too big for 
Ga
3+
 complexation, thus originating distorted octahedral (N4O2) complexes [10, 12, 23, 
24]. Good matching of the macrocycle cavity of NOTA with the ionic radius of Ga
3+
 
results in Ga(NOTA) complexes exhibiting exceptional thermodynamic stability and 
kinetic inertness (16, 17). Moreover, NOTA-type chelators display faster Ga
3+
 chelation 
kinetics at lower temperatures than DOTA-type chelators [25]. NOTA-monoamide 
conjugates, although amenable through facile synthetic routes, are likely to result in 
complexes exhibiting lower thermodynamic stability and higher kinetic lability than 
their parent Ga(NOTA) complex, compromising their potential for biological 
applications [26]. Replacing an acetate arm on the NOTA scaffold, by an acetate group 
α-substituted with a reactive group, endows the NOTA scaffold with conjugability 
whilst preserving its N3O3 denticity mandatory for stable coordination with Ga
3+
. The 
aspartate and glutamate derivatives of NOTA, NODASA (NODASA = 1,4,7-
triazacyclononane-N-succinic-N′,N″-diacetic acid) [27] and NODAGA (NODAGA = 
1,4,7-triazacyclononane- N-glutaric-N′,N″-diacetic acid) [28], respectively, are the gold 
standards for the synthesis of targeted Ga
3+
 tracers for PET. More recently, the TRAP 
(TRAP = 1,4,7-triazacyclononane- 1,4,7-tris(methylenephosphinic acid)) family of 
chelators, generated by replacement of the pendant carboxylates by phosphinate groups 
on the triazacyclononane macrocycle scaffold, revealed excellent chelating properties 
for Ga
3+
 allied to conjugability [29–31]. Tris-NODASA/NODAGA [32] and tris- TRAP 
[29] derivatives allow facile preparation of multivalent conjugates with biomolecules 
such as peptides, exhibiting enhanced avidity (affinity and/or specificity) for cellular 
receptors. Pendant reactive groups on the ethylenediamine bridges of the NOTA 
scaffold allow also bioconjugation whilst retaining the high thermodynamic stability 
and kinetic inertness of the Ga(NOTA) complex, although at the expense of difficult 
and lengthy synthetic pathways [33]. 
In our efforts to obtain thermodynamically stable and kinetically inert conjugates of 
metal chelates as potential medical imaging agents, we have reported recently efficient 
methodologies for the synthesis of the DO3A-N-(α-amino)propionate chelator [34] and 
for the preparation of amide conjugates [35–37]. The Gd[DO3A-N-(α-
amino)propionate] chelate and its amide conjugates combine high thermodynamic 
stability and kinetic inertness with (fast) water exchange properties, ideal for attaining 
high relaxivities at (intermediate/high) fields relevant for magnetic resonance imaging 
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[34–37]. In this work we extend the synthetic methodologies developed for DO3A-N-
(α-amino)propionate chelators to the triazacyclononane scaffold. This includes the 
NO2A-N-(α-amino)propionic acid (L1) chelator and the two amide derivatives NO2A-
N-(α-benzoylamido)- propionic acid (L2) and NO2A-N-(α-pyrenebutanamido)propionic 
acid (L3) (Scheme 4.1). 
 
Scheme 4.1- Synthetic pathway for the metal chelators NO2A-N- (α-amino)propionic acid (L1), 
NO2A-N-(α-benzoylamido)propionic acid (L2) and NO2A-N-(α-pyrenebutanamido)propionic 
acid (L3). (a) K2CO3/MeCN; (b) tert-butyl bromoacetate, K2CO3/MeCN; (c) i. hydrochloric 
acid/EtOH, ii. Dowex 1X2 OH
−
, elution with diluted hydrochloric acid; (d) GaCl3·xH2O; (e) i. 
TFA/CH2Cl2; ii. ethyl bromoacetate, K2CO3/MeCN; (f ) Dowex 1X2 OH
−
, elution with diluted 
hydrochloric acid. 
 The complexation of the new chelators with Ga
3+
 was studied by multinuclear NMR 
(
1
H, 
71
Ga). The luminescence properties of the GaL3 complex were also analysed in 
order to evaluate its potential as a bimodal PET/optical imaging agent. Serum stability 
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and biodistribution studies were also performed to evaluate the potential of the new 
chelators as 
68
Ga
3+
-labeled PET tracers. 
4.2 Results and discussion 
4.2.1 Synthesis and characterization 
In this work we aimed at extending the synthetic methodologies developed for DO3A-
N-(α-amino)propionate chelators [34–37] to the triazacyclononane scaffold, to explore 
the coordination properties of NO2A-N-(α-amino)propionic acid chelators for Ga3+ as 
potential tracers for PET imaging (Scheme 4.1). 
Michael addition of the Boc2-Δ-AlaOMe 2 [34] and Boc-(amide)-Δ-AlaOMe blocks 3 
[36] and 4 [37] to triazacyclononane 1 proceeds smoothly in acetonitrile at room 
temperature, using K2CO3 as a base, in 3–4 hours, as reported before for the cyclen 
analogue. An excess of triazacyclononane, 1.5 molar equivalents, affords the 
monoalkylated nonanes as the main reaction products. Small amounts of bis- and tris-
alkylated derivatives are easily removed by flash chromatography. Further N-alkylation 
of nonane 5 with tert-butyl bromoacetate, followed by sequential deprotection with 
hydrochloric acid (4 M) and Dowex 1X2 OH
−
 resin, and elution with diluted 
hydrochloric acid afforded the NO2A-N-(α-amino)propionic acid chelator (L1) as 
hydrochloride in (non-optimised) 36% overall yield. Alkylation of monoalkylated 
cyclen 5 with ethyl bromoacetate offers the opportunity to deprotect selectively the 
amine group for further conjugation [35]. This (direct) conjugation pathway was not 
pursued in this work. Instead, we have explored the indirect pathway for preparing 
amide conjugates of the NO2A-N-(α-amido)propionic acid chelator [36]. The NO2A-N-
(α-benzoylamido) propionic acid chelator (L2) is likely to result in soluble non-
associating chelates; the pyrenyl conjugate NO2A-N-(α-pyrenebutanamido) propionic 
acid chelator (L3) was designed as a self-assembling, fluorescent chelator, potentially 
useful for bimodal PET/fluorescence imaging (37). Michael addition of Boc-
(dehydroamide)-Δ-AlaOMe blocks 3 and 4 introduces directly the amide 
(targeting/kinetic modulator) group into the triaza scaffold. Removing the Boc group at 
the monoalkylated stage averts retro-elimination during the second alkylation step. One 
step deprotection of the ester protected prochelators 9 and 10 with Dowex 1X2 OH
−
 
resin affords the fully deprotected chelators L2 and L3 as hydrochlorides, after elution 
with aqueous hydrochloric acid. 
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Many other amide conjugates are accessible using the expeditious methodologies 
described in this work. 
4.2.2 1H and 71Ga NMR studies 
Given the current interest in 
68
Ga PET, unleashed by the commercial availability of 
cyclotron-independent 
68
Ga generators (4–7), we carried out a multinuclear NMR study 
(
1
H and 
71
Ga) of the GaL1 and GaL2 chelates to ascertain the coordination properties of 
the novel chelators and their potential for PET imaging applications. 
71
Ga (38.89%) is a quadrupolar nucleus (I = 3/2) exhibiting a relatively high receptivity 
and a wide range of chemical shifts.38 The quadrupolar nature of its relaxation 
mechanism leads to NMR signals whose linewidth is sensitive to the symmetry of the 
coordination environment. Spherical, octahedral, cubic and tetrahedral symmetries 
should, in principle, originate sharp 
71
Ga NMR signals. This is the case for NOTA-type 
triazamacrocyclic complexes, whose predominant coordination geometry is distorted 
octahedral, as opposed to DOTA-type tetraazamacrocyclic complexes like Ga(DOTA)- 
and its monoamide derivatives, whose low coordination symmetry makes their 
71
Ga 
NMR signals too broad to be detected [12]. The chemical shift is characteristic of the 
coordination geometry of the metal ion [39, 40]. 
The pH dependence of the 
1
H (Figure 4.3) and 
71
Ga NMR spectra (Figure 4.1) for the 
GaL1 and GaL2 complexes was studied in D2O to probe the coordination environment 
of the Ga
3+ 
metal ion. 
A)       B) 
  
Figure 4.1- pH dependence of the 
71
Ga NMR spectra for: (A) the GaL1 and (B) GaL2 
complexes (400 MHz, 20 mM in D2O, 25 °C). 
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Table 4.1 summarizes the 
71
Ga NMR chemical shifts and linewidths for the species 
observed in solution for the GaL1 and GaL2 complexes studied in this work, compared 
with other triazamacrocyclic complexes reported in the literature (Figure 4.2). 
Table 4.1- 
71
Ga NMR chemical shifts and linewidths for the GaL1 and GaL2 complexes 
studied in this work, compared with other triazamacrocyclic complexes reported in the 
literature.[40] 
Complex  (ppm) 1/2 (Hz) Coordination 
GaL1
a
        
 
+ 141 
+ 186 
900 
550 
N3O3 
N4O2 
GaL2
a 
+ 140 900 N3O3 
Ga(NOTA)
b 
+ 171 235 N3O3 
Ga(NO2A-N-Methylacetamide)
c
  
 
Ga(NO2A-N-Benzylacetamide)
c 
+ 171 
+ 175 
+ 170 
+ 174 
283 
9085 
279 
4818 
N3O3 
N4O2 
N3O3 
N4O2 
Ga(NOTP)
d
 + 110 434 N3O3 
Ga(NOTMP)
e
 + 136 215 N3O3 
 
Ga(TRAP-H)
f
 
+ 132 
+ 134 
+ 138 
+ 141 
154 
200 
186 
162 
N3O3 
N3O3 
N3O3 
N3O3 
a
This work; 
b
ref. [17,41]; 
c
ref. [42]; 
d
ref. [43]; 
e
ref. [44]; 
f
ref. [30] 
 
 
Figure 4.2- Struture of triazacyclononane ligands compared in Table 4.1 and discussed in the 
manuscript: NOTP (1,4,7-triazacyclononane-N,N´,N´´-tris(methylenephosphonic) acid); 
NOTMP (1,4,7-triazacyclononane-N,N´,N´´-tris(methylene(metylphosphinate))); TRAP-H 
(1,4,7-triazacyclononane-1,4,7-tris(methylenephosphinic acid). 
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The number and population of the species present over the pH range 3–11, as well as 
their chemical shifts and linewidths, are quite different for the GaL1 and GaL2 
complexes. 
The GaL2 complex displays only one 
71
Ga NMR signal in the pH range 3–9: a singlet at 
δ = 140 ppm with a relatively large linewidth, Δν1/2= 900 Hz. Above pH 9.0, hydroxide 
catalyzed demetallation leads to the formation of the [Ga(OH)4]−species characterized 
by a sharp signal at δ= 224 ppm [40]. In contrast, the 71Ga NMR spectrum of the GaL1 
chelate is pH dependent. At pH 3.0 there is only one signal with a chemical shift (141 
ppm) and width (900 Hz) identical to that displayed by the GaL2 complex. A new 
sharper (Δν1/2= 550 Hz) signal at δ= 186 ppm becomes apparent at pH 4.1. The 
intensity of this signal increases, at the expense of the signal at δ= 141 ppm, when the 
pH increases, eventually becoming the only signal in the pH range 6–10. At pH 11, the 
[Ga(OH)4]
−
 species is also present. This process is fully reversible, reproducing the 
same features upon pH decrease. These results strongly suggest that for the amide 
complex GaL2, the coordination polyhedron is likely to be represented by a distorted 
octahedron involving the carboxylate group of the propionate arm to form a six member 
chelate (coordination polyhedron N3O3). Although coordination through the amide 
nitrogen, forming a five member chelate, is also possible, the preference of the hard 
Ga
3+
 ion for the carboxylate group is likely to compensate for the energy cost of 
forming a six member chelate [42]. The GaL1 chelate seems to undergo the same 
chelation scheme (N3O3) as the amide complex at low pH, presumably due to the 
unavailability of the protonated amine group for binding. At higher pH (6–11) the 
formation of a five member chelate with the deprotonated amine group (coordination 
polyhedron N4O2) seems to be more favorable than the formation of a six member 
chelate with the harder carboxylate group. The N4O2 chelation mode for the GaL1 
chelate (all five member chelates) is likely to generate a coordination polyhedron of 
higher symmetry, similar to Ga(NOTA), than the N3O3 geometry involving a six 
member chelate – thus, the sharper 71Ga NMR signal  and higher chemical shift of the 
N4O2 isomer of GaL1 at pH 6–11. For the GaL3 complex at 20 mM concentration, the 
71
Ga NMR spectrum becomes too broad to be measured, reflecting provably the 
micellar state of the complex.45 Both GaL1 and GaL2 complexes are stable in the 
physiological pH range undergoing hydroxide catalyzed demetallation above pH 10 and 
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9, respectively. This is apparent in the 
71
Ga NMR spectra by the disappearance of the 
signals assigned to the complexes and by the appearance of the sharp signal at δ = 224 
ppm, assigned to the [Ga(OH)4]
−
 ion. All known Ga
3+
 complexes undergo hydroxide 
catalyzed demetallation in the alkaline pH region [40]. In this respect, the GaL1 
complex seems to be more stable than the amide conjugate GaL2 chelate, requiring a 
higher pH for complete demetallation. This can be ascribed to the preference for N4O2 
coordination of the GaL1 complex at high pH, compared to the N3O3 coordination of 
GaL2. A similar isomerization process involving coordination of the Ga
3+
 ion to the 
nitrogen or oxygen atom of the amide linkage (five member chelates) has been observed 
for the Ga(NO2A-N-benzylacetamide) and Ga(NO2A-N-methylacetamide) complexes 
(Figure 4.2 and Table 4.1), both in the solid state and in aqueous solution. At low pH 
the N3O3 coordination predominates over N4O2 coordination (42). As can be seen in 
Table 4.1, the two isomers of the Ga(NO2A-N-benzylacetamide) and Ga(NO2A-N-
methylacetamide), involving in both cases five member chelates, show much smaller 
shift differences and are much broader than the isomers found in the present study for 
GaL1. The phosphonate complex Ga(NOTP) [43] and some phosphinate complexes, 
like Ga(NOTMP) [44], lead to the presence of only one species in solution. In all the 
NOTA-type complexes with N3O3 coordination, the Ga
3+
 ion is placed between twisted 
trigonal O3 and N3 planes, an arrangement which leads to chiral complexes. This is 
caused by the combination of the conformation of the chelate rings in the macrocyclic 
moiety (δδδ/λλλ) with the helicity of the coordinated pendant arms (Δ/Λ), which leads to 
two diastereoisomeric pairs Δδδδ/Λλλλ and Λδδδ/Δλλλ. In the NOTA derivatives bearing 
three phosphinate pendant arms, those chiralities are combined with the R/S chirality of 
the phosphorus atom upon metal coordination, leading to four possible diastereomeric 
pairs, Λδδδ –RRR/Δλλλ–SSS, Λδδδ–RRS/Δλλλ– SSR, Λδδδ–RSS/Δλλλ–SRR and Λδδδ–
SSS/Δλλλ–RRR. In the Ga3+ phosphinate complexes with alkyl substituents (CH3 in Ga-
(NOTMP) (449 or CH2OH in Ga(TRAP-OH) [30], only the Λδδδ–RRR/ Δλλλ–SSS 
diastereoisomer is observed in solution, leading to a single 
71
Ga signal, while for more 
electron-withdrawing substituents, like H in Ga(TRAP-H) [30], the full mixture of 
possible isomers is observed in solution as a set of four narrow resonances with very 
small shift differences (Table 4.1). 
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The 1D 
1
H and 2D COSY and NOESY spectra of the GaL1 complex solutions were 
also obtained at 25 ºC in the pH range 3.0–9.0, and at pH 3.0–5.5 for GaL2 (Figure 
4.3).  
 
Figure 4.3- pH dependence of the proton NMR resonances of the CH protons of the propionate 
side arm of the GaL1 and GaL2 complexes (400 MHz, 20 mM in D2O, 25 °C). 
 
The proton resonance signals from the macrocyclic backbones were only tentatively 
assigned due to superimposed multiplet signals in the 3.7–2.8 ppm range (Figure SI4.1 
and SI4.2).The NCH2CO2H acetate arm protons give a multiplet at 3.85 ppm, while the 
phenyl group of GaL2 originates three multiplets at 7.70, 7.45 and 7.40 ppm with a 2 : 2 
: 1 intensity ratio, corresponding to the ortho, para and meta CH protons. The most 
informative resonances correspond to the NCH2CH protons of the substituted 
propionate arm of the complexes, in the form of a characteristic ABX pattern, with the 
CH proton resonances outside the envelope of other protons (Figure SI4.1 and SI4.2). 
The AB patterns of the CH2 signal coupled to the CH group (NCH2CH) could be traced 
to the COSY spectra of both complexes (Figure SI4.1 and SI4.2). In the case of GaL2 
the CH multiplet has a single component at 5.05 ppm (Fig. 3), in accordance with the 
single 
71
Ga resonance at +140 ppm, corresponding to N3O3 coordination (Figure 4.1). 
In the case of GaL1 the CH proton signals are pHdependent, in parallel with what was 
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observed for the 
71
Ga NMR spectra (Figure 4.3). Whereas at pH 3.3, it consists of a 
single multiplet (doublet of triplets) at 4.47 ppm (labeled I), corresponding to the single 
71
Ga resonance at 141 ppm (N3O3 coordination isomer), at pH 4.1 there are two CH 
multiplets at 4.50 (I) and 4.38 ppm (II), corresponding to the 
71
Ga signals at 141 and 
186 ppm, assigned to the N3O3 and N4O2 isomers, respectively. The relative intensity of 
the N4O2 signals (4.38 ppm and 186 ppm) increases with pH in relation to the N3O3 
signals (4.50 and 141 ppm) and at pH 6.1 only the 4.38 ppm signal is present. The 
corresponding CH2 multiplets are observed between 3.60 and 3.20 ppm (Figure SI4.1 
and SI4.2). Therefore, the proton NMR spectra confirm the isomer information 
provided by the 
71
Ga NMR spectra. 
4.2.3 Fluorescence studies 
The GaL3 complex was designed to have properties compatible with a bimodal 
PET/fluorescence imaging agent. The lipophilic pyrene moiety was selected due to its 
special aggregationsensitive fluorescence properties [37, 46]. The absorption (Figure 
SI4.3) and the fluorescence emission properties (Figure SI4.4) of the free ligand L3 
and of the GaL3 complex (Figure 4.4) were studied in non-deoxygenated water (pH 
7.0) by UV-Vis and steady-state fluorescence spectroscopy (Table 4.2). 
 
Figure 4.4- Normalized fluorescence spectra for GaL3 in non-deoxygenated water over the 
concentration range 5 × 10
−7–5 × 10−3 mol dm−3 (λexc= 345 nm). 
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Table 4.2- Quantum yields (F) for the ligand L3 and GaL3 complex (ex= 345 nm) in non-
deoxygenated water. 
F
 a,b
 
L3 GaL3 
0.20 0.30 
    
a
Relative to anthracene in ethanol ( = 0.27) 
b
Ligand and complex at 1.0x10
-6 
M concentration, non-deoxygenated solutions 
 
The absorption spectra of L3 and GaL3 (1 × 10
−5
 M, pH 7.0) exhibit bands in the 
wavelength range 300–350 nm characteristic of pyrene intraligand π–π* transitions 
(Figure SI4.3) [47]. The steady state fluorescence spectra of L3 (Figure SI4.4) and 
GaL3 (Figure 4.4) at low micromolar concentrations (1 × 10
−6
 M, λex=345 nm) display 
the typical vibronically structured band, attributed to the pyrene monomer (
1π–π* 
transitions) [37, 48]. The fluorescence quantum yields for L3 and for the pyrene-centred 
emission in GaL3 are of the same order of magnitude as those reported for other pyrene 
conjugates [37, 47, 48]. Complex formation with diamagnetic Ga
3+
 enhances slightly 
the fluorescence quantum yield of L3. The concentration dependence of the steady state 
fluorescence properties of L3 (Figure SI4.4) and GaL3 (Figure 4.4) indicates that both, 
ligands and complex, undergo self-assembly, presumably into micelle-type structures, 
in aqueous solution. 
Increasing the concentration of L3 and GaL3 triggers a gradual switch from the 
characteristic structured pyrene monomer spectrum to the broad featureless typical 
excimer (excited dimer) spectrum, indicating self-assembly in solution, presumably in 
the form of micelle-type structures [37]. Attempts to calculate the critical micelle 
concentration (cmc) for L3 and GaL3, by fitting the concentration dependence of the 
ratio of fluorescence emission intensities for the excimer (490 nm) and for the monomer 
(377 nm) (IE/IM) to a sigmoidal curve model, proved unsuccessful [37, 49, 50]. 
Nonetheless, the aggregationsensitive nature of the fluorescence emission is clearly 
observable. Above the cmc, aggregates and monomers (at a concentration equal to the 
cmc value) are present in solution. Increasing the ligand or chelate concentration leads 
to an increase of the number of micelles, enhancing excimer emission.  
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4.2.4 In vitro stability and biodistribution studies 
The kinetic stability of the [
67
Ga]L2 chelate towards in vivo transchelation was assessed 
by incubating the 
67
Ga
3+
-labeled chelate with fresh human serum, followed by 
precipitation of the protein fraction and measurement of the activity in the pellet and in 
the soluble fraction (Figure 4.5). 
 
Figure 4.5- Percentage of activity in the protein and in the soluble fraction at different 
incubation times of [
67
Ga]L2 with human serum. 
 
The percentage of total activity in the protein pellet reached immediately a value of 10% 
after incubating the complex with serum. This value remained constant over 1 hour 
incubation, revealing early association of the complex with blood proteins, presumably 
involving the lipophilic benzoyl moiety (Log Pcalculated(GaL2)= 0.69, see ESI). Radio-
TLC analysis of the soluble fraction after 1 hour incubation revealed that the complex 
remains intact. 
Biodistribution profiles were obtained for the [
67
Ga]L3 labelled complex at 1 and 24 
hour post-injection in Wistar rats (Figure 4.6, Table SI4.1). 
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Figure 4.6- Biodistribution profiles, presented as % injected activity per gram of organ or 
tissue, for the [
67
Ga]L3 complex at 1 and 24 hours postinjection. Results are the average of 4 
animals. 
At 1 hour post-injection the activity is manly located in the kidneys, liver and blood and 
to a lesser extent in the lungs and intestines. The high kidney uptake, compared to liver, 
indicates that the main elimination pathway is renal. The relatively high activity in the 
blood at 1 hour post injection suggests association of the complex with plasma proteins, 
probably albumin or lipoproteins, presumably through the lipophilic pyrene moiety 
(Log Pcalculated.(GaL3) = 3.31, see ESI) [37]. The very low spleen and lung uptake 
suggests that in the blood the complex is not aggregated. A motivating factor for 
performing the biodistribution study was to ascertain potential brain uptake of GaL3. 
Biodistribution studies of the analogous [
153
Sm][DO3A-N-(α-
pyrenebutanamido)propionate] complex suggested a low, although not negligible, 
activity uptake at the brain-cerebellum at 1 hour pi.37 The higher lipophilicity of GaL3 
(overall neutral complex), compared to its DOTA analogue Sm[DO3A-N-(α-
pyrenebutanamido)propionate] complex (overall charge −1), could conceivably result in 
higher brain uptake. The current study excludes brain uptake of [
67
Ga]L3. Most 
importantly, no significant activity remains in the liver and spleen and there is no 
activity deposition in the bones after 24 hours, indicating that complex demetallation is 
not occurring in vivo. 
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4.3 Conclusions 
In this work we extend the synthetic pathways, reported previously for the DO3A-N-(α-
amino)propionate family of chelators, to the triazacyclononane scaffold. A reversible 
pHtriggered switch from Ga
3+
 coordination to the carboxylate group of the substituted 
propionate arm (at pH values below 4.0) to amine coordination (at pH values above 6.0) 
was uncovered by 
1
H and 
71
Ga NMR studies of the Ga[NO2A-N-(α-amino)propionate] 
complex. The Ga
3+
 chelate of the benzoylamide conjugate displays pH-independent 
Ga
3+
 complexation to the carboxylate of the amide-substituted propionate arm in the pH 
range 3–11. Both complexes are stable in the physiological pH range. Moreover, the 
[
67
Ga][NO2A-N-(α-benzoylamido) propionate] chelate is also stable in human serum. 
The pyrenebutyric acid conjugate, Ga[NO2A-N-(α-pyrenebutanamido) propionate] 
chelate, was designed as a potential bimodal PET/fluorescence imaging agent with 
aggregationsensitive fluorescence properties. 
The facile synthesis of conjugates of the NO2A-N-(α-amino)- propionic acid chelator, 
together with the serum stability of their Ga
3+
 chelates and fast renal elimination of the 
lipophilic pyrene conjugate, without any liver/spleen retention and activity deposition in 
the bones, warrants further evaluation of this novel class of chelators as potential tracers 
for PET. The reversible pH-triggered coordination switch demonstrated for the 
Ga[NO2A-N-(α-amino)propionate] complex can conceivably be translated into a 
method for pH measurement in vivo by 
71
Ga NMR.  
4.4 Experimental 
4.4.1 Materials and methods 
Chemicals were purchased from Sigma-Aldrich and used without further purification. 
Analytical grade solvents were used without further purification, unless otherwise 
specified. Reactions were monitored by TLC on a Kieselgel 60 F254 (Merck) on an 
aluminum support, with detection by examination under UV light (254 nm and 365 nm), 
by adsorption of iodine vapor and by spraying with ninhydrin. Flash chromatography 
was performed on a Kieselgel 60 (Merck, mesh 230–400). Ion exchange 
chromatography was performed on Dowex 1X2 OH
−
 resin (Sigma Aldrich). The resin 
was purchased as the Cl
−
 form and converted to the OH
−
 form by the standard 
procedure. The relevant fractions from chromatography were pooled and concentrated 
under reduced pressure, T < 40 °C. 
1
H and 
13
C NMR spectra (assigned by 2D DQF-
COSY and HMQC techniques) were run on a Varian Unity Plus 300 and a Bruker 
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Avance-3 400 Plus NMR spectrometer, operating at 299.938 MHz and 75.428 MHz, 
and 400.13 MHz and 100.61 MHz, for 
1
H and 
13
C, respectively. 
1
H 1D and 2D DQF-
COSY and NOESY spectra were also run on a Varian VNMRS 600 at 599.72 MHz. 
Chemical shifts (δ) are given in ppm relative to the CDCl3 solvent (
1H, δ 7.27; 13C 
77.36) as an internal standard. For 
1
H and 
13
C NMR spectra recorded in D2O, chemical 
shifts (δ) are given in ppm, respectively, relative to T P as an internal reference (1H, δ 
0.0) and tert-butanol as an external reference (
13
C, CH3 δ 30.29). 71Ga NMR spectra 
were recorded at 122.026 MHz on a Bruker Avance-3 400 Plus spectrometer, using the 
signal of [Ga(H2O)6]
3+
 present in a 0.1 M Ga(NO3)3 solution in D2O, at 0 ppm as an 
external reference. pH measurements were performed on a pH meter Crison micro TT 
2050 with an electrode Mettler Toledo InLab 422. For D2O solutions, the isotopic 
correction pD = pH + 0.4 was done (51). Mass spectrometry was performed at CACTI, 
Vigo, Spain. 
4.4.2 Synthetic procedures 
Preparation of monoalkylated nonanes 5, 6 and 7  
4.4.2.1 Synthesis of bis(tert-butoxycarbonyl)amino-methoxycarbonylethyl- 1,4,7-triaza 
cyclononane – monoalkylated nonane (5).  
Boc2-Δ-Ala-OMe 2 (158 mg, 0.51 mmol) was added in one portion to a suspension 
containing 1,4,7-triazacyclononane (98 mg, 0.76 mmol) and K2CO3 (279 mg, 2.0 mmol) 
in MeCN (20 mL). The suspension was vigorously stirred at room temperature for 2 
hours. The suspended solid was removed by filtration and the solvent was evaporated 
under reduced pressure. The residue was purified by flash chromatography (100% 
CH2Cl2 → CH2Cl2–EtOH–NH4OH–H2O (50 : 50 : 1 : 1)) to afford compound 5 (120 
mg, 55%). 
1
H NMR (300 MHz, CDCl3): δ = 1.51 (s, 18 H, Boc), 2.58–2.80 (m, 12 H, 
N(CH2)2N), 3.65 (dd, J = 14.1 and 8.4 H z, 1 H, ABX), 3.70 (dd, J = 14.1 and 4.5 Hz, 1 
H, ABX), 3.71 (s, 3 H, C(O)OMe), 5.01 (dd, J = 8.4 and 4.5 Hz, 1 H, ABX).
13
C NMR 
(75.4 MHz, CDCl3): 28.02 (C(CH3)3), 46.45 (CH2), 46.83 (CH2), 52.16 (C(O)OCH3), 
53.16 (CH2), 56.52 (CH2), 56.67 (CH), 83.34 (C(CH3)3), 152.28 (C(O), carbamate), 
170.73 (C(O), ester). HRMS (ESI): m/z: calcd for C20H39N4O6, [M + H]
+
: 431.2864, 
found: 431.2859. 
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4.4.2.2 Synthesis of N-tert-butoxycarbonylbenzamido-methoxycarbonylethyl- 1,4,7-
triaza cyclononane – monoalkylated nonane (6). 
(Benzyl)Boc-Δ-AlaOMe 3 (385 mg, 1.23 mmol) was added in one portion to a 
suspension containing 1,4,7-triazacyclo- nonane (242 mg, 1.87 mmol) and K2CO3 (691 
mg, 4.5 mmol) in MeCN (70 mL). The suspension was vigorously stirred at room 
temperature for 3 hours. The suspended solid was removed by filtration and the solvent 
was evaporated under reduced pressure. The residue was purified by flash 
chromatography (100% CH2Cl2 → CH2Cl2–EtOH–NH4OH–H2O (70 : 30 : 1 : 1)) to 
afford monoalkylated nonane 6 as a viscous light yellow oil (364 mg, 59%). 
1
H NMR 
(300 MHz, CDCl3): δ = 1.47 (s, 9 H, C(CH3)3), 2.50–2.90 (m, 12 H, N(CH2)2N), 3.01 
(dd, J = 14.1 and 6.0 Hz, 1 H, ABX), 3.49 (dd, J = 14.4 and 5.1 Hz, 1 H, ABX), 3.76 (s, 
3 H, C(O)OMe), 5.25 (t, J = 6.0 and 5.1 Hz, 1 H, ABX), 7.30–7.70 (5 H, m, Ar). 13C 
NMR (75.4 MHz, CDCl3): δ = 27.27 (C(CH3)3), 44.77 (CH2), 45.83 (CH2), 46.70 
(CH2), 51.27 (CH2), 52.51 (C(O)OCH3), 55.61 (NCH2CH), 56.08 (CH), 83.88 
(C(CH3)3), 127.87 (Ar), 127.96 (Ar), 131.27 (Ar), 137.02 (Ar), 152.72 (C(O), 
carbamate), 170.57 (C(O), amide), 172.62 (C(O), ester). HRMS (ESI): m/z: calcd for 
C22H35N4O5, [M + H]
+
: 435.2602, found: 435.2601. 
4.4.2.3 Synthesis of methoxycarbonyl-(2-(N-t-butoxycarbonyl-4-pyrenebutanamido))-
ethyl-4,7-bis-(ethoxycarbonylmethyl)-1,4,7-triazacyclononane– monoalkylated (7). 
(Pyrenyl)Boc-Δ-AlaOMe 4 (1.01 g, 2.14 mmol) was added in one portion to a 
suspension containing 1,4,7-triazacyclononane (0.43 g, 3.33 mmol) and K2CO3 (1.76 g, 
12.7 mmol) in MeCN (40 mL). The suspension was vigorously stirred at room 
temperature for 5 hours. The suspended solid was removed by filtration and the solvent 
was evaporated under reduced pressure. The residue was purified by flash 
chromatography (100% CH2Cl2 → CH2Cl2–EtOH–NH4OH–H2O (70 : 30 : 1 : 1)) to 
afford monoalkylated nonane 7 as a viscous light yellow oil (0.76 g, 59%). 
1
H NMR 
(300 MHz, CDCl3): δ = 1.42 (s, 9 H, C(CH3)3), 2.21 (m, 2 H, NHC(O)-CH2CH2), 2.64 
(m, 8 H, 2 × N(CH2)2N), 2.90 (m, 1 H, ABX), 3.12 (m, 6 H, N(CH2)2N and 
NHC(O)CH2), 3.38–3.50 (m, 3 H, NHC-(O)CH2CH2CH2 and ABX), 3.43 (m, 2 H, 
N(CH2)2N), 3.70 (s, 3 H, C(O)OMe), 5.44 (t, J = 6.9 and 4.8 Hz, 1 H, ABX), 7.95–8.40 
(9 H, m, Ar). 
13
C NMR (75.4 MHz, CDCl3): δ = 27.03 (CH2), 27.83 (C(CH3)3), 32.83 
(CH2), 37.85 (CH2), 45.71 (CH2), 46.20 (CH2), 46.45 (CH2), 52.11 (CH2), 52.20 
(C(O)OCH3), 54.24 (CH), 58.17 (NCH2CH), 84.34 (C(CH3)3), 123.44 (Ar), 123.87 
(Ar), 124.72 (Ar), 125.02 (Ar), 125.76 (Ar), 126.58 (Ar), 127.28 (Ar), 127.47 (Ar), 
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128.66 (Ar), 129.85 (Ar), 130.82 (Ar), 130.92 (Ar), 131.33 (Ar), 151.86 (C(O), 
carbamate), 170.75 (C(O), ester). HRMS (ESI): m/z: calcd for C35H45N4O5, [M + H]
+
, 
601.3390, found: 601.3407. 
Synthesis of tris-alkylated nonanes 8, 9 and 10 
4.4.2.4 Synthesis of bis(tert-butoxycarbonyl)amino-methoxycarbonylethyl-4,7-bis-(tert-
butoxycarbonyl methyl)-1,4,7-triazacyclononane – tris-alkylated nonane (8).  
tert-Butyl bromoacetate (85 μL, 0.57 mmol) was added in one aliquot to a suspension 
containing monoalkylated compound 5 (100 mg, 0.23 mmol) and K2CO3 (125 mg, 0.90 
mmol) in MeCN (20 mL). The suspension was vigorously stirred at room temperature 
for 3 hours. The suspended solid was removed by filtration and the solvent was 
evaporated under reduced pressure. The residue was purified by flash chromatography 
(100% CH2Cl2 → CH2Cl2–EtOH (50 : 50)) to afford tris-alkylated compound 8 (69 mg, 
45%). 
1
H NMR (300 MHz, CDCl3): δ = 1.44 (s, 18 H, C(CH3)3, Boc), 1.65 (s, 18 H, 
C(CH3)3, ester), 2.75–3.78 (m(br) 12 H, N(CH2)2N), 3.03 (t, J = 4.2 Hz, 1 H, ABX), 
3.20 (t, J = 4.2 Hz, 1 H, ABX), 3.73 (s, 4 H, NCH2C(O)), 3.78 (s, 3 H, C(O)OMe), 5.01 
(t, J = 4.2 Hz 1 H, ABX). 
13
C NMR (75.4 MHz, CDCl3): 28.02 (C(CH3)3, Boc and tBu 
ester), 44.53 (3 C, NCHCH2, CH2), 50.80 (2 C, CH2), 53.16 (2 C, CH2), 52.33 (3 C, 
OCH3, 2 × CH2), 56.52 (CH), 81.00 (2 C, C(CH3)3), 83.50 (2 C, C(CH3)3), 150.59 (1 C, 
C(O)), 151.98 (1 C, C(O), carbamate), 163.95 (1 C, C(O)OCH3), 170.98 (2 C, C(O)). 
HRMS (ESI): m/z: calcd for C32H59N4O10, [M + H]+, 659.4226, found: 659.4218. 
4.4.2.5 Synthesis of benzamido-methoxycarbonylethyl-4,7-bis-(ethoxycarbonylmethyl)- 
1,4,7-triaza cyclononane – tris-alkylated nonane 9. 
A solution of monoalkylated compound 6 (340 mg, 0.78 mmol) in trifluoroacetic acid in 
dichloromethane (60%, 25 mL) was stirred overnight at room temperature. The solvent 
was evaporated at reduced pressure. The residue was redissolved in dichloromethane 
and the solvent was evaporated. This procedure was repeated several times to give a 
light yellow thick oil. 
1
H NMR spectroscopy (CDCl3) revealed the disappearance of the 
signals assigned to the Boc group in the precursor compound. The oil (0.78 mmol, 
assuming quantitative deprotection) was dissolved in MeCN (30 mL), K2CO3 (1.0 g, 7.8 
mmol) was added and the suspension was vigorously stirred at room temperature for 15 
minutes. Ethyl bromoacetate (0.21 mL, 1.88 mmol) was added and the suspension was 
further stirred at room temperature for 2.5 hours. The suspended solid was removed by 
filtration, the solvent was evaporated under reduced pressure and the residue was 
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purified by flash chromatography (100% CH2Cl2 → CH2Cl2–EtOH (7 : 3)) to afford 
compound 9 (355 mg, 37%) as a white foam. 
1
H NMR (300 MHz, CDCl3): δ = 1.22 (m, 
6 H, C(O)OCH2CH3), 2.2–3.60 (broad multiplet, 18 H, N(CH2)2N, NCH2C(O) and 
NCH2CH), 3.71 (s, 3 H, C(O)OCH3), 4.11 (t, J = 7.5 Hz, C(O)OCH2CH3), 5.14 (m (br), 
1 H, NCH2CH), 7.44–8.03 (5H, m, Ar). 
13
C NMR (75.4 MHz, CDCl3): selected signals: 
13.95 (C(O)OCH2CH3), 48.74 (CH), 49.04 (CH2), 50.38 (CH2), 51.48 (CH2), 52.59 
(CH2), 52.95 (C(O)OCH3), 53.62 (NCH2CH), 53.62 (CH2), 54.86 (CH2), 54.96 (CH2), 
55.19 (CH2), 55.37 (CH2), 55.75 (CH2), 56.18 (CH2), 60.62 (CH2), 60.94, 61.13, 61.21 
(C(O)OCH2), 127.83 (Ar), 128.12 (Ar), 128.41 (Ar), 131.53 (Ar), 131.84 (Ar), 132.62 
(Ar), 167.79 (C(O), amide), 170.29 (2 × C(O), ethyl ester), 170.52 (C(O), methyl ester), 
170.91 (C(O), ethyl ester). HRMS (ESI): m/z: calcd for C25H39N4O7, [M + H]
+
, 
507.2813, found: 507.2807. 
4.4.2.6 Synthesis of 1-(4-pyrenebutanamido)-carboxyethyl-4,7-bis- 
(ethoxycarbonylmethyl)-1,4,7-triaza cyclononane – tris-alkylated nonane (10).  
A solution of monoalkylated nonane 7 (0.69 g, 1.16 mmol) in trifluoroacetic acid in 
dichloromethane (60%, 25 mL) was stirred overnight at room temperature. The solvent 
was evaporated at reduced pressure. The residue was re-dissolved in dichloromethane 
and the solvent was evaporated. This procedure was repeated several times to give a 
light yellow thick oil. 
1
H NMR spectroscopy (CDCl3) revealed the disappearance of the 
signals assigned to the Boc group in precursor 7. The oil (1.16 mmol, assuming 
quantitative deprotection) was dissolved in MeCN (30 mL), K2CO3 (1.6 g, 11.5 mmol) 
was added and the suspension was vigorously stirred at room temperature for 15 
minutes. To this suspension was added ethyl bromoacetate (0.31 mL, 2.77 mmol). The 
suspension was vigorously stirred at room temperature overnight. The suspended solid 
was removed by filtration, the solvent was evaporated under reduce pressure and the 
residue was purified by flash chromatography (100% CH2Cl2 → CH2Cl2–EtOH (1 : 1)) 
to afford compound 10 (0.425 g, 55%) as a white foam. 
1
H NMR (300 MHz, CDCl3): δ 
= 1.26 (m, 6 H, 2 × C(O)OCH2CH3), 2.24 (m, 2 H, NHC(O)CH2CH2), 2.44 (m, 2 H, 
NHC(O)CH2), 2.60–2.90 (m, 4 H, NCH2C(O)), 2.50–3.40 (m, 16 H, N(CH2)2N, 
NCH2C(O), NCH2CH), 3.37 (m, 2 H, NHC(O)(CH2)2CH2), 3.73 (s, 3 H, C(O)OMe), 
3.92 (m, 4 H), 4.10 (m, 6 H, C(O)OCH2), 4.81(d(br), 1 H, NCH2CH), 7.80–8.40 (9 H, 
m, Ar). 
13
C NMR (75.4 MHz, CDCl3): selected signals: 14.05 and 14.13 (C(O)-
OCH2CH3), 27.23 (NHC(O)CH2CH2), 32.67 (NHC(O)(CH2)2-CH2), 35.39 
(NHC(O)CH2), 43.50 (CH2), 43.76 (CH2), 43.98 (CH2), 48.06 (CH2), 51.22 (CH2), 
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51.72(CH2), 51.86 (C(O)OCH3), 52.51 (CH), 52.60 (CH2), 55.40 (CH2), 55.64 (CH2), 
60.82, 60.98 (C(O)OCH2), 123.63 (Ar), 124.62 (Ar), 124.75 (Ar), 124.85 (Ar), 125.76 
(Ar), 126.51 (Ar), 127.18 (Ar), 127.41 (Ar), 127.46 (Ar), 128.67 (Ar), 129.72 (Ar), 
130.87 (Ar), 131.32 (2 × Ar), 136.43 (C), 136.53 (Ar), 171.36 (C(O), ethyl ester), 
171.39 (C(O), ethyl ester), 171.54 (C(O), methyl ester), 173.64 (C(O), amide).  
Synthesis of fully deprotected ligands L1, L2 and L3 
4.4.3.7 Synthesis of aminocarboxyethyl-4,7-bis-(carboxymethyl)-1,4,7- 
triazacyclononane – fully deprotected NO2A-N-(α-amino)propionic acid ligand (L1). 
A solution of prochelator 8 (50 mg, 0.076 mmol) in a mixture of hydrochloric acid 6 
M–ethanol (12 mL; 2/1 (v/v)) was stirred at room temperature for 2 hours. The solvent 
was evaporated under reduced pressure and the residue was re-dissolved in a mixture of 
water–ethanol (10 mL; 1/1 (v/v)). The solution was adjusted to pH ∼ 10 with Dowex 
1X2 OH
−
 resin (10 mL, wet resin) and the suspension was stirred for 1 hour at room 
temperature. The resin was transferred into a column, washed with water and further 
eluted with hydrochloric acid 0.1 M. The relevant fractions, identified by TLC (ethanol–
water 1/1, revelation with iodine vapor) were pooled together and evaporated at reduced 
pressure to afford ligand L1 in the hydrochloride form as an off-white solid (25 mg, 
quantitative yield). 
1
H NMR (300 MHz, D2O): δ = 2.73–3.67 (m, 16 H, N(CH2)2N and 
NCH2CO2H), 3.06 (d, J = 3.9 Hz and x Hz, 1 H, ABX), 3.31 (dd, J = 12.3 and 3.9 Hz, 1 
H, ABX), 5.01 (dd, J = 10.5 and 3.9 Hz, 1 H, ABX). 
13
C NMR (75.4 MHz, D2O): 48.71 
(CH2), 49.04 (CH2), 49.50 (CH2), 50.93 (CH2), 51.68 (CH2), 53.35 (CH), 57.31 (CH2), 
57.93 (CH2), 58.46 (CH2), 173.31 (CO2H), 174.99 (CO2H), 176.42 (CO2H). HRMS 
(ESI) m/z: calcd for C13H25N4O6 [M + H]
+
: 333.1769, found: 333.1769. 
4.4.2.8 Synthesis of benzamido-carboxyethyl-4,7-bis-(carboxymethyl)- 1,4,7-
triazacyclononane – fully deprotected NO2A-N-(α-benzoylamido)propionic acid ligand 
(L2). 
Prochelator 9 (323 mg, 0.89 mmol) was dissolved in a mixture of ethanol–water (20 
mL, 1/1 (v/v)). The solution was adjusted to pH ∼ 10 by adding small portions of 
Dowex 1X2 OH
−
 resin. The suspension was stirred gently at room temperature for 2 
hours. The wet resin was transferred into a chromatography column, washed with water 
(∼50 mL) and eluted with hydrochloric acid 0.1 M. The relevant fractions, identified by 
TLC (ethanol–water 1/1, revelation with iodine vapor), were pooled, concentrated at 
room temperature and further dried under vacuum to afford ligand L2, in the 
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hydrochloride form, as a light yellow solid (180 mg, 71%). 
1
H NMR (300 MHz, D2O): 
δ = 2.9–3.6 (broad, overlapped signals with an integration corresponding to 14 H, 
N(CH2)2N and NCCH2CH), 3.81 (broad, overlapped signals with an integration 
corresponding to 4 H, NCH2CO2H), 4.80 (m (broad), 1 H, CH), 7.53–7.88 (5 H, m, Ar). 
13
C NMR (75.4 MHz, D2O): selected signals: 43.02 (CH2), 48.11 (CH2), 48.93 (CH2), 
49.03 (CH2), 49.78 (CH2), 51.39 (CH2), 51.71 (CH), 51.91 (CH2), 54.53 (CH2), 56.08 
(CH2), 56.77 (CH2), 127.46 (Ar), 129.04 (Ar), 132.60 (Ar), 133.32 (Ar), 170.20 
(CO2H), 177.17 (C(O), amide). HRMS (ESI): m/z: calcd for C20H29N4O7, [M + H]
+
, 
437.2031, found: 437.2027. 
4.4.2.9 Synthesis of 1-(4-pyrenebutanamido)-carboxyethyl-4,7-bis-(carboxymethyl)- 
1,4,7-triazacyclononane – fully deprotected NO2A-N- (α-pyrenebutanamido)propionic 
acid ligand (L3). 
Prochelator 10 (0.360 g, 0.53 mmol) was dissolved in a mixture of ethanol–water (1/1 
v/v, 20 mL). The solution was adjusted to pH ∼ 10 by adding small portions of Dowex 
1X2 OH
−
 resin. The suspension was kept under stirring at room temperature for 2 hours. 
The wet resin was transferred into a chromatography column, washed with water (∼50 
mL) and eluted with 0.1 M hydrochloric acid, followed by a mixture of hydrochloric 
acid 0.2 M–ethanol (1/1 v/v). The relevant fractions, identified by TLC (ethanol–water, 
1/1 v/v, revelation with iodine vapor and visualization under UV light λ365 nm), were 
pooled, concentrated at room temperature and further dried under vacuum to afford 
deprotected chelator L3 in the hydrochloride form, as a light yellow solid (0.149 g, 
46%). 
1
H NMR (400 MHz, D2O/CD3OD): δ = 1.9–3.3 (broad, overlapped signals with 
an integration corresponding to 24 H, NHC(O)CH2CH2CH2, NCH2CO2H, NCH2CH and 
N(CH2)2N), 4.49 (m (br), 1 H, CH), 7.80–8.40 (9 H, m, Ar). 
13
C NMR (75.4 MHz, 
D2O/CD3OD): selected signals: 28.22 (NHC(O)CH2CH2), 33.25 ((NHC(O)- 
(CH2)2CH2), 36.23 ((NHC(O)CH2), 48.92 (CH), 50.49 (CH2), 54.95 (CH2), 122.75 
(Ar), 123.97 (Ar), 124.03 (CH-Ar), 124.58 (2 × (CH-Ar)), 125.71 (CH-Ar), 126.19 
(CH-Ar), 126.93 (C-Ar), 126.99 (CH-Ar), 127.28 (CH-Ar), 127.92 (CH-Ar), 129.24 (C-
Ar), 130.20 (C-Ar), 130.70 (C-Ar), 135.44 (C-Ar), 171.98 (CO2H), 172.19 (2 × CO2H), 
175.41 (NHC(O)). HRMS (ESI): m/z: calcd for C33H38N4NaO7, [M + Na]
+
, 625.2638, 
found: 625.2621. 
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4.4.2.10 Preparation of Ga3+ chelates for 1H and 71Ga NMR.  
To an aqueous solution of the ligand (pH = 3.0) was added dropwise an aqueous 
solution of GaCl3 in a 1 : 1 mole ratio. The pH was kept below 3.8 by the addition of 
aqueous NaOH. The solution was stirred at room temperature overnight and the solvent 
was removed at reduced pressure. Solutions for NMR measurements (20 mM, D2O) 
were obtained by dissolution of the solid complexes in D2O (0.75 mL). 
1
H and 
71
Ga 
NMR spectra of the complexes were obtained at 298 K on a Bruker Avance-3 400 Plus 
spectrometer, operating at 400.02 and 121.98 MHz, respectively. The proton NMR 
spectra of the complexes were assigned by 2D COSY and NOESY techniques using a 
Varian VNMRS 600 NMR spectrometer. The 
1
H and 
71
Ga NMR pH study of the 
complexes was performed by adding small portions of NaOD or DCl to the complex 
solutions to obtain the desired pH. 
4.4.2.11 Fluorescence measurements 
The absorption and the fluorescence emission spectra of the free ligand L3 and the GaL3 
complex were recorded, respectively, with a Jasco V-630 UV-Vis spectrophotometer 
and a HORIBA Jobin Yvon Fluoromax-4 spectrofluorimeter, equipped with a 
monochromator in both excitation and emission and a temperature controlled cuvette 
holder. Fluorescence spectra were corrected for the instrumental response of the system. 
The fluorescence quantum yields (F) were determined using the standard method [52, 
53]. Anthracene in ethanol (r= 0.27) [54] was used as a reference. 
4.4.2.12 Radiochemistry 
67
Ga
3+ 
complexes for in vivo and in vitro experiments were prepared by adding 1 mCi of 
[
67
Ga]citrate (produced at IBA Molecular, Louvain-la-Neuve) to a solution of 1 mg of 
the chelator in HEPE  buffer (400 μL, 0.4 M, pH 4) and heated at 80 ºC for ca. 1 hour. 
The radiochemical purity of the final products was determined by TLC. The percentage 
of the bound metal was above 95% in all cases. 
4.4.2.13 Calculation of log P 
The lipophilicity of GaL2 and GaL3 complexes was assessed by computing their log P 
values using the ALOGPS software (free software available at 
http://www.vclab.org/lab/alogps) [55]. 
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4.4.2.14 Stability in blood serum 
For the blood serum stability studies, 5 μCi of a standard solution of [67Ga]L2 were 
added to 5 mL of fresh human serum, previously equilibrated in 5% CO2 (95% air) 
environment at 37 °C. The mixture was kept in the same environment, and aliquots of 
100 μL (in triplicate) were taken at appropriate periods of time (0 min, 30 min, and 1 
hour). The aliquots were treated with 200 μL of ethanol, cooled (4 °C), and centrifuged 
for 15 min at 4000 rpm, at 4 °C, in order to precipitate the serum proteins. A 100 μL 
aliquot of supernatant was collected for activity counting in a γ well-counter. The 
sediment was washed twice with 1 mL of EtOH and its activity was counted. The 
activity of the supernatant was compared to that of the sediment in order to determine 
the percentage of the chelate associated with the proteins. The activity of the 
supernatant at 1 hour was evaluated by TLC in order to check whether the chelate 
remained intact. 
4.4.2.15 Biodistribution studies 
All animal studies were performed by authorized researchers in strict adherence to the 
Portuguese laws for animal protection. 
Groups of four animals (Wistar male rats weighting ca. 200 g) were anaesthetized with 
ketamine (50.0 mg mL
−1
)–chloropromazine (2.5%) (10 : 3), injected in the tail vein with 
ca. 100 μCi of [67Ga]L3 and sacrificed 1 and 24 hours later. The major organs were 
removed, weighed and counted in a γ wellcounter. The biodistribution is stated as 
percentage of injected dose per gram of organ (%ID g
−1
). 
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A) 
B)  
 
Figure SI4.1- A) 1D proton and B) 2D COSY NMR spectrum (600 MHz) of GaL1 at pH 3.0 
(20 mM in D2O, 25 ºC). 
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A)
 
B)
 
Figure SI4.2- A) 1D proton and B) 2D COSY NMR spectrum (600 MHz) of GaL1 at pH 4.0 
(20 mM in D2O, 25 ºC). 
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Figure SI4.3- UV-Vis spectra for the free ligand L3 and of the GaL3 complex (1.0x10
-5 
M). 
 
 
 
Figure SI4.4- Fluorescence spectra for ligand L3 in non-deoxygenated water over the 
concentration range 1x10
-7
 and 5x10
-3
 mol.dm
-3
 (exc= 345 nm). 
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Table SI4.1- Computed LogP values for the GaL2 and GaL3 complexes after structure 
optimization with Mopac PM6 COSMO, water implicit solvent. 
 
 
 
 
 
Figure SI4.5- Optimized structure of GaL3 (Mopac PM6 COSMO, water implicit solvent). 
 
  
 Calculated logP 
GaL2 0.69 
GaL3 3.31 
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Table SI4.2- Biodistribution, stated as percentage of injected dose per gram of organ (%ID/g 
±SD), of [
67
Ga]L3 in Wistar rats at 1 and 24 hours after i.v. injection. Results are the mean of 4 
animals. 
 
Organ 
1h 
%ID 
24h 
%ID 
blood 0.10007 0.000406308 
liver 0.350711 0.019477613 
spleen 0.04807 0.010971577 
kidney 0.817741 0.033667745 
heart 0.028524 0.002091018 
brain + cerebellum 0.002673 0.000355646 
lung 0.101831 0.006952801 
s. intestine 0.064156 0.004023468 
l. intestine 0.04826 0.003821414 
bone 0.027221 0.000864891 
muscle 0.023675 0.000383012 
 
  
5- Gold nanoparticles functionalised with 
stable, fast water exchanging Gd3+ chelates 
as high relaxivity contrast agents for MRI 
 
 Adapted from Dalton Trans., 2012,41, 5472-5475 
 
Gold nanoparticles functionalized with Gd
3+
 chelates displaying fast water exchange, 
superb pH stability and inertness towards transmetalation with Zn
2+
 have been prepared 
and characterized as a new high relaxivity (29 mM
−1
s
−1
, 30 MHz, 25 ºC) contrast agent 
potentially safe for in vivo MRI applications. The Lipari–Szabo treatment for internal 
rotation was used to evaluate the effect of linker flexibility on the relaxivity of the gold 
nanoparticles. The effect of fast water exchange on the relaxivity of gold nanoparticles 
functionalized with Gd
3+
 chelates is also addressed in this communication. 
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5.1 Introduction 
Magnetic resonance imaging (MRI) is at the forefront of biomedical and clinical 
imaging. Its superb spatial resolution, noninvasive nature and use of benign radiation 
outweigh its intrinsic low detection sensitivity. Paramagnetic relaxers can enhance 
dramatically the contrast between healthy and diseased tissues (contrast agents, CAs) by 
shortening the relaxation times of the water protons in their vicinity. The selective 
reduction of the relaxation times of the water protons brought about by a 1 mM 
concentration of paramagnetic centers, relaxivity (units mM
−1
s
−1
), measures the efficacy 
of CAs [1, 2]. Gd
3+
 chelates are the most efficacious CAs for MRI. The Solomon–
Bloembergen–Morgan (SBM) theory has established the physical–chemical principles 
guiding the design and synthesis of a plethora of CAs [3] : multimeric, self-assembling, 
targeted, responsive, etc. Nonetheless, the predicted high relaxivities, of the order of 
magnitude 100 mM
−1
s
−1
, are still to be achieved.  
Nanotechnology is a promising new paradigm in science and in biomedicine in 
particular. Different nanoplatforms (nanoparticles, quantum dots, fullerenes, carbon 
nanotubes, viral capsules) have been used to improve the performance of CAs by 
integrating (intrinsic) reporting capabilities with properties inherent to the nanoscale and 
its interplay with biological systems and barriers [4]. There is extensive experience on 
the use of Au compounds and colloidal (metallic) Au in medicinal chemistry. The 
accepted biocompatibility of gold allied to its resistance to oxidation and facile 
preparation of nanostructures displaying tunable size, shape (nanoparticles, nanorods) 
and surface properties, makes Au nanoparticles (NPs) ideal objects for developing 
multifunctional CAs [5]. Clustering of reporters on the surface of gold NPs 
(multimerisation) can lead to dramatic enhancements of detection sensitivity. Mixed 
monolayer nanoparticles containing reporters and targeting moieties allow integrating 
multimodality, targeting, imaging, and therapy (e.g. hyperthermia) in the same 
platform-theragnostics. 
Au NPs functionalized with Gd
3+
 chelates are promising high relaxivity CAs for MRI 
[6]. Spectacular relaxivities per nanoparticle (high density of relaxivity) have been 
attained by chelate clustering (multimerisation). Still, relaxivity enhancement per Gd
3+
 
chelate is, in most cases, only moderate [7, 8]. This has been ascribed to suboptimal R 
resulting from inefficient coupling of global (whole particle) and (independent) local 
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rotational rotions due to linker flexibility. Large surface curvature (small nanoparticles) 
and/or geometric constraints related to ligand structure prevent efficient monolayer 
packing, which would otherwise restrict linker/spacer flexibility [9, 10]. Helm and co-
workers. have reported so far, the most impressive relaxivity per Gd
3+
 chelate 
immobilized on gold nanoparticles, 60 mM
−1
s
−1
 (30 MHz, 25 °C), using Gd
3+
 chelates 
of diethylenetriaminetetraacetic acid (DTTA)-type ligands [11]. Such high relaxivities 
have been ascribed to 2 exchanging inner sphere water molecules coupled to (complete) 
monolayer rigidity. Relaxivity was limited by slow water exchange. In fact, most 
systems reported to date use Gd
3+
 chelates based on facile to synthesize 
diethylenetriaminetetraacetic acid (DTPA)-(bis)amide [6–8] and 1,4,7,10-
tetraazacyclododecane- 1,4,7,10-tetraacetic acid (DOTA)-monoamide [12] -thiol 
ligands. Besides compromising the thermodynamic and kinetic stability of the chelates, 
critical for in vivo applications [13], amides display slow water exchange, in relation to 
their parent carboxylate chelates [14], limiting the relaxivity potentially achievable by 
rigid slow tumbling nanoparticles [11]. 
As far as we know, the effect of water exchange on the relaxivity of Au NPs 
functionalized with Gd
3+
 chelates has not been explicitly addressed. We have reported 
recently the synthesis of a novel macrocyclic metal chelator of the DOTA-type 1,4,7,10-
tetraazacyclododecane-1,4,7-triacetic acid (DO3A-N-(α-amino)propionate). The 
Gd[DO3A-N-(α-amino)propionate] chelate revealed exceptional inertness towards 
transmetallation, stability in a wide pH range 2–10 and fast water exchange, in the range 
considered ideal for attaining high relaxivities at intermediate fields. The pendant amine 
group on the propionate arm can be used for conjugation purposes [15]. Building on 
these results, we have demonstrated meanwhile that Gd
3+
 chelates of amide conjugates 
of the DO3A-N-(α-amino)propionate chelator retain the fast water exchange and 
stability properties of its parent complex [15, 16].  
5. 2 Results and discusion 
A cysteine conjugate of the DO3A-N-(α-amino)propionate ligand 5 (Scheme 5.1) was 
designed for decorating gold nanoparticles with Gd
3+
 chelates. Orthogonally protected 
prochelator 2 was synthesized in 3 steps from cyclen 1 [15] (Scheme 5.1). 
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Scheme 5.1- Synthesis of cysteine conjugate DO3A-N-(-cystamido)propionate (4) and 
preparation of gold nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] 
chelates (5): a) i. TFA/DCM; ii. DIPEA/DCM, N-Boc-S-Trt-Cys, DCC/HOBt b) i. aqueous 
HCl, ii. Dowex 1X2 OH
-
 resin, elution with hydrochloric acid 0.1 M; c) i. aqueous HAuCl4, 
NaBH4, ii) GdCl3.6H2O, iii) SEC- Sephadex G10, iv) dialysis cellulose membrane MWCO 
1000 
 
The amine group on compound 2 can be made available for conjugation by orthogonal 
deprotection with trifluoroacetic acid (TFA). Conjugate 4 was prepared in reasonable 
yield, as a mixture of diastereoisomers, by coupling amine-deprotected bifunctional pro-
chelator 2 with N-Boc-S-trityl cysteine using standard coupling conditions: 
diisopropylethylamine–dicyclohexylcarbodiimide–hydroxybenzotriazol (DIPEA–DCC–
HOBt). Purified amide was deprotected by sequential treatment with hydrochloric acid 
followed by Dowex 1X2 OH
−
 resin and resin elution with diluted hydrochloric acid. 
Conjugate 4 was obtained as thiol, presumably due to the acidic conditions used for 
deprotection and resin elution. Gold nanoparticles functionalized with chelator 4 were 
prepared in aqueous medium using a modification of Brust‘s method [17]. A molar 
equivalent of Gd
3+
, in relation to the amount of chelator used for nanoparticle 
preparation, was used to ensure complete loading of immobilized chelators. A final 
purification step by size exclusion chromatography (SEC) (Sephadex G10) followed by 
extensive dialysis (cellulose membrane MWCO 1.000) against water afforded the final 
nanoparticle, free of soluble complex and Gd
3+
 ions. No attempt was made to 
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fractionate the sample during SEC purification. The NPs are stable over extended time 
periods. They can be freeze dried (and even rota-evaporated) and re-dissolved in water 
without any apparent aggregation and precipitation. Dynamic light scattering (DLS) 
analysis (Figure SI5.3) revealed nanoparticles displaying an average hydrodynamic 
diameter of about 3.9 nm. Transmission electron microscopy (TEM) analysis (Figure 
SI5.5) confirmed this result showing spherical highly crystalline particles. The Au and 
Gd content of the NPs preparation were determined by inductively coupled plasma mass 
spectrometry (ICP-MS) analysis after digestion with aqua regia ([Au]= 3.77 mM; [Gd]= 
1.24 mM; ratio Au/Gd = 2.9). The thickness of the chelator monolayer on the Au NPs 
displaying an hydrodynamic diameter (determined by DLS) of 4.8 nm has been 
estimated by molecular modeling as being around 1.3 nm [11]. Taking into 
consideration the structural differences between the chelates and linkers reported and 
the ones disclosed in this work, one could estimate the gold core diameter of our 
nanoparticles to be around 1.9 nm. From these results, one can calculate that the Au 
core contains on average 210 Au atoms and the organic monolayer 70 Gd
3+
 chelates. A 
rough estimation states that nearly all Au atoms at the surface are bonded to gadolinium 
chelates. The stability of the immobilized chelates regarding transmetallation against 
Zn
2+
, the most abundant endogenous metal ion, was evaluated by relaxometric 
measurements (25 ºC, 20 MHz) using the protocol established for soluble Gd
3+
 chelates 
[18]. The gold nanoparticles were challenged with phosphate buffer and phosphate 
buffer containing Zn
2+
 ions. The time evolution of the relaxivity (Figure SI5.9) 
suggests that virtually no transmetallation occurs over 30 hours. Moreover, the 
relaxivity is nearly constant in the pH range 2–12, indicating that immobilized chelates 
are stable (Figure SI5.8). Importantly, these assays also evaluate (whole) nanoparticle 
stability towards metal ion (Zn
2+
) and pH induced nanoparticle aggregation and 
precipitation, which would be apparent as time dependent relaxivity decrease. These 
results strongly suggest that the nanoparticles are safe for in vivo use, although further 
studies are necessary to evaluate chelate and nanoparticle stability in high protein media 
such as serum. The nuclear magnetic relaxation dispersion (NMRD) profile was 
measured in the Larmor frequency range 0.01–400 MHz and fitted to the Solomon– 
Bloembergen–Morgan (SBM) theory including the Lipari–Szabo treatment for internal 
rotation (Figure 5.1) [19].  
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Figure 5.1- 
1
H nuclear magnetic relaxation dispersion profiles for gold nanoparticles 
functionalized with Gd[DO3A-N-(-cystamido)propionate] complex (5 mM): 25 °C (□), and 
37°C (○). 
 
It was not possible to fit the whole NMRD profile, only frequencies above 6 MHz were 
fitted, as the SBM theory does not work properly at low magnetic fields for slow 
rotating objects. The best fit parameters obtained for the Au NPs from the analysis of 
1
H 
NMRD data are shown in Table 5.1.  
Table 5.1- Best fit parameters obtained for Au-NPs functionalized with Gd[DO3A-N-(-
cystamido)propionate] chelates from the fitting of the 
1
H NMRD data.
a
 
Parameters Value 
q(H2O) 1 
H‡ [J/mol] 17
b 
kex
298
 [10
7
 s
-1
] 5.14
b
 
ER [kJ/mol] (global) 18 ± 1.3 
RH
298
[ps] (global) 2470 ± 151 
ER [kJ/mol] (local) 18
 
RH
298
[ps] (local) 177 ± 27 
S
2
 0.48 ± 0.02 
EV [kJ/mol] 1 
V
298
 [ps] 11 ± 1 
2 [1020 s-2] 0.040 ± 0.003 
Parameters underlined have been fixed; 
a
 a 
full list of parameters is given in Table 
1SI; 
b,
ref. 16
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The water exchange rate constant and the activation enthalpy for water exchange were 
fixed in the fittings to values (   
   = 5.14 × 10
7
 s
−1
 and ΔH‡= 17 J mol−1) determined by 
us for the analogous low molecular weight chelate Gd[DO3A-N-(α-benzoylamido) 
propionate] [16]. As far as we are aware, there are no reports in the literature on the 
measurement of the exchange rate on Gd
3+
 chelates immobilized on gold nanoparticles. 
Several authors have reported independently that     for the CA MS-325 drops by a 
factor of 2–3 upon binding to human serum albumin (HSA) [20]. Non-covalent (non-
specific) association of Gd
3+
 chelates to hydrophobic pockets on large proteins such as 
HSA is bound to restrict water access to chelates. In the case of Au NPs, Gd
3+
 chelates 
are covalently bound to the nanoparticles surface in a well defined orientation, via a 
relatively long linker, ensuring unrestricted water access to chelates. It is thus 
reasonable to assume that chelate immobilization has no effect on the water exchange 
rate. Other parameters were fixed to values characteristic of DOTA-type chelates. The 
NMRD profile is characteristic of slow-rotating particles with a shallow decrease of r1 
at about 1 MHz and a broad peak centered at 20–30 MHz [11, 21]. Exceptional 
relaxivities per Gd
3+
 chelate (29 mM
−1
s
−1
, 30 MHz, 25 ºC) were obtained compared to 
other q= 1 systems reported before (6–10, 12). The temperature dependence of 
relaxivity at high field reveals that r1 is not limited by water exchange. In fact,    
    can 
be varied a lot in simulations without influencing the results. Chelate flexibility seems 
to be the main factor limiting relaxivity. In fact, the ―modified Florence method‖ [22], 
which assumes (total) chelate rigidity, is not suitable for fitting the NMRD data. The 
Lipari–Szabo treatment for internal rotation used in the fitting reveals a long global 
(whole particle) rotational correlation time (RH 
298
 (global)= 2470 ps) and a short local 
rotational correlation time (RH 
298
 (local)= 177 ps). The order factor value (S
2
 = 0.48) is 
of the same order of magnitude as those reported before for micellar systems, indicating 
chelate flexibility [21]. This is somehow surprising considering the relatively short 
(cysteine) linker used for chelate immobilization. However, the structure of the linker 
might limit monolayer packing density, which could otherwise restrict local movements 
[9, 10]. The (unprecedented) high relaxivity per Gd
3+
 attained at intermediate field (29 
mM
−1
s
−1
, 30 MHz, 25 ºC) together with the inertness and stability of the chelates and 
whole nanoparticles suggest that this system is promising for biological applications. It 
is also worth noting that the relaxivity peak at intermediate field is very broad extending 
into the high field region. Relaxivity values at 100 and 200 MHz (15 and 8 mM
−1
s
−1
, 
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respectively, at 37 °C) are still remarkable for biological applications as a high field 
CA.23  
5.3 Conclusions 
The relaxivity displayed by the system described by Helm and co-workers is limited by 
slow water exchange (rigid system, S
2
= 1). For the system described here, at magnetic 
fields relevant for MRI the relaxivity is limited by the flexibility of the linker used to 
bind the chelate to the nanoparticle (Figure SI5.10). Metal ion mediated self-assembly 
of Gd
3+
 complexes into rigid metallostars [24], placement of Gd
3+
 chelates on the 
barycenter of sugar constructs [25] and anchoring Gd
3+
 chelates functionalized with two 
alkyl chains into micelles [26, 27] have been successful strategies for coupling local and 
global motions. It is thus conceivable that Gd
3+
 chelates of conjugates of the DO3A-N-
(α-amino)propionate chelator, bearing long thiol linkers able to self-assemble into dense 
packing, rigid monolayers on Au, might attain unprecedented high relaxivities. The 
relaxation enhancement generated at 37 ºC and 1.5 T (60 MHz) by our Au NPs is about 
1400 mM
−1
s
−1
. Therefore, a local 700 nM concentration of particles would still lead to a 
relaxation enhancement of 1 s
−1
.  
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5.4.1 Materials and methods  
Chemicals were purchased from Sigma-Aldrich and used without further purification. 
Cyclen was purchased from Chematech, France. Analytical grade solvents were used 
and, unless specified, not further purified. Reactions were monitored by TLC on silica 
gel by examination under UV light (250 nm) and staining with iodine vapour. 
Preparative chromatography was carried on Silica Gel 60 (230-400 mesh). Ion exchange 
chromatography was performed on Dowex 1X2 OH
-
 (50-100 mesh) resin. Size 
Exclusion Chromatography (SEC) was performed on Sephadex G10 (40-120 m). 
Dialysis was performed against water on cellulose membranes with MWCO of 1KDa. 
UV-VIS spectra were acquired with a Shimadzu UV-2501PC spectrophotometer. The 
size distribution and zeta potential of the gold nanoparticles were determined with a 
Malvern Zetasizer, NANO ZS (Malvern Instruments Limited, UK), using a He-Ne laser 
(wavelength of 633 nm) and a detector angle of 173º. Mass spectrometry was performed 
at CACTI- Vigo, Spain. 
1
H and 
13
C NMR spectra were run on Varian Unity Plus 300, 
Bruker Avance-3 400 Plus and Varian VNMRS 600 NMR spectrometers. Chemical 
shifts (δ) are given in ppm relative to the CDCl3 solvent (
1H, δ 7.27; 13C 77.36) as 
internal standard. For 
1
H and 
13
C NMR spectra recorded in D2O, chemical shifts (δ) are 
given in ppm, respectively, relative to TSP as internal reference (
1H, δ 0.0) and tert-
butanol as external reference (
13
C, CH3 δ 30.29). 
13
C NMR spectra were proton broad-
band decoupled using a GARP-1 modulated decoupling scheme.  
 
The 
1
H Nuclear Magnetic Resonance Dispersion (NMRD) measurements were 
performed by using a Stelar Spinmaster FFC NMR relaxometer (0.01-20 MHz) 
equipped with a VTC90 temperature control unit. At higher fields, the 
1
H relaxivity 
measurements were performed on Bruker Minispecs mq30 (30 MHz), mq40 (40 MHz) 
and mq60 (60 MHz), as well as Bruker Avance spectrometers connected to 2.35 T, 4.7 
T and 9.4 T superconducting magnets. In each case, the temperature was measured by a 
substitution technique. Variable temperature measurements were performed at 25 and 
37 ºC. The relaxometric pH dependence and transmetallation studies with Zn
2+
 of the 
nanoparticles were performed on a Bruker Minispec mq20 (20 MHz). The NMRD 
profiles have been analysed using the Visualiseur/Optimiseur 3.6 program [1] running 
on a Matlab® 6.5 platform.  
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5.4.2 Synthesis and characterization 
5.4.2.1 Preparation of the DO3A-N-(-cystamido)propionate ligand (4): 
Synthesis of amide (3): Orthogonally protected cyclen 2 [2] (1.62 g, 2.21 mmol) was 
dissolved in a mixture of dichlorometane/trifluoroacetic acid (45 cm
3
, 1/3 v/v) and 
stirred overnight at room temperature. The solvent was evaporated at reduced pressure 
and the residue was re-dissolved in dichlorometane and evaporated again. This 
procedure was repeated several times to give a thick light yellow oil. 
1
H NMR 
spectroscopy (CDCl3) revealed the disappearance of the signals assigned to the Boc 
groups in precursor compound 2. The integration ratio between the methine proton 
NCH2CH and the methyl or methylene protons (from the ethyl ester groups) indicated 
that no deprotection of the ethyl ester groups occurred. Amine deprotected compound 
(2) (2.21 mmol, assuming quantitative deprotection) was dissolved in dicholorometane 
(30 cm
3
). The solution was adjusted to pH 8-9 (pH paper) by dropwise addition of 
DIPEA (~7.0 cm
3
). To this solution was sequentially added N-Boc-S-Trityl-L-cysteine 
(1.02 g, 2.21 mmol), Hydroxybenzotriazole (0.557 g, 2.64 mmol) and a solution of DCC 
(0.752 g, 2.64 mmol) in dichloromethane (5 cm
3
). The reaction mixture was left stirring 
at room temperature overnight. The DCU byproduct was removed by filtration and the 
sample was concentrated under reduced pressure. The residue was re-dissolved in ethyl 
acetate (100 cm
3
), and the solution was washed sequentially with KHSO4 (1M, 3 x 30 
cm
3
), NaHCO3 (saturated solution, 3 x 30 cm
3
) and brine (3 x 30 cm
3
). The organic 
phase was concentrated under reduced pressure and the residue was purified by a flash 
chromatography (100% CH2Cl2 → CH2Cl2/EtOH (70:30)) to afford amide (3) (0.736 g, 
34%). 
1
H NMR (300 MHz, CDCl3): δ= 1.26 (m, 9 H, C(O)OCH2CH3), 1.46 (s, 9H, 
C(CH3)3), 2.2-3.60 (broad, overlapped signals with a integration corresponding to 26 H; 
N(CH2)2N, NCH2CO2Et, NHBocCHaHbCH, NCHaHbCH), 3.80 (s, 3H, C(O)OCH3), 
4,15 (m, 6H, OCH2CH3), 4.77 (m (br), 1H, NHBocCHaHbCH), 5.87 (m (br), 1H, 
NCHaHbCH), 7.1-7.6 (m, 15 H, Trt). HRMS (ESI): m/z: cacd for C51H73N6O11S 
[M+H]
+
: 977.5058, found: 977.5021. 
 
5.4.2.2 Preparation of fully deprotected DO3A-N-(-cystamido)propionate metal 
chelator (4):  
Compound (3) (0.706 g, 0.722 mmol) was dissolved in hydrochloric acid 3 M (20 cm
3
; 
water (5 cm
3
)/ethanol (10 cm
3
)/hydrochloric acid 37% (5 cm
3
)). The solution was left 
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stirring at room temperature overnight. The solvent was removed under reduced 
pressure at room temperature and the residue was taken up into a small volume of water 
(~ 20 cm
3
) and filtered. The solution was concentrated at reduced pressure, the residue 
was dissolved in water (~ 15 cm
3
) and the solution was adjusted to pH ~ 10-11 by 
adding small portions of Dowex 1X2 OH
-
 resin. The suspension was kept under stirring 
at room temperature for 2 hours. The wet resin was transferred into a chromatography 
column, washed with water (~ 50 cm
3
) and eluted with 0.1 M hydrochloric acid. The 
relevant fractions, identified by TLC (ethanol water 1/1, revelation with iodine vapor) 
were pooled, concentrated at room temperature and further dried under vacuum to 
afford the final deprotected compound (4) in the hydrochloride form, as a light yellow 
solid (0.276 g, 71.2%). 
1
H NMR (300 MHz, D2O): δ= 2.2-4.40 (broad, overlapped signals with an integration 
corresponding to, 22 H: N(CH2)2N and NCH2COOH), 3.07 (m, 2H, CH2SH), 3.33 (m, 
2H, CH2CH), 4.22 (m, 1H, CH2CH), 4.61 (m, 1H, SHCH2CH). 
13
C NMR (75.4 MHz, 
D2O): selected signals: 22.14 (CH2SH), 46.34 (CH2), 47,63 (CH2), 48.16 (CH2), 48.69 
(CH2), 49.98 (CH2), 51.01 (CH2), 53.43 (CH2), 53.80 (CH2CH), 54.03 (CHCH2SH), 
54.14 (CH2), 54.27 (CH2), 55.15 (CHCH2), 56.09 (CH2), 169.03 (NHC(O)), 169.14 
(C(O)), 170.60 (C(O)), 176.61 (CHC(O)), 177.93 (C(O)). HRMS (ESI): m/z: cacd for 
C20H37N6O9S [M+H]
+
: 537.2343, found: 537.2325.  
 
5.4.2.3 Preparation gold nanoparticles functionalized with Gd[DO3A-N-(-cystamido) 
propionate] chelates.  
The strategy envisaged for preparing gold nanoparticles funcionalized with Gd[DO3A-
N--(cystamido)propionate] chelates is depicted (as cartoon) in Scheme SI5.1).   
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Scheme SI5.1- General strategy (cartoon representation) for the preparation of gold 
nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] chelates 
 
An aqueous solution of DO3A-N-(-cystamido)propionate (4) ligand (46.13 mM, 4.66 
cm
3
, 0.099 mmol) was added dropwise, under magnetic stirring, to an aqueous solution 
of HAuCl4 (58.85 mM, 1.64 cm
3
, 0.096 mmol; molar ratio Au/ligand (1/1)). Addition of 
the ligand to the Au
3+
 solution generated initially a dark orange color which faded away 
with further ligand addition. To the stirring reaction mixture was added, in one aliquot, 
a solution of NaBH4 (20.40 mM, 0.217 cm
3
, 0.094 mmol; molar ratio Au/ligand/NaBH4 
1/1/1). The reaction mixture turned immediately dark brown and was left stirring at 
room temperature for 24 hours. The nanoparticles preparation was adjusted to pH ~ 7.0 
with aqueous NaOH 1 M and filtered through a 0.20 m PTFE syringe filter. A small 
sample (1.0 cm
3
) was kept for further characterization. To the remaining sample (~ 6.0 
cm
3
) was added a solution of GdCl3.6H2O (0.0211 g, 0.080 mmol; 1 molar equivalent in 
relation to the total amount of ligand used in the nanoparticles synthesis) in water (1.0 
cm
3
). During the addition of the Gd
3+
 ion the solution was kept at pH ~ 5.5 by adding 
NaOH 0.1 M. The reaction mixture was left stirring at room temperature for 24 hours, 
adjusted to pH ~7 by with aqueous NaOH (1 M solution) and filtered through a 0.20 m 
PTFE syringe filter. The gold nanoparticle preparation was purified by size exclusion 
chromatography using Sephadex G10 (40-120 m) eluting with water. During elution a 
colored broad band separated in the column. No attempt was made to fractionate the 
sample, the full band was collected as a single fraction (~ 20 cm
3
). The nanoparticles 
preparation was further purified by dialysis against water using a cellulose membrane 
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with 1 KDa MWCO. The xylenol orange test indicated the absence of free Gd
3+
 in the 
gold nanoparticles preparation. The Gd and Au concentration of the nanoparticle´s 
preparation ([Au]= 3.77 mM; [Gd]= 1.24 mM; [Au]/[Gd]= 2.9) was determined by ICP 
analysis.  
The binding mode of the Gd(DO3A-N-(-cystamido)propionate) chelates to the gold  
surface, represented in Scheme 1SI through the tiol group of the cysteine linker, is the 
most likely anchorage mode. Several authors have suggested the simultaneous binding 
of the thiol and amine groups of cysteine to gold (forming a chelate ring) as the (most 
likely) anchorage mode of cysteine containing peptides to gold NPs [3]. The band at 
3500 cm
-1
 in the IR spectrum (KBr pellets) of our nanoparticles (Figure SI5.1) is 
assigned by several authors to vibrational modes of the -NH3
+
 group in cysteine 
functionalized gold nanoparticles [4].  
 
Figure SI5.1- IR spectrum (KBr) of gold NPs functionalized with Gd(DO3A-N-(-
cystamido)propionate) chelates 
 
The IR spectrum of the functionalized gold NPs suggests that the nanoparticles are 
linked to the gold core through the thiol group only. The broad band at around 3500 cm
-
1
 has been assigned to vibrational modes of the -NH3
+
 in cysteine functionalized gold 
NP´s [3, 4].  
If the amine group is not involved in the binding to gold, then the effect of the solution 
pH on the overall charge of the immobilized complexes should be apparent as a pH-
dependent zeta potential. The negative Zeta potential values measured at pH 7.0 and 
10.0 (Figure SI5.3B) suggest that the chelates (and whole nanoparticles) bear net 
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negative charges. Moreover, the value and shape of the Zeta potential distribution 
curves at pH 7.0 and 10.0 suggests a higher extent of ionization of the amine group at 
pH 10. None the less the putative ionization of the amine group seems not to affect 
substantially the relaxivity of the NP´s in the pH range 2-12 (Figure SI5.7A).         
 
5.4.2.3 UV-VIS spectroscopy 
A very ill-defined plasmon band is apparent in the UV-VIS spectrum of the gold 
nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] chelates, 
suggesting that the nanoparticles display a diameter bellow 6 nm.  
 
 
Figure SI5.2- UV-VIS spectrum for the preparation of nanoparticles functionalized with 
Gd[DO3A-N-(-cystamido)propionate] chelates (diluted by a factor of 3, pH 7.0). 
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5.4.2.4 Size and zeta potential characterization by DLS 
From the DLS experiments (Figure SI5.3), one can conclude that the main  population 
of nanoparticles  in solution displays an average hydrodynamic diameter around 3.9 nm.   
 
 
Peak 
Diam. (nm) % Volume Width (nm) 
3.885 100 1.258 
Figure SI5.3- DLS size distribution (Volume) for the preparation of nanoparticles 
functionalized with Gd[DO3A-N-(-cystamido)propionate] chelates at pH 7.0.  
 
Figure SI5.4 shows that the nanoparticles display negative zeta potential both at pH 7.0 
and pH 10.0, with a broader distribuition at pH 7.0.   
 
 
Figure SI5.4- Zeta potential distribution at pH 7.0 (red curve) and pH 10.0 (green curve) for the 
preparation of nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] 
chelates. 
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5.4.2.5 TEM analysis of the nanoparticles 
 
 
Figure SI5.5- TEM image of the Au-NPs. The image was measured with a JEOL 2010 UHR 
transmission electron microscope at the Interdisciplinary Centre for Electron Microscopy 
(CIME) at EPFL, Lausanne. TEM samples have been prepared by dropping solutions of gold 
nanoparticles onto carbon-coated-copper grids and evaporating the solvent (water) to dryness. 
 
5.4.2.6 Estimation of the number of Au atoms 
The diameter of the Au-core of the gold nanoparticles has been estimated by choosing 
the thickness of the organic layer at the surface as 1 nm. This layer should be less thick 
as in ref. [6] because there are only 4 connecting atoms between the N in the chelate and 
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the S at the Au surface compared to 5 in ref. [6]. The Au-core has therefore a diameter 
of ~1.9 nm. Following ref. 7 the total number of Au atoms can be estimated to be ~210 
from NAu = 30.9·D
3
. Taking the experimental Au/Gd ratio of 2.9 there are ~70 Gd
3+
-
ions bound to a particle which corresponds roughly to 1 Gd
3+
 ion per gold atom at the 
surface. 
 
5.4.2.7 Relaxometric characterization of the gold nanoparticles 
 
 
Figure SI5.6- Dependency of the proton longitudinal paramagnetic relaxation rates (R1p) on the 
Gd
3+
 concentration for the preparation of nanoparticles functionalized with Gd[DO3A-N-(-
cystamido)propionate] chelates (20 MHz, 25 ºC, pH 7.5). Preparations with different 
concentrations Gd
3+ 
were obtained by dilution of the stock solution [Gd
3+
]= 1.238 mM. 
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Figure SI5.7- Dependency of the proton longitudinal paramagnetic relaxation rates (R1p) on 
temperature for the preparation of nanoparticles functionalized with Gd[DO3A-N-(-
cystamido)propionate] chelates ([Gd
3+
]= 1.238 mM, 20 MHz, 25 ºC, pH 7.5). 
 
 
Figure SI5.8- Dependency of the proton longitudinal paramagnetic relaxation rates (R1p) on the 
solution‘s pH for the preparation of nanoparticles functionalized with Gd[DO3A-N-(-
cystamido)propionate] chelates ([Gd
3+
]= 1.238 mM, 20 MHz, 25 ºC). 
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Figure SI5.9- Time evolution of the relative water proton paramagnetic relaxation rate 
R1p(t)/R1p(0) (20 MHz, 37 ºC) for the preparation of nanoparticles functionalized with 
Gd[DO3A-N-(-cystamido)propionate] chelates ([Gd3+] = 0.928 mM) in PBS 2.5 mM, pH 7.1 
in the presence (■) and in the absence (♦) of 0.75 mM ZnCl2. 
 
5.4.2.8 Fitting of NMRD profiles 
Table SI5.1- Full list of parameters used for the fitting of the high-field part of the NMRD 
profiles using SBM theory. 
Parameters Value 
q(H2O) 1 
H‡ [J/mol] 17
a 
kex
298
 [10
7
 s
-1
] 5.14
a
 
ER [kJ/mol] (global) 18 ± 1.3 
RH
298
[ps] (global) 2470 ± 151 
ER [kJ/mol] (local) 18
b 
RH
298
[ps] (local) 177 ± 27 
S
2
 0.48 ± 0.02 
EV [kJ/mol] 1 
V
298
 [ps] 11 ± 1 
2 [1020 s-2] 0.040 ± 0.003 
rGdH [Å] 3.1
c
 
DGdH
298
[10
-10
m
2
s
-1
] 23
c 
EDGdH
298
[kJ/mol] 20
c 
d [Å] 3.6
c
 
Parameters underlined have been fixed: 
a
 from reference [5]; 
b
 fixed to 
ER(global) after a preliminary fit, 
c
 fixed to usual parameters  
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Figure SI5.10- 
1
H nuclear magnetic relaxation dispersion profiles for gold nanoparticles 
functionalized with Gd[DO3A-N-(α-cystamido)propionate] complex (5 mM): 25 °C (□), and 
37°C (○). The full drawn lines are from the fit with parameters in Table SI5.1. The dashed lines 
are calculated using the same parameters except S
2
 = 1. 
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6 - Gold nanoparticles functionalised 
with Gd3+ chelates: effect of linkers on 
the relaxivity 
  
 
 
In a previous study we addressed the effect of fast water exchange on the relaxivity of 
gold nanoparticles functionalized with Gd
3+
 chelates of the cysteine conjugate DO3A-
N-(-cystamido)propionate chelator.  
In Chapter 5 we addressed the effect of fast water exchange on the relaxivity of gold 
nanoparticles functionalized with Gd[DO3A-N-(-cystamido)propionate] chelates. In 
this Chapter we report the synthesis of the lipoyl conjugate DO3A-N-(-
lipoamido)propionate and the preparation and characterization of AuNPs functionalized 
with Gd[DO3A-N-(-lipoamido)propionate] chelates as CA for MRI. The immobilized 
chelates display superb relaxivity (r1= 27 mM
-1
s
-1
; 20 MHz, 25 ºC) thanks to slow 
rotation in solution and fast water exchange. The relaxivity is still limited by fast 
rotational motions of the chelates around the linker anchoring the chelates to the NPs 
core. The effect of the length of the linker on the size and on the relaxivity of the NPs is 
address in this work: the length of the linker seems to determine the size of the NPs but 
seems not to affect substantially the flexibility of the immobilized chelates. A 
biodistribution study was carried out using NPs labeled with 
153
Sm[DO3A-N-(-
lipoamido)propionate] chelates. MRI studies in mice were carried out using NPs 
functionalized with Gd[DO3A-N-(-lipoamido)propionate] chelates and Gd[DO3A-N-
(-cystamido)propionate] chelates as Contrast Agents.  The NPs functionalized with 
Gd[DO3A-N-(-cystamido)propionate] chelates (HD= 3.9 nm) behave in vivo like low 
molecular weight CA- fast renal clearance and avoidance of the RES organs. The NPs 
functionalized with Gd[DO3A-N-(-lipoamido)propionate] chelates (HD= 4.8 nm) 
undergo predominantly hepatobiliary excretion. These results emphasize the complex 
interplay between the physical chemical properties of NPs and their behavior in vivo. 
Keywords: Gold Nanoparticles; DO3A-N-(-amido)propionate chelators; Lipoic acid; 
fast water exchange; pH stability; safety; in vivo MRI
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6.1 Introduction 
MRI has become the ―central imaging modality‖ in hospitals [1]. MRI is based on the 
nuclear magnetic resonance phenomenon (NMR). In MRI scans the relaxation times (T1 
and T2) of the water protons of tissues (intrinsically different) are acquired and 
reconstructed into tridimensional anatomical images [2]. MRI is inherently non-
invasive, makes use of (benign) non-ionizing radiation (magnetic fields and 
radiofrequencies), is depth independent and displays superb spatial resolution. Low 
detection sensitivity (inherent to the NMR phenomenon) is the main limitation of MRI 
[3]. Paramagnetic species (Gd
3+
, Mn
2+
, Fe
3+
, stable organic radicals, Iron Oxide 
nanoparticles, etc) promote selective reduction of T1 or T2 of the water protons of tissues 
(paramagnetic relaxers) resulting in dramatic contrast enhancements - Contrast Agents 
(CA). The selective enhancement of the relaxation rates, R1,2, (R1,2= 1/T1,2), normalized 
to 1 mM concentration of paramagnetic centres - relaxivity (r1,2, units mM
-1
s
-1
), 
measures CA efficacy [3, 4]. Approved CA for clinical MRI are either Gd
3+
 complexes 
with linear (DTPA-type) and macrocyclic (DOTA-type) poly(aminocarboxylate) ligands 
(T1-weighed MRI) [5] or Iron Oxide Nanoparticles (IONPS) stabilized with dextran (T2-
T2*-weighed MRI) [6]. Low molecular weight Gd-based CA display relaxivities of the 
order of magnitude 3-5 mM
-1
s
-1
 at magnetic fields relevant for clinical MRI (20-120 
MHz). Low relaxivity, combined with fast renal clearance (owing to high 
hydrophylicity), distribution into the interstitial compartment and featureless 
biodistributions, demand standard CA doses of 0.1 mmol/Kg body weight in clinical 
diagnosis [5]. Attaining much higher relaxivities, which would allow suitable contrast at 
much lower doses (safety concerns and lower prices), has been the driving force in CA 
research.
 
The Solomon-Bloembergen-Morgan (SBM) theory predicts that substantial 
relaxivity enhancements, at magnetic fields relevant for clinical imaging (20-120 MHz), 
are attainable by increasing the effective molecular volume (longer rotational 
correlation times, R) of Gd
3+
 chelates [3, 4].  Covalent linkage of Gd
3+ 
chelates to 
macromolecular carriers [7], non-covalent association with Human Serum Albumin 
(HAS) [8] and self-association [9], have proved successful for attaining high relaxivities 
at intermediate fields via R optimization. Tuning the water exchange rate (kex) into an 
optimal range, up to three orders of magnitude higher than that displayed by the 
Gd(DTPA) and Gd(DOTA) chelates, predicts very high relaxivities for macromolecular 
CA owing to simultaneous optimization of R and kex [10-12]. Extension of an 
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ethylenediamine to a propylenediamine bridge [11, 13], or replacement of a pendant 
acetate by a propionate [12, 14],
 
in the structure of the DTPA and DOTA chelators, 
results in water exchange accelerations suitable for attaining the very high relaxivities 
predicted for macromolecular CA exhibiting simultaneous optimization of kex. In 
practice, fast local rotational motions of the immobilized chelates (around connecting 
linkers/spacers) superimposed to slow rotational motions of the entire macromolecular 
objects, often limit the attainable relaxivity [11, 12, 15]. Multimodal imaging, 
combining different reporters in the same molecular platform, can overcome the 
shortcomings of individual modalities. High detection sensitivity, quantifiable 
modalities (e.g. fluorescence, PET or CT) can complement the depth independent high 
spatial resolution of MRI [16, 17].  
The nanotechnoly revolution is underway with a dramatic impact in many fields, 
particularly in medical imaging [18]. The recent development of the Magnetic Particle 
Imaging (MPI) imaging modality, relying on Superparamagnetic Iron Oxide 
Nanoparticles (SPION) is an paradigmatic example [19]. Some nanostructures 
(nanoparticles, quantum dots, carbon based nanomaterials, etc) exhibit intrinsic 
reporting properties (fluorescence, MRI, X-Ray attenuation) and/or therapeutic 
properties (PDT, hyperthermia, X-ray sensitization) [20]. Elaboration of nanostructures 
with (extra) reporting capabilities and/or therapeutic properties/cargos and targeting 
ability, can create exquisite platforms for coupled imaging/therapy, benefiting from the 
interplay of nanosize and the nature of biological structures and barriers [21, 22]. Safety 
concerns limit in vivo applications of (inherently) toxic nanostructured materials, e.g. 
Cd-based quantum dots [23]. Colloidal gold is generally considered biocompatible and 
safe in vivo [24]. Gold  nanoclusters (AuNCs) [25, 26], gold NPs (AuNPs) [27], and 
gold nanorods (AuNRs) [28] can be prepared by bottom-up strategies in a controlled 
fashion, with tunable size and surface properties. Moreover, AuNPs and AuNRs display 
intrinsic reporting and therapeutic properties (optical/X-ray attenuation and 
hyperthermia/X-ray sensitization) owing to the localized plasmon resonance 
phenomenon and the high electron density of gold [29, 30].  As CA for MRI, AuNPs 
decorated with a monolayer of Gd
3+
 chelates  display high density of relaxivity thanks 
to clustering of a high number of chelates in small molecular volume, optimization of R 
and restricted local rotational motions of the immobilized chelates [31]. Mixed 
monolayer AuNPs, incorporating Gd
3+
 chelates and targeting epitopes, are promising for 
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targeted imaging and therapeutic intervention [32]. The first generation of AuNPs CA 
made use of easy to synthesize thiol-functionalised Gd(DTPA-(bis)amide) [31, 33, 34] 
and Gd(DO3A)-type chelates [35]. Superb relaxivities (per nanoparticle) were attained 
thanks to chelate clustering. In vivo MRI studies proved the merits of AuNPs as CA for 
MRI, bimodal MRI/X-ray imaging and as theragnostics MRI/X-ray sensitization [29, 
31, 33, 34]. Nonetheless, slow water exchange and flexibility of the immobilized 
chelates result only in modest relaxivity enhancements per chelate [31-34, 36]. Helm 
and co-workers reported the highest relaxivity per chelate immobilized onto AuNPs (60 
mM
-1
s
-1
; 30 MHz; 25 ºC), attributed to two exchanging inner sphere water molecules in 
Gd(DTTA)-type chelates and complete rigidity of  the immobilized chelates- via a short 
aromatic linker [37]. The relaxivity was limited by slow water exchange. Nanoparticles 
functionalized with Gd
3+
 complexes of DTTA-, DTPA- and DO3A-type ligands, are 
good models for physical-chemical and animal pharmacological studies, but are 
unsuitable to clinical translation owing to insufficient thermodynamic stability and 
kinetic lability of the chelate payload [38, 39]. 
Our efforts towards the development of AuNPs functionalized with Gd
3+
 chelates as 
efficacious and potentially safe CA for MRI, have addressed, for the first time, the 
limitations imposed by slow water exchange on the relaxivity [15]. We have established 
in previous studies that the Gd[DO3A-N-(-amino)propionate] chelate and amide 
conjugates display water exchange rates within the ideal range for attaining high 
relaxivities at intermediate fields [12, 14, 40]. AuNPs functionalized with Gd
3+
 
complexes of the cysteine conjugate DO3A-N-(-cystamido)propionate revealed stable 
in a wide pH range (2-11) and inert towards transmetallation with Zn
2+
, suggesting 
potential for safe in vivo uses. High relaxivities at intermediate and high field (27 and 
8.0 mM
-1
s
-1
; 20 and 200 MHz, respectively, 25 ºC) were attained thanks to simultaneous 
optimization ofR and kex. The (short) cysteine linker still allows considerable flexibility 
of the immobilized chelates, limiting the relaxivity attainable (of the order of magnitude 
60 mM
-1
s
-1
, 20 MHz, 25 ºC) considering total rigidity of the Au-anchored chelates [15].
 
 
In this work we address the effect of the length of the -thiol linker anchoring the 
coordination cage (and ligand bulkiness) to the gold nanocrystal core, on the size and 
relaxivity of the NPs. Biodistribution and in vivo MRI studies with AuNPs CA are also 
reported.  
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6.2 Results and Discution 
6.2.1 Synthesis and characterization 
A lipoyl conjugate of the DO3A-N-(-amino)propionate chelator was synthesized to 
study the effect of the length of the -thioalkyl linker on the size and relaxivity of 
AuNPs functionalized with Gd
3+
 chelates (Scheme 6.1).  
 
 
Scheme 6.1- Synthetic pathway for -thioalkyl conjugates of the DO3A-N-(-
amino)propionate chelator: a) K2CO3/MeCN; b) ethyl bromoacetate, K2CO3/MeCN; c) i. 
TFA/CH2Cl2, ii. DIPEA/CH2Cl2, lipoic acid, DCC/HOBt; d) i. NaOH aq. ii. Flash 
chromatography silica gel, iii. SEM (Sephadex G10); e) GdCl3.xH2O; f) i. HAuCl4, ii. 
GdCl3.xH2O, iii. SEM (Sephadex G10) followed by dialysis (cellulose tubing MWCO 10 KDa). 
The lipoic acid conjugate (L1) was prepared following the synthetic methodology 
reported before for the cysteine conjugate of the DO3A-N-(-amino)propionate chelator 
(L3) [15]. The synthetic pathway excludes, all along, acidic conditions likely to 
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promote oligomerization of the chelator through the lipoic acid moiety [41]. 
Deprotection of the fully alkylated orthogonally protected intermediate 6 allows direct 
conjugation of lipoic acid to the preformed DO3A-N-(-amino)propionate scaffold 
[15]. 
Final deprotection was performed in one step by saponification with ethanolic NaOH. 
Following pH adjustment to neutrality with diluted hydrochloric acid, chelator L1 was 
adsorbed onto silica and purified by flash chromatography followed by Size Exclusion 
Chromatography (SEC) on Sepahdex G10 with water elution.  
 
6.2.2 Relaxometric studies of GdL1  
The concentration dependence of the paramagnetic water proton relaxation rate (R1p) 
was measured for GdL1 (20 MHz, 25 ºC, pH 7.1) (Figure 6.1). 
 
 
Figure 6.1- Concentration dependence of the paramagnetic water proton relaxation rate R1p = 
(R1obs-R1d) for GdL1  
 
The relaxation rate data for GdL1 can be well fitted to a straight line (equation 1) 
affording a relaxivity of 8.6 ± 0.9 mM
-1
s
-1
 (20 MHz, 25 ºC, pH 7.1), characteristic of  
low/intermediate molecular weight chelates in fast rotation in solution. Chelate self-
assembly, ca thus, be excluded in this concentration range. 
The pH dependence (Figure SI6.2) of the protonic relaxation rate shows that GdL1 is 
stable in the physiological pH range [42]. 
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6.2.3 Preparation of gold nanoparticles functionalized with GdL1 chelates 
A modified Brust´s methodology in aqueous solution was employed for preparing 
AuNPs functionalized with GdL1 [15, 27]. Using directly GdL1 as nanoparticle 
stabilizer resulted in extensive precipitation upon addition of the reducing agent 
(NaBH4). Attempts to functionalize, via place exchange, citrate-stabilized AuNPs with 
the GdL1 chelate revealed also unsuccessful [34]. A two step methodology, using 
initially the L1 chelator as NPs stabilizer, followed by Gd
3+
 complexation, revealed 
successful for preparing AuNPs functionalized with GdL1 chelates (Scheme 6.1) [15].
 
Solutions containing equimolar amounts of L1 and HAuCl4 turned immediately dark 
brown upon addition, in one aliquot, of one molar equivalent of NaBH4. Adding a molar 
equivalent of Gd
3+
, in relation to the total amount of L1, to the crude mixture, resulted 
in stable NPs. Size Exclusion Chromatography (SEC) (Sephadex G10, elution with 
water) followed by extensive dialysis against water (cellulose tubing MWCO 10 000), 
afforded stable AuNPs functionalized with GdL1 chelate. A single fraction, including 
the broad colored band eluting on SEC, was collected. The absence of (free) 
uncomplexed Gd
3+
 was confirmed by the xylenol orange test [43].  
6.2.4 Characterization of GdL1@AuNPs  
The Gd content of the functionalized AuNPs was estimated by susceptibility 
measurements and further confirmed by ICP-OES following sample digestion with 
aqua regia (HCl/HNO3; 3/1 v/v) (Table 1) [15, 44]. 
The AuNPs were characterized regarding size distribution by Dynamic Light Scattering 
(DLS) (Figure 6.2) and Transmission Electron Microscopy (TEM) (Figure 6.3). 
 
Figure 6.2- Size distribution (% Volume) for GdL1@AuNPs. 
Gold nanoparticles functionalised with Gd3+ chelates 
213 
 
 
 
Figure 6.3-. Transmission Electron Microscopy (TEM) for GdL1@AuNPs  
 
DLS measurements give the hydrodynamic diameter (HD) of NPs, including the Au 
nanocrystal core, the chelate monolayer and the immobile ionic layer surrounding the 
NPs. An average HD of 4.8 nm (NPs distribution in the range 3-10 nm with a maximum 
at 3-4 nm) was measured for GdL1@AuNps. TEM measurements reveal only the 
nanocrystal core. The low resolution TEM images obtained for GdL1@AuNPs do not 
allow to determine the average diameter of the Au core owing to the very small size of 
the NPs. From the TEM images one can only conclude that most GdL1@AuNPs have a 
nanocrystal core with a diameter under 2 nm. The average diameter of the Au core of 
GdL1@AuNPs (~ 1.6 nm) was roughly calculated from the DLS measurements, taking 
into account the thickness of the chelate monolayer estimated by PM6 semi-empirical 
calculations for the most provable conformation of GdL1 (1.6 nm) (Figure SI6.3) [36]. 
The absence of a well defined plasmon absorption band in the UV-Vis spectra of 
GdL1@AuNPs (Figure SI6.4), corroborates the very small size of the NPs core [45].  
Table 6. 1 Characterization of GdL1@AuNPs  
 GdL1@AuNPs
a 
GdL2@AuNPs
b
 GdL3@AuNPs
c 
[Gd] (mM)
d 0.57  1.30  1.24 
 HD (nm)
e
 4.8 5.9 3.9 
Zeta potential (mV) -6.3 -13.7 -12.3 
DAu
f 1.6  1.3 1.1
g
 
a
This work;
b
Ref [46]: 
c
Ref [15]; 
d
Determined by ICP-OES; 
e
DLS measurements; 
f
Estimated form the HD and 
semi-empirical calculations of the chelate monolayer thicknes- see Table SI6.2; 
g 
Revised value according to 
semi-empirical calculations for the length of GdL3. 
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Regarding the size of the AuNPs core (DAu= 1.6, 1.3 and 1.1 nm, for GdL1, GdL2 and 
GdL3@AuNPs), the observed trend does not appear to follow a simple correlation with 
ligand bulkiness, i.e. the overall wedge-like geometry of the chelator defined by the area 
of the coordination cage and the length of the linker. Bulkier ligands are expected to lead 
to smaller Au cores (higher surface curvature) in accordance to a model suggesting that 
bulkier thiol ligands terminate the growth of AuNPs earlier than less bulky ligands [47]. 
This correlation is followed roughly by L2 and L3 but not by L1, probably due to 
different sulfur binding. 
GdL1@AuNPs was found to be stable in solution for extended time periods and could 
be freeze-dried and re-dissolved without aggregation/precipitation. This can be ascribed 
to the overall negative charge (-1) of the immobilized Gd
3+
 complexes, resulting in NPs 
displaying negative zeta-potential (Figure SI6.5, Table SI6.1).  
6.2.5 Relaxometric characterization of GdL1@AuNPs  
The concentration dependence of the protonic longitudinal relaxation rate (R1p) was 
evaluated for GdL1@AuNPs (r1 = 27 mM
-1
s
-1
, 20 MHz, 25 ºC, pH 7.1) (Figure SI6.6).  
For relevant clinical applications chelates immobilized onto NPs must be stable 
regarding demetallation and inert towards transmetallation with physiological metal 
ions, mainly Zn
2+ 
[38, 42]. In addition to releasing toxic Gd
3+
, demetallation and 
transmetallation processes of immobilized chelates can also trigger particle aggregation 
and precipitation in vivo. Stability at low pH is particularly important as protonation-
assisted mechanisms have been implicated in demetallation, presumably followed by 
transmetallation with serum ions, of macrocyclic Gd(DOTA)-type chelates. The pH 
dependence of the protonic relaxation rate (R1p) was evaluated for GdL1@AuNPs in the 
pH range 3-10 (Figure SI6.7). The kinetic stability of the immobilized chelates (and 
entire nanoparticles) was evaluated by challenging GdL1@AuNps with Zn
2+
 ions in 
phosphate buffer (Figure SI6.8) [42]. According to the criteria established by Muller 
and co-workers, the immobilized chelates (and whole NPs) can be classified as 
kinetically inert and thermodynamically stable [42]. Taken together, the pH stability and 
the transmetallation assay indicate that the NPs are potentially safe for in vivo 
applications. 
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6.2.6 Nuclear Magnetic Relaxation Dispersion Profiles   
The magnetic field dependence of the protonic relaxivity (r1) (Nuclear Magnetic 
Relaxation Dispersion - NMRD profiles) was obtained for GdL1@AuNPs in the 
Larmor frequency range 0.01-400 MHz. The most important parameters that govern 
relaxivity are the hydration number (q), the water exchange rate (kex), the rotational 
correlation time (R) and the electron relaxation parameters (v and 
2
) [3, 4]. The 
number of water molecules in the first coordination sphere, the water exchange rate and 
the rotational correlation time can be tuned by chelate design. Clear rules to tune the 
electron relaxation parameters are still elusive [48]. Treating chelates immobilised onto 
macromolecular/nanosized objects (micelles, proteins, polymers, dendrimers, 
nanoparticles, viral particles) as rigid entities, often fails to deliver reliable parameters 
from the fitting of the NMRD profiles to the SBM theory. In fact, it is necessary to 
assume in the fittings that the interactions that generate the relaxation are influenced by 
both fast local motions (Rlocal) of the immobilized chelates around linkers/spacers and a 
slower, global motion, common to the entire object (Rglobal). The degree of spatial 
restriction of the local motion (interpreted as chelate flexibility), is measured by the 
generalized, model independent order parameter- S
2
. The order parameter can assume 
values in the range 0-1: S
2
= 0 if the internal motions are isotropic, S
2
= 1 if the internal 
motions are completely restricted [49].
 
In this work it was assumed in the fittings that the immobilised GdL1 complex has one 
inner sphere water molecule (q= 1) like other Gd
3+
 complexes of the DO3A-N-(α-
amino/amido)propionate family [12, 14, 40]. The water exchange rate and its activation 
parameters (kex
298
, H‡) were fixed to values determined for the analogous Gd[DO3A-
N-(-benzoylamido)propionate] chelate [40]. The fittings (continuous lines in Figure 4) 
are restricted to frequencies above 6 MHz as the SBM theory is not suitable for 
describing the rotational dynamics of slow-rotating objects at low magnetic fields. The 
best fit parameters for GdL1@AuNPs, obtained from the analysis of 
1
H NMRD data, 
are represented in Figure 6.4 and summarized in Table 6.2. 
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Figure 6.4- 
1
H Nuclear Magnetic Relaxation Dispersion (NMRD) profiles for: GdL1@AuNPs 
(0.56 mM; pH 7.0) 25 °C (■) and 37 °C (●). The fitted curves are represented as continuous 
lines. 
 
Table 6.2- Best fit parameters obtained for GdL1@AuNPs from the fitting of the 
1
H NMRD 
profiles to the SMB theory, including the Lipari-Szabo approach for internal flexibility 
 GdL1@AuNPs 
Parameters Value 
q 1 
H‡ [J/mol] 17 
kex
298
 [10
7
 s
-1
] 5.14 
ER [kJ/mol] (global) 19.4 ± 1.1 
RH
298
[ps] (global) 1900 ± 140 
ER [kJ/mol] (local) 20 
RH
298
[ps] (local) 460 ± 50 
S
2 
0.41 ± 0.04 
EV [kJ/mol] 1 
V
298
 [ps] 27 ± 4 
GH
298
 [10
-10 
m
2
s
-1
]  23 
EDGH [kJ/mol] 20 
Gd-O [Å] 2.5 
2 [1020 s-2]  0.044 ± 0.002 
Gd-HW 1
st
 [Å] 3.1 
Gd-HW 2
nd 
[Å] 3.6 
 
The NMRD profiles are characteristic of macromolecular objects in slow rotation, 
confirming the immobilization of the GdL1 chelate onto the gold nanocrystals: a plateau 
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in the frequency range 0.01 to 1 MHz, a simple dispersion at about 1-10 MHz and a 
broad hump centered at 20-60 MHz. The AuNPs prepared in this work display 
exceptional relaxivities (per Gd
3+
 chelate) (r1max= 27 mM
-1
s
-1 
for GdL1@AuNPs; 30 
MHz, 25 ºC), much higher than those reported by other authors for AuNPs 
functionalized with Gd
3+
 complexes [31, 32, 35] (Table 6.3). 
Table 6.3- Selected molecular parameters for GdL1AuNPs and other related systems reported 
in the literature. 
 
The temperature dependence of the relaxivity, higher relaxivity at lower temperature, 
for GdL1@AuNPs, indicates that the water exchange rate is not limiting the relaxivity. 
The superb relaxivities attained can be ascribed to simultaneous optimization of the 
water exchange rate (fast water exchange regime) and of the rotational correlation time. 
The value obtained for the order parameter (S
2
~ 0.40) indicates that fast local motions 
of the chelates anchored onto the Au core are still limiting the relaxivity. Simulations, 
using the same parameters as on Table 3, but assuming total rigidity of the immobilized 
chelates (S
2
= 1), afford much higher relaxivities (of the order of magnitude 60 mM
-1
s
-1
; 
20 MHz; 25 ºC) for GdL2@AuNPs [46] and GdL3@AuNPs [15]. The higher relaxivity 
attained by GdL2@AuNPs, comparing to GdL1@AuNPs and GdL3@AuNPs, has to be 
ascribed to its significantly larger global rotational correlation time (Rg), reflecting the 
larger hydrodynamic diameter of the GdL2@AuNPs nanoparticles. The length of the 
linker (ligand bulkiness) seems to determine the size of the NPs core. ―Bigger cores 
(lower surface curvature) associated to longer linkers (less bulkier ligands), could allow 
better packing of the chelate monolayer restricting local rotational motions of the 
immobilized chelates‖. This hypothesis is not supported by our results. In fact, the 
Parameter GdL1@AuNPs
a 
GdL2@AuNPs
b 
GdL3@AuNPs
c
 GdL4
d
 
q 1 1 1 1 
kex
298
 [10
7
 s
-1
] 5.14 5.14 5.14 6.2  
g
298
 [ps] 1900  3500 2470  3780 
lo
298
 [ps] 460  970 177  930 
S
2
 0.41 0.42 0.48  0.24 
HD (nm)
e 4.8 5.9 3.9 49
f 
r1 (mM 
-1
s
-1
) 
 27
g,i 
38
g,i 
28
g,i 
32
h,i 
11.2
g,j 
8.4
g,j 
8.5
g,j 
n.d. 
a 
This work; 
b
Ref[46] ;
c
Ref [15] Chapter 5 of this Thesis; 
d
 Ref  [12] Chapter 3 of this Thesis; 
e 
from 
DLS measurements; 
f 
Z-average from a bimodal distribution of  particles; 
g
relaxivity per chelate; 
h 
relaxivity of the aggregated form; 
i 
20 MHz, 25 ºC; 
j 
200 MHz, 37 ºC. 
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length of the thioalkyl linker seems not to have much influence on the internal 
flexibility of the immobilized chelates: the order parameter S
2
 is identical for 
GdL1@AuNPs and GdL2@AuNPs, despite the longer linker anchoring GdL2 to the Au 
core. Moreover, the shorter cysteine linker anchoring GdL3 to the Au core (possibly in 
a bidentate (N,S)  fashion similar to GdL1 (S,S)),  results only in slightly higher rigidity 
of the immobilized chelates. Despite this, a relaxivity enhancement of more than 300% 
for GdL1 and over 500% for GdL2 [46] was attained upon immobilization onto AuNPs, 
demonstrating the benefits of simultaneous optimization of R and kex. From a practical 
standpoint, covalent immobilization of chelates onto AuNPs is more efficacious for 
attaining high relaxivities than self-assembly into micelle-type structures (38 vs 15 mM
-
1
s
-1
; 20 MHz, 25 ºC, for GdL2@AuNPs and for the aggregated (micellar) form of 
GdL2, respectively). This can be ascribed to higher rigidity of Au-immobilised chelates 
comparing to (non-covalent) self-assembled structures. In fact, the micellar form of the 
Gd[DO3A-N-(-pyrenebutanamido)propionate] chelate (sharing the same coordination 
cage with GdL1,2,3) is significantly more flexible (S
2
= 0.24 vs 0.42) than the Au-
anchored GdL1 and GdL2 chelates [46]. This translates into higher relaxivity for 
GdL2@AuNPs comparing to micellar form of GdL4 (38 vs 32 mM
-1
s
-1
; 20 MHz, 25 ºC, 
for GdL2@AuNPs and for the aggregated (micellar) form of GdL4, respectively) 
despite a similar value of Rg [12].  
Novel applications of MRI, such as cell labeling and in vivo tracking, can be achieved 
only, without compromising cell integrity and viability, with CA displaying high 
density of relaxivity, i.e. concentrating a high number of high relaxivity chelates in a 
small molecular volume (r1vol= Nchelxr1/V; mM
-1
s
-1 
nm
-3
). The (volumetric) density of 
relaxivity tends to decrease with increasing diameter of NPs [50]. Moreover, small NPs, 
with HD diameter bellow 3 nm, are readily eliminated by renal filtration, independently 
of surface composition and charge, reducing the risks associated with metal NPs 
accumulation in the RES organs- liver and spleen [51]. The volumetric density of 
relaxivity of GdL3@AuNPs (r1vol ~ 12.62 mM
-1
s
-1
nm
-3
; 25 ºC, 20 MHz) (Table SI6.2) 
compares favorably with other nano-objects (dendrimers, viral nanocapsules, micelles), 
functionalized with Gd
3+
chelates [52]. High density of relaxivity, associated to stability 
and small size make the GdL1@AuNPs and GdL3@AuNPs promising CA for MRI.   
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6.2.7 Biodistribution studies  
The biodistribution of [
153
Sm]L1@AuNPs was obtained at 2 and 24 hours post-injection 
(Figure 6.5). 
 
Figure 6.5- Biodistribution of [
153
Sm
3+
]L1@AuNPs in rats, stated as percent of injected dose 
per gram of organ (% ID/ g): a) 2 and b) 24 hour post-injection. Inset- time evolution of activity 
in the blood. The results are from a group of four animals in each experiment. 
The activity in the blood was measured after 30 minutes, 60 minutes, 2 and 24 hours 
(inset in Figure 6) revealing a fast clearance of activity from the blood with a reduction 
of approximately 50% between 30 minutes and two hours. After 2 hours pi, the NPs are 
mainly found in the organs the reticulo-endothelial system (RES), liver and spleen, and 
to a lesser extent in the blood and lungs. These results suggest that the nanoparticles are 
cleared mainly by phagocytosis by the macrophage rich organs, liver and spleen, with a 
less important contribution from renal elimination [12, 53]. This is in accordance with 
what was found by MRI for GdL1@AuNPs. 
At 24 hours pi significant activity is found only in the organs of the reticulo-endothelial 
system, RES. The activity approximately doubled in the spleen, showing only a slightly 
increase in the liver. The activity in bones is negligible excluding chelate demetallation 
and the formation of insoluble metal colloids. 
6.2.8 MRI Studies 
MRI studies were performed in male Swiss mice (~ 20 g) in a preclinical imaging 
platform (PharmaScan) operating at 7.0 Tesla (300 MHz). A Dynamic Contrast 
Enhancement (DCE) study was performed with GdL1@AuNPs (0.1 mmol Gd/kg body 
weight) and GdL3@AuNPs (0.1 and 0.05 mmol Gd/kg body weight) and for 
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comparison purposes with Gd(DTPA) (Magnetvist
®
, Bayer) at the same doses (Figure 
6.6).  
 
 
Figure 6.6- Representative coronal T1-weighted spin echo MR images of mice before and after 
injection of contrast agents: (A) Gd(DTPA) (0.1 mmol Gd kg
-1
 BW), (B) GdL1@AuNPs (0.1 
mmol Gd kg
-1
 BW), (C) GdL3@AuNPs (0.1 mmol Gd kg
-1
 BW); (D) Gd(DTPA) (0.05 mmol 
Gd kg
-1
 BW), (E) GdL3@AuNPs (0.05 mmol Gd kg
-1
 BW). 
 
Figure 6.6 shows a representative series of T1-weighted spin-echo axial images. In the 
pre-injection images, the kidney structures (cortex, inner and outer medulla) and 
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adjacent tissues appear dark. After bolus injection in the vascular system, a strong signal 
enhancement was observed in the kidneys for Gd(DTPA), GdL1@AuNPs and 
GdL3@AuNPs as result of T1 shortening. A much slighter signal enhancement was 
observed in the liver. Both NPs follow mainly renal elimination by glomerular filtration, 
with significant hepatobiliary contribution to excretion seen for GdL1@AuNPs only. 
The time course of the average intensity (mean values of groups of four animals) within 
different regions of interest (ROIs) placed on the several organs allows to understand 
better the features of DCE images (Figure 6.7). 
 
Figure 6.7- Time course of signal intensity, up to 60 min post-injection,  for several regions of 
interest, relative to the initial value, during dynamic contrast enhancement MRI experiments in 
rats administrated with: (A) Gd(DTPA) (0.1 mmol kg
-1
 BW) and (B) GdL3@AuNPs (0.1 mmol 
kg
-1
 BW), (C) GdL1@AuNPs (0.1 mmol kg
-1
 BW); (D) Gd(DTPA) (0.05 mmol kg
-1
 BW); (E) 
GdL3@AuNPs (0.05 mmol kg
-1
 BW). The time courses are data from mean values of four 
animals. 
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In order to compare the results for all the animals under study (n= 4), the data were 
normalized by calculating the mean relative enhancement of each ROI. The scattering in 
the time course curves was caused by animal respiratory motion. The relative 
enhancement obtained with Gd(DTPA) at 0.1 mmol kg
-1
 BW dose (Figure 8A), 
increased almost immediately after intravenous injection, from 0 up to about 160% in 
the kidney medulla and 100% in the kidney cortex, followed by a steady decrease to 
values around 60% and 30%, respectively, within 60 minutes. This time course is in 
agreement with the literature for the Gd(DTPA) and Gd(DOTA) low molecular weight 
CA [54, 55]. 
The enhancement profiles of GdL1@AuNPs (Figure 6.8B)  and GdL3@AuNPs 
(Figure 6.8C) at 0.1 mol Gd kg
-1
 BW dose are considerably different from the 
enhancement profile of Gd(DTPA) at the same concentration: there is an immediate 
enhancement of the kidney structures (cortex and medulla) followed by a steady liver 
enhancement. For GdL3@AuNPs at 0.1 mmol Gd kg
-1
 BW dose (Figure 6.8B) is 
noticeable a fast strong enhancement of the kidney medulla and kidney cortex (~ 150%) 
which slowly decreases to ~100% over the time course of the experiment. A much 
lower muscle and liver enhancement is also noticeable. Reducing the dose of 
GdL3@AuNPs to 0.05 mmol Gd Kg
-1
 BW results in a imaging profile virtually 
equivalent to Gd(DTPA): fast renal elimination with negligible hepatobiliary 
contribution. There is a fast enhancement of the kidney cortex (~150 % at 20 minutes) 
which steadly decreases over the time course of the experiment.  These results strongly 
suggest that while GdL1@AuNPs is mostly eliminated through hepatobiliary excretion, 
or is taken up by resident macrophages (Kupfer cells) in liver, GdL3@AuNPs behaves 
in vivo as a low molecular weight CA following mainly renal elimination. The steady, 
liver and presumably spleen enhancement observed with GdL1@AuNPs is in sharp 
contrast to the ―clean‖ renal elimination observed for GdL3@AuNPs. This behaviour 
can only be explain by the difference in size between GdL1@AuNPs and 
GdL3@AuNPs- average HD 4.8 and 3.9 nm, respectively, stressing the complex 
interplay between the physical-chemical properties of nanostructures and biological 
structures and barriers. 
The animal MRI studies were performed at high field (300 MHz, 7 Tesla). This study 
illustrates the mismatch between the performance of macromolecular/nanosized CA, 
optimized for intermediate fields (20-60 MHz), and the trend for increasingly higher 
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magnetic field imagers. The overwhelming advantage of the AuNPs, over low 
molecular weight CA at intermediate fields (20-60 MHz), is partially lost at higher 
magnetic fields (Figure 4). Nonetheless, the AuNPs studied in this work still exhibit 
relaxivities significantly higher than Gd(DTPA) at high fields (11.2, 8.4 and 8.5  vs ~ 2 
mM
-1
s
-1 
for GdL1@AuNPs, GdL2@AuNPs and GdL3@AuNPs, respectively, and   
Gd(DTPA), 200 MHz, 25 ºC ). 
In addition to MRI, the strong X-ray attenuation properties of AuNPs allows combining 
the high detection sensitivity of CT with the depth independent high spatial resolution 
of MRI and imaging targeted therapy by X-ray sensitization.  
 
6.3 Conclusions 
In this work we studied the effect of the length of-thiolalkyl linkers, anchoring Gd3+ 
chelates displaying fast water exchange onto AuNPs, on the relaxivity and in vivo 
performance of AuNPs as CA for MRI. Superb relaxivities at magnetic fields relevant 
for clinical imaging (of the order of magnitude 30 mM
-1
s
-1
, 20-60 MHz, 25 ºC) were 
attained thanks to simultaneous optimization of the rotational correlation time and of the 
water exchange rate. The relaxivity is still limited by internal flexibility of the 
immobilized chelates. Our results suggest that longer linkers (less bulky ligands) lead to 
AuNPs displaying larger nanocrystal cores (and larger hydrodynamic diameter). The 
degree of internal flexibility of the immobilized chelates (measured by the order 
parameter S
2
) seems not to be determined by the length of the linker. Relaxivities, still 
relevant for clinical high field applications (of the order of magnitude 10 mM
-1
s
-1
; 200 
MHz, 37 ºC) here attained. A MRI study in mice demonstrated that while 
GdL3@AuNPs (HD= 3.9 nm) behaves in vivo much like the low molecular weight CA 
Gd(DTPA), undergoing fast renal elimination without liver (and presumably spleen) 
uptake, GdL1@AuNPs (HD= 4.8 nm) shows considerable hepatobiliary contribution to 
elimination. A biodistribution study in rats using the surrogate 
153
SmL1@AuNPs tracer 
confirmed extensive activity uptake and accumulation over time in liver and spleen. The 
in vivo results highlight the complex interplay between nanosize and in vivo behavior of 
nanoparticles.  
The GdL3@AuNPs CA, amenable to further elaboration with targeting moieties, seems 
particularly promising for MRI applications. 
Chapter 6  
224 
 
6.4 Experimental  
6.4.1 Materials and methods  
Chemicals were purchased from Sigma-Aldrich and used without further purification. 
Cyclen was purchased from Chematech, France. Analytical grade solvents were used 
and not further purified, unless specified. Reactions were monitored by TLC on silica 
gel by examination under UV light (250 and 365 nm) and staining with iodine vapour 
and Ellman´s reagent. Preparative chromatography was carried out on Silica Gel 60 
(230-400 mesh). Ion exchange chromatography was performed on Dowex 1X2 OH
-
 
(50-100 mesh) resin. Size Exclusion Chromatography (SEC) was performed on 
Sephadex G10 (40-120 m) with water elution. Dialysis was performed against water 
on cellulose membranes (MWCO 10 K). UV-VIS spectra were acquired with a 
Shimadzu UV-2501PC spectrophotometer. The size distribution and zeta potential of 
the AuNPs was determined with a Malvern Zetasizer, NANO ZS (Malvern Instruments 
Limited, UK), using a He-Ne laser (wavelength of 633 nm) and a detector angle of 173º. 
Mass spectrometry was performed at CACTI - Vigo, Spain.  
1
H and 
13
C NMR spectra were run on Varian Unity Plus 300, Bruker Avance-3 400 Plus 
and Varian VNMRS 600 NMR spectrometers. Chemical shifts (δ) are given in ppm 
relative to the CDCl3 solvent (
1H, δ 7.27; 13C 77.36) as internal standard. For 1H and 13C 
NMR spectra recorded in D2O, chemical shifts (δ) are given in ppm, relative to T P as 
internal reference (
1H, δ 0.0) and tert-butanol as external reference (13C, CH3 δ 30.29), 
respectively.  
6.4.2 Preparation of the lipoic acid conjugate DO3A-N-(α-lipoamide)propionic acid- L1 
6.4.2.1 Synthesis of the fully protected conjugate 7: triethyl 2,2',2''-(10-(2-(5-(1,2-
dithiolan-3-yl)pentanamido-methoxycarbonylethyl-4,7,10-tris-(ethoxycarbonylmethyl)-
1,4,7,10 tetrazacyclododecane 
Orthogonally protected compound 6 was synthesized as described before by us. A 
solution of compound 6 (85 mg; 1.12 mmol) in a mixture DCM/TFA (24 ml, 3:1, v/v) 
was stirred at room overnight. The solvent was removed under reduced pressure, the 
residue was redissolved in DCM and the solvent was evaporated. This procedure was 
repeated several times. The resulting oil was dried under vacuum to afford a white foam. 
1
H NMR (CDCl3) revealed the disappearance of the signals assigned to the Boc groups 
on compound 6. Quantitative deprotection was assumed. The residue (1.12 mmol, 
assuming quantitative deprotection) was dissolved in DCM (20 ml) and the solution was 
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adjusted to pH 9-10 (pH paper) by drop-wise addition of DIPEA. To this solution was 
added sequentially Lipoic acid (288 mg; 1.40 mmol), HOBt (214 mg; 1.40 mmol) and a 
solution of DCC (288 mg; 1.40 mmol) in DCM (5 ml). The solution was stirred at room 
temperature overnight. The DCU byproduct was removed by filtration and the reaction 
mixture was concentrated under reduced pressure. The residue was re-dissolved in ethyl 
acetate (100 ml), and the solution was washed with NaHCO3 (50 ml, saturated solution) 
and brine (3x50 ml). The organic phase was dried (MgSO4) and concentrated under 
reduced pressure to afford the title compound (7) (358 mg; 44 %). 
1
H NMR (300 MHz, 
CDCl3): = 1.28 (m, 9 H, C(O)OCH2CH3), 1.48 (m, 2 H, NHC(O)CH2CH2CH2), 1.70 
(m, 2 H, NHC(O)CH2CH2), 2.18 (m, 2 H, NHC(O)CH2CH2CH2CH2), 2.70 (m, 4 H, 
NHC(O)CH2, CHCH2CH2S), 2.60-3.60 (broad overlapped signals, integrating for 16 H, 
N(CH2)2N; 2 H, ABX; 2H, CHCH2CH2S, 1 H, CHSCH2CH2S), 3.73 (m, 6H, 
C(O)CH2N), 3.97 (s, 3H, C(O)OCH3), 4.19 (m, 6H, C(O)CH2CH3), 4.90 (bb,1H, ABX). 
HRMS (ESI): m/z: cacd for C32H58N5O9S2: 720.3676, found: 720.3645. 
6.4.2.2 Preparation of the fully deprotected chelator DO3A-N-(-lipoamido)propionate 
(L1)- 2,2',2''-(10-(2-(5-(1,2-dithiolan-3-yl)pentanamido)-carboxyethyl-4,7,10-tris-
(carboxymethyl)-1,4,7,10-tetrazacyclododecane 
Compound (7) (2.26 g, 3.15 mmol) was dissolved in a mixture water/ethanol (40 ml, 1/1 
v/v). The solution was adjusted to pH ~ 11 with aqueous NaOH 1 M (pH paper) and 
was left stirring at room temperature overnight. Then the reaction mixture was adjusted 
to pH ~7 with hydrochloric acid 1 M (pH paper) and concentrated under reduced 
pressure. The residue was adsorbed onto silica and purified by flash chromatography 
(CH2Cl2CH2Cl2/EtOH 1/1EtOHEtOH/H2O 1:1H2O) to afford a light yellow 
foam. The final compond (L1) was further purified by size exclusion chromatography 
on Sephadex G10 (0.42 m) with elution with water. The conductivity of the collected 
fractions was measured and also tested by TLC (ethanol/water (1/1), revelation with 
iodine vapor). The high conductivity fractions (salt) were discarded and the 
medium/low conductivity fractions showing a signal on the TLC were pooled, 
concentrated at room temperature and further dried under vacuum to afford the final 
deprotected compound as a light yellow solid (9) (0.685 g, 35%). 
1
H NMR (300 MHz, 
D2O): = 1.46 (q, J= 7.8 Hz, 2H, NHC(O)CH2CH2CH2), 1.64- 1.72 (m, 6H, 
NHC(O)CH2CH2, NHC(O)CH2CH2CH2CH2, CHCH2CH2S), 2.01 (m, 2H, 
NHC(O)CH2), 2.34 (t, J= 7.5 Hz 2H, CHCH2CH2S), 2.49 (m, 1H, CHSCH2CH2S), 2.10-
3.40 (broad overlapped signals integrating to 16 H, 4 x N(CH2)2N, 6H, 3 x NCH2C(O) 
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and 2H, ABX), 4.49 (m, 1 H, ABX). 
13
C NMR (75.4 MHz, D2O): 25.02 (1C, CH2), 
28.32 (1 C, CH2), 33.93 (1 C, CH2), 35.73 (1 C, CH2), 38.22 (1 C, CH2), 40.46 (2 C, 
2xCH2), 47.81 (3 C, 3xCH2), 49.46 (1 C, CH2), 51.37 (1C, CHCH2), 51.94 (2 C, CH2), 
54.51 (2 C, CH2), 56.08 (2 C, CH2), 56.76 (2 C, CH2), 170.94 (1 C, C(O), 176.65 (2 C, 
2xC(O), 177.36 (2 C, 2xC(O)). HRMS (ESI): m/z: cacd for C25H44N5O9S2: 622.2580, 
found: 622.2572.  
6.4.3 Preparation of GdL1 complex for relaxometric measurements 
A solution of GdCl3.6H2O was added drop-wise, under magnetic stirring, to an 
equimolar solution of L1 (5% excess), while keeping the solution pH around 5.8 (pH 
meter) by the addition of diluted NaOH. The solution was left stirring at room 
temperature overnight. Then, the solution was adjusted to pH 7.0 with NaOH (0.1 M) 
and filtered through a 0.2 m seringe filter. The absence of free Gd3+ was confirmed by 
the Xylenol Orange test.  The final concentration of Gd was determined by ICP-OES 
following sample digestion with nitric acid.  
6.4.4 Preparation gold nanoparticles functionalized with GdL1. 
An aqueous solution of ligand DO3A-N-(-Lipoamido)propionate (L1) (20.5 mM, 4.53 
ml, 0.091mmol) was added drop-wise, under magnetic stirring at room temperature, to 
an aqueous solution of HAuCl4 (58.86 mM, 1.545 ml, 0.091mmol). During the initial 
stages of the addition of L1, the light yellow HAuCl4 solution turned dark orange, 
fading away in color to light yellow with further addition of ligand. To the reaction 
mixture was added, in one aliquot, a freshly prepared aqueous NaBH4 solution (522 
mM, 0.179 ml, 0.093 mmol). The reaction mixture turned instantaneously dark brown 
and was left stirring at room temperature for 16 hours. The NPs solution was adjusted to 
pH ~ 7 (pH meter) by adding aqueous NaOH (0.1 M) and was filtered through a 0.20 
m PTFE syringe filter. A small volume of solution (1 ml) was retained for further 
characterization. To remaining NPs solution (~ 5.3 ml) was added slowly a solution of 
GdCl3.6H2O in water (303 M, 0.300 ml, 0.091 mmol) while keeping the solution pH 
around 5.5 (pH meter) by adding aqueous NaOH 0.1 M. The NPs solution was left 
stirring at room temperature for 16 hours and was adjusted to pH 7 with aqueous NaOH 
(1 M solution). The nanoparticles were purified by size exclusion chromatography 
(Sephadex G10, 0.42 m) with elution with water. The whole colored broad band 
eluting from the column was collected without attempting to fractionate the sample. The 
nanoparticles solution was further purified by extensive dialysis against water using a 
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10 KDa MWCO cellulose membrane. The xylenol orange test indicated the absence of 
free Gd
3+
 in the gold nanoparticles preparation. 
The Gd and Au content of the NPs preparations ([Au]= 0.85 mM; [Gd]= 0.57 mM; 
[Au]/[Gd]= 1.40, for GdL1@AuNPs) was determined by ICP-OES analysis following 
sample digestion with aqua regia. 
6.4.5 NMRD measurements 
The NMD measurements were performed using a StelarSpinmaster FFC NMR 
relaxometer (0.01-20 MHz) equipped with a VTC90 temperature control unit. At higher 
fields, the 
1
H relaxivity measurements were performed on Bruker Minispecs mq30 (30 
MHz), mq40 (40 MHz) and mq60 (60 MHz), as well as Bruker Advance spectrometers 
connected to 2.35 T, 4.7 T and 9.4 T superconducting magnets. In each case, the 
temperature was measured by a substitution technique. Variable temperature 
measurements were performed at 25 and 37
◦
C. The NMRD profiles were analysed using 
the Visualiseur/Optimiseur 3.6 program running on a Matlab®6.5 platform.  
6.4.6 Relaxivity studies of pH dependence and Zn2+ transmetallation 
The transmetallation reaction of the metal chelate-decorated NPs GdL1@AuNps 
against Zn
2+
, was studied by following the time-dependent decrease of the protonic 
longitudinal relaxation rate, R1, (20 MHz, 25 ºC) of phosphate-buffered saline solutions 
(PBS, pH 7.1, 10 mM), containing GdL1@AuNPs 0.42 mM, before and after adding an 
equimolar amount of ZnCl2, while vigorously stirring the solutions. 
The pH dependence of the relaxivity was measured by adjusting the solution pH with 
aqueous diluted NaOH (0.1 M) or diluted hydrochloric acid (0.1 M), using a Crison 
micro TT 2050 pH meter equipped with a Mettler Toledo 422 electrode. A Bruker 
Minispec mq20 relaxometer was used for all measurements (20 MHz, 25 ºC). 
6.4.7 MRI experiments 
6.4.7.1 Preparation of the GdL1@AuNPs and GdL2@AuNPs CA solutions for MRI 
studies. 
The GdL1@AuNPs and GdL2@AuNPs CA for the MRI studies were prepared 
following the procedure described above. The final nanoparticles solutions were freeze-
dryed and their Gd and Au contents (per mg of solid material) were determined by ICP-
OES following digestion with aqua regia.  
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6.4.7.2 In vivo MRI studies. 
The experimental protocols were approved by the appropriate institutional review 
committees and meet the guidelines of their responsible governmental agency. The 
Magnetic Resonance Imaging (MRI) experiments were all performed on a Bruker 
Pharmascan platform (Bruker Medical Gmbh, Ettlingen, Germany) using a 7.0 T (300 
MHz) horizontal-bore superconducting magnet, equipped with a 
1
H selective 60 mm 
birdcage resonator and a Bruker gradient insert with 90 mm diameter (maximum 
intensity 360 mT/m). Data were acquired using a Hewlett-Packard console running 
Paravision software (Bruker Medical Gmbh, Ettlingen, Germany) under a LINUX 
environment.  
All MRI examinations were carried out on mice (n= 4, ~20 g body weight) 
anaesthetized initially by inhalation in an induction box with O2 (1 L/min) containing 3 
% isoflurane, and maintained during the experiment using a face mask allowing free 
breathingand 1-2 % isoflurane on O2. Animals were taped down into a holder, to 
minimize breathing-related motion, and were then placed in a heated probe, which 
maintained the core body temperature at 37 ± 0.5 °C, monitored by a rectal probe. The 
physiological state of the animal was monitored throughout the entire experiment by a 
Biotrig physiological monitor (Bruker Medical Gmbh, Ettlingen, Germany), using the 
respiratory rate and body temperature.  
Solutions of GdL1@AuNPs and GdL3@AuNPs 10 mM in [Gd] were prepared by 
dissolving the freeze-dryed NPs in the appropriate volume of PBS buffer. The solutions 
were filterred through a 0.2 m seringe filter before injection. 10 mM Gd(DTPA) 
(Magnevist

, Schering, Berlin, Germany) solutions were also prepared. The solutions 
were injected into the catheterized tail vein as a bolus in 20 s (0.05 and 0.1 mmol Gd  
kg
-1
 body weight) using an infusion pump (Panlab, Barcelona, Spain). Regional contrast 
agent uptake was assessed using Dynamic Contrast Enhanced (DCE) MRI. DCE MRI 
experiments were performed with series of T1-weighted spin echo images sequentially 
acquired over 1 h, before and following the injection of the contrast agent 10 min after 
the beginning of the study. The acquisition parameters were: TR= 310 ms, TE= 10.58 
ms, number of averages = 2, ten coronal slices, slice thickness = 2 mm, FOV = 5.0 x 5.0 
cm, matrix = 256 x 256, 30 repetitions with a total acquision time of 119 s.  
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6.4.7.3 MRI data analysis 
Data were analyzed with the public domain software Image J (http://rsbweb.nih.gov/ij/). 
With the aim of comparing the pharmacokinetics obtained from different animals, the 
data were normalized by calculating the percentage of relative, rather than absolute, 
enhancement: 
   100
)(
0
0 


I
II
RE  
where I is the signal intensity at any given time after CA injection and I0 is the intensity 
before injection. Pharmacokinetic behaviour was analyzed by calculating the average 
enhancements within the different regions of interest (ROIs) placed on each one of the 
following regions: liver, kidney medulla, kidney cortex and muscle. 
 
6.4.7.4 Biodistribution of radiolabeled nanoparticles 
Preparation of [
153
Sm]L1@AuNPs chelates for the biodistribution studies  
In these studies 
153
Sm
3+
 was used as a radioactive surrogate of Gd
3+
. [153SmCl3] (1 mCi) 
was added to a solution of L1@AuNPs (5 mg freez-dryed NPs) in sodium acetate buffer 
(400 μL, 0.4 M, pH 5). The solution was stirred at 80 ºC for 5 h. After that, cold SmCl3 
was added to each solution in order to obtain an equimolar Sm
3+
:Chelator ratio. The 
final solution was heated at 80 ºC for 2 h and stayed overnight at room temperature. The 
radiolabeled nanoparticles were purified by size exclusion chromatography using a 
Sephadex G-25 column eluted with 0.4 M acetate buffer. The whole colored broad band 
eluting from the column was collected. The nanoparticle solution was then concentrated 
by centrifugal filtration (centricons, MWCO 10 kDa) to afford the pure radioligands.  
 
6.4.7.5 Biodistribution studies 
Groups of four animals (Wistar rat males weighting ca 200 g) were anaesthetized with 
Ketamine (50.0 mg/mL)/chloropromazine (2.5%) (10:3) and injected in the femoral vein 
with ca 100 Ci of [153Sm]L1@AuNPs and sacrificed 2 and 24 hours later. The major 
organs were excised, weighed and tissue radioactivity measured in a  well-counter. 
Blood samples were obtained at appropriate periods of time, weighted and radioactivity 
counted. 
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The national regulations for the care and use of laboratory animals have been observed 
in this study. 
6.4.8 Semiempirical calculations, molecular modelling and NPs size estimates  
All calculations were performed with Mopac code [56] using the semiempirical model 
Hamiltonian PM6 [57] and COSMO [58] implicit water solvent model (ε= 74.8 with Gd 
and Au tesserae radius taken as 0.2 nm). The chelate lengths have been estimated from 
various chelate conformers averaged over several  …O and  …H top bottom distances 
within conformers (Figure SI6.5); ascribing an error of 0.1 nm appears reasonable for 
this methodology. The average AuNPs diameter is estimated from the diameter 
exclusion of the left and right chelates (Table SI6.2). 
 
Acknowledgements 
This work was financially supported by Fundação para a Ciência e a Tecnologia, 
Portugal: SFRH/BD/63994/2009 to M.F.F. and Rede Nacional de RMN 
(REDE/1517/RMN/2005) for the acquisition of the Varian VNMRS 600 NMR 
spectrometer in Coimbra. T.B.R. was supported by a Marie Curie Fellowship (FP/-
PEOPLE-2009-IEF 254380) and an EMBO Fellowship (ALTF 1145-2009). Financial 
support Ministerio de Ciencia e Innovación, Spain: projects SAF2011-23622 (S.C.) and 
CTQ2010-20960-C02-02 (P.L.-L.), and Comunidad de Madrid, Spain, project 
S2010/BMD-2349 (S.C. and P.L.-L). B. Mousavi and L. Helm acknowledge financial 
support by the Swiss National Science Foundation. This work was carried out in the 
frame of the CO T D38 Action ―Metal Based  ystems for Molecular Imaging‖ and 
COST TD1004. 
Other authors contributions:  
The 1H NMRD and 17O NMR studies were performed by Bibimaryam Mousavi under 
the supervision of Professor Lothar Helm at Laboratoire de Chimie Inorganique et 
Bioinorganique, Ecole Polytechnique Féderale de Lausanne, Lausanne.  
Preliminary relaxometric characterization of GdL1@AuNPs  (20 MHz) was performed in 
collaboration with of Professor Carlos F. G. C. Geraldes at the NMR Laboratory, CNC 
Coimbra.  
The MRI study was performed at Instituto de Investigaciones Biomédicas “Alberto 
Sols”, CSIC-UAM, Madrid, Spain, in the group of Professor Sebastian Cerdan. The 
experiments were designed, performed and analysed by Tiago B. Rodrigues and Pilar 
López-Larrubia.  
Gold nanoparticles functionalised with Gd3+ chelates 
231 
 
The biodistribution studies were performed in collaboration with Professor Isabel 
Prata at ICNAS and IBILI, Faculty of Medicine, University of Coimbra 
The molecular modeling studies were performed by Professor Sergio Rodrigues at 
Center of Chemistry and Department of Chemistry, University of Coimbra. 
 
6.5 References 
 
1. M. L. James and S. S. Gambhir, Physiological reviews, 2012, 92, 897-965. 
2. G. J. Stanisz, E. E. Odrobina, J. Pun, M. Escaravage, S. J. Graham, M. J. 
Bronskill and R. M. Henkelman, Magnetic Resonance in Medicine, 2005, 54, 507-512. 
3. P. Caravan, J. J. Ellison, T. J. McMurry and R. B. Lauffer, Chemical reviews, 
1999, 99, 2293-2352. 
4. B.-T. Doan, S. Meme and J.-C. Beloeil, in The Chemistry of Contrast Agents in 
Medical Magnetic Resonance Imaging, John Wiley & Sons, Ltd, 2013, pp. 1-23. 
5. G. J. Strijkers, W. J. Mulder, G. A. van Tilborg and K. Nicolay, Anti-cancer 
agents in medicinal chemistry, 2007, 7, 291-305. 
6. Y. X. Wang, Quantitative imaging in medicine and surgery, 2011, 1, 35-40. 
7. Y. Li, M. Beija, S. Laurent, L. v. Elst, R. N. Muller, H. T. T. Duong, A. B. 
Lowe, T. P. Davis and C. Boyer, Macromolecules, 2012, 45, 4196-4204. 
8. E. Boros and P. Caravan, Journal of medicinal chemistry, 2013. 
9. J. P. André, É. Tóth, H. Fischer, A. Seelig, H. R. Mäcke and A. E. Merbach, 
Chemistry – A European Journal, 1999, 5, 2977-2983. 
10. P. Caravan, C. T. Farrar, L. Frullano and R. Uppal, Contrast media & molecular 
imaging, 2009, 4, 89-100. 
11. S. Torres, J. A. Martins, J. P. André, C. F. G. C. Geraldes, A. E. Merbach and É. 
Tóth, Chemistry – A European Journal, 2006, 12, 940-948. 
12. M. F. Ferreira, G. Pereira, A. F. Martins, C. I. O. Martins, M. I. M. Prata, S. 
Petoud, E. Toth, P. M. T. Ferreira, J. A. Martins and C. F. G. C. Geraldes, Dalton 
Transactions, 2014, 43, 3162-3173. 
13. R. Ruloff, E. Toth, R. Scopelliti, R. Tripier, H. Handel and A. E. Merbach, 
Chemical Communications, 2002, 2630-2631. 
Chapter 6  
232 
 
14. M. F. Ferreira, A. F. Martins, J. A. Martins, P. M. Ferreira, E. Toth and C. 
Geraldes, Chemical Communications, 2009, 6475-6477. 
15. M. F. Ferreira, B. Mousavi, P. M. Ferreira, C. I. O. Martins, L. Helm, J. A. 
Martins and C. F. G. C. Geraldes, Dalton Transactions, 2012, 41, 5472-5475. 
16. R. T. de Rosales, Journal of labelled compounds & radiopharmaceuticals, 2014, 
57, 298-303. 
17. Z. Hashim, M. Green, P. H. Chung, K. Suhling, A. Protti, A. Phinikaridou, R. 
Botnar, R. A. Khanbeigi, M. Thanou, L. A. Dailey, N. J. Commander, C. Rowland, J. 
Scott and D. Jenner, Nanoscale, 2014, 6, 8376-8386. 
18. S. Y. A. M. M. V. Joshua E. Rosen and X. G. Frank, Journal of Nanomedicine & 
Nanotechnology, 2011, 0, -. 
19. E. U. Saritas, P. W. Goodwill, L. R. Croft, J. J. Konkle, K. Lu, B. Zheng and S. 
M. Conolly, Journal of Magnetic Resonance, 2013, 229, 116-126. 
20. J. W. Kim, E. I. Galanzha, D. A. Zaharoff, R. J. Griffin and V. P. Zharov, 
Molecular pharmaceutics, 2013, 10, 813-830. 
21. T. Lammers, F. Kiessling, W. E. Hennink and G. Storm, Molecular 
pharmaceutics, 2010, 7, 1899-1912. 
22. Q. Mu, G. Jiang, L. Chen, H. Zhou, D. Fourches, A. Tropsha and B. Yan, 
Chemical reviews, 2014. 
23. K. M. Tsoi, Q. Dai, B. A. Alman and W. C. W. Chan, Accounts of Chemical 
Research, 2012, 46, 662-671. 
24. R. Shukla, V. Bansal, M. Chaudhary, A. Basu, R. R. Bhonde and M. Sastry, 
Langmuir, 2005, 21, 10644-10654. 
25. P. Zhang, X. X. Yang, Y. Wang, N. W. Zhao, Z. H. Xiong and C. Z. Huang, 
Nanoscale, 2014, 6, 2261-2269. 
26. G. Liang, D. Ye, X. Zhang, F. Dong, H. Chen, S. Zhang, J. Li, X. Shen and J. 
Kong, Journal of Materials Chemistry B, 2013, 1, 3545-3552. 
27. M. Brust, M. Walker, D. Bethell, D. J. Schiffrin and R. Whyman, Journal of the 
Chemical Society, Chemical Communications, 1994, 801-802. 
Gold nanoparticles functionalised with Gd3+ chelates 
233 
 
28. H. Qin, T. Zhou, S. Yang, Q. Chen and D. Xing, Nanomedicine, 2013, 8, 1611-
1624. 
29. I. Miladi, C. Alric, S. Dufort, P. Mowat, A. Dutour, C. Mandon, G. Laurent, E. 
Bräuer-Krisch, N. Herath, J.-L. Coll, M. Dutreix, F. Lux, R. Bazzi, C. Billotey, M. 
Janier, P. Perriat, G. Le Duc, S. Roux and O. Tillement, Small, 2014, 10, 1116-1124. 
30. Y. Liu, Z. Chang, H. Yuan, A. M. Fales and T. Vo-Dinh, Nanoscale, 2013, 5, 
12126-12131. 
31. C. Alric, J. Taleb, G. L. Duc, C. Mandon, C. Billotey, A. L. Meur-Herland, T. 
Brochard, F. Vocanson, M. Janier, P. Perriat, S. Roux and O. Tillement, Journal of the 
American Chemical Society, 2008, 130, 5908-5915. 
32. M. F. Warsi, R. W. Adams, S. B. Duckett and V. Chechik, Chemical 
Communications, 2010, 46, 451-453. 
33. P. J. Debouttière, S. Roux, F. Vocanson, C. Billotey, O. Beuf, A. Favre-
Réguillon, Y. Lin, S. Pellet-Rostaing, R. Lamartine, P. Perriat and O. Tillement, 
Advanced Functional Materials, 2006, 16, 2330-2339. 
34. J. A. Park, P. A. N. Reddy, H. K. Kim, I. S. Kim, G. C. Kim, Y. Chang and T. J. 
Kim, Bioorganic & Medicinal Chemistry Letters, 2008, 18, 6135-6137. 
35. M. Marradi, D. Alcantara, J. M. de la Fuente, M. L. Garcia-Martin, S. Cerdan 
and S. Penades, Chemical Communications, 2009, 3922-3924. 
36. M. F. Warsi and V. Chechik, Physical Chemistry Chemical Physics, 2011, 13, 
9812-9817. 
37. L. c. Moriggi, C. Cannizzo, E. Dumas, C. d. R. Mayer, A. Ulianov and L. Helm, 
Journal of the American Chemical Society, 2009, 131, 10828-10829. 
38. M. Port, J.-M. Idée, C. Medina, C. Robic, M. Sabatou and C. Corot, BioMetals, 
2008, 21, 469-490. 
39. S. K. Morcos, European Journal of Radiology, 2008, 66, 175-179. 
40. M. F. Ferreira, A. F. Martins, C. I. O. Martins, P. M. Ferreira, É. Tóth, T. B. 
Rodrigues, D. Calle, S. Cerdan, P. López-Larrubia, J. A. Martins and C. F. G. C. 
Geraldes, Contrast media & molecular imaging, 2013, 8, 40-49. 
Chapter 6  
234 
 
41. R. Wei, L. Cheng, M. Zheng, R. Cheng, F. Meng, C. Deng and Z. Zhong, 
Biomacromolecules, 2012, 13, 2429-2438. 
42. S. Laurent, L. Vander Elst, C. Henoumont and R. N. Muller, Contrast media & 
molecular imaging, 2010, 5, 305-308. 
43. A. Barge, G. Cravotto, E. Gianolio and F. Fedeli, Contrast media & molecular 
imaging, 2006, 1, 184-188. 
44. H. Hinterwirth, S. Kappel, T. Waitz, T. Prohaska, W. Lindner and M. 
Lämmerhofer, ACS Nano, 2013, 7, 1129-1136. 
45. M.-C. Daniel and D. Astruc, Chemical reviews, 2003, 104, 293-346. 
46. J. Gonçalves, Chemistry Department, 2012, Master thesis. 
47. P. J. Krommenhoek, J. Wang, N. Hentz, A. C. Johnston-Peck, K. A. Kozek, G. 
Kalyuzhny and J. B. Tracy, ACS Nano, 2012, 6, 4903-4911. 
48. A. Borel, J. F. Bean, R. B. Clarkson, L. Helm, L. Moriggi, A. D. Sherry and M. 
Woods, Chemistry – A European Journal, 2008, 14, 2658-2667. 
49. F. A. Dunand, É. Tóth, R. Hollister and A. E. Merbach, Journal of Biological 
Inorganic Chemistry, 2001, 6, 247-255. 
50. H. D. Hill, J. E. Millstone, M. J. Banholzer and C. A. Mirkin, ACS Nano, 2009, 
3, 418-424. 
51. C. Alric, I. Miladi, D. Kryza, J. Taleb, F. Lux, R. Bazzi, C. Billotey, M. Janier, 
P. Perriat, S. Roux and O. Tillement, Nanoscale, 2013, 5, 5930-5939. 
52. M. A. Bruckman, X. Yu and N. F. Steinmetz, Nanotechnology, 2013, 24, 
462001. 
53. S. Torres, M. I. M. Prata, A. C. Santos, J. P. André, J. A. Martins, L. Helm, É. 
Tóth, M. L. García-Martín, T. B. Rodrigues, P. López-Larrubia, S. Cerdán and C. F. G. 
C. Geraldes, NMR in biomedicine, 2008, 21, 322-336. 
54. N. Raghunand, C. Howison, A. D. Sherry, S. Zhang and R. J. Gillies, Magnetic 
Resonance in Medicine, 2003, 49, 249-257. 
55. D. Baumann and M. Rudin, Magn Reson Imaging, 2000, 18, 587-595. 
56. MOPAC2012, Colorado Springs, CO, USA, HTTP://OpenMOPAC.net (2012). 
Gold nanoparticles functionalised with Gd3+ chelates 
235 
 
57. J. P. Stewart, J Mol Model, 2007, 13, 1173-1213. 
58. A. Klamt and G. Schuurmann, Journal of the Chemical Society, Perkin 
Transactions 2, 1993, 799-805. 
  
Chapter 6  
236 
 
Supplementary Information 
 
Gold nanoparticles functionalised with Gd
3+
 chelates: linker effects on the relaxivity 
  
 
Miguel F. Ferreira,
a 
Janaina Gonçalves,
a 
B. Mousavi,
b
 M. I. M. Prata,
c
 S. P. J. 
Rodrigues,
d 
Pilar López-Larrubia,
e 
Sebastian Cerdan,
e 
Tiago B. Rodrigues,
f,g
 L. Helm,
b*
 
 
José A. Martins
a* 
and Carlos F.G.C. Geraldes
,h
 
 
a
Centro de Química, Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal. E-
mail: jmartins@quimica.uminho.pt  
b
Laboratoire de Chimie Inorganique et Bioinorganique, Ecole Polytechnique Fédérale de 
Lausanne, EPFL-BCH CH-1015 Lausanne, Switzerland. E-mail: lothar.helm@epfl.ch; Fax: +41 
(0)21 693 98 95;Tel: +41 (0)21 693 98 76 
c
IBILI, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal. 
d
Center of Chemistry and Department of Chemistry, University of Coimbra, 3004-535, 
Coimbra, Portugal. 
e
Instituto de Investigaciones Biomédicas ―Alberto  ols‖, C IC-UAM, Madrid, Spain 
f
Cancer Research UK, Cambridge Research Institute, Li KaShing Centre, Cambridge CB2 0RE, 
United Kingdom.   
g
Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, United 
Kingdom. 
h
Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, P.O. 
Box 3046, 3001-401 Coimbra, Portugal. 
 
Corresponding authors:  
José A. Martins, Centro de Química, Campus de Gualtar, Universidade do Minho, 4710-057 
Braga, Portugal. 
Lothar Helm, Ecole Polytechnique Féderale de Lausanne, EPFL-BCH CH-1015 Lausanne, 
Switzerland. 
Gold nanoparticles functionalised with Gd3+ chelates 
237 
 
 
Figure SI6.1-Temperature dependence of the water proton relaxivity for GdL1 (20 MHz, 1.0 
mM pH 7.0) 
 
 
 
Figure SI6.2- pH dependence of the water proton relaxivity for GdL1 (20 MHz, 1.0 mM, 25 
ºC). 
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Figure SI6.3- Typical chelate lenght estimates from several  …O and  …H top-bottom 
distances measured over the optimized conformations of (A) GdL1, (B) GdL2 and (C) GdL3 
obtained from PM6 semi-empirical calculations. 
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Figure SI6.4- UV-Vis spectrum of GdL1@AuNPs. 
 
 
Figure SI6.5- Zeta potential distribution, expressed as total counts, for GdL1@AuNPs. 
 
Table SI6.1- Zeta potencial for GdL1@AuNPs 
AuNPs Zeta potential (mV) 
GdL1@AuNPs -6.3 
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Figure SI6.6- Concentration dependence of the paramagnetic water proton relaxation rate R1p 
(R1p = R1obs-R1d) for GdL1@NPs (20 MHz, 25ºC, pH=7.1)  
 
 
Figure SI6.7- pH dependence of the paramagnetic water proton relaxation for GdL1@AuNPs 
(20 MHz, 25 ºC, 0.53 mM). 
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Figure SI6.8- Time evolution of the relative water proton paramagnetic relaxation rate 
R1p(t)/R1p(0) (20 MHz, 25 ºC) for a solution of GdL1@NPs (0.53 mM in PBS 2.5 mM, pH 7.1) 
(♦) and following addition of 0.75 mM ZnCl2 (●). 
 
Table SI6.2-. Characterization of GdL1@AuNPs  
 GdL1@AuNPs
a 
GdL2@AuPs
b
 GdL3@AuNPs
c 
[Gd] (mM)
d 0.57 1.30 1.24 
HD (nm)
e
 4.8 5.9 3.9 
Chelate length (nm)
f
 1.6 2.3 1.4
g 
Au core diam (nm)
h 1.6 1.3 1.1
g 
Zeta potential (mV) -6.3 -13.7 -12.3 
NAu core
i 127 68 41
g
 
NChel/NP n.d.
 
n.d. 14
g,j 
r1 (mM
-1
s
-1
; 20 MHz, 25 ºC) 27
 
38
 
28
 
r1vol (mM
-1
s
-1
nm
-3
; 20 MHz, 25 ºC)
k
 n.d. n.d. 12.62 
 
a
The synthesis and characterization of L1, , GdL1 and of the functionalized GdL1@AuNPs is 
described in this work.  
b
From reference [1] 
c
The synthesis and characterization of L3 and GdL3@AuNPs was described in Chapter 5[2]. 
d
The concentration of Gd on the NPs solutions was determined by ICP-OES following digestion 
of the NPs with aqua regia. Reproducible values for the concentration of Au could not be 
obtained by ICP-OES.   
e
The hydrodynamic diameter (HD, nm) of the NPs was measured by DLS. 
f
The length of GdL1 and GdL2 was estimated by PM6 semi-empirical calculations for the most 
provable distended conformations (Figure SI5).  
g
The length of GdL3 was estimated by PM6 semi-empirical calculations for the most provable 
distended conformation, affording a revised value of 1.4 nm comparing to previous estimates of 
1 nm [2].  
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h
The diameter of the gold core was estimated by taking into account the hydrodynamic diameter 
of the NPs measured by DLS, and the thickness of the chelate monolayer: Aucore = HD-
2xChellenght  
i  
Knowing  the diameter (D, nm) of the Au core allows to calculate the number of Au atoms in 
the core[3]:  NAu= 30.9D
3
.   
j 
The number of immobilized complexes was calculated from Au/Gd ratio determined by ICP-
OES. 
k 
The volumetric density of relaxivity was calculated using the relaxivity per NP and the HD 
diameter of the naoparticles [4]: r1vol= (Nchel  x r1)/4/3π(HD/2)
3
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7- Conclusions and perspectives 
 
The main objective of the present work was to develop general and versatile synthetic 
methodologies for metal complexes exhibiting optimized properties as efficacious 
molecular imaging agents for MRI (in particular) and other imaging modalities. 
Building-up on previous work on the synthesis and characterization of the  
DO3A-N-(-amino)propionate chelator and its Gd3+ chelate as ―leads for targeted high 
relaxivity potentially safe contrast agents for MRI‖, synthetic routes were developed for 
amide conjugates of the DO3A-N-(-amino)propionate chelator. The synthetic routes 
devised were extended to the triazacyclononane scaffold with the synthesis of the 
NO2A-N-(α-amino)propionate chelator and amide conjugates.  
Relaxometric characterization (
1
H NMRD profiles and 
17
O NMR studies) of the low 
molecular weight Gd[DO3A-N-(-benzoylamido)propionate] complex established that 
―amide conjugates retain the fast water exchange rate and stability of the parent amine 
complex‖. Moreover, MRI studies in rats demonstrated that the amide complex in stable 
in vivo and follows fast renal elimination.  
Macromolecular/nanosized Gd
3+
 chelates of amide conjugates were explored as high 
relaxivity CA for MRI. The Gd[DO3A-N-(-pyrenebutanamido)propionate] complex 
was designed as a self-assembling MRI/fluorescence bimodal CA. Relaxometric 
measurements (20 MHz, 25 ºC) allowed to determine the parameters that characterize 
the self-assembly process. Simultaneous fitting of 
1
H NMRD and 
17
O NMR data to the 
SBM theory, including the Lipary-Szabo approach to internal flexibility, gave the 
parameters that govern the relaxivity of the aggregated form. The high relaxivity 
attained at intermediate fields (32 mM
-1
s
-1
, 20 MHz) was attributed to simultaneous 
optimization of R and kex. The relaxivity is still limited by internal flexibility of the 
non-covalently associated chelates. Beyond self-assembly, the pyrene moiety endowed 
also the complex with concentration-sensitive fluorescence reporting properties, making 
the complex a potential bimodal MRI/Fluorescence imaging agent. The Yb
3+
 and Nd
3+
 
chelates display sensitized NIR emission. 
AuNPs functionalised with Gd
3+
 chelates have emerged in recent years as attractive 
platforms for bimodal MRI/X-ray imaging associated to therapy (hyperthermia and X-
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ray sensitization).  In addition to substantial relaxivity enhancements at intermediate 
magnetic fields, as result of optimization of R of the immobilised chelates, clustering 
many chelates in a small volume has the potential to generate objects displaying high 
density of relaxivity.  
This work developed in this Thesis addressed explicitly, for the first time, the effect of 
fast water exchange on the relaxivity of AuNPs functionalised with Gd
3+
 complexes.  
Cysteine and lipoic acid amide conjugates of the DO3A-N-(-amino)propionate 
chelator were designed to functionalise AuNPs with Gd
3+
 chelates as CA for MRI. 
Synthetic methodologies were developed for preparing and purifying AuNPs 
functionalised with Gd[DO3A-N-(-cystamido)propionate] and Gd[DO3A-N-(-
lipoamido)propionate] chelates. The NPs were characterized regarding size (DLS and 
TEM) and charge (zeta potential measurements). The Au and Gd content of the NPs 
were determined by ICP-OES. The immobilized chelates and (entire NPs) revealed 
stable and resistant to transmetallation against Zn
2+
. High relaxivities (~ 28 mM
-1
s
-1
; 20 
MHz, 25 ºC) were attained by the functionalized NPs thanks to simultaneous 
optimization of R and kex. The relaxivity was still limited by fast rotational motions of 
the immobilized chelates around the anchoring linkers. The length of the linker does not 
seems not influence much the internal flexibility of the immobilized chelates, although 
ligand bulkiness seems to determine the size of the nanocrystal core of the AuNPs.  
Biodistribution studies using the surrogate 
153
Sm[DO3A-N-(-
lipoamido)propionate]@AuNPs complex and MRI studies in vivo (mice) revealed that 
the fate of the NPs in vivo is mainly determined by their size, hydrodynamic diameter: 
while the Gd[DO3A-N-(-cystamido)propionato]@AuNPs CA (HD= 3.9 nm) follows 
renal elimination the Gd[DO3A-N-(-lipoamido)propionato]@AuNPs (HD= 4.8 nm) 
follows mainly hepatobiliary clearance.  
The animal MRI studies, performed in a dedicated preclinical imaging platform 
operating at high magnetic field  (7T ~ 300 MHz) emphasise  the mismatch between the 
performance of nanosized/macromolecular CA, optimized for intermediate magnetic 
fields (20-60 MHz) and the trend for increasingly higher magnetic fields seen in clinical 
imaging. The next generation of clinical MRI imagers operates at 120 MHz. For the 
AuNPs described in this thesis, the relaxivity hump characteristic of 
macromolecular/nanosized CA, centred at intermediate fields (20-60 MHz), extends 
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into the high field region. Relaxivities still relevant for clinical high field applications (~ 
18 and 7 mM
-1
s
-1
 at 120 and 300 MHz respectively, compared with ~ 2-3 mM
-1
s
-1
 for 
Gd(DTPA)) are attained by the AuNPs described in this work. Moreover, the nanosize 
advantage over low molecular weight CA is illustrated by longer circulation of the 
Gd[DO3A-N-(-cystamido)propionato]@AuNPs CA in vivo, without liver and spleen 
uptake, comparing to Gd(DTPA) (elimination in ~ 20 minutes). 
The bifunctional NODSA e NODAGA chelators (NOTA analogues) are the gold 
standard for preparing targeted 
68
Ga
3+
 chelates for use as PET tracers.   
In this work, the synthetic methodologies developed for the DO3A-N-(α-
amino/amido)propionate chelators were extended to the triazacyclononane scaffold.  
The Ga[NO2A-N-(α-amino)propionate] and Ga[NO2A-N-(α-benzoylamido)propionate] 
chelates were studied by multinuclear (
1
H e 
71
Ga) NMR. The chelate Ga[NO2A-N-(α-
benzoylamido)propionate] displays N3O3 coordination in the pH range 3-11. The 
complex Ga[NO2A-N-(α-amino)propionate] undergoes pH trigged coordination 
isomerisation in the pH range 3-5 At pH values bellow 4 the complex displays N3O3 
coordination while at pH values above 6 the N4O2 isomer is predominant in solution. 
Biodistribution studies revealed that the 
67
Ga[NO2A-N-(α-
pyrenebutanamido)propionato] chelate follows mainly renal elimination with low 
liver/spleen accumulation and no visible deposition of activity in the bones after 24 
hours. 
The synthetic methodologies developed in this thesis, open access to a variety of amide 
conjugates of the DO3A-N-(α-amino)propionate and  NO2A-N-(α-amino)propionate 
chelator families  suitable for stable complexation of Ln
3+
 ions and Ga
3+
, and probably 
transition metal ions (e.g. Cu
2+
), for medical imaging and therapeutic applications.   
In this work we illustrate the scope of these methodologies with the design, synthesis 
and characterization of high relaxivity nanosized (nanoparticles and micelles) CA. The 
potential of Ga[NO2A-N-(α-amino/amido)propionate] chelates  as potential tracers for 
68
Ga-mediated PET was demonstrated also.  
AuNPs, associating biocompatibility, targeting ability, high density of relaxivity, 
multimodal imaging and therapeutic properties are likely to have a great impact in 
biomedical research and clinical imaging.   
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Preliminary steps towards this aim have been undertaken in this thesis. Mixed 
monolayer NPs containing Gd[DO3A-N-(-cystamido)propionate] chelates and 
molecular constructs consisting of a terminal cysteine moiety (for anchorage to the Au 
core), a PEG linker and a terminal folic acid targeting group, were prepared during this 
work. In the future we plan to perform the full physico-chemical characterization and in 
vitro (cancer cell lines) and in vivo (animal cancer models) evaluation of targeted mixed 
monolayer nanoparticles as potential imaging/therapeutic agents. Gold nanorods 
functionalised with Gd
3+
 are also very promising theragnostics given their superior 
properties for hyperthermia.  
Medical imaging has gained tremendous impetus from nanotechnology. We are 
convinced that the synthetic methodologies developed, together with the applications 
illustrated in this thesis, will find many applications in the medical imaging field. 
